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Protein	  ubiquitylation	  represents	  a	  versatile	  mechanism	  to	  regulate	  multiple	  
cellular	   processes,	   including	   protein	   turnover,	   transcription,	   cell	   signaling,	  
membrane	  trafficking	  and	  DNA	  damage	  repair.	  The	  attachment	  of	  ubiquitin	  moieties	  
to	  a	  target	  substrate	  is	  sequentially	  catalysed	  by	  three	  enzymes,	  namely	  E1,	  E2	  and	  
E3,	   and	   this	   process	   can	   be	   reversed	   by	   the	   deubiquitylases	   (DUBs).	   This	   research	  
project	  seeks	  to	  decipher	  the	  involvement	  of	  DUBs	  in	  regulation	  of	  the	  components	  
of	  the	  adherens	  junction	  (AJ),	  E-­‐cadherin	  and	  β-­‐catenin,	  in	  particular,	  which	  are	  the	  
core	  components	  of	  the	  AJ.	  	  
	  
It	  is	  found	  in	  MCF7	  cells,	  a	  breast	  cancer	  cell	  line,	  that	  E-­‐cadherin	  undergoes	  
constitutive	  turnover	  via	  the	  lysosomal	  pathway,	  as	  indicated	  by	  the	  accumulation	  of	  
an	  80kDa	  fragment	  of	  E-­‐cadherin	  degradative	  fragment	  following	  treatment	  of	  MCF7	  
cells	  with	  Folimycin,	  a	  lysosomal	  v-­‐ATPase	  inhibitor.	  Using	  the	  ratio	  of	  the	  full	  length	  
and	  80kDa	  degradative	  fragment	  as	  a	  biochemical	  readout	  for	  the	  trafficking	  status	  
of	   E-­‐cadherin,	   a	   siRNA	   human	   DUB	   library	   screen	  was	   performed	   and	   USP38	  was	  
identified	  as	  a	  leading	  candidate.	  siRNA	  depletion	  of	  USP38	  led	  to	  increase	  in	  the	  full	  
length	  to	  80kDa	  E-­‐cadherin	  ratio.	  Notably,	  the	  loss	  of	  USP38	  led	  to	  significant	  loss	  of	  
total	  E-­‐cadherin	  level	  (sum	  of	  full	  length	  E-­‐cadherin	  and	  80kDa	  E-­‐cadherin	  fragment).	  
	   III	  
The	   loss	   of	   E-­‐cadherin	   at	   the	   protein	   level	   following	   USP38	   knockdown	   was	   not	  
accompanied	   by	   a	   decrease	   in	   its	   mRNA	   level	   or	   increase	   in	   degradation	   rate,	  
suggesting	   that	   translational	   effects	   could	   operate.	   Preliminary	   characterisation	   of	  
this	  enzyme	  showed	  that	   it	  has	  both	  nuclear	  and	  cytosolic	   localisation.	  Mapping	  of	  
nuclear	  localisation	  determinants	  revealed	  a	  role	  for	  a	  46	  amino	  acid	  insertion	  within	  
the	  core	  catalytic	  domain,	  and	  the	  last	  100	  amino	  acid	  on	  C-­‐terminus	  of	  USP38.	  	  
	  
In	   a	   separate	   siRNA	   DUB	   library	   screen	   performed	   on	   A549	   cells,	   the	  
established	   tumour	   suppressor	  BAP1	  was	   identified	  as	  a	  DUB	   regulating	  β-­‐catenin.	  
siRNA	  depletion	  of	  BAP1	  resulted	  in	  a	  loss	  of	  β-­‐catenin	  and	  loss	  of	  cell-­‐cell	  contacts,	  
whereas	  its	  overexpression	  led	  to	  an	  increase	  in	  β-­‐catenin	  level,	  indicating	  a	  positive	  
regulatory	  role	  of	  BAP1	  on	  β-­‐catenin	  level.	  	  
	  
To	   facilitate	   further	   screening	   efforts	   and	   to	   provide	   an	   extra	   layer	   of	  
validation	   to	   my	   own	   screens,	   a	   human	   DUB	   endonuclease-­‐prepared	   small	  
interfering	   RNA	   (esiRNA)	   library	   was	   developed.	   EsiRNA	   is	   a	   complex	   mixture	   of	  
siRNAs	  generated	  by	  random	  cleavage	  of	  long	  double-­‐stranded	  RNA	  and	  is	  argued	  to	  
be	   able	   to	   circumvent	   the	   problem	   of	   siRNA-­‐induced	   off-­‐target	   effects.	   	   EsiRNAs	  
were	  made	   for	   91	   out	   of	   the	   currently	   predicted	   93	   human	  DUBs.	  Quality	   control	  
experiments	  were	  carried	  out	  upon	  a	  sample	  of	  selected	  DUBs	  and	  optimisation	  of	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S.O.C.	   Super	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STAM	   Signal	  Transducing	  Adaptor	  Molecule	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  Binding	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  Zinc	  finger	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  Specific	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UTR	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1.1 Adherens	  Junctions	  	  
	  
The	   integrity	   of	   tissue	   architecture	   and	   functional	   diversification	   of	   a	  
multilayered	   metazoan	   organism	   is	   dependent	   on	   the	   physical	   coupling	   of	  
neighbouring	   cells	   as	  well	   as	   interaction	   between	   the	   cells	   and	   their	   environment	  
(Franke,	   2009;	   Yap	   et	   al.,	   1997).	   This	   is	   achieved	   by	   four	   major	   types	   of	   cell-­‐cell	  
junctions,	   namely	   adherens	   junctions	   (AJ),	   desmosomes,	   tight	   junctions	   and	   gap	  
junctions	   (Franke,	   2009).	   Among	   these,	   the	   AJ	   is	   the	   key	   determinant	   of	   cell-­‐cell	  
adhesion	  and	  it	  provides	  physical	  links	  between	  membrane	  proteins	  and	  cytoskeletal	  
components	  at	  discrete	  contact	  regions	  between	  cells	  (Niessen	  and	  Gottardi,	  2008).	  	  
	  
By	   performing	   ultrastructural	   analysis	   of	   animal	   tissues	   using	   electron	  
microscopy,	   Farquhar	  and	  Palade	  provided	   the	   first	  detailed	  description	  of	   zonular	  
AJ,	   which,	   together	   with	   desmosomes	   and	   tight	   junctions,	   forms	   a	   tripartite	  
junctional	  complex	  between	  the	  apices	  of	  a	  variety	  of	  simple	  epithelia	  (Farquhar	  and	  
Palade,	   1963).	   AJ,	   as	   described	   by	   Farquhar	   and	   Palade,	   comprises	   of	   apposed	  
membrane	   separated	   by	   an	   intercellular	   space	   of	   ~200Å	   with	   dense	   plaques	   of	  
cytoplasmic	   microfilaments	   on	   both	   sides.	   A	   subsequent	   study,	   using	   deep-­‐etch	  
electron	  microscopy,	  identified	  actin	  filaments	  as	  major	  components	  of	  the	  plaques	  
and	  revealed	  numerous	  cylindrical	  projections	  from	  the	  apposing	  membrane,	  filling	  
the	  intercellular	  space	  at	  the	  AJ	  (Hirokawa	  and	  Heuser,	  1981).	  	  
	  
Based	  on	  these	  ultrastructural	  observations,	  one	  would	  anticipate	  there	  are	  
at	   least	  three	  classes	  of	  proteins	  present	  at	  the	  AJ:	  (i)	  adhesive	  protein	  units	  which	  
span	   the	   intercellular	   space,	   thereby	  providing	  physical	   link	  between	  neighbouring	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cells;	  (ii)	  a	  cytoskeletal	  network	  onto	  which	  the	  adhesive	  proteins	  are	  anchored,	  and	  
(iii)	   proteins	   which	   mediate	   association	   of	   the	   adhesive	   proteins	   with	   the	  
cytoskeletal	  network	  (Niessen	  and	  Gottardi,	  2008).	  	  
	  
	  
1.1.1	  	   Functions	  of	  AJ	  
	  
At	   the	   cellular	   and	  molecular	   level,	   AJ	   is	   important	   for	   processes	   including	  
initiation	  and	  stabilisation	  of	  cell-­‐cell	  adhesion,	  modulation	  of	  the	  actin	  cytoskeleton,	  
intracellular	  signalling	  events	  and	  regulation	  of	  transcriptional	  events	  (Niessen,	  2007;	  
Hartsock	  and	  Nelson,	  2008).	  	  
	  
Evidence	  suggests	  that	  E-­‐cadherin-­‐based	  AJ	  is	  a	  prerequisite	  for	  the	  assembly	  
of	   the	   other	   intercellular	   junctions	   (Gumbiner	   et	   al.,	   1988).	   The	   conditional	  
inactivation	  of	  E-­‐cadherin	  gene	  in	  mice	  resulted	  in	  mislocalisation	  of	  tight	  junctional	  
proteins	   and	   hence	   a	   leaky	   epidermal	   water	   barrier	   that	   led	   to	   perinatal	   death	  
(Tunggal	   et	   al.,	   2005).	   Multiple	   studies	   have	   also	   demonstrated	   that	   ablation	   of	  
cadherin-­‐based	   AJ	   disrupts	   or	   delays	   the	   assembly	   of	   desmosomes	   (Lewis	   et	   al.,	  
1994;	  Lewis	  et	  al.,	  1997).	  	  
	  
	  
1.1.3 Core	  Components	  of	  AJ	  –	  the	  Cadherin/Catenin	  Complex	  	  
	  
There	   are	   two	   alternative	   adhesive	   protein	   units	   of	   AJ,	   namely	  
cadherin/catenin	  complex	  and	  nectin/afadin	  complex	  (Niessen	  and	  Gottardi,	  2008).	  
Cadherin,	  specifically,	  E-­‐cadherin	  (due	  to	   its	  epithelial	  origin)	  was	  the	  first	  adhesive	  
component	  of	  AJ	  that	  was	  discovered	  (Takeichi	  1977;	  Yoshida-­‐Noro	  et	  al.,	  1984).	   It	  
was	   shown	   to	   be	   essential	   for	   morula	   compaction	   during	   early	   stage	   of	  
embryogenesis,	  a	  cell-­‐cell	  adhesion	  dependent	  event,	  and	  that	  this	  process	  was	  Ca2+	  
dependent,	  hence	   the	  name	  cadherin.	   Since	   it	   is	   the	   first	  member	  of	   the	   cadherin	  
superfamily	   to	   be	   identified,	   E-­‐cadherin,	   together	   with	   its	   subfamily	   members,	   P-­‐
	   3	  
cadherin	   (placenta),	   N-­‐cadherin	   (neuronal),	   VE-­‐cadherin	   (vasoendothelial),	   are	  




Figure	  1.1.	  Core	  components	  of	  adherens	   junction	  complex.	  E-­‐cadherin	  molecules	  
expressed	  on	  neighbouring	  cells	  form	  homophilic	  interaction	  in	  a	  calcium-­‐dependent	  
manner,	   forming	  the	  core	  of	  the	  AJ.	  On	  the	  cytoplasmic	  tail,	  p120-­‐catenin	  binds	  to	  
the	   juxtamembrane	  domain,	  stabilising	  the	  AJ	  on	  the	  plasma	  membrane.	  β-­‐catenin	  
binds	  to	  the	  cytoplasmic	  tail	  of	  E-­‐cadherin,	  and	  interacts	  with	  monomeric	  α-­‐catenin.	  
With	   high	   concentration	   of	   the	   cadherin-­‐catenin	   complex	   at	   the	   AJ,	   the	  α-­‐catenin	  
switches	  between	  monomeric	  and	  homo-­‐dimeric	  form,	  where	  the	  dimeric	  α-­‐catenin	  




The	  cytoplasmic	  domain	  of	  cadherin	  is	  associated	  with	  three	  armadillo	  repeat	  
proteins,	   namely	  β-­‐catenin,	  α-­‐catenin	   and	  p120-­‐catenin	   (Figure	  1.1)	   (Ozawa	  et	   al.,	  
1989).	   This	   association	   is	   important	   for	   the	   adhesion	   and	   signalling	   activities	  
mediated	   by	   cadherin	   (Niessen	   and	   Gottardi,	   2008;	   van	   Roy	   and	   Berx,	   2008).	   The	  
binding	  of	  β-­‐catenin	  to	  cadherin	  is	  a	  prerequisite	  for	  cell	  adhesion,	  as	  the	  association	  
of	   the	   two	   proteins	   at	   endoplasmic	   reticulum	   (ER)	   facilitates	   the	   transport	   of	   the	  
complex	  to	  cell	  surface	  (Chen	  et	  al.,	  1999)	  and	  the	  binding	  of	  β-­‐catenin	  masks	  a	  PEST	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which,	   if	   exposed,	   renders	   the	   molecule	   for	   proteolytic	   processing	   (Huber	   et	   al.,	  
2001).	  	  
α-­‐catenin	   has	   long	   been	   thought	   to	   provide	   the	   physical	   link	   between	   the	  
cadherin/β-­‐catenin	  complex	  and	   the	  actin	  cytoskeleton,	   since	   it	  was	  demonstrated	  
to	  bind	  actin	  filaments	  (Rimm	  et	  al.,	  1995)	  and	  β-­‐catenin	  in	  vitro	  (Aberle	  et	  al.,	  1994).	  
However,	   Yamada	   and	   colleagues	   demonstrated	   that	   α-­‐catenin	   cannot	  
simultaneously	   bind	  β-­‐catenin	   and	   actin	   (Yamada	   et	   al.,	   2005).	   This	   is	   because	  α-­‐
catenin	   switches	   between	   a	   monomeric	   and	   a	   homo-­‐dimeric	   state,	   where	   the	  
monomeric	  α-­‐catenin	  binds	  only	  to	  β-­‐catenin	  (but	  not	  actin)	  whereas	  the	  dimeric	  α-­‐
catenin	   binds	   only	   to	   actin	   (but	   not	   β-­‐catenin)	   (Figure	   1.1);	   and	   that	   the	   region	  
required	   for	   binding	   to	   β-­‐catenin	   overlaps	   with	   the	   region	   for	   α-­‐catenin	  
homodimerisation	  (Pokutta	  and	  Weis,	  2000;	  Yamada	  et	  al.,	  2005).	  	  Moreover,	  in	  vitro	  
studies	  show	  that	  a	  10-­‐fold	  higher	  concentration	  of	  monomeric	  α-­‐catenin	  is	  required	  
for	  its	  dimerisation	  (Drees	  et	  al.,	  2005).	  Putting	  this	  into	  the	  context	  of	  AJ	  assembly,	  
it	   therefore	   indicates	  requirement	  for	   local	  concentration	  of	  monomeric	  α-­‐catenin,	  
possibly	  by	  clustering	  of	  α-­‐catenin-­‐bound	  cadherin/β-­‐catenin	  complex	  at	  the	  plasma	  
membrane,	  to	  allow	  subsequent	  dimerisation	  of	  α-­‐catenin	  to	  mediate	  actin-­‐filament	  
organisation	   (from	   branched	   to	   bundled)	   at	   cell-­‐cell	   contact	   site.	   Such	   a	   working	  
model	  allows	  dynamic	  coupling	  of	  the	  adherens	  junction	  complex	  assembly	  and	  actin	  
remodelling	  (Niessen	  and	  Gottardi,	  2008).	  	  	  
	  
P120-­‐catenin	   binds	   to	   a	   highly	   conserved	   8-­‐amino-­‐acid	   motif	   (YDEEGGGE)	  
(Ferber	   et	   al.,	   2002)	   within	   the	   juxtamembrane	   domain	   (JMD)	   of	   E-­‐cadherin	  
(Reynolds	  et	  al.,	  1996;	  Ohkubo	  and	  Ozawa,	  1999).	  Peifer	  and	  Yap	  proposed	  the	  role	  
of	  p120-­‐catenin	  as	  a	  gatekeeper	  of	  classical	  cadherins,	  which	  dictates	  the	  stability	  of	  
the	  cadherins	  on	  plasma	  membrane	  and	  fate	  of	  cadherin	  during	  endocytic	  trafficking	  
(Peifer	   and	   Yap,	   2003;	   Xiao	   et	   al.,	   2007).	   In	   a	   colon	   cancer	   cell	   line	   SW48,	   which	  
harbors	  a	  mutation	  leading	  to	  the	  truncation	  of	  p120-­‐catenin,	  there	  is	  a	  low	  level	  of	  
E-­‐cadherin	   protein	   despite	   high	   level	   of	   E-­‐cadherin	   messenger	   ribonucleic	   acid	  
(mRNA)	  (Ireton	  et	  al.,	  2002).	  The	  prominent	  loss	  of	  E-­‐cadherin	  could	  be	  reverted	  by	  
reintroduction	  of	  wildtype	  p120-­‐catenin,	  suggesting	  regulation	  of	  E-­‐cadherin	  protein	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turnover	   by	   p120-­‐catenin.	   In	   line	   with	   this	   observation,	   the	   small	   siRNA	   (small	  
interfering	   ribonucleic	   acid)	   depletion	   of	   p120-­‐catenin	   in	   cells	   expressing	  wildtype	  
p120-­‐catenin	   results	   in	   loss	  of	   classical	   cadherins,	   including	  E-­‐cadherin,	  N-­‐cadherin	  
and	   VE-­‐cadherin	   (Davis	   et	   al.,	   2003;	   Xiao	   et	   al.,	   2003).	   The	   loss	   of	   p120-­‐catenin	  
results	   in	   internalisation	  of	  cadherin	  molecules	  on	  the	  plasma	  membrane	  and	  their	  
subsequent	  trafficking	  to	  the	  lysosomes	  for	  proteolytic	  degradation.	  	  
	  
	  
1.1.2.1	  	   E-­‐cadherin	  
	  
	  
Figure	   1.2.	   Domain	   architecture	   of	   E-­‐cadherin.	   E-­‐cadherin	   is	   synthesised	   as	  
precursor	  polypeptide,	  with	  a	  propeptide	  and	  ER	  signal	  peptide	  at	  the	  N-­‐terminus.	  A	  
mature	   protein	   consists	   of	   5	   tandemly	   repeated	   domains:	   4	   extracellular	   cadherin	  
repeats	  (EC1	  to	  EC4)	  followed	  by	  membrane	  proximal	  extracellular	  domain	  (MPED).	  
A	  transmembrane	  domain	  allows	  the	  protein	  to	  be	  embedded	  across	  the	  membrane.	  
The	  cytoplasmic	  domain	  of	  E-­‐cadherin	  contains	  binding	  sites	  for	  p120-­‐catenin	  and	  β-­‐
catenin,	  which	  are	  named	  CH2	  and	  CH3	  respectively.	  	  
	   	  
	  
	   	  E-­‐cadherin	   is	   synthesised	   as	   a	   precursor	   polypeptide,	  with	   a	   propeptide	   of	  
about	  154	  amino	  acids	  (aa)	  on	  its	  N-­‐terminus	  (Figure	  1.2)	  (van	  Roy	  and	  Berx,	  2008).	  
The	  propeptide	  has	  an	  ER	   signal	  peptide	   for	   import	   into	   the	  ER	  and	   the	  127	  aa	  C-­‐
terminal	  to	  the	  signal	  peptide	  is	  cleaved	  off	  as	  the	  polypeptide	  matures,	  giving	  rise	  to	  
a	   final	   mature	   polypeptide	   of	   728	   aa.	   Mature	   E-­‐cadherin	   is	   a	   single-­‐span	  
transmembrane	  glycoprotein.	  	  
	  
The	   550	   aa	   extracellular	   domain	   consists	   of	   5	   tandemly	   repeated	   domains,	  
where	  the	  first	  4	  domains	  are	  known	  as	  extracellular	  cadherin	  repeats	  (EC1	  to	  EC4).	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The	   EC	   repeat	   is	   characteristic	   of	   all	   the	   cadherins	   but	   only	   varies	   with	   number	  
among	  the	  different	  members	  of	  cadherin	  superfamily.	  	  The	  fifth	  domain	  is	  known	  as	  
the	  membrane	  proximal	  extracellular	  domain	  (MPED).	  This	  domain	   is	  characterised	  
by	   4	   highly	   conserved	   cysteine	   residues,	   which	   form	   disulphide	   bridges	   that	   are	  
important	   for	   the	  adhesive	  properties	  of	   the	  molecule	   (Ozawa	  et	  al.,	   1990).	   There	  
are	  Ca2+	  binding	  sites	  in	  between	  the	  EC	  repeats	  and	  the	  binding	  of	  Ca2+	  helps	  ensure	  
the	   rigidity	   of	   the	  molecule	   in	   an	   elongated	   conformation	   (Yap	   et	   al.,	   1997).	   The	  
extracellular	   domain	   of	   E-­‐cadherin	   is	   responsible	   for	   homophilic	   interaction	   of	   E-­‐
cadherin	   molecules	   expressed	   on	   neighbouring	   cells	   (Nose	   et	   al.,	   1988)	   and	   the	  
specificity	  of	   interaction	   is	  determined	  by	  a	  highly	   conserved	  HAV	  motif	   and	   the	  2	  
amino	  acids	  flanking	  the	  motif	  in	  EC1	  (Blaschuk	  et	  al.,	  1990;	  Tsuji	  et	  al.,	  1990).	  	  	  
	  
The	  cytoplasmic	  domain	  of	  E-­‐cadherin	  also	  plays	  an	  equally	  important	  role	  in	  
determining	   cell	   adhesion	   through	   its	   interaction	  with	   the	   catenins	   (Ozawa	   et	   al.,	  
1989).	   	   The	   juxtamembrane	   domain,	   also	   known	   as	   cadherin	   homology	   domain	   2	  
(CH2)	  of	  30-­‐35	  aa,	  contains	  a	  sequence	  motif	   for	  binding	  of	  p120-­‐catenin,	  whereas	  
the	  CH3	  domain	  allows	  binding	  of	  β-­‐catenin	   (Rimm	  and	  Morrow	  1994).	  Within	   the	  
CH3	  domain,	  there	  is	  a	  cluster	  of	  8	  serine	  residues	  between	  amino	  acids	  684	  to	  699	  
(corresponding	   to	   amino	   acids	   838	   –	   853	   in	   preprotein	   of	   E-­‐cadherin),	   which	   is	  
important	  for	  regulation	  of	  interaction	  between	  E-­‐cadherin	  and	  β-­‐catenin	  (Lickert	  et	  
al.,	   2000).	   The	   phosphorylation	   of	   3	   serines	   residues,	   namely	   Ser684,	   Ser686	   and	  
Ser692	   by	   Casein	   Kinase	   II	   	   (CK	   II)	   and	   glycogen	   synthase	   kinase	   3	   β	   (GSK3β)	  
significantly	  strengthens	  interaction	  between	  the	  two	  proteins.	  	  
	  
	  
1.1.3.1.1 Transcriptional	  regulation	  of	  E-­‐cadherin	  	  
	  
E-­‐cadherin	  is	  encoded	  by	  CDH1	  gene.	  Our	  understanding	  of	  the	  transcriptional	  
regulation	   of	   E-­‐cadherin	   owes	  much	   to	   the	   elucidation	  of	   regulatory	   sequences	   of	  
the	   mouse	   CDH1	   gene,	   which	   is	   characterised	   by	   modules	   of	   binding	   regions	   for	  
different	   transcription	   factors	   (Figure	   1.3)	   (van	   Roy	   and	   Berx,	   2008;	   Comijn	   et	   al.,	  
2001).	   On	   the	   5-­‐prime	   (5’)	   end	   of	   CDH1	   gene,	   there	   are	   2	   positive	   regulatory	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elements,	  namely	  a	  CCAAT	  Box	  and	  2	  GC	  boxes.	   In	  mouse,	  E-­‐cadherin	  transcription	  
can	  be	  initiated	  by	  the	  transcription	  factor	  AP2	  upon	  binding	  to	  the	  GC	  box	  (Hennig	  
et	  al.,	  1996).	  Moreover,	  the	  tumour	  suppressor,	  retinoblastoma	  protein	  (Rb)	  and	  the	  
proto-­‐oncogene,	  c-­‐Myc	  can	  act	  as	  co-­‐activators	  of	  AP2	  in	  epithelial	  cells	  to	  induce	  E-­‐
cadherin	  expression	  (Batsche	  et	  al.,	  1998;	  Decary	  et	  al.,	  2002).	  The	  binding	  of	  WT1,	  a	  
tumour	  suppressor	  gene	  that	   is	  mutated	   in	  Wilm’s	   tumor,	   to	  GC	  Box	  of	  E-­‐cadherin	  
can	  induce	  fibroblasts	  to	  undergo	  differentiation	  and	  acquire	  epithelial	  phenotypes,	  




Figure	  1.3.	  Transcriptional	  regulation	  of	  E-­‐cadherin.	  The	  regulatory	  sequence,	  most	  
of	   which	   are	   upstream	   of	   the	   5’	   end,	   of	   the	   CDH1	   gene	   encoding	   for	   E-­‐cadherin	  
exhibits	   a	   modular	   structure.	   The	   CCAAT	   box	   and	   GC	   box	   are	   positive	   regulatory	  
sequences	   that	   enable	   E-­‐cadherin	   expression,	   upon	   binding	   of	   transcription	   factor	  
such	  as	  AP2	  and	  WT1	  to	  the	  GC	  box.	  The	  E-­‐boxes	  are	  negative	  regulatory	  sequences,	  
the	   binding	   of	   which	   by	   transcriptional	   repressors	   such	   as	   δEF1/ZEB1,	   Snail,	  
SIP1/ZEB2,	  Slug	  and	  E47	  prevents	  E-­‐cadherin	  expression.	  	  
	  
	  
Birchmeier	   group	   has	   also	   reported	   presence	   of	   a	   palindromic	   sequence	  
(termed	   E-­‐box)	   between	   position	   about	   75	   to	   86	   base	   5’	   of	   CDH1	   gene,	   which	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potentiates	   activity	   of	   E-­‐cadherin	   promoter	   in	   epithelial	   but	   inhibits	   promoter	  
activity	  in	  non-­‐epithelial	  cells	  (Behrens	  et	  al.,	  1991).	  Notably,	  the	  inactivation	  of	  the	  
E-­‐box	   in	   mesenchymal	   cells	   induces	   E-­‐cadherin	   promoter	   activity,	   suggesting	   the	  
presence	  of	  an	  E-­‐cadherin	  transcriptional	  repressor	  in	  non-­‐epithelial	  cells.	  Using	  one-­‐
hybrid	   screening	   with	   the	   E-­‐box	   sequence	   as	   bait,	   Cano	   and	   colleagues	   identified	  
Snail	   as	   the	   first	  potent	   transcriptional	   repressor	  of	  E-­‐cadherin	   (Cano	  et	  al.,	   2000).	  
This	  was	  then	  followed	  by	  identification	  and	  characterisation	  of	  δEF1/ZEB1	  (Eger	  et	  
al.,	  2005),	  SIP1/ZEB2	  (Comijn	  et	  al.,	  2001),	  Slug	  (Hajra	  et	  al.,	  2002;	  Bolos	  et	  al.,	  2003)	  
and	   E12/E47	   (Perez-­‐Moreno	   et	   al.,	   2001),	   which	   exert	   their	   transcriptional	  
repression	  activity	  via	  the	  E-­‐box.	  	  
	  
	  
1.1.3.1.2 Endocytic	  regulation	  of	  E-­‐cadherin	  	  
	  
Throughout	  the	   life-­‐span	  of	  an	  E-­‐cadherin	  molecule,	  a	  significant	  amount	  of	  
this	   time	   is	   attributed	   to	   trafficking	   via	   the	   different	   subcellular	   membrane	  
compartments	  (Figure	  1.4).	  	  
	  
Upon	   its	  biosynthesis	   in	   the	  ER,	  E-­‐cadherin	   is	   coupled	   to	  β-­‐catenin	  and	   this	  
association	   is	   crucial	   for	   ER	   exit	   of	   the	   complex	   and	   subsequent	   baso-­‐lateral	  
trafficking	   to	   plasma	   membrane	   via	   the	   trans	   Golgi	   network	   (TGN)	   (Chen	   et	   al.,	  
1999).	   The	   correct	   sorting	   of	   the	   E-­‐cadherin-­‐β-­‐catenin	   complex	   to	   the	   plasma	  
membrane	   is	   dependent	   on	   a	   highly	   conserved	   dileucine	  motif	   at	   the	  membrane	  
proximal	  cytoplasmic	  domain	  (Miranda	  et	  al.,	  2001;	  Miranda	  et	  al.,	  2003).	  Deletion	  
of	   this	   motif	   results	   in	   missorting	   of	   the	   E-­‐cadherin-­‐β-­‐catenin	   complex	   and	  
consequently	  the	  disruption	  of	  cell	  polarity.	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Figure	  1.4.	   Endocytic	   regulation	  of	   E-­‐cadherin.	   (1)	  Upon	   its	  synthesis	  at	   the	  rough	  
endoplasmic	   reticulum	   (ER),	   E-­‐cadherin	   is	   associated	   with	   β-­‐catenin	   and	   this	  
association	  enables	  ER	  exit	  of	  the	  complex,	  and	  subsequent	  trafficking	  to	  the	  plasma	  
membrane	   via	   the	   trans-­‐Golgi	   network	   (TGN).	   At	   the	   plasma	   membrane,	   the	   E-­‐
cadherin-­‐β-­‐catenin	   is	   stabilised	   by	   the	   binding	   of	   p120-­‐catenin	   at	   the	   JMD	   of	   E-­‐
cadherin,	  thereby	  allowing	  assembly	  of	  the	  AJ.	  (3)	  The	  AJ	  is	  a	  dynamic	  structure	  that	  
undergoes	  constitutive	  or	  inducible	  internalisation	  via	  different	  endocytic	  pathways	  
(clathrin-­‐dependent	   or	   –independent	   pathways).	   (4)	   Following	   endocytosis,	   the	   E-­‐
cadherin	   enters	   the	   early	   endosomes,	   and	   is	   later	   either	   (5)	   sorted	   into	   the	   late	  
endosomes/multivesicular	  body	  (MVB)	  for	  subsequent	  degradation	  via	  the	  lysosomal	  
pathway	  or	   is	   (6)	   transported	   to	   the	   recycling	   endosome	   for	   recycling	   back	   to	   the	  
plasma	  membrane.	  	  
	  
?
The	  multiple	  endocytic	  routes	  can	  commit	  E-­‐cadherin	  to	  very	  different	  fates:	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such	   as	   sorting	   and	   recycling	   endosomes	   or	   routing	   to	   late	   endosomes	   for	  
subsequent	   lysosomal	   degradation	   (Bryant	   and	   Stow,	   2004).	   	   Superimposed	   onto	  
these	   possible	   routes	   of	   trafficking	   are	   the	   physiological	   events	   that	   trigger	   E-­‐
cadherin	  internalisation	  in	  the	  first	  place.	  It	  is	  reasonable	  to	  deduce	  that	  a	  particular	  
physiological	   condition	   induces	   E-­‐cadherin	   internalisation	   via	   a	   particular	   uptake	  
route,	  which	  will	   lead	   to	  a	  definite	   fate	  of	  E-­‐cadherin.	  For	  example,	   internalised	  E-­‐
cadherin	   by	  macropinocytosis	   following	   stimulation	  of	   non-­‐confluent	  MCF7	   cells	   is	  
recycled	  back	  to	  the	  plasma	  membrane	  (Bryant	  et	  al.,	  2007).	  While	  such	  deduction	  is	  
plausible,	   there	   are	   reports	   of	   E-­‐cadherin,	   whether	   internalised	   via	   the	   clathrin-­‐
dependent	   or	   independent	   pathways,	   entering	   cellular	   compartment	   positive	   for	  
early	  endosome	  antigen	  1	  (EEA1)	  (Xiao	  et	  al.,	  2003).	  Hence,	  it	  suggests	  that	  the	  fate	  
of	   E-­‐cadherin	   is	   determined	   at	   or	   after	   leaving	   the	   early	   endosomal	   compartment	  
(Yap	   et	   al.,	   2007).	   Early	   endosome	   is	   predominantly	   a	   tubulovesicular	   membrane	  
compartment,	   which	   serves	   as	   a	   major	   platform	   for	   transiting	   plasma	  membrane	  
proteins	  (Williams	  and	  Urbé,	  2007).	  It	  is	  believed	  that	  the	  structure	  and	  components	  
of	   this	   compartment	   undergoes	   progressive	   changes	   and	   eventually	   becomes	   late	  
endosomes	   characterised	   by	   the	   presence	   of	   multiple	   intraluminal	   vesicles.	  
Therefore,	  the	  late	  endosome	  is	  also	  known	  as	  multivesicular	  body	  (MVB).	  The	  MVB	  
eventually	   fuses	   with	   lysosomes	   and	   its	   contents	   are	   therefore	   hydrolytically	  
digested.	   Ubiquitylation	   is	   the	   best-­‐characterised	   sorting	   signal,	   which	   commits	  
membrane	  proteins	  into	  the	  degradative	  MVB	  pathway	  (Clague	  et	  al.,	  2012).	  	  
	  
Ubiquitylation	   of	   E-­‐cadherin	   was	   first	   demonstrated	   in	   MDCK	   cells	   by	  
Birchmeier’s	   group	   (Fujita	   et	   al.,	   2002).	   It	   was	   shown	   that	   the	   tyrosine	  
phosphorylation	   of	   E-­‐cadherin	   by	   vSrc,	   was	   accompanied	   by	   its	   ubiquitylation	   as	  
well,	  and	  the	  consequence	  of	  which	  was	  the	  disassembly	  of	  the	  E-­‐cadherin-­‐catenin	  
complex	   and	   endocytosis	   of	   E-­‐cadherin.	   By	   virtue	   of	   yeast-­‐two-­‐hybrid	   technique,	  
using	  an	  ingeniously	  designed	  chimeric	  protein	  of	  E-­‐cadherin	  and	  active	  Met	  kinase	  
to	  enable	  E-­‐cadherin	  phosphorylation	   in	  yeast,	  Fujita	  and	  colleagues	   identified	  a	  c-­‐
cbl	   like	   really	   interesting	   new	   gene	   (RING)	   E3	   ligase	   and	   named	   it	   Hakai,	   which	  
means	   destruction	   in	   Japanese.	   Hakai	   specifically	   interacts	   with	   tyrosine	  
phosphorylated	   E-­‐cadherin	   and,	   together	   with	   E1	   and	   E2	   ubiquitylating	   enzymes,	  
	   11	  
catalyses	   ubiquitylation	   of	   E-­‐cadherin	   (Figure	   1.5).	   The	   ubiquitylated	   E-­‐cadherin	   is	  
then	  endocytosed	  and	  targeted	  for	  lysosomal	  degradation.	  	  
	  
Figure	  1.5.	  Ubiquitin-­‐dependent	  regulation	  of	  E-­‐cadherin.	  (a)	  Following	  stimulation	  
by	  receptor	  tyrosine	  kinase	  (RTK)	  or	  non-­‐receptor	  tyrosine	  kinase	  (NRTK),	  E-­‐cadherin	  
and	   β-­‐catenin	   are	   phosphorylated,	   leading	   to	   dissolution	   of	   the	   AJ.	   (b)	   The	  
phosphorylated	   E-­‐cadherin	   is	   then	   recognised	   by	   Hakai,	   the	   E3	   ligase,	   which	  
catalyses	   its	   ubiquitylation	   with	   the	   presence	   of	   E1	   and	   E2	   enzymes.	   (c)	   The	  
polyubiquitylated	  E-­‐cadherin	  is	  subsequently	  internalised	  via	  the	  clathrin	  dependent	  
pathway,	   (d)	   while	   the	   polyubiquitylated	   β-­‐catenin	   is	   targeted	   for	   proteasomal	  
degradation.	   The	   internalised	   E-­‐cadherin	   subsequently	   localises	   to	   the	   early	  
endosome,	  where	  its	  fate	  was	  decided	  between	  (e)	  sorting	  to	  the	  late	  endosome	  for	  
lysosomal	   degradation	   or	   (f)	   recycling	   back	   to	   the	   plasma	   membrane	   for	   AJ	  
assembly.	  	  
	  
	   Another	   indication	   of	   ubiquitylation-­‐dependent	   regulation	   of	   E-­‐cadherin	  
involves	   the	  DUB	  Fat	   facet	   in	  mouse	   (FAM),	  also	  known	  as	  USP9X.	  USP9X	  was	   first	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and	   was	   identified	   to	   interact	   with	   and	   stabilise	   β-­‐catenin	   (Taya	   et	   al.,	   1999).	  
Subsequent	   study	   by	  Murray	   et	   al.	   (2004)	   showed	   that	   USP9X	   colocalised	  with	   E-­‐
cadherin	   and	   β-­‐catenin	   at	   multiple	   points	   of	   protein	   trafficking	   in	   subconfluent	  
epithelial	   cells,	   but	   did	   not	   colocalise	   with	   E-­‐cadherin	   and	   β-­‐catenin	   at	   plasma	  
membrane	  upon	  formation	  of	  stable	  AJ	   in	  a	  confluent	   layer	  of	  epithelial	  cells.	  Such	  
association	   was	   confirmed	   biochemically	   too,	   where	   USP9X	   was	   found	   to	   form	   a	  
complex	  with	  E-­‐cadherin	  and	  β-­‐catenin	  in	  a	  Triton	  X-­‐100	  soluble	  fraction	  (E-­‐cadherin-­‐
β-­‐catenin	  complex	  not	  involved	  in	  AJ	  formation	  is	  Triton	  X-­‐100	  soluble)	  and	  the	  DUB	  
was	  not	  found	  in	  a	  Triton	  X-­‐100	  insoluble	  fraction.	  Together	  these	  results	  suggested	  
that	  USP9X	  is	  involved	  in	  the	  trafficking	  of	  the	  E-­‐cadherin-­‐β-­‐catenin	  complex	  in	  their	  
biosynthetic	  pathway	  but	   is	  not	   involved	   in	   their	   regulation	  upon	  AJ	   formation.	  Of	  
note,	   this	   represents	   a	   more	   general	   role	   of	   USP9X	   in	   protein	   trafficking	   as	   it	  
colocalises	  on	  endocytic	  vesicles	  with	  multiple	  other	  proteins,	  such	  as	  alpha	  actinin	  
and	  myosin	  II,	  rather	  than	  a	  specific	  regulatory	  relationship	  between	  USP9X	  and	  the	  
E-­‐cadherin-­‐β-­‐catenin	  complex.	  	  
	  
1.1.3.1.3 Mechanisms	  of	  dysregulation	  of	  E-­‐cadherin	  expression	  and	  cancer	  	  
	  
Given	   the	   pivotal	   roles	   of	   E-­‐cadherin	   in	   tissue	   morphogenesis	   and	  
development,	  it	  is	  no	  surprise	  that	  the	  loss	  or	  dysregulation	  of	  E-­‐cadherin	  expression	  
has	   severe	   pathological	   consequences,	   such	   as	   that	   in	   cancer.	   Birchmeier’s	   group	  
provided	   one	   of	   the	   first	   experimental	   evidence	   that	   induction	   of	   E-­‐cadherin	   loss	  
confers	  epithelial	  cells	  with	  invasive	  properties	  (Behrens	  et	  al.,	  1989).	  	  Subsequently,	  
there	   were	   multiple	   reports	   of	   reversion	   of	   invasive	   to	   benign	   epithelial	   tumour	  
phenotype	  following	  ectopic	  expression	  of	  E-­‐cadherin	  in	  carcinoma	  cells,	  establishing	  
the	   tumour	   suppressive	   role	   of	   E-­‐cadherin	   (Frixen	   et	   al.,	   1991;	   Birchmeier	   and	  
Behrens	   1994;	   Bracke	   et	   al.,	   1996).	   Seminal	   work	   by	   Perl	   and	   colleagues	   in	   1998	  
demonstrated	   a	   causal	   role	   of	   E-­‐cadherin	   loss	   for	   the	   transition	   from	   well-­‐
differentiated	   to	   invasive	   carcinoma	   in	   a	   transgenic	   mice	   model,	   Rip1Tag2,	   for	  
development	   of	   pancreatic	   cancer	   (Perl	   et	   al.,	   1998).	   Notably,	   tumorigenesis	   is	  
arrested	   at	   the	   adenoma	   stage	   in	   cells	   preserving	   E-­‐cadherin	   expression,	  whereas	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expression	   of	   a	   dominant	   negative	  mutant	   of	   E-­‐cadherin	   instigated	   early	   invasion	  
and	  metastasis,	  indicating	  loss	  of	  E-­‐cadherin	  as	  a	  rate-­‐limiting	  step	  in	  carcinogenesis.	  	  	  
	  
	   Oda	  and	  colleagues	  undertook	  one	  of	  the	  first	  efforts	  to	  decipher	  molecular	  
events	  leading	  to	  loss	  of	  E-­‐cadherin	  expression	  (Oda	  et	  al.,	  1994).	  They	  analysed	  10	  
human	  cancer	  cell	  lines	  which	  exhibited	  loose	  cell-­‐cell	  adhesion	  and	  this	  early	  work	  
already	  hinted	  at	  the	  multiple	  mechanisms	  by	  which	  E-­‐cadherin	  can	  be	  dysregulated.	  
Out	  of	  the	  10	  human	  cell	  lines,	  4	  of	  them	  expressed	  high	  level	  of	  wildtype	  E-­‐cadherin	  
mRNA	   and	   protein,	   suggesting	   an	   aberration	   in	   E-­‐cadherin	   regulation	   or	   in	   other	  
components	  of	  cell	  adhesion	  system.	  (Indeed,	  mutations	  in	  α-­‐catenin	  (Shimoyama	  et	  
al.,	  1992;	  Oda	  et	  al.,	  1993)	  and	  β-­‐catenin	  (Oyama	  et	  al.,	  1994)	  have	  been	  implicated	  
in	  disruption	  of	  cell	  adhesion).	  Another	  4	  did	  not	  express	  E-­‐cadherin,	   indicating	  the	  
occurence	  of	   gene	   silencing	   event.	   In	   the	   other	   2,	  mutations	  were	   found	   at	   exon-­‐
intron	   junctions,	  which	   resulted	   in	   aberrant	   splicing	   and	   presence	   of	   4	   transcripts	  
with	   different	   inserts.	   By	   genetic	   profiling	   of	   familial	   gastric	   cancer,	  Guilford	  et	   al.	  
identified	  germline	  mutations	  in	  E-­‐cadherin,	  which	  were	  responsible	  for	  diffuse-­‐type	  
gastric	   cancer	   (Guilford	   et	   al.,	   1998).	   This	   firmly	   established	   the	   key	   role	   of	   E-­‐
cadherin	  mutations	  in	  cancer	  development	  (Birchmeier	  2005).	  	  
	  
	   In	  addition	  to	  genetic	  aberration,	  loss	  of	  E-­‐cadherin	  expression	  also	  happens	  
as	  a	  consequence	  of	  epigenetic	  alterations	  (Baranwal	  and	  Alahari,	  2009).	  Yoshiura	  et	  
al.	   revealed	   that	   the	   promoter	   region	   of	   the	   E-­‐cadherin	   gene	   is	   hypermethylated	  
around	  CpG	  islands	   in	  some	  E-­‐cadherin-­‐negative	  cancer	  cell	   lines,	  thereby	  resulting	  
in	   the	   silencing	   of	   its	   expression	   (Yoshiura	   et	   al.,	   1995).	   Such	   a	   mechanism	   of	  
silencing	   has	   also	   been	   observed	   with	   the	   tumour	   suppressors,	   Rb	   (Greger	   et	   al.,	  
1989;	   Sakai	   et	   al.,	   1991)	   and	   von	   hippel	   lindau	   (VHL)	   (Herman	   et	   al.,	   1994).	  	  
Transcriptional	   repression	   represents	   another	   mode	   of	   epigenetic	   regulation	   that	  
can	   suppress	  E-­‐cadherin	  expression	   (see	   section	  1.1.2.1.1).	  Multiple	   transcriptional	  
repressors	  have	  already	  been	  implicated	  in	  cancer	  development	  (van	  Roy	  and	  Berx,	  
2008).	   A	   strong	   correlation	   was	   obtained	   between	   overexpression	   of	   Snail	  
transcription	   factors	   and	   reduced	   E-­‐cadherin	   expression	   in	   invasive	   ductal	   breast	  
carcinoma	   (Cheng	   et	   al.,	   2001).	   In	   line	   with	   this,	   inhibition	   of	   Snail	   function	   in	   E-­‐
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cadherin-­‐negative	   epithelial	   tumour	   cells	   restores	   E-­‐cadherin	   expression	   (Battle	   et	  
al.,	  2000).	  Different	  gastric	  cancers	  subtypes	  have	  also	  been	  shown	  to	  be	  associated	  
with	  different	  E-­‐cadherin	  transcription	  repressors	  (Rosivatz	  et	  al.,	  2002).	  For	  diffuse	  
gastric	   cancers,	   arising	   due	   to	   inactivating	   mutation	   of	   E-­‐cadherin,	   a	   strong	  
correlation	   was	   observed	   between	   Snail	   upregulation	   and	   E-­‐cadherin	   loss.	  
Interestingly,	  Snail	  is	  not	  upregulated	  in	  intestinal	  type	  gastric	  cancer.	  Instead,	  these	  
gastric	   cancer	   samples	  are	  associated	  with	  high	  expression	   level	  of	   SIP1/ZEB2.	  The	  
differential	   expression	   level	   of	   the	   different	   transcription	   repressors	   in	   different	  
gastric	  cancer	  subtypes	  therefore	  suggests	  that	  they	  are	  not	  functionally	  redundant	  
and	  hence	  play	  different	  roles	  in	  tumour	  development.	  Twist,	  a	  basic	  helix-­‐loop-­‐helix	  
(bHLH)	   transcription	   factor,	   which	   is	   capable	   of	   repressing	   E-­‐cadherin	   expression,	  
was	  found	  highly	  expressed	  in	  metastatic	  breast	  cancer	  samples	  (Yang	  et	  al.,	  2004).	  	  
	  
	   It	   is,	   perhaps,	   no	   coincidence	   that	   these	   transcription	   factors	   are	   also	   key	  
players	   in	   inducing	   the	   transcriptional	   program	   required	   for	   epithelial-­‐to-­‐
mesenchymal	   transition	   (EMT)	   (Huber	   et	   al.,	   2005;	   Yang	   and	   Weinberg,	   2008).	  
Morphologically,	   as	   its	   name	   implies,	   EMT	   refers	   to	   a	   cellular	   process	   by	   which	  
epithelial	   cells	   undergo	   transformation	   to	   shed	   epithelial	   features	   and	   assume	  
mesenchymal	  characteristics,	  such	  as	  enhanced	  migratory	  capacity,	  invasiveness	  and	  
heightened	  resistance	  to	  apoptosis	  (Kalluri	  and	  Neilson,	  2003).	  The	  concept	  of	  EMT	  
was	  firmly	  established	  by	  a	  series	  of	  elegant	  experiments	  carried	  out	  by	  Greenburg	  
and	   Hay,	   which	   demonstrated	   that	   epithelial	   cells	   in	   culture	   may	   acquire	  
mesenchymal	  characteristics	  (Greenburg	  and	  Hay,	  1982;	  Greenburg	  and	  Hay,	  1986;	  
Greenburg	   and	   Hay,	   1988).	   	   It	   is	   a	   cellular	   programme	   that	   is	   induced	   at	   several	  
morphogenetic	   stages	   of	   embryonic	   development	   and	   during	   wound	   healing	  
(Weinberg,	   2007).	   	   It	   is	  widely	   accepted	   now	   that	   this	   physiological	   programme	   is	  
hijacked	  by	  cancer	  cells	  to	  break	  away	  from	  cell-­‐cell	  adhesion	  and	  acquire	  motility,	  
i.e.	   to	   become	   metastatic	   (Thiery	   and	   Sleeman,	   2006;	   Hugo	   et	   al.,	   2007).	   In	  
agreement	  with	  the	  E-­‐cadherin-­‐repression	  role	  of	  these	  transcriptional	  factors,	   loss	  
of	  E-­‐cadherin	  is	  considered	  a	  hallmark	  of	  EMT	  (Weinberg,	  2007;	  Yang	  and	  Weinberg,	  
2008).	  Stoker	  and	  Perryman	  provided	  the	  first	  evidence	  that	  EMT	  can	  be	  elicited	  by	  
growth	   factor	   signalling	   (Stoker	   and	   Perryman,	   1985).	   They	   discovered	   that	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incubation	   of	   polarised	  MDCK	   epithelial	   cells	   with	   conditioned	   fibroblast	   medium	  
induced	   scattering	   of	   the	   cells,	  whereby	   the	   cells	  were	   detached	   from	   each	   other	  
and	   acquired	   fibroblastic	   features,	   and	   subsequently	   isolated	   the	   “scatter	   factor”,	  
which	   is	   also	   known	   as	   hepatocyte	   growth	   factor	   (HGF).	   This	   was	   followed	   by	  
discovery	   of	   transforming	   growth	   factor-­‐β	   (TGF-­‐β),	   a	   serine/threonine	   receptor	  
kinase,	  as	  a	  potent	  inducer	  of	  E-­‐cadherin	  repression	  and	  EMT	  in	  mammary	  epithelial	  
cells	   (Miettinen	   et	   al.,	   1994).	  With	   the	   establishment	   of	   EMT	   as	   a	   key	   process	   in	  
tumour	   progression,	   the	   immense	   research	   interest	   drawn	   towards	   this	   cellular	  
program	  has	  elucidated	  other	  signalling	  pathways	  that	  are	  capable	  of	  eliciting	  EMT,	  
such	   as	   canonical	  Wnt	   signalling,	   Hedgehog	   signalling,	   Notch	   signalling,	   epidermal	  
growth	   factor	   receptor	   (Siegfried	   et	   al.,	   1992),	   signalling,	   platelet-­‐derived	   growth	  
factor	  receptor	  (PDGFR)	  signalling	  and	  nuclear	  factor	  kappa-­‐light-­‐chain-­‐enhancer	  of	  
activated	  B	  cell	  (NF-­‐κB)	  signalling	  (Huber	  et	  al.,	  2005;	  Thiery,	  2006).	  These	  pathways	  
can	  be	  activated	  by	   the	  presence	  of	   their	   specific	   ligands	  or	   regulated	  by	  crosstalk	  
among	  each	  other.	  Notably,	  these	  pathways	  have	  been	  shown	  to	  induce	  EMT	  via	  the	  
E-­‐cadherin	   repressors,	   Snail,	   Slug,	   SIP1/ZEB2	   and	   Twist	   (Figure	   1.6)	   (Huber	   et	   al.,	  
2005;	   Yang	   and	   Weinberg,	   2008).	   Therefore,	   the	   aberrant	   signalling	   of	   these	  
pathways	  can	  all	  lead	  to	  loss	  of	  E-­‐cadherin	  expression.	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Figure	   1.6.	   Silencing	   of	   E-­‐cadherin	   expression	   downstream	   of	   various	   signalling	  
pathway	   involved	   in	   epithelial-­‐to-­‐mesenchymal	   transition	   (EMT).	   Activation	   of	  
receptor	  tyrosine	  kinase	  (RTK),	  Wnt	  signalling,	  TGFβR	  and	  Notch	  signalling	  pathways	  
induces	   the	   transcriptional	   repressors,	   including	   Snail,	   Slug,	   Twist	   and	   SIP1,	   which	  
repress	  E-­‐cadherin	  expression.	  The	  	  loss	  of	  E-­‐cadherin	  is	  considered	  a	  hallmark	  and	  a	  
pre-­‐requisite	  for	  induction	  of	  a	  full	  EMT	  program.	  	  
	  
	  
	   Beside	   the	   genetic	   and	   epigenetic	   mechanisms	   by	   which	   E-­‐cadherin	  
expression	   is	   silenced,	   dysregulation	   at	   the	   post-­‐translational	   level	   can	   also	  
contribute	   to	   disruption	   of	   normal	   E-­‐cadherin	   function	   in	   pathological	   conditions	  
such	  as	  cancer	  (van	  Roy	  and	  Berx,	  2008).	  The	  activation	  of	  receptor	  tyrosine	  kinases,	  
such	  as	  HGF	  and	  the	  subsequent	  activation	  of	  its	  downstream	  effector	  Src,	  results	  in	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al.,	   2002).	   This	   is	   followed	   by	   recruitment	   of	   Hakai,	   a	   ubiquitin	   ligase,	   which	  
specifically	  interacts	  with	  and	  ubiquitylates	  the	  cytoplasmic	  tail	  of	  phosphorylated	  E-­‐
cadherin,	   thereby	   promoting	   its	   internalisation	   and	   subsequent	   clearance	   via	   the	  
lysosomal	   pathway.	   Besides,	   the	   stability	   of	   AJ	   complex	   is	   also	   determined	   by	   its	  
cytoplasmic	  tail	  binding	  partner	  –	  p120-­‐catenin	  and	  β-­‐catenin.	  Reynolds’	  laboratory	  
has	   demonstrated	   that	   p120-­‐catenin	   plays	   a	   crucial	   role	   in	   regulating	   E-­‐cadherin	  
stability,	  where	   the	   siRNA	  depletion	  of	   p120-­‐catenin	   is	   accompanied	  by	   significant	  
loss	   of	   E-­‐cadherin	   protein,	   but	   not	   mRNA	   (Davis	   et	   al.,	   2003).	   Downregulation	   of	  
p120-­‐catenin	  has	  been	  reported	  in	  multiple	  cancer	  types,	   including	  colon,	  prostate,	  
breast	  and	   lung	  carcinoma	  (Thoreson	  and	  Reynolds,	  2002;	  Reynolds	  and	  Carnahan,	  
2004).	   Therefore,	   it	   is	   possible	   that,	   at	   least	   for	   a	   subset	   of	   these	   cancers,	   the	   E-­‐
cadherin	   deficiency	   occurs	   as	   a	   result	   of	   the	   decreased	   level	   of	   p120-­‐catenin.	   In	  
addition,	  cleavage	  of	  E-­‐cadherin	  ectodomain	  by	  matrix	  metalloproteases	   (MMP)	  or	  
the	   serine	   proteases	   kallikrein,	   represents	   another	   way	   through	   which	   E-­‐cadherin	  
function	  is	   inhibited	  (De	  Wever	  et	  al.,	  2007;	  van	  Roy	  and	  Berx,	  2008).	  For	  example,	  
overexpression	  of	  kallikrein	  6	  (klk6)	  in	  pancreatic	  adenocarcinomas	  enhances	  release	  
of	   soluble	   E-­‐cadherin	   fragment	   (Klucky	   et	   al.,	   2007),	   which	   may	   functions	   as	  
pseudoligands	  that	  interfere	  with	  normal	  E-­‐cadherin	  interaction,	  thereby	  promoting	  
invasion	  (De	  Wever	  et	  al.,	  2007;	  Klucky	  et	  al.,	  2007).	  	  
	  
	  
1.1.2.2	  	  	  	  	  	  	  β-­‐catenin	  	  
	  
β-­‐catenin	   was	   first	   identified	   in	   Drosophila	   as	   a	   product	   of	   the	   segment	  
polarity	   gene	   Armadillo,	   which	   when	   mutated,	   resulted	   in	   deletion	   of	   a	   defined	  
fraction	   of	   the	   pattern	   in	   each	   segment	   (Nusslein-­‐Volhard	   and	  Wieschaus,	   1980).	  
Subsequently,	   together	  with	   its	   close	   relative	  plakoglobin,	  β-­‐catenin	  was	   shown	   to	  
be	  component	  of	  adherens	   junctions	  and	  form	  a	  direct	   interaction	  with	  E-­‐cadherin	  
(Ozawa	  et	  al.,	   1989;	  McCrea	  et	  al.,	   1991).	  β-­‐catenin	   is	   a	  781	  aa	   long	  protein,	  with	  
approximately	  130	  aa	  on	  its	  N-­‐terminus,	  followed	  by	  a	  central	  region	  of	  about	  550aa	  
that	   contains	   12	   armadillo	   repeats	   and	   another	   100	   aa	   on	   its	   C-­‐terminus	   (Figure	  
1.7A)	  (Huber	  et	  al.,	  1997).	  The	  armadillo	  repeat	  represents	  an	  imperfect	  repeat	  of	  a	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42	  aa	  motif,	  which	  was	  originally	   defined	   in	   the	  Drosophila	   segment	  polarity	   gene	  
Armadillo	  (Riggleman	  et	  al.,	  1989)	  and	  is	  capable	  of	  forming	  a	  triple	  α-­‐helix	  (Huber	  et	  
al.,	   1997).	   The	   12	   repeating	   triple	   α-­‐helices	   altogether	   form	   a	   right-­‐handed	   α-­‐
solenoid	   protein	   structure,	   where	   the	   polypeptide	   chain	   forms	   a	   continuous	  
superhelix	   (Figure	  1.7B)	   (Kobe	  and	  Kajava,	  2000).	  The	  armadillo	  superhelix	   forms	  a	  
positively	   charged	   shallow	   groove	   and	   allows	   for	   binding	  with	  multiple	   interacting	  
partners,	  such	  as	  E-­‐cadherin	  (Hulsken	  et	  al.,	  1994),	  the	  scaffolding	  protein	  axin	  (Xing	  
et	   al.,	   2003),	   T-­‐cell	   factor/Lymphoid	  enhancer	   factor	   (TCF/LEF)	   family	   transcription	  
factors	   (Behrens	   et	   al.,	   1996)	   and	   adenomatous	   polyposis	   coli	   (APC)	   tumour	  
suppressor	   protein	   (Hulsken	   et	   al.,	   1994;	   Rubinfeld	   et	   al.,	   1995).	   	   Notably,	   the	  
binding	  of	  β-­‐catenin	  with	  the	  different	  partners	  is	  mutually	  exclusive	  and	  hence	  the	  
binding	  partner	  dictates	   the	   function	  of	  β-­‐catenin	   (Hulsken	  et	  al.,	  1994;	  Daugherty	  
and	  Gottardi,	   2007).	   At	   the	  N-­‐terminus	   of	  β-­‐catenin,	   there	   is	   a	   cluster	   of	   4	   serine	  
(S)/threonine	   (T)	   residues	   (S33,	   S37,	   T41	   and	   S45),	   which	   are	   conserved	   from	  
Drosophila	   to	  human	   (Peifer	  et	  al.,	  1994).	  The	  sequential	  phosphorylation	  of	   these	  
S/T	   residues,	   first	   a	   priming	   phosphorylation	   of	   S45	   by	   CK1,	   followed	   by	  
phosphorylation	  of	  S33,	  S37	  and	  T41	  by	  GSK3β, alters	  the	  stability	  of	  β-­‐catenin	  (Liu	  
et	   al.,	   2002).	   	   The	   phosphorylated	   S33	   and	   S37	   residues	   allow	   recognition	   of	   β-­‐
catenin	   by	   the	   β-­‐transduction	   repeat	   containing	   protein	   (βTrCP)	   E3-­‐ligase,	   which	  
ubiquitylates	   β-­‐catenin	   and	   earmarks	   it	   for	   proteasomal	   degradation	   (Hart	   et	   al.,	  
1999).	   The	   C-­‐terminus	   of	   β-­‐catenin	   represents	   a	   transactivation	   domain,	   which	  
allows	  transcriptional	  activation	  when	  β-­‐catenin	   is	  bound	  to	  TCF/LEF1	  transcription	  
















Figure	  1.7.	  β-­‐catenin	  structure.	   (a)	  Domain	  architecture	  of	  β-­‐catenin.	  β-­‐catenin	  is	  
characterised	   by	   the	   12-­‐armadillo	   repeats	   at	   the	   centre	   of	   the	   protein.	   Tyrosine	  
residues	  (Y142,	  Y489	  and	  Y654)	  in	  the	  armadillo	  repeats	  which	  disrupts	  E-­‐cadherin-­‐β-­‐
catenin	   interaction	   upon	   phosphorylation	   are	   shown.	   The	   highly	   conserved	  
consensus	  motif	  for	  GSK3β	  phosphorylation	  near	  the	  N-­‐terminal	  end	  is	  shown,	  with	  
the	  Serine/Threonine	  phosphorylation	  sites	  highlighted	  in	  bold.	  	  The	  C-­‐terminus	  of	  β-­‐
catenin	   is	   involved	   in	   transcriptional	   activation	   upon	   binding	   with	   TCF/LEF1.	   The	  
binding	  sites	   for	  different	  β-­‐catenin	   interacting	  partners,	  α-­‐catenin,	  axin,	  TCF/LEF1,	  
APC	  and	  E-­‐cadherin	  are	  marked	  by	  the	  dark	  lines.	  (b)	  Crystal	  structure	  of	  armadillo	  
repeat	  of	  β-­‐catenin.	  Each	  armadillo	  repeat	  folds	  into	  a	  triple-­‐helix	  structure	  and	  the	  
12	   armadillo	   repeats	   of	   together	   form	  a	   superhelix,	  with	   a	   shallow	   grove	   to	   allow	  
binding	   of	   the	   β-­‐catenin	   interacting	   partners.	   	   The	   structure	   was	   retrieved	   from	  
Research	   Collaboratory	   for	   Structural	   Bioinformatics	   Protein	   Data	   Bank	   (PBD	   ID	   =	  
2BCT).	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1.1.2.2.1	   Cell	  adhesion	  function	  of	  β-­‐catenin	  
	  
As	  described	  at	  the	  beginning	  of	  Section	  1.1.2,	  β-­‐catenin	  is	  a	  core	  component	  
of	  the	  AJ.	  It	  associates	  with	  E-­‐cadherin	  at	  the	  ER	  and	  this	  interaction	  is	  a	  prerequisite	  
for	   subsequent	   transport	   of	   the	   E-­‐cadherin-­‐β-­‐catenin	   complex	   to	   the	   plasma	  
membrane	  (Chen	  et	  al.,	  1999).	  At	  the	  AJ,	  it	  provides	  a	  link	  between	  E-­‐cadherin	  and	  
α-­‐catenin,	  and	  its	  stable	  association	  with	  E-­‐cadherin	  at	  the	  plasma	  membrane	  is	  also	  
important	   for	   the	  maintenance	  of	   cell	   adhesion	   (Gloushankova,	   2008).	  Amino	  acid	  
residues	   625-­‐723	   of	   mature	   E-­‐cadherin	   interact	   across	   the	   entire	   superhelix	  
consisting	  of	  12	  Armadillo	   repeats	   (Huber	  and	  Weis,	  2001).	  As	  suggested	  by	  Huber	  
and	  Weis,	  this	  extended	  interface	  allows	  “multiple,	  quasi-­‐independent	  interactions”	  
that	   “can	   be	   regulated	   independently,	   enabling	   combinatorial	   regulation	   of	   the	  
interaction	  and	  the	  integration	  of	  multiple	  input	  signals”.	  	  
	  
The	   interaction	  between	  E-­‐cadherin	   and	  β-­‐catenin	   is	   very	  much	  dependent	  
upon	  the	  phosphorylation	  status	  of	  the	  two	  proteins	  (Daugherty	  and	  Gottardi,	  2007).	  
In	  vitro	  phosphorylation	  of	  the	  cytoplasmic	  tail	  of	  E-­‐cadherin	  at	  S838,	  S840	  and	  S846	  
generates	  more	  molecular	  contacts	  on	  the	  binding	  surfaces,	  thereby	  enhancing	  the	  
affinity	  of	  β-­‐catenin	   for	  E-­‐cadherin	  by	  300-­‐fold	   (Huber	  and	  Weis,	  2001;	  Choi	  et	  al.,	  
2006).	  However,	  the	  in	  vivo	  kinases	  responsible	  for	  such	  phosphorylation	  remain	  to	  
be	  elucidated	  (Daugherty	  and	  Gottardi,	  2007).	  On	  the	  other	  hand,	  phosphorylation	  
of	   S844	   by	   Casein	   Kinase	   1	   (CK1)	   weakens	   β-­‐catenin	   binding	   to	   E-­‐cadherin	   and	  
promotes	  E-­‐cadherin	  internalisation	  (Dupre-­‐Crochet	  et	  al.,	  2007).	  	  	  
	  
There	  are	  3	  conserved	  tyrosine	  (Y)	  residues	  in	  β-­‐catenin	  at	  the	  E-­‐cadherin-­‐β-­‐
catenin	  interface,	  namely	  Y142,	  Y489	  and	  Y654	  (Lilien	  and	  Balsamo,	  2005).	  Phospho-­‐
regulation	   of	   these	   residues	   represents	   a	  mechanism	   by	  which	   integrity	   of	   the	   AJ	  
complex	   is	   regulated.	   Y142	   is	   located	   within	   the	   α-­‐catenin	   binding	   region	   of	   β-­‐
catenin	   (aa	   118	   –	   149)	   and	   its	   phosphorylation	   disrupts	   interaction	   between	   β-­‐
catenin	  and	  α-­‐catenin,	  followed	  by	  loss	  of	  cell-­‐cell	  adhesion	  (Piedra	  et	  al.,	  2003).	  The	  
tyrosine	   kinases	   targeting	   Y142	   include	   c-­‐Met	   (Brembeck	   et	   al.,	   2004),	   Fyn	   and	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activated	   Fer	   kinases	   (Piedra	   et	   al.,	   2003).	   Phosphorylation	   of	   Y654,	   in	   the	   12th	  
Armadillo	  repeat,	  by	  EGFR	  or	  Src	  resulted	  in	  a	  6-­‐fold	  decrease	  in	  affinity	  with	  which	  
β-­‐catenin	   binds	   E-­‐cadherin	   (Huber	   and	   Weis,	   2001).	   This	   is	   because	   the	  
phosphorylated	   Y654	   clashes	   with	   a	   key	   aspartate	   residue	   on	   E-­‐cadherin.	  
Phosphorylation	  of	  Y489	  by	  the	  Abelson	  (Abl)	  kinase	  has	  been	  shown	  to	  disrupt	  N-­‐
cadherin/β-­‐catenin	   interaction	   (Rhee	   et	   al.,	   2002).	   Therefore,	   phosphorylation	   of	  
Y489	  may	  disrupt	  E-­‐cadherin/β-­‐catenin	  association	  as	  well.	  	  	  
	  
1.1.2.2.2	   β-­‐catenin	  –	  at	  the	  heart	  of	  canonical	  Wnt	  signalling	  	  
	  
β-­‐catenin	   was	   first	   recognised	   for	   its	   cell	   adhesive	   function	   (Ozawa	   et	   al.,	  
1989).	  The	  first	  hint	  of	   its	  signalling	  function	  came	  only	  when	  it	  was	   identified	  as	  a	  
mammalian	   homologue	   of	   armadillo,	   a	   segment	   polarity	   gene	   involved	   in	   the	  
wingless	  signalling	  pathway,	  which	  is	  crucial	  for	  development	  of	  Drosophila	  (McCrea	  
et	  al.,	  1991).	  Mutations	  of	  armadillo	  and	  other	  genes	  including	  wingless,	  dishevelled,	  
shaggy/zeste-­‐white	  3	   (homologue	  of	  GSK3β)	   all	   resulted	   in	   cuticle	  abnormalities	   in	  
the	  embryo	  of	  Drosophila	  (Nusslein-­‐Volhard	  and	  Wieschaus,	  1980).	  Multiple	  epistatic	  
analyses	   carried	   out	   to	   assess	   cuticle	   structure	   in	   double	  mutants	   of	   these	   genes	  
revealed	   that	   these	   genes	   are	   core	   components	   of	   a	   new	   signal	   transduction	  
pathway	  –	  Wnt	  signalling	  (Siegfried	  et	  al.,	  1992;	  Noordermeer	  et	  al.,	  1994;	  Peifer	  et	  
al.,	   1994).	   The	   Wnt	   signalling	   pathway	   plays	   fundamental	   roles	   in	   regulating	   cell	  
proliferation,	  cell	  polarity	  and	  determining	  cell	  fate	  during	  cellular	  processes	  such	  as	  
metazoan	  development,	   tissue	  homeostasis	   and	   cancer	   (Clevers,	   2006;	  Macdonald	  
et	  al.,	  2009;	  Mosimann	  et	  al.,	  2009).	  	  
	  
In	  human,	  there	  are	  12	  subfamilies	  of	  secreted	  Wnt	  proteins	  and	  a	  total	  of	  20	  
members	  (Clevers,	  2006).	  There	  are	  three	  different	  pathways	  known	  to	  be	  triggered	  
upon	  Wnt	   receptor	   activation,	   namely	   the	   canonical	  Wnt	   signalling	   pathway,	   non-­‐
canonical	   planar	   cell	   polarity	   (PCP)	   pathway	   and	   the	   Wnt/Ca2+	   pathway,	   among	  
which	   the	   former	   is	   most	   well-­‐characterised.	   β-­‐catenin	   is	   the	   key	   effector	   of	   the	  
canonical	  Wnt	  signalling	  pathway	  and	  regulation	  of	  its	  expression	  level	  is	  central	  to	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the	  signalling	  events	  triggered	  upon	  activation	  of	  the	  pathway	  (Morin,	  1999).	  In	  the	  
absence	   of	   Wnt	   ligand,	   β-­‐catenin	   is	   continually	   synthesised	   and	   is	   bound	   to	   a	  
“destruction	  complex”	  consisting	  of	  axin,	  APC,	  GSK3β	  and	  CK1	  (reviewed	  in	  Clevers,	  
2006;	  Mosimann,	  2009).	  In	  this	  complex,	  Axin	  is	  the	  scaffolding	  protein	  with	  specific	  
binding	   sites	   for	   β-­‐catenin,	   CK1,	   GSK3β	   and	   APC	   (Daugherty	   and	   Gottardi,	   2007).	  
Upon	  binding	  of	  β-­‐catenin	  to	  the	  “destruction	  complex”,	  CK1	  first	  phosphorylates	  β-­‐
catenin	   at	   its	   S45	   and	   this	   priming	   phosphorylation	   then	   enables	   subsequent	  
phosphorylation	  of	   S33,	   S37	  and	  T41	  by	  GSK3β	   (Liu	  et	  al.,	   2002).	   The	  N-­‐terminally	  
phosphorylated	   β-­‐catenin	   is	   then	   recognised	   by	   the	   βTrCP	   E3	   ligase,	   which	  
ubiquitylates	  it	  and	  targets	  it	  for	  proteasomal	  degradation	  (Hart	  et	  al.,	  1999).	  	  
	  
	   When	  Wnt	  ligand	  is	  present	  and	  binds	  to	  the	  seven	  transmembrane	  domain	  
receptor	   Frizzled	   and	   the	   co-­‐receptor,	   low	   density	   lipoprotein	   receptor-­‐related	  
protein	   5	   or	   6	   (LRP5/6),	   the	   LRP5/6	   becomes	   phosphorylated	   by	   CK1	   and	   GSK3β 	  
(Figure	  1.8)	  (Davidson	  et	  al.,	  2005;	  Zeng	  et	  al.,	  2005)	  and	  the	  cytoplasmic	  dishevelled	  
(Dvl)	   is	  recruited	  to	  Frizzled,	  where	   it	  polymerises	  with	  other	  Dvl	   (Bilic	  et	  al.,	  2007;	  
Schwarz-­‐Romond	  et	  al.,	  2007).	  The	  phosphorylation	  of	  LRP5/6	  and	  polymerisation	  of	  
Dvl	  at	  the	  receptor	  complex	  allows	  efficient	  recruitment	  of	  Axin,	  thereby	  preventing	  
assembly	   of	   the	   destruction	   complex.	   As	   a	   result,	  β-­‐catenin	   is	   not	   phosphorylated	  
and	   ubiquitylated,	   therefore	   not	   degraded.	   The	   accumulating	   hypophosphorylated	  
form	  of	  β-­‐catenin	  then	  translocates	  into	  the	  nucleus	  (Henderson	  and	  Fagotto,	  2002)	  
and	   interacts	   with	   the	   TCF/LEF1	   family	   proteins	   to	   form	   a	   bipartite	   transcription	  
complex,	  which	  interacts	  with	  other	  co-­‐activators	  such	  as	  BCL9,	  Pygopus	  and	  CREB-­‐
binding	   protein	   (CBP)	   (reviewed	   in	   Klaus	   and	   Birchmeier,	   2008)	   and	   initiates	  
transcription	  of	  β-­‐catenin	  target	  genes	  (Behrens,	  1996;	  Mosimann	  et	  al.,	  2009).	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Figure	   1.8.	   Wnt	   signalling	   pathway.	   In	   the	   absence	   of	   Wnt	   ligands,	   β-­‐catenin	   is	  
bound	  by	   the	  destruction	  complex	  consisting	  of	  GSK3β,	  Casein	  kinase	  1	   (CK1),	  APC	  
and	  Axin.	  The	  GSK3β	  and	  CK1	  phosphorylates	  β-­‐catenin	  on	   its	  N-­‐terminus,	  and	  the	  
phosphorylated	  β-­‐catenin	  is	  then	  targeted	  by	  the	  SCF-­‐βTrCP	  ubiquitin	  ligase	  complex	  
for	  polyubiquitylation	  and	  is	  subjected	  to	  proteasomal	  degradation.	  In	  the	  presence	  
of	   Wnt	   ligand,	   the	   desctruction	   complex	   is	   disassembled	   due	   to	   sequestration	   of	  
Axin	   to	   the	   plasma	   membrane,	   which	   is	   partly	   mediated	   by	   the	   multimerised-­‐
Dishevelled	   associated	   with	   the	   	   Frizzled	   receptor.	   β-­‐catenin	   is	   therefore	   not	  
phosphorylated	   and	   not	   targeted	   for	   polyubiquitylation	   and	   proteasomal	  
degradation,	   and	   becomes	   stabilised	   in	   the	   cytoplasm.	   The	   accumulating	  
hypophosphorylated	  β-­‐catenin	   then	   translocates	   to	   the	  nucleus	   and	   interacts	  with	  




1.1.2.2.3	   β-­‐catenin/Wnt	  Signaling	  and	  cancer	  
	  
Aberrant	  regulation	  of	  cell	  signalling	  pathway,	  normally	  involved	  in	  control	  of	  
cell	  proliferation,	  motility	  and	  survival,	  has	  become	  a	  common	  mechanism	  by	  which	  
cancers	  develop	  (Martin	  2003).	  Wnt	  signalling	  is	  no	  exception	  to	  this	  general	  theme.	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The	   first	   link	   of	   Wnt	   signalling	   and	   cancer	   was	   demonstrated	   when	   the	   tumour	  
suppressor	  gene	  APC,	   first	   found	  mutated	   in	   familial	   adenomatous	  polyposis	   (FAP)	  
(Groden	   et	   al.,	   1991;	   Nishisho	   et	   al.,	   1991),	   was	   found	   interacting	   with	   β-­‐catenin	  
(Rubinfeld	   et	   al.,	   1993).	   As	   mentioned	   in	   the	   previous	   section,	   APC	   is	   a	   core	  
component	  of	  the	  β-­‐catenin	  destruction	  complex.	  The	  mutational	  inactivation	  of	  this	  
gene	   therefore	   leads	   to	   inappropriate	   stabilisation	   of	   β-­‐catenin	   (Rubinfeld	   et	   al.,	  
1996),	   its	   translocation	   to	   the	   nucleus	   and	   subsequent	   activation	   of	   the	   genetic	  
program	   elicited	   by	   the	   β-­‐catenin/TCF	   transcription	   complex	   (Reya	   and	   Clevers,	  
2005;	  Brembeck	  et	  al.,	  2006).	  In	  fact,	  nuclear	  accumulation	  of	  β-­‐catenin	  is	  regarded	  
as	   the	   hallmark	   of	   canonical	   Wnt	   pathway	   activation	   (Giles	   et	   al.,	   2003)	   and	  
persistence	  of	  β-­‐catenin/TCF	  complex	   forms	  the	  basis	  of	   tumour	   transformation	  of	  
epithelial	  cells	  (Clevers	  2004;	  Reya	  and	  Clevers,	  2005).	  	  
	  
Multiple	   components	   of	   the	  Wnt	   signalling	   pathway	   are	   found	  mutated	   in	  
cancers	   (Polakis	   2000;	   Brembeck	   et	   al.,	   2006).	   Regardless	   of	   the	   nature	   of	   the	  
mutations	   or	   identity	   of	   the	   mutated	   components,	   the	   end	   effect	   is	   β-­‐catenin	  	  
stabilisation.	  In	  addition	  to	  mutations	  in	  hereditary	  cancer	  like	  FAP,	  APC	  is	  also	  found	  
mutated	  in	  80%	  of	  sporadic	  colorectal	  cancers	  (Kinzler	  and	  Vogelstein,	  1996).	  	  Most	  
of	  these	  mutations	  result	  in	  truncation	  of	  APC,	  which	  diminishes	  its	  ability	  to	  bind	  β-­‐
catenin	  or	  Axin	  and	  hence	  β-­‐catenin	  is	  stabilised	  (Polakis,	  2000).	  However,	  mutation	  
of	  APC	  alone	  is	  not	  sufficient	  to	  drive	  tumour	  progression,	  but	  additional	  mutations	  
in	   other	   pathway	   components,	   such	   as	   oncogenic	   activation	   of	   Ras	   and	   loss-­‐of-­‐
function	  mutation	  of	  p53,	  are	  also	  required	  (Vogelstein	  and	  Kinzler,	  1993;	  Vogelstein	  
and	  Kinzler,	   2004).	  Mutations	   in	   the	  N-­‐terminal	   regulatory	   region	  of	  β-­‐catenin	   are	  
also	  responsible	  for	  activation	  of	  Wnt	  signalling	  pathway	  in	  a	  wide	  range	  of	  cancers,	  
including	   colon	   cancer,	   melanoma,	   prostate	   cancer,	   hepatocellular	   carcinoma,	  
ovarian	   cancer,	   endometrial	   carcinomas,	   medulloblastomas	   and	   pilomatricomas	  
(reviewed	   in	   Morin,	   1999).	   Figure	   1.9	   summarises	   the	   mutations	   that	   have	   been	  
identified	   in	   regulatory	   region	   of	  β-­‐catenin	   in	   a	   range	   of	   cancers.	   As	   discussed	   in	  
section	   1.1.2.2,	   this	   regulatory	   region	   contains	   4	   conserved	   serine/threonine	  
residues,	   the	   phosphorylation	   of	   which,	   by	   CK1	   and	   GSK3β,	   is	   important	   for	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subsequent	  polyubiquitylation	  by	  β-­‐TrCP	  E3	  ligase	  and	  degradation	  (Liu	  et	  al.,	  2002).	  
In	  line	  with	  this	  experimental	  evidence,	  these	  conserved	  serine/threonine	  residues	  in	  
the	   regulatory	   region	  of	  β-­‐catenin	  are	  most	   frequently	  mutated	   (Morin,	  1999).	  For	  
example,	   in	  50%	  of	   colon	   tumors	  with	  wildtype	  APC,	  mutations	  were	   found	   in	   the	  
regulatory	  region	  of	  β-­‐catenin	  (Sparks	  et	  al.,	  1998).	  In	  two	  APC-­‐positive	  colon	  cancer	  
cell	   lines	  harbouring	  mutations	   in	   the	  β-­‐catenin	   regulatory	   region,	  namely	  HCT116	  
(deletion	  of	  S45)	  and	  SW48	  (S33T	  mutation),	  the	  mutant	  β-­‐catenin	  is	  not	  regulated	  
by	  APC	  and	   the	  cell	   lines	  exhibit	   increased	  β-­‐catenin/TCF	   transcriptional	  activity	  as	  
measured	  by	  a	  reporter	  assay	  (Morin	  et	  al.,	  1997).	  Mutations	  were	  also	  found	  at	  D32	  
and	   G34,	   both	   of	   which	   are	   next	   to	   the	   conserved	   phosphorylation	   residue	   S33.	  
These	  mutations	  possibly	  results	  in	  conformational	  changes	  around	  the	  S33	  residue,	  
which	   prevents	   phosphorylation	   or	   recognition	   by	   the	   β-­‐TrCP	   E3-­‐ligase,	   as	   this	  
residue	   is	  part	  of	  a	  ubiquitin-­‐dependent	   recognition	  sequence	   (Aberle	  et	  al.,	  1997;	  
Orford;	  et	  al.,	  1997).	  Biallelic	  inactivation	  of	  Axin	  leading	  to	  truncated	  mutants	  of	  the	  
proteins	  was	  detected	  in	  hepatocellular	  carcinoma	  and	  cell	  lines	  (Satoh	  et	  al.,	  2000).	  
These	  mutants	  were	  predicted	  to	  lack	  β-­‐catenin	  binding	  activities	  and	  therefore	  not	  
able	  to	  target	  β-­‐catenin	  for	  ubiquitin-­‐dependent	  proteasomal	  degradation.	  	  
	  
In	   addition	   to	   mutations,	   changes	   in	   the	   expression	   level	   of	   the	   different	  
components	  may	  contribute	  to	  aberrant	  Wnt	  signalling	  as	  well	  (Barker	  and	  Clevers,	  
2006).	  For	  example,	  overexpression	  of	  Wnt	  ligands	  and	  Frizzled	  receptors	  have	  been	  
reported	  in	  colon	  cancer	  (Holcombe	  et	  al.,	  2002),	  breast	  cancer	  (Milovanovic	  et	  al.,	  
2004)	   and	   head	   and	   neck	   cancer	   (Rhee	   et	   al.,	   2002).	   Increased	   expression	   of	  
dishevelled	  family	  members	  has	  also	  been	  associated	  with	  mesothelioma	  (Uematsu	  
et	  al.,	   2003),	  non-­‐small-­‐cell	   lung	   cancer	   (Uematsu	  et	  al.,	   2003)	  and	   cervical	   cancer	  
(Vogelstein	  and	  Kinzler,	  1993).	  On	  the	  other	  hand,	  reduced	  expression	  of	  the	  natural	  
Wnt	  inhibitors	  of	  the	  SFRP	  (secreted	  Frizzled-­‐related	  protein)	  and	  WIF	  (Wnt	  inhibitor	  
factor)	  family	  have	  also	  been	  reported	  in	  colon	  cancer	  (Caldwell	  et	  al.,	  2004;	  Suzuki	  
et	  al.,	  2004),	  breast	  cancer	  (Ugolini	  et	  al.,	  2001;	  Ai	  et	  al.,	  2006),	  and	  mesothelioma	  
(Lee	  et	  al.,	  2004;	  Batra	  et	  al.,	  2006).	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Figure	  1.9.	  Cancer	  associated	  mutations	  found	  in	  the	  N-­‐terminal	  regulatory	  region	  
of	   β-­‐catenin.	   The	   conserved	   phosphorylation	   Serine/Threonine	   residues	   are	  
highlighted	  in	  bold,	  and	  the	  red	  letters	  below	  are	  the	  residues	  found	  after	  mutation	  
in	   cancer.	   Region	   highlighted	   in	   yellow	   is	   the	   ubiquitylation	   motif.	   (∆	   =	   deletion	  
mutation;	  Endom.	  =	   	  endometrial	   carcinoma;	  Medullo.	  =	  medulloblastomas;	  Pilo.	  =	  
pilomatricomas)	  (reviewed	  in	  Morin,	  1999).	  
	  
	  
The	  research	  efforts	  around	  Wnt	  signalling	  pathway	  has	  provided	  substantial	  
understanding	  of	   the	  molecular	  mechanisms	  regulating	   the	  pathway	  and	   therefore	  
allowed	  design	  of	  therapeutic	  strategies	  to	  treat	  cancer	  with	  activated	  Wnt	  signalling	  
(Barker	  and	  Clevers,	  2006;	  Klaus	  and	  Birchmeier,	  2008).	  For	  example,	  in	  the	  case	  of	  
overexpressed	  Wnt	  and	  Frizzled,	  where	  there	  is	  no	  mutation	  among	  components	  of	  
the	   signalling	   pathway,	   antibodies	   against	   the	   two	   proteins	   represent	   a	   potential	  
cancer	  therapeutic	  (You	  et	  al.,	  2006).	  Indeed,	  by	  treating	  a	  head	  and	  neck	  cancer	  cell	  
line	   with	   overexpressed	   Wnt1	   with	   a	   Wnt1	   antibody,	   Rhee	   and	   colleagues	  
demonstrated	  that	  Wnt	  signalling	  was	  suppressed	  in	  the	  cell,	  and	  the	  cells	  stopped	  
proliferating	  and	  underwent	  apoptosis	  (Rhee	  et	  al.,	  2002).	  Small-­‐molecule	  inhibitors,	  
which	   can	   specifically	   disrupt	   formation	   of	  β-­‐catenin-­‐TCF	   complex,	   also	   hold	   great	  
promise	  for	  treatment	  of	  Wnt	  signalling	  activated	  cancer	  (Barker	  and	  Clevers,	  2006).	  
However,	   efforts	   remain	   to	   be	  made	   in	   the	   search	   for	   safe	   and	   effective	   drugs	   to	  
block	  Wnt	  signalling	  activity	  in	  cancers.	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1.2	   Post-­‐translational	  modification	  by	  ubiquitin	  	  
	  
1.2.1	   Emergence	  of	  the	  concept	  of	  protein	  degradation	  	  	  
	  
It	  is	  now	  a	  fundamental	  understanding	  of	  cell	  biology	  that	  all	  proteins	  have	  a	  
definite	   life-­‐span	   and	   are	   all	   eventually	   degraded.	   However,	   up	   until	   the	   early	  
decades	   of	   the	   20th	   century,	   the	   general	   view	   was	   that	   intracellular	   proteins,	  
whether	  structural	  or	  functional,	  represent	  stable	  constituents	  of	  the	  body	  whereas	  
dietary	   proteins	   serve	   the	   sole	   purpose	   of	   energy	   provision	   (Ciechanover,	   2005).	  
With	  a	  new	  tool	  –	  heavy	   isotope	   labeling	  –	  becoming	  available,	  Schoenheimer	  and	  
Rittenberg	   decided	   to	   challenge	   this	   paradigm	   (Schoenheimer	   et	   al.,	   1939).	   By	  
feeding	  rat	  with	  15N-­‐labelled	  tyrosine,	  they	  discovered	  that	  only	  50%	  of	  the	  heavily	  
labeled	  amino	  acid	  was	  recovered	  in	  the	  urine	  while	  the	  remainder	  was	  incorporated	  
into	  tissue	  proteins,	  and	  this	  was	  accompanied	  by	  excretion	  of	  an	  equivalent	  amount	  
of	  protein	  nitrogen.	  Such	  observation	  demonstrated	  unequivocally	  that	  intracellular	  
proteins	   are	  dynamic	   entities,	  which	   are	   continually	   synthesized	   and	  degraded.	  As	  
unambiguous	   as	   the	   experimental	   result	  was,	   the	   concept	   of	   protein	   turnover	   did	  
not	  receive	  wide	  acceptance	  and	  was	  still	  challenged	  until	  mid	  1950s.	  	  
	  
Another	  significant	  milestone	  in	  establishing	  the	  concept	  of	  protein	  turnover	  
was	   finally	   laid	   when	   Christian	   de	   Duve	   and	   his	   colleagues	   identified	   lysosomes,	  
elucidating	   the	   first	   cellular	   machinery	   that	   mediates	   intracellular	   proteolysis	   (De	  
Duve	   et	   al.,	   1953).	   Lysosome	   is	   a	   membrane-­‐bound	   vacuolar	   structure	   with	  
hydrolytic	  enzymes	  bathed	   in	  an	  acidic	   internal	  environment	  and	   is	   the	   site	  where	  
engulfed	   macromolecules,	   endocytosed	   membrane	   proteins,	   worn-­‐out	   organelles	  
and	   certain	   intracellular	   proteins	   are	   degraded	   (Pillay	   et	   al.,	   2002).	   However,	  
accumulating	   evidence	   in	   the	   next	   two	   decades	   hinted	   at	   existence	   of	   a	   non-­‐
lysosomal	  proteolytic	  pathway	  (Ciechanover,	  2005).	  Firstly,	   it	  was	  revealed	  that	  the	  
degradation	   of	   proteins	   in	   bulk	  mediated	   by	   lysosome	   is	   non-­‐selective	   and	   it	   was	  
conceptually	  difficult	   to	   reconcile	   this	  observation	  with	   the	  emerging	   concept	   that	  
the	  turnover	  rate	  of	  proteins	  varies	  from	  one	  to	  the	  other	  (Schimke	  and	  Doyle,	  1970;	  
Goldberg	   and	   St	   John,	   1976).	   Secondly,	   inhibition	   of	   lysosomal	   proteases	   using	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specific	   inhibitors	   had	   differential	   effects	   on	   different	   populations	   of	   proteins,	  
suggesting	  existence	  of	  an	  alternative	  degradative	  mechanism.	  The	  key	  experiment	  
leading	  to	  this	  proposal	  was	  performed	  by	  Poole	  and	  colleagues	  (Poole	  et	  al.,	  1977).	  
They	   demonstrated	   that	   degradation	   of	   extracellular	   proteins,	   but	   not	   of	  
intracellular	   proteins,	   was	   sensitive	   to	   inhibition	   of	   lysosomal	   function	   by	   weak	  
bases.	   Thirdly,	   while	   it	   was	   known	   that	   the	   proteolytic	   actions	   carried	   out	   by	  
lysosomal	   proteases	   occur	   exergonically,	   there	   was	   mounting	   evidence	   indicating	  
the	  energy	  requirement	  of	  degradation	  of	  cellular	  proteins.	  	  	  	  
	  
These	   findings	   have	   prompted	   the	   quest	   for	   a	   proteolytic	   mechanism	  
alternative	   to	   lysosome	   that	   exhibits	   high	   degree	   of	   specificity	   towards	   its	  
substrates.	  	  
	  
1.2.2	   Discovery	  of	  ubiquitin	  proteasome	  system	  	  
	   	  
A	  major	  challenge	  in	  identifying	  a	  non-­‐lysosomal	  proteolytic	  system	  lay	  in	  the	  
development	  of	  an	  in	  vitro	  biochemical	  assay	  that	  can	  faithfully	  recapitulate	  the	  non-­‐
lysosomal	   cellular	  proteolytic	   events	   (Ciechanover,	   2005).	   	   This	  was	  made	  possible	  
by	  the	  important	  discovery	  of	  Rabinovitz	  and	  Fisher,	  who	  found	  that	  mature	  rabbit	  
reticulocytes	  which	  lack	  lysosomes	  are	  capable	  of	  degrading	  abnormal	  haemoglobin,	  
providing	   a	   lysosome-­‐free	   cell-­‐based	   system	   for	   investigation	   of	   an	   alternative	  
proteolytic	   system	   (Rabinovits	   and	   Fisher,	   1964).	   Following	   this,	   Etlinger	   and	  
Goldberg	  was	  the	  first	  to	  prepare	  a	  crude	  extract	  from	  reticulocytes,	  which	  preserves	  
proteolytic	   activity	   against	   abnormal	   haemoglobin,	   in	   an	   adenosine	   triphosphate	  
(ATP)-­‐dependent	  manner	   and	   at	   a	   neutral	   pH	   (indicating	   its	   non-­‐lysosomal	   origin)	  
(Etlinger	   and	   Goldberg,	   1977).	   This	   crude	   extract	   from	   reticulocytes	   proved	   to	   be	  
instrumental	  in	  the	  efforts	  to	  identify	  the	  alternative	  proteolytic	  system.	  	  
	  
	   Ciechanover	   and	   Hershko	   demonstrated	   that	   the	   crude	   extract	   could	   be	  
fractionated	  on	  an	  anion-­‐exchange	  resin	  into	  2	  fractions,	  fractions	  I	  and	  II,	  and	  that	  
both	  of	  them	  were	  required	  for	  reconstitution	  of	  proteolytic	  activity	  (Ciechanover	  et	  
al.,	   1978).	   They	   identified	   a	   ~8.5kDa	   heat-­‐stable	   protein	   in	   fraction	   I,	   which	   was	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thought	   to	  be	  an	  activator	   for	  a	  protease	   in	   fraction	   II.	  This	  active	  component	  was	  
later	  demonstrated	  to	  be	  covalently	  conjugated	  to	  target	  substrate	  in	  the	  presence	  
of	   fraction	   II	   in	   an	   ATP-­‐dependent	   manner,	   and	   was	   then	   named	   ATP-­‐dependent	  
proteolysis	  factor	  1	  (APF1)	  (Ciechanover	  et	  al.,	  1980;	  Hershko	  et	  al.,	  1980).	  A	  model	  
of	  protein	  degradation	  was	  then	  proposed:	  covalent	  conjugation	  of	  several	  moieties	  
of	   APF1	   to	   a	   protein	   substrate	   targets	   it	   for	   degradation	   by	   a	   yet-­‐to-­‐be-­‐identified	  
protease	  which	   does	   not	   recognize	   the	   unmodified	   protein.	   Independent	   to	   these	  
findings,	  a	  protein	  named	  “ubiquitin”	  (due	  to	  its	  ubiquitous	  expression)	  was	  found	  to	  
be	   covalently	   conjugated	   to	   histones	   H2A	   and	   H2B	   (Goldknopf	   and	   Busch,	   1975;	  
Goldknopf	   and	   Busch,	   1977;	  Hunt	   and	  Dayhoff,	   1977),	   in	   a	   similar	   fashion	   to	   how	  
APF1	   is	   conjugated	   to	   target	   substrates.	   This	   raised	   the	   suspicion	   that	   APF1	   and	  
ubiquitin	  could	  be	  the	  same	  protein	  and	  sequence	  analysis	  revealed	  that	  was	  indeed	  
the	  case	  (Wilkinson	  et	  al.,	  1980).	  Using	  immobilized	  ubiquitin	  as	  a	  ‘covalent’	  affinity	  
bait,	  Hershko,	  Ciechanover	  and	  colleagues	  purified	  the	  three	  enzymes	  which	  act	  in	  a	  
sequential	  manner	   to	   catalyse	   ubiquitin	   conjugation.	   The	   enzymes	   are	   namely	   E1,	  
the	   ubiquitin	   activating	   enzyme,	   E2,	   the	   ubiquitin-­‐conjugating	   enzyme	   and	   E3,	   the	  
ubiquitin	  ligase	  (Ciechanover	  et	  al.,	  1982;	  Hershko	  et	  al.,	  1983).	  	  
	  
	   The	  last	  piece	  of	  the	  puzzle	  however	  remained	  to	  fall	  in	  place:	  	  the	  identity	  of	  
the	  downstream	  protease	  in	  fraction	  II	  that	  recognises	  ubiquitin-­‐modified	  substrates	  
remained	  elusive.	   It	  was	  known	   that	   there	  was	  a	   second	  ATP-­‐requiring	   step	   in	   the	  
proteolytic	   system	   following	   ubiquitin	   conjugation	   based	   on	   work	   by	   Tanaka	   and	  
colleagues	   (Tanaka	   et	   al.,	   1983),	   and	   Hershko	   and	   colleagues	   subsequently	  
demonstrated	   that	   degradation	   of	   ubiquitin-­‐modified	   proteins	   requires	   energy	  
(Hershko	   et	   al.,	   1984).	   An	   important	   breakthrough	   was	   made	   by	   Hough	   and	  
colleagues,	   when	   they	   purified	   a	   high-­‐molecular-­‐mass	   proteolytic	   complex	   that	  
degraded	  ubiquitylated	  lysozyme	  in	  an	  ATP-­‐dependent	  manner	  (Hough	  et	  al.,	  1986).	  	  
The	  proteolytic	   complex	   fitted	  all	   the	   criteria	   for	  a	  ubiquitin-­‐regulated	  degradative	  
machinery	  and	  was	  later	  named	  proteasome.	  	  	  
	  
The	  eukaryotic	  26S	  proteasome	   is	  a	  barrel-­‐like	  protein	  complex,	   comprising	  
of	  two	  subcomplexes:	  a	  20S	  proteolytic	  core	  particle	  and	  one	  or	  two	  19S	  regulatory	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particles	  (Figure	  1.10)	  (Groll	  and	  Clausen,	  2003;	  Pickart	  and	  Cohen,	  2004).	  The	  core	  
particles	  consists	  of	  28	  subunits,	  which	  are	  arranged	  into	  four	  seven-­‐membered	  rings	  
that	  stack	  on	  top	  of	  each	  other.	  The	  two	  middle	  rings	  are	  made	  up	  of	  β-­‐subunits	  only	  
and	  together	  they	  form	  the	  catalytic	  chamber,	  whereas	  the	  two	  outer	  rings	  consists	  
of	   α-­‐subunits	   only	   and	   serve	   as	   a	   narrow	   gate	   to	   control	   entry	   and	   exit	   of	  
polypeptides	   and	   degradative	   products	   respectively.	   The	   19S	   regulatory	   particle	  
consists	  of	  a	  base,	  which	  is	  made	  up	  of	  six	  ATPase	  and	  two	  non-­‐ATPase	  proteins;	  and	  
a	   lid,	  which	   is	  composed	  of	  eight	  non-­‐ATPase	  proteins.	  The	  base	  and	   lid,	  of	  human	  
proteasomes,	   are	   linked	   by	   a	   subunit	   called	   S5a.	   The	   lid	   of	   the	   regulatory	   particle	  
plays	   a	   dual	   role	   in	   recognition	   of	   polyubiquitylated	   substrate	   and	   unfolding	   of	  
substrate.	  The	  S5a,	  Rad23	  and	  Dsk2	  subunits	  of	  the	  regulatory	  particle	  have	  all	  been	  
shown	  to	  be	  able	   to	  bind	  and	  sense	  the	   length	  of	  polyubiquitin	  chains	  attached	  to	  
substrate	  (Elsasser	  et	  al.,	  2004;	  Zhang	  et	  al.,	  2009),	  whereas	  the	  unfolding	  of	  protein	  
into	   polypeptide	   chains	   is	   mediated	   by	   the	   activities	   of	   the	   ATPases	   (Pickart	   and	  
Cohen,	  2004).	  Once	  a	  polypeptide	  chain	  enters	  the	  chamber	  of	  the	  core	  particle,	  it	  is	  
degraded	  non-­‐specifically.	  	  
	  
	   In	   summary,	   the	   series	   of	   findings	   discussed	   herein	   had	   led	   to	   the	  
identification	  of	   the	  core	  components	  of	  a	  non-­‐lysosomal	  proteolytic	  system:	  a	   tag	  
for	  specific	  degradation	  of	  protein,	  the	  ubiquitin	  and	  an	  executer	  of	  proteolysis,	  the	  
proteasome,	   hence	   the	   ubiquitin	   proteasome	   system	   (UPS).	   Perhaps	   what	   was	  
unexpected	   and	   only	   became	   apparent	   after	   more	   than	   a	   decade	   following	   the	  
discovery	  of	  UPS,	  is	  that	  regulated	  lysosomal	  degradation	  of	  endocytosed	  membrane	  
protein	   requires	  modification	   of	   the	   substrate	   protein	   by	   ubiquitin	   as	  well	   (Hurley	  
and	  Stenmark,	  2011).	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Figure	   1.10.	   The	   structure	   of	   the	   eukaryotic	   26S	   proteasome.	   The	  eukaryotic	  26S	  
proteasome	  consists	  of	  a	  20S	  proteolytic	  complex,	  which	  is	  the	  core	  particle	  and	  one	  
or	  two	  19S	  complexes,	  which	  is	  the	  regulatory	  particle.	  The	  core	  particle	  consists	  of	  
four	  seven-­‐membered	  rings	  stacked	  on	  top	  of	  each	  other:	  two	  outer	  a-­‐rings	  and	  two	  
inner	  b-­‐rings.	  The	  19S	  regulatory	  particle	  consists	  of	  a	  base,	  which	  is	  made	  up	  of	  six	  
ATPase	   and	   two	   non-­‐ATPase	   proteins;	   and	   a	   lid,	  which	   is	   composed	   of	   eight	   non-­‐




1.2.3	   Ubiquitin	  and	  Reversible	  Ubiquitylation	  	  
	  
Ubiquitin	   is	   a	   globular	   protein	   of	   76	   amino	   acids	   that	   is	   highly	   conserved	  
among	   all	   eukaryotes	   (Hershko	   and	   Ciechanover,	   1998).	   It	   was	   first	   isolated	   from	  
samples	   of	   bovine	   thymus	   and	   was	   named	   ubiquitin	   owing	   to	   its	   ubiquitous	  
expression	   across	   species	   (Goldstein	   et	   al.,	   1975).	   Ubiquitin	   is	   encoded	   by	   four	  
different	  genes,	  namely	  UBB,	  UBC,	  UBA52	  and	  RB27A	  in	  human.	  Translation	  of	  UBB	  
and	   UBC	   mRNA	   gives	   rise	   to	   polyproteins	   consisting	   of	   tandem	   repeats	   of	   nine	  
ubiquitin	   (Wiborg	   et	   al.,	   1985),	   whereas	   UBA52	   and	   RB27A	   give	   rise	   to	   ubiquitin	  
fused	  N-­‐terminally	  to	  the	  ribosomal	  proteins,	  L40	  and	  S27a,	  respectively	  (Baker	  and	  
Board,	   1991).	   Therefore,	   ubiquitin	   is	   translated	   as	   precursor	   polypeptides,	   which	  
need	  to	  be	  processed	  to	  produce	  the	  free	  ubiquitin	  pool	  for	  conjugation	  with	  other	  
proteins.	  The	  resulting	  polypeptide	  folds	  into	  a	  barrel	  like	  structure,	  characterised	  by	  
four	   antiparallel	   β-­‐sheets	   on	   one	   side	   and	   an	  α-­‐helix	   on	   the	   other	   side,	   and	   the	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contains	  seven	  highly	  conserved	  lysine	  (K)	  residues	  (K6,	  K11,	  K27,	  K29,	  K33,	  K48	  and	  
K63).	  These	   lysine	  residues	  and	  the	  N-­‐terminus	  glycine	  can	  all	  be	  used	  for	  covalent	  
conjugation	  with	  other	  proteins.	  
	  
Figure	  1.11.	  Crystal	  structure	  of	  ubiquitin.	  Ubiquitin	  is	  a	  76	  aa	  protein	  comprised	  of	  
a	  globular	  domain	  containing	  four	  stranded	  mixed	  β-­‐sheet	  (in	  yellow),	  an	  α-­‐helix	  (in	  
pink)	  and	  a	  flexible	  C-­‐terminal	  tail	  terminating	  in	  a	  glycine.	  Ubiquitin	  has	  seven	  highly	  
conserved	   lysine	   residues	   (blue	   dots).	   The	   structure	   was	   retrieved	   from	   Research	  
Collaboratory	  for	  Structural	  Bioinformatics	  Protein	  Data	  Bank	  (PBD	  ID	  =	  1UBQ).	  	  
	  
	  
The	   biochemical	   reaction	   by	   which	   ubiquitin	   is	   covalently	   conjugated	   to	  
another	   protein	   is	   called	   ubiquitylation.	   Essentially,	   it	   involves	   formation	   of	   an	  
isopeptide	   bond	   between	   the	   C-­‐terminal	   glycine	   residue	   of	   ubiquitin	   and	   the	   ε-­‐
amino	  group	  of	  a	   lysine	  residue	  of	  substrate	  protein.	  Modification	  of	  substrates	  by	  
ubiquitylation	   can	   take	   many	   forms	   (Komander,	   2009).	   Conjugation	   of	   a	   single	  
ubiquitin	  moiety	   is	   termed	  monoubiquitylation.	   Accordingly,	  modification	   of	  more	  
than	   one	   lysine	   by	   a	   single	   ubiquitin	   moiety	   is	   referred	   to	   as	   multi-­‐
monoubiquitylation	   whereas	   modification	   of	   substrate	   proteins	   by	   chains	   of	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modifications	   (PTM)	   such	   as	   phosphorylation	   and	   acetylation,	   ubiquitylation	   is	   a	  
reversible	   process,	   where	   the	   ubiquitin	   moieties	   can	   be	   removed	   by	   the	  
deubiquitylases	  (DUBs).	  	  
	  
	  
1.2.3.1	  	   The	  ubiquitylation	  cascade	  and	  ubiquitylating	  enzymes	  	  
	  
	   Soon	   after	   discovery	   of	   ubiquitin,	   it	   was	   already	   demonstrated	   that	  
ubiquitylation	  involves	  sequential	  actions	  of	  three	  classes	  of	  enzymes,	  namely	  E1,	  E2	  
and	  E3,	  which	  is	  considered	  the	  paradigm	  of	  ubiquitylation	  mechanism	  (Ciechanover	  
et	  al.,	  1982;	  Hershko	  et	  al.,	  1983).	  	  
	  
E1,	   the	   ubiquitin-­‐activating	   enzyme,	   initiates	   the	   cascade	   of	   reaction	   by	  
activating	   a	   ubiquitin	   in	   an	   ATP-­‐	   and	  Mg2+-­‐dependent	  manner,	  where	   the	   enzyme	  
binds	  sequentially	  to	  ATP•Mg2+	  and	  ubiquitin,	  and	  catalyses	  acyl-­‐adenylation	  of	  the	  
C-­‐terminal	   glycine	   (Figure	   1.12)	   (Schulman	   and	   Harper,	   2009).	   Then,	   the	   catalytic	  
cysteine	  residue	  of	  the	  E1	  attacks	  the	  ubiquitin-­‐adenylate	  intermediate,	  resulting	  in	  
the	   formation	  of	   a	  high-­‐energy	   thiolester	  bond	  between	   itself	   and	  ubiquitin.	  Next,	  
the	   E1-­‐activated	   ubiquitin	   is	   transferred	   to	   the	   active	   site	   cysteine	   of	   an	   E2	  
conjugating	   enzyme	   (Wenzel	   et	   al.,	   2011).	   In	   the	   final	   step,	   the	   ubiquitin	   is	  
conjugated	  to	  the ε-­‐amino	  group	  of	  a	  lysine	  residue	  on	  the	  protein	  substrate	  in	  the	  
presence	  of	   an	  E3	   ligase.	   In	   the	   case	  where	  a	  HECT	   (homologous	   to	   E6AP	   carboxy	  
terminus)	  E3	   ligase	   is	  engaged,	  an	   intermediate	  thiolester	  bond	  is	  formed	  between	  
the	   enzyme	   and	   the	   ubiquitin	   before	   the	   subsequent	   transfer	   to	   the	   substrate	  
protein.	  For	  the	  case	  of	  RING	  (really	  interesting	  new	  gene)	  E3	  ligase,	  the	  E3	  enzyme	  
acts	   as	   a	   scaffold	   to	   bring	   the	   substrate	   and	   the	   E2	   in	   close	   proximity	   so	   that	   the	  
ubiquitin	   moiety	   is	   transferred	   directly	   from	   the	   E2	   to	   the	   substrate.	   For	  
polyubiquitylation	   or	   multi-­‐monoubiquitylation,	   the	   discharged	   E2	   is	   displaced	   by	  
another	   charged	   E2,	   enabling	   the	   transfer	   of	   another	   ubiquitin	   moiety	   to	   the	  
substrate	  or	  the	  substrate-­‐conjugated	  ubiquitin.	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Figure	   1.12.	   Overview	   of	   the	   biochemical	   steps	   in	   protein	   ubiquitylation	   and	  
deubiquitylation.	  (1)	  Ubiquitin	  activation	  by	  a	  ubiquitin	  activating	  enzyme	  (E1).	  (Ott	  
et	   al.,	   1998)	   Transfer	   of	   ubiquitin	   to	   a	   ubiquitin-­‐conjugating	   enzyme	   (E2).	   (3)	  
Transfer	  of	  ubiquitin	  to	  a	  HECT	  domain	  ubiquitin	  ligase	  (HECT	  E3).	  (4)	  Association	  of	  
HECT	  E3-­‐ubiquitin	   intermediate	  with	  a	   substrate	  protein.	   (5)	  Association	  of	  a	  RING	  
finger	  ubiquitin	  ligase	  (RING	  E3)	  with	  a	  ubiquitin-­‐carrying	  E2	  and	  a	  substrate	  protein.	  




In	   human,	   there	   are	   two	   E1s	   for	   ubiquitylation,	   namely	   UBA1	   and	   UBA6.	  
Structural	  analysis	  of	  the	  E1	  reveals	  three	  structural	  features:	  a	  ubiquitin	  adenylation	  
domain,	  a	  Cys	  domain	  that	  contains	  the	  cysteine	  required	  for	  thiolester	  transfer	  and	  
a	   ubiquitin-­‐fold	   domain	   (UFD)	   (Schulman	   and	   Harper,	   2009).	   The	   E1	   enzymes	   are	  
highly	  conserved	  proteins	  with	  prokaryotic	  antecedents	   (Figure	  1.13).	  The	  bacterial	  
proteins	   molybdopterin	   converting	   factor	   subunit	   1	   (MoaD)	   and	   thiamine	  
biosynthesis	  protein	  S	  (ThiS),	  which	  have	  a	  ubiquitin-­‐like	  (UBL)	  fold	  (Lake	  et	  al.,	  2001;	  
Wang	  et	  al.,	  2001),	  are	  also	  activated	  by	  C-­‐terminal	  acyl-­‐adenylation	  by	  the	  enzymes	  
molybdopterin	   biosynthetic	   enzyme	  B	   (MoeB)	   and	   ThiF,	   respectively	   (Taylor	  et	   al.,	  
1998;	   Leimkuhler	   et	   al.,	   2001),	   in	   a	   similar	   fashion	   to	   ubiquitin	   adenylation.	   The	  
human	  E1s	  share	  sequence	  homology	  with	  these	  bacterial	  enzymes	  in	  the	  domains	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Figure	  1.13.	  Structural	  homology	  between	  the	  bacterial	  MoeB	  or	  Thif	  and	  human	  
E1.	   The	  bacterial	   enzymes	  molybdopterin	  biosynthetic	  enzyme	  B	   (MoeB)	  and	  ThiF,	  
are	   characterised	   by	   their	   adenylation	   domain.	   The	   human	   E1s	   share	   sequence	  
homology	  with	  these	  bacterial	  enzymes	  in	  the	  domains	  responsible	  for	  adenylation,	  
but	  the	  human	  adenylation	  domains	  are	  pseudosymmetrical:	  one	  MoeB/ThiF	  repeat	  
binds	   to	   ATP•Mg2+	   and	  UBL	   (active	   adenylation	   domain)	  while	   the	   other	   provides	  
structural	   stability	   (inactive	   adenylation	  domain).	   The	  human	  E1	   also	   contains	   two	  
additional	  E1-­‐specific	  domains,	  which	  are	  responsible	  for	  UBL	  transfer	  to	  E2.	  	  
	  
	  
There	  are	  at	   least	  38	  different	  E2	  enzymes	  encoded	  by	   the	  human	  genome	  
(Ye	   and	   Rape,	   2009;	   Wenzel	   et	   al.,	   2011).	   The	   E2s	   are	   characterised	   by	   their	  
evolutionarily	   conserved	   ubiquitin-­‐conjugating	   (Ubc)	   domain,	   which	   is	   150	   amino	  
acids	  in	  length.	  The	  Ubc	  domain	  contains	  the	  catalytic	  cysteine	  residue	  for	  thiolester	  
bond	   formation	   and	   allows	   interaction	   with	   E1s.	   As	   initial	   efforts	   in	   the	   ubiquitin	  
field	  were	  focused	  on	  E3s,	  which	  confer	  substrate	  specificity,	  E2s	  were	  long	  regarded	  
simply	  as	   “ubiquitin	   carriers”	  with	  auxiliary	   roles.	  However,	   accumulating	  evidence	  
indicate	   their	   multiple	   decisive	   roles	   in	   the	   process	   of	   ubiquitylation,	   including	  
determination	  of	   length	  and	  linkage-­‐type	  of	  ubiquitin	  chain	  and	  regulation	  of	  chain	  
assembly	   reaction.	   For	   example,	   the	   E2	   enzyme	   UBE2S	   specifically	   catalyses	  
formation	  of	  Lys11-­‐linked	  ubiquitin	  chains	  (Baboshina	  and	  Haas,	  1996).	  	  Besides,	  E2s	  
specifically	   involved	   in	   ubiquitin	   chain	   elongation	   often	   lacks	   chain-­‐initiating	  
capability	   and	   therefore	   often	   work	   in	   concert	   to	   catalyse	   ubiquitylation.	   For	  
instance,	   modification	   of	   proliferating	   cell	   nuclear	   antigen	   (PCNA)	   during	   post-­‐
replicative	  DNA	   (deoxyribonucleic	   acid)	   repair	  with	   Lys63-­‐linked	  ubiquitin	   chain	   by	  
the	  E2	  Ubc13-­‐Mms2	   in	   yeast	   (UBE2N-­‐UBE2V1	   in	  human)	  needs	   to	  be	  preceded	  by	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The	  E3s	  represent	   the	   largest	   family	  among	  the	  ubiquitylating	  enzymes	  and	  
the	   human	   genome	   encodes	   more	   than	   600	   potential	   E3	   ligases	   (Deshaies	   and	  
Joazeiro,	  2009;	  Rotin	  and	  Kumar,	  2009;	  Metzger	  et	  al.,	  2012).	  Such	  a	  large	  number	  of	  
members	  is	  necessary	  to	  enable	  specificity	  in	  ubiquitin-­‐dependent	  regulations.	  There	  
are	   two	  major	   types	   of	   E3s	   in	   eukaryotes	   as	   defined	   by	   their	   conserved	   catalytic	  
domain,	  namely	  the	  HECT	  E3	  ligases	  which	  consist	  of	  28	  members	  (Rotin	  and	  Kumar,	  
2009)	   and	   the	   RING	   E3	   ligases	   comprising	   of	   about	   616	   members	   (Deshaies	   and	  
Joazeiro,	  2009).	  HECT	  is	  a	  C-­‐terminal	  domain	  of	  about	  350	  amino	  acids	  and	  structural	  
analysis	   reveals	   that	   the	   HECT	   has	   two	   lobes.	   The	   C-­‐terminus	   lobe	   of	   the	   domain	  
contains	   the	   catalytic	   cysteine	   residue	  whereas	   the	  N-­‐terminus	   lobe	   is	   responsible	  
for	  binding	   to	  E2s.	  Region	  outside	  of	   the	  HECT	  domain	   is	   responsible	   for	   substrate	  
binding	   (Rotin	   and	   Kumar,	   2009).	   The	   RING	   domain	   is	   characterised	   by	   a	   defined	  
pattern	  of	  cysteine	  and	  histidine	  residues,	  which	  enable	  binding	  of	  two	  zinc	  atoms	  in	  
a	   cross-­‐brace	   arrangement	   (Borden	  2000).	   This	   zinc	   ligation	   is	   essential	   for	   proper	  
folding	  of	  the	  domain,	  hence	  for	  its	  function.	  Structure	  of	  the	  RING	  domain	  indicates	  
that	   the	   E3s	   are	   incapable	   of	   chemical	   catalysis	   but	   rather	   function	   as	   scaffolding	  
proteins	   to	   enable	  ubiquitin	   transfer	   from	  E2s	   to	   substrates.	   The	  RING	  E3s	   can	  be	  
subdivided	  further	  into	  those	  that	  function	  as	  a	  single	  subunit	  and	  those	  that	  act	  in	  a	  
multimeric	   complex,	   the	   Cullin	   RING	   ligases	   (CRL)	   (Li	   et	   al.,	   2008).	   The	   proto-­‐
oncogene	  Cbl	   is	   a	  well-­‐studied	  example	  of	   the	   former	  and	   is	   characterised	  by	   two	  
conserved	   regions:	   the	   tyrosine	   kinase	  binding	   (TKB)	   domain	  on	  N-­‐terminus	  which	  
allows	   substrate	   recognition	   and	   the	   C-­‐terminal	   RING	   finger	   domain	   (Zhang	  et	   al.,	  
2000).	  	  Cbl	  is	  well	  known	  for	  its	  key	  role	  in	  mediating	  receptor	  tyrosine	  kinases	  (RTK)	  
ubiquitylation	   and	   subsequent	   degradation	   (Fukazawa	   et	   al.,	   1996;	   Miyake	   et	   al.,	  
1998).	  The	  SCF	  complex	  consists	  of	  the	  subunits	  Skp1,	  Cullin1	  and	  the	  F-­‐box	  protein	  
is	  a	  well-­‐known	  example	  of	  the	  CRLs.	  In	  the	  SCF	  complex,	  the	  Cullin	  is	  responsible	  for	  
E2	   recruitment,	   Skp1	   functions	   as	   a	   scaffold	   while	   the	   F-­‐box	   protein	   confers	  
substrate	  specificity	  (Zheng	  et	  al.,	  2002).	  There	  are	  approximately	  70	  F-­‐box	  proteins	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1.2.3.2	  	   Different	  ubiquitin	  linkages	  and	  their	  physiological	  roles	  
	  
	   As	   mentioned	   earlier,	   all	   the	   seven	   lysine	   residues	   and	   the	   N-­‐terminus	  
methionine	   residue	   in	   a	   ubiquitin	   molecule	   can	   be	   conjugated	   to	   the	   C-­‐terminal	  
glycine	   of	   another	   ubiquitin	   molecule	   for	   extension	   of	   a	   polyubiquitin	   chain.	   The	  
different	   forms	   of	   polyubiquitylation	   (including	   multiple	   mono-­‐ubiquitylation	   and	  
ubiquitin	   chains	   linked	   by	   different	   lysine	   residues)	   appended	   to	   a	   protein	  
constitutes	  another	  layer	  of	  control	  in	  the	  regulation	  of	  cellular	  function	  (Wong	  and	  
Cuervo,	  2010).	  The	  differently	   linked	  ubiquitin	  chains	  adopt	  different	  conformation	  
and	   topologies	   (Ikeda	   and	   Dikic,	   2008),	   and	   therefore	   provide	   different	   binding	  
surfaces	   for	   different	   ubiquitin-­‐binding	   proteins	   (Hicke	   et	   al.,	   2005;	   Raasi	   et	   al.,	  
2005).	  	  Accordingly,	  the	  attachment	  of	  a	  different	  ubiquitin	  linkage	  dictates	  a	  distinct	  
cellular	  fate	  of	  the	  protein	  modified.	  	  
	  
	  By	  virtue	  of	  mass	  spectrometry,	  it	  was	  shown	  in	  yeast	  cells	  that	  all	  the	  seven	  
lysine	  residues	  are	  used	  for	  ubiquitin	  chain	  formation,	  but	  the	  different	  linkages	  vary	  
in	   abundance	   (Peng	   et	   al.,	   2003;	   Xu	   et	   al.,	   2009).	   According	   to	   data	   by	   Xu	   and	  
colleagues,	   Lys48-­‐	   and	   Lys11-­‐linked	   ubiquitin	   chains	   are	   the	   most	   abundant,	  
followed	   by	   Lys63-­‐,	   Lys6-­‐,	   Lys27-­‐,	   Lys29-­‐	   and	   Lys33-­‐linked	   chains	   (Xu	  et	   al.,	   2009).	  
Besides,	   they	   also	   showed	   that	   all	   the	   ubiquitin	   chains,	   except	   for	   Lys63-­‐linked	  
chains	  can	  serve	  as	  proteolytic	  signals.	  
	  
	   The	   specific	   roles	   of	   most	   ubiquitin	   linkages	   are	   still	   poorly	   understood.	  
Figure	   1.14	   summarises	   the	   known	   functions	   of	   different	   ubiquitin	   chain	   linkages.	  
The	  Lys48-­‐linked	  chain	  is	  the	  best	  characterised	  so	  far	  as	  a	  proteolytic	  signal	  (Chau	  et	  
al.,	   1989).	   The	   Lys63-­‐linked	   ubiquitin	   chains	   are	   implicated	   in	   modulation	   of	   cell	  
signalling	  pathways	  (such	  as	  NFκB	  (Skaug	  et	  al.,	  2009)	  and	  Wnt	  signalling	  (Tauriello	  
et	  al.,	  2010;	  Tran	  et	  al.,	  2008)),	  DNA	  repair	   (Stelter	  and	  Ulrich,	  2003)	  and	  receptor	  
endocytosis	  (Duncan	  et	  al.,	  2006).	  Monoubiquitylation	  of	  substrate	  has	  been	  shown	  
to	  regulate	  receptor	  endocytosis	  (Hurley	  and	  Stenmark,	  2011),	  DNA	  repair	  (Huang	  et	  
al.,	   2006)	   and	   viral	   budding	   (Ott	   et	   al.,	   1998).	   	   Multiple	   monoubiquitylation	   of	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receptor	   tyrosine	   kinases	   can	   also	   lead	   to	   their	   endocytosis	   and	   degradation	  
(Haglund	  et	  al.,	  2003).	  	  
	  
	   Among	  the	  unconventional	  polyubiquitin	  chains,	  Lys11-­‐linked	  chain	  has	  been	  
shown	  to	  be	  the	  preferred	  linkage	  type	  for	  degradation	  of	  cell	  cycle	  related	  proteins,	  
which	   are	   the	   substrate	   of	   anaphase	   promoting	   complex	   (APC/C)	   (Jin	  et	   al.,	   2008;	  
Matsumoto	  et	  al.,	   2010;	  Wu	  et	  al.,	   2010).	   	   Lys11-­‐linked	   chain	   is	   also	   implicated	   in	  
endoplasmic	   reticulum-­‐associated	   degradation	   (ERAD)	   pathway	   by	   targeting	  
misfolded	  proteins	  for	  proteasomal	  degradation	  (Xu	  et	  al.,	  2009).	  Lys6-­‐linked	  chain	  is	  
implicated	  in	  DNA	  damage	  and	  replication	  stress	  (Morris	  and	  Solomon,	  2004).	  It	  was	  
shown	   that	   upon	   induction	   of	   DNA	   damage	   by	   hydroxyurea,	   the	   sites	   of	   DNA	  
damage	  repair	  is	  concentrated	  with	  proteins	  modified	  by	  Lys6-­‐linked	  ubiquitin	  chain	  
and	  the	  ubiquitylation	  relies	  on	  the	  activity	  of	  BRCA1.	  	  
	  
AIP4,	   a	  HECT	  E3	   ligases	  modifies	  Deltex,	   a	  RING	  E3	   ligase	  with	   Lys29-­‐linked	  
ubiquitin	  chain	  and	  targets	  it	  for	  lysosomal	  degradation	  (Chastagner	  et	  al.,	  2006).	  On	  
the	   other	   hand,	   Lys27-­‐linked	   ubiquitin	   (together	   with	   Lys63-­‐linked	   chain)	   is	  
implicated	   in	   mitophagy,	   where	   the	   formation	   of	   the	   ubiquitin	   chain	   on	  
mitochondrial	   proteins	   such	   as	   VDAC1	   (voltage	   dependent	   anion	   channel	   1),	   is	  
catalysed	  by	  the	  E3	  ligase	  Parkin	  (Geisler	  et	  al.,	  2010).	  	  
	  
Both	  Lys33-­‐linked	  and	  linear	  ubiquitin	  chains	  have	  been	  shown	  to	  play	  roles	  
in	   modulating	   cell	   signalling	   events.	   The	   AMPK	   kinases	   have	   been	   shown	   to	   be	  
modified	  by	  Lys-­‐33	  linked	  chain	  (as	  well	  as	  Lys29-­‐linked	  chain)	  and	  such	  modification	  
leads	   to	   inhibition	  of	   their	   activities	  and	  phosphorylation	  by	   LKB1	   (Al-­‐Hakim	  et	  al.,	  
2008).	  These	  chains	  can	  be	  removed	  by	  the	  DUB	  USP9X.	  Linear	  ubiquitin	  chain	  has	  
also	  been	   implicated	   in	  regulation	  of	  NFκB	  signalling	   (Haas,	  et	  al.,	  2009;	  Rahighi	  et	  
al.,	   2009;	   Ikeda	  et	   al.,	   2011;	   Tokunaga	  et	   al.,	   2011).	  Modification	   of	  NEMO	   (NFκB	  
essential	   modulator)	   by	   linear	   ubiquitin	   chain	   enhances	   its	   interaction	   with	   the	  
Tumour	  Necrosis	  Factor-­‐R1	  signaling	  complex	   (TNF-­‐RSC),	   thereby	  ensuring	  efficient	  
TNF-­‐induced	  activation	  of	  NFκB	  (Haas	  et	  al.,	  2009).	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   Notably,	   existence	  of	   heterologous	  ubiquitin	   chains	   has	   also	  been	   reported	  
(Ben-­‐Saadon	  et	  al.,	  2006).	  The	  Ring1B	  E3	  ligase	  catalyses	  its	  own	  autoubiquitylation	  
and	  generates	  mixture	  of	  Lys6-­‐,	  Lys27	  and	  Lys48-­‐linked	  ubiquitin	  chain	  all	  on	  a	  single	  
ubiquitin	   molecule.	   The	   presence	   of	   this	   mixture	   of	   ubiquitylation	   is	   required	   to	  
enable	  Ring1B	   to	  monoubiquitylate	  histone	  H2A.	  Based	  on	   these	  different	   studies,	  
other	   than	   the	   proteolytic	   signals	   encoded	   by	   the	   non-­‐Lys63-­‐linked	   ubiquitin	  
linkages,	   all	   the	   ubiquitin	   linkages	   (except	   for	   Lys48-­‐linkages)	   can	   lead	   to	   diverse	  
cellular	  outcomes.	  	  
	  
	  
Figure	  1.14.	  Cellular	  roles	  of	  different	  ubiquitin	  linkages.	  All	  the	  lysine	  residues	  and	  
the	   N-­‐terminal	   methionine	   of	   ubiquitin	   can	   be	   used	   for	   conjugation	   to	   form	  
polyubiquitin	  chains.	  The	  different	  ubiquitin	  linkages	  dictate	  distinct	  cellular	  fates	  of	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1.2.3.3	  	   Ubiquitin	  binding	  domains	  	  
	  
	   The	  use	  of	  ubiquitylation	  to	  encode	  diverse	  signaling	   functions	   is	   likened	  to	  
the	   use	   of	  Quipus,	   the	   talking	   knots,	   by	   people	   of	   the	   Inca	   Empire	   as	   a	   system	  of	  
record	   keeping,	   in	   which	   information	   was	   represented	   by	   knots	   along	   a	   piece	   of	  
thread	  (Komander	  and	  Rape,	  2012).	   	   Just	  as	  how	  the	  knots	  can	  only	  be	  deciphered	  
by	  Quipucamayocs	  who	  can	  read	  Quipus,	  the	  ubiquitin	  modifications	  of	  a	  substrate	  
require	   recognition	  by	   other	   proteins	   to	   enable	   the	   signal	   to	   be	   conveyed.	   Such	   a	  
role	  was	  fulfilled	  by	  the	  ubiquitin	  binding	  domains	  (UBD)	  containing	  proteins,	  which	  
are	   capable	   of	   recognising	   the	   ubiquitylation	   status	   of	   a	   protein	   through	   non-­‐
covalent	  interactions.	  	  
	  
	   	  The	  UBDs	  are	  found	  in	  an	  expanding	  number	  of	  cellular	  proteins	  of	  diverse	  
roles,	  which	   is	  currently	  estimated	  at	  about	  150	   (Dikic	  et	  al.,	  2009).	  To	  date,	  more	  
than	   20	   UBD	   families	   are	   identified	   and	   they	   all	   differ	   in	   term	   of	   structure	   and	  
binding	  modes	   (Kirkin	  and	  Dikic,	  2007).	   There	  are	  UBDs	  which	  bind	  monoubiquitin	  
whereas	  the	  others	  recognize	  ubiquitin	  chains	  of	  specific	  linkage	  type.	  The	  UBDs	  can	  
be	   broadly	   categorised	   into	   three	   major	   classes	   as	   dictated	   by	   their	   structural	  
features:	   α-­‐helix,	   zinc-­‐finger	   and	   β-­‐sheets	   (Hurley	   et	   al.,	   2006;	   Kirkin	   and	   Dikic,	  
2007).	  The	  α-­‐helix	  (e.g.	  UIM	  and	  UBA)	  and	  zinc-­‐finger	  UBDs	  (e.g.	  NZF	  and	  UBZ)	  are	  
the	   more	   common	   classes	   of	   UBDs,	   whereas	   the	   β-­‐sheets	   UBDs	   constitute	   the	  
ubiquitin	  binding	  sites	  in	  DUBs,	  E2s	  and	  E3s.	  	  
	   	  	  
	   By	   bioinformatic	   analysis	   of	   region	   of	   homology	   among	   some	   of	   the	  
ubiquitylation	  machineries,	  the	  E2,	  E3	  and	  DUBs,	  Hofmann	  and	  Buher	  identified	  the	  
first	  UBD,	  the	  ubiquitin	  associated	  domain	  (UBA)	  (Hofmann	  and	  Bucher,	  1996).	  The	  
UBA	  has	  a	  size	  of	  about	  55	  aa	  and	  consists	  of	  a	  compact	  three-­‐helix	  bundle	  (Mueller	  
and	  Feigon,	  2002).	  A	  few	  years	  later,	  Wilkinson	  and	  colleagues	  showed	  that	  the	  UBA	  
domain	  is	  capable	  of	  binding	  directly	  to	  polyubiquitin	  chains	  (Wilkinson	  et	  al.,	  2001).	  
On	  the	  other	  hand,	  the	  yeast	  proteasomal	  subunit	  S5a	  was	  the	  first	  ubiquitin-­‐binding	  
protein	  that	  is	  identified	  biochemically	  (Young	  et	  al.,	  1998).	  This	  discovery	  offers	  an	  
explanation	   for	   the	   ability	   of	   the	   26S	   proteasome	   to	   recognize	   polyubiquitylated	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substrate.	   The	  UBD	   of	   the	   yeast	   S5a	  was	   named	   ubiquitin	   interacting	  motif	   (UIM)	  
and	   its	   discovery	   has	   enabled	   identifications	   of	   other	   UIM-­‐containing	   proteins,	  
including	   Eps15,	   Epsin	   and	   HRS	   (Hofmann	   and	   Falquet,	   2001).	   Interestingly,	   these	  
proteins	   are	   involved	   in	   receptor	   endocytosis	   and	   this	   early	   finding	   therefore	  
highlights	   a	   more	   general	   role	   of	   ubiquitin	   modification	   in	   regulation	   of	   protein	  
trafficking.	   Indeed,	   these	   proteins	   play	   important	   roles	   in	   recognition	   of	  
ubiquitylated	  cargo	  and	  their	  subsequent	  sorting	  into	  the	  MVB	  (Williams	  and	  Urbé,	  
2007).	   A	   crystal	   structure	   of	   UIM	   shows	   that	   the	   domain	   consists	   of	   an	   α-­‐helix	  
centred	  around	  an	  alanine	  residue	  (Swanson	  et	  al.,	  2003).	  	  
	  
The	  UBDs	  differ	  in	  their	  mode	  of	  binding	  to	  ubiquitin.	  For	  instance,	  binding	  to	  
monoubiquitin	   involves	   interaction	  with	  the	  hydrophobic	  patch	   (HP)	   in	   the	  β-­‐sheet	  
of	  ubiquitin	  (Dikic	  et	  al.,	  2009).	  While	  the	  UIM	  and	  ubiquitin-­‐binding	  zinc	  finger	  (UBZ)	  
domain	   interact	   with	   the	   HP	  with	   a	   single	  α-­‐helix	   apposed	   next	   to	   the	   central	  β-­‐
sheets,	   the	   UBA	   and	   coupling	   of	   ubiquitin	   conjugation	   to	   ER	   degradation	   domain	  
(CUE)	  bind	  ubiquitin	  using	  two	  discontinuous	  α-­‐helices.	  It	  is	  intriguing	  that	  an	  array	  
of	  helical	  structures	  and	  binding	  strategies	  have	  evolved	  simply	  for	  interaction	  with	  
ubiquitin.	  On	  the	  other	  hand,	  binding	  of	  polyubiquitin	  chain	  is	  enabled	  by	  positioning	  
UBDs	   in	   tandem.	   Linkage	   specificity	   can	   also	   be	   achieved,	   provided	   if	   the	   tandem	  
UBDs	   are	   of	   the	   same	   type,	   since	   their	   avidity	   are	   exactly	   the	   same	   so	   that	  
simultaneous	   high-­‐affinity	   interaction	   is	   favoured	   for	   one	   linkage	   type	  but	   not	   the	  
other.	   	   	  For	  example,	  BRCA1	  which	  mediates	  DNA	  repair	  has	  a	  double	  UIM	  domain	  




1.2.3.4	  	   Deubiquitylases	  (DUBs)	  
	  
	   Another	  important	  feature	  of	  ubiquitin-­‐dependent	  regulatory	  mechanisms	  is	  
the	   plasticity	   and	   diversity	   enabled	   by	   the	   DUBs,	   which	   are	   capable	   of	   ubiquitin-­‐
chain	  editing	  or	  removal.	  The	  human	  genome	  encodes	  about	  90	  DUBs	  and	  they	  fall	  
into	   5	   categories,	   namely	   the	   ubiquitin	   specific	   proteases	   (USPs),	   ubiquitin	   C-­‐
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terminal	   hydrolases	   (UCHs),	   Machado	   Joseph	   Disease	   proteins	   (MJDs),	   ovarian	  
tumour	   proteases	   (OTUs)	   and	   JAB1/MPN/Mov4	   metalloenzymes	   (JAMMs)	  
(Komander	  et	  al.,	  2009).	  Among	  these,	  the	  USPs,	  UCHs,	  MJDs	  and	  OTUs	  are	  cysteine	  
proteases	  while	  JAMMs	  are	  metalloproteases.	  	  
	  
	   There	  are	  three	  major	  functional	  roles	  of	  DUBs	  (Figure	  1.15):	  (1)	  processing	  of	  
newly	   translated	   polyubiquitin	   chains	   or	   ubiquitin	   fused	   to	   ribosomal	   proteins	   to	  
produce	  free	  ubiquitin;	  (2)	  removal	  of	  ubiquitin	  chains	  from	  ubiquitylated	  proteins,	  
leading	   to	   alteration	   of	   stability,	   by	   rescue	   from	   proteasomal	   or	   lysosomal	  
degradation,	   or	   activity	   of	   target	   proteins.	   In	   case	   where	   target	   proteins	   are	  
committed	   for	   degradation,	   the	   retrieval	   of	   ubiquitin	   molecules	   contribute	   to	  
ubiquitin	   homeostasis;	   and	   (3)	   editing	   of	   ubiquitin	   modifications	   by	   trimming	  




Figure	  1.15.	  Functions	  of	  deubiquitylases.	  Functions	  of	  DUBs	  include	  (a)	  processing	  
of	  newly	  translated	  polyubiquitin	  chains	  or	  ubiquitin	  fused	  to	  ribosomal	  proteins	  to	  
produce	   free	   ubiquitin,	   (b)	   rescuing	   protein	   from	   degradation,	   (c)	   removing	   non-­‐
degradative	  signal	   from	  substrates,	   (d)	  maintaining	  ubiquitin	   	  homeostasis	   through	  
recycling	   of	   ubiquitin,	   (e)	   disassembly	   of	   ubiquitin	   chains	   generated	   by	   en	   bloc	  
removal	   from	   substrates	   and	   (f)	   editing	   ubiquitin	   chains	   to	   exchange	   one	   type	   of	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1.2.3.4.1	   Mechanism	  of	  deubiquitylation	  
	  
	   The	  catalytic	  residues	  of	  cysteine	  protease	  DUBs	  either	  consist	  of	  a	  complete	  
catalytic	  triad	  comprising	  a	  cysteine,	  a	  histidine	  and	  an	  aspartic	  acid	  or	  asparagine,	  
or	  a	  catalytic	  diad	  without	  the	  aspartic	  or	  asparagine	  residues	   (Stoner	  and	  Menard	  
1994;	  Komander	  et	  al.,	  2009).	  This	   catalytic	  mechanism	   is	  highly	  conserved	  among	  
the	  cysteine	  and	  serine	  proteases.	  In	  a	  folded	  catalytic	  site,	  the	  histidine,	  which	  is	  in	  
close	   proximity	   to	   the	   cysteine,	   deprotonates	   the	   cysteine	   residue,	   enabling	   its	  
nucleophilic	   attack	   on	   the	   isopeptide	   bond	   between	   ubiquitin	   and	   the	   conjugated	  
substrate	   (Figure	   1.16).	   If	   the	   aspartic	   acid	   or	   asparagine	   is	   present,	   it	   aligns	   and	  
polarizes	  the	  histidine.	  The	  nucleophilic	  attack	  by	  the	  thiol	  group	  of	  the	  cysteine	  then	  
leads	  to	   formation	  of	  a	  negatively	  charged	  acyl-­‐intermediate,	  arising	  from	  covalent	  
conjugation	   of	   the	   thiol	   group	   with	   carboxyl	   group	   of	   the	   conjugated	   ubiquitin,	  
referred	   to	   as	   the	   distal	   ubiquitin.	   At	   the	   final	   step	   of	   the	   reaction,	   the	   acyl-­‐
intermediate	  is	  hydrolysed	  by	  a	  water	  molecule,	  thereby	  releasing	  the	  ubiquitin	  and	  
the	  reaction	  is	  completed.	  	  
	  
The	  JAMM	  family	  DUBs	  are	  zinc-­‐dependent	  metalloproteases,	  characterised	  
by	   three	   highly	   conserved	   residues	   in	   their	   catalytic	   site,	   namely	   histidine,	  
asparagine	  and	  serine,	  which	  coordinate	  two	  zinc	  ions.	  During	  catalysis,	  the	  zinc	  ion	  
incorporated	  in	  the	  catalytic	  site	  activates	  a	  water	  molecule	  to	  form	  a	  hydroxide	  ion,	  
which	  attacks	  the	  carboxyl	  carbon	  of	  the	  isopeptide	  bond,	  leading	  to	  formation	  of	  a	  
non-­‐covalent	  intermediate	  with	  the	  substrate.	  Finally,	  proton	  transfer	  from	  a	  nearby	  
water	  molecule	   further	   breaks	   down	   the	   intermediate,	   resulting	   in	   the	   release	   of	  
ubiquitin	  and	  the	  DUB	  (Komander,	  2010).	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Figure	   1.16.	   Mechanism	   of	   deubiquitylation	   by	   cysteine	   protease	   DUBs.	   (A)	  
Nucleophilic	   attack	  on	   the	   carbonyl	  of	   the	   isopeptide	  bond	  between	   the	   substrate	  
and	  ubiquitin	  by	  the	  catalytic	  cysteine.	  (B)	  The	  resulting	  oxyanion	  intermediate	  turns	  
into	  an	  acyl	   intermediate,	  (C)	  while	  the	  substrate	  is	  being	  released.	  (D)	  and	   (E)	  The	  
hydrolysis	   of	   the	   ubiquitin-­‐DUB	   intermediate	   that	   leads	   to	   (F)	   the	   release	   of	   the	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1.2.3.4.2	   Substrate	  specificity	  of	  DUBs	  	  
	  
	   The	  DUBs	  exhibit	  specificity	  for	  their	  substrates	  at	  multiple	  levels,	  in	  term	  of	  
their	   ability	   to	   distinguish	   between	   ubiquitin	   and	   ubiquitin-­‐like	   molecules,	   sub-­‐
cellular	   localisation,	   specific	   binding	   interactions	   and	   the	   preference	   for	   particular	  
type	  of	  ubiquitin	  chain	  linkages.	  	  
	  
	   The	   human	   genome	   encodes	   17	   ubiquitin-­‐like	   modifiers,	   which	   all	   take	   a	  
characteristic	  ubiquitin	  fold,	  and	  ubiquitin	  is	  one	  of	  them	  (Reviewed	  in	  Hochstrasser,	  
2009).	  Among	  these,	  SUMO	  (small	  ubiquitin-­‐like	  modifier),	  Nedd8	  (neural	  precursor	  
cell	   expressed,	   developmentally	   down-­‐regulated	   8),	   ISG15	   (Interferon	   stimulated	  
gene	   15)	   and	   Atg12	   (autophagy	   related	   protein	   12)	   are	   conjugated	   to	   their	  
substrates	   in	   a	   similar	   mechanism	   to	   ubiquitin,	   resulting	   in	   topologically	   similar	  
modifications	   (Dye	  and	  Schulman,	  2007;	  Komander,	  2010).	  However,	   the	  DUBs	  are	  
able	   to	   distinguish	   between	   these	   modifications	   and	   the	   selectivity	   for	   ubiquitin	  
modifications	  lies	  partly	  in	  the	  four	  residues	  preceding	  the	  diglycine	  motif	  at	  the	  C-­‐
terminus	   of	   ubiquitin.	   SUMO	   and	   Atg12	   do	   not	   share	   sequence	   similarity	   with	  
ubiquitin	  in	  this	  region	  and	  are	  therefore	  not	  recognised	  by	  DUBs.	  However,	  Nedd8	  
and	  ISG15	  have	  identical	  sequence	  as	  ubiquitin	  in	  this	  region,	  so	  it	  is	  not	  unexpected	  
that	  both	  Nedd8	  and	  ISG15	  modifications	  can	  be	  hydrolysed	  by	  some	  cross-­‐reactive	  
DUBs,	  such	  as	  USP21	  which	  can	  process	  Nedd8	  modifications	  (Gong	  et	  al.,	  2000)	  and	  
USP2,	  USP5,	  USP13,	  USP14	  and	  USP18,	  which	  are	   crossreactive	   for	   ISG15	   (Catic	  et	  
al.,	  2007).	  	  
	  
	   Many	  DUBs	  contain	  additional	  protein	   interaction	  domains	   to	  allow	  specific	  
sub-­‐cellular	   localisation	   or	   substrate	   recognition	   (Komander,	   2000).	   	   For	   example,	  
the	   ubiquitin	   specific	   proteases	   (USPs),	   USP19	   and	   USP30	   have	   predicted	  
transmembrane	   domain,	   which	   enables	   them	   to	   specifically	   localise	   to	   the	   ER	  
(Hassink	  et	  al.,	   2009)	  and	  mitochondria	   (Nakamura	  and	  Hirose,	  2008)	   respectively.	  	  
USP19	   is	   implicated	   in	   regulation	   of	   the	   unfolded	   protein	   response	   and	   ER-­‐
associated	  degradation	   (ERAD)	   (Hassink	  et	  al.,	   2009)	  whereas	  USP30	   is	   involved	   in	  
regulation	   of	  mitochondrial	  morphology	   (Nakamura	   and	   Hirose,	   2008).	   In	   another	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instance,	  many	  DUBs	   contain	   additional	   ubiquitin	  binding	  domains,	  which	   regulate	  
their	  activity	  and/or	  specificity,	  and	  allow	  them	  to	  recognise	  ubiquitylated	  substrates	  
(Komander	   et	   al.,	   2009).	   The	  UIMs	   of	   USP25	   (Meulmeester	   et	   al.,	   2008),	   OTUD25	  
(Kagayaki	  et	  al.,	  2007)	  and	  ATXN3	  (Mao	  et	  al.,	  2005)	  are	  essential	  for	  the	  activities	  of	  
the	  DUBs	  to	  efficiently	  hydrolyse	  polyubiquitin	  chains.	  	  
	  
	   Another	   distinct	   feature	   of	   DUB	   specificity	   is	   the	   ability	   of	   some	   DUBs	   to	  
distinguish	  between	  different	  ubiquitin	  chain	  linkages	  (Komander	  et	  al.,	  2009).	  	  Our	  
laboratory	  provided	  the	  first	  description	  of	   linkage	  specificity	  exhibited	  by	  the	  DUB	  
AMSH	   (associated	  molecule	   with	   SH3	   domain	   of	   STAM)	   (McCullough	   et	   al.,	   2004;	  
McCullough	   et	   al.,	   2006).	   AMSH	   (McCullough	   et	   al.,	   2004)	   and	   its	   close	   relative,	  
AMSH-­‐like	  protein	   (AMSH-­‐LP)	   (Nakamura	  et	  al.,	   2006)	  have	  been	  demonstrated	   to	  
be	   stringently	   selective	   for	   Lys63-­‐	   linked	   ubiquitin	   chains.	   	   A	   structural	   analysis	   of	  
AMSH-­‐LP	   bound	   to	   a	   Lys63-­‐linked	   diubiquitin	   chain	   provided	   important	   insight	   of	  
Lys63	  specificity	  of	  DUBs	   (Sato	  et	  al.,	  2008).	  A	  Lys63-­‐linked	  polyubiquitin	  chain	  has	  
an	  extended	  conformation	  (Komander	  et	  al.,	  2009b)	  and	  is	  stretched	  maximally	  upon	  
binding	  to	  AMSH-­‐LP.	  Notably,	  the	  sequence	  context	  of	  the	  Lys63	  residue,	  Gln62	  and	  
Glu64,	  make	   specificity-­‐determining	   contacts	   to	   the	  AMSH-­‐LP	  protein.	  Other	  DUBs	  
which	   have	   been	   shown	   to	   exhibit	   linkage	   specificity	   include	   CYLD,	   which	   also	  
cleaves	   Lys63-­‐linked	   ubiquitin	   chains	   (Komander	   et	   al.,	   2008);	   Cezanne,	   which	  
cleaves	  Lys11-­‐linked	  ubiquitin	  chains	  (Bremm	  et	  al.,	  2010);	  TRABID,	  which	  is	  capable	  
of	  cleaving	  Lys29-­‐linked	  ubiquitin	  chains	  (Virdee	  et	  al.,	  2010).	  	  	  
	  
	  
1.2.3.4.3	   Ubiquitin	  specific	  proteases	  (USPs)	  
	  
	   The	  USPs	   represent	   the	   largest	  and	  most	  diverse	   family	  of	  DUBs	   in	  human,	  
comprising	  of	  56	  distinct	  members	  with	  size	  ranging	  from	  350	  to	  3400	  amino	  acids	  
and	  are	  defined	  by	  presence	  of	   catalytic	  USP	  domain	   (Komander,	   2010).	   	   The	  USP	  
domain	   varies	   in	   size	   across	   the	   USP	  members,	   from	   295	   aa	   to	   850	   aa	   (Ye	   et	   al.,	  
2009).	  Among	  these,	  27	  out	  of	  the	  56	  USP	  domains	  are	   less	  than	  400aa.	  Structural	  
analysis	   of	   the	  USP	  domain	   reveal	   a	   structure	   resembling	   right	  hand,	   consisting	  of	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three	  structural	  sub-­‐domains:	  Palm,	  Thumb	  and	  Fingers.	  The	  catalytic	  site	  lies	  at	  the	  
interface	  between	  the	  Palm	  and	  Thumb,	  while	  the	  Fingers	  domain	  binds	  to	  the	  distal	  
ubiquitin	  (Komander,	  2010).	  	  
	  
Multiple	   sequence	   alignment	   of	   all	   the	   USP	   domains	   reveals	   that	   the	   core	  
catalytic	  domain	  has	  a	   length	  of	  about	  350	  aa	  and	   there	  are	  6	  conserved	  boxes	  of	  
amino	   acid	   residues.	   These	   conserved	   boxes	   are	   interspersed	   with	   insertions	   of	  
amino	  acids	   stretches,	   some	  of	  which	   fold	   into	   functional	  domains	   like	  UBL	   (USP4,	  
USP6,	  USP11,	  USP15,	  USP19,	  USP31,	  USP32	  and	  USP43),	  B-­‐box	  (CYLD)	  and	  ubiquitin	  
binding	   domains	   (ubiquitin	   associated	   domain	   (UBA)	   in	   USP5	   and	   ubiquitin	  
interacting	  motif	  (UIM)	  in	  USP37).	  The	  regions	  outside	  of	  the	  USP	  domains	  comprise	  
numerous	  other	   (predicted)	  domains,	  which	   confer	  protein	  binding	  ability,	   such	  as	  
the	  CAP-­‐Gly	  domain,	  UIM	  and	  UBA;	   and	  which	  determines	   subcellular	   localization,	  
such	   as	   transmembrane	   domain	   and	   CAAX-­‐box	   in	   USP32	   (Komander	   et	   al.,	   2009;	  
Komander,	   2010).	   As	   mentioned	   before,	   USP19	   and	   USP30,	   which	   localise	   to	  
endoplasmic	   reticulum	   and	   mitochondria	   respectively,	   both	   have	   a	   predicted	  
transmembrane	   domain.	   The	   UBL	   domains	   are	   also	   found	   outside	   of	   the	   catalytic	  
region	   and	   there	   are	   at	   least	   18	   DUBs	   containing	   one	   or	  more	  UBL	   domain	   (both	  
inside	   and	   outside	   of	   USP	   domain),	   suggesting	   a	   general	   role	   of	   this	   domain	   in	  
regulation	  of	  the	  DUB	  activity,	  which	  remains	  to	  be	  understood.	  	  
	  
	  
1.2.3.4.4	   Ubiquitin	  C-­‐terminal	  hydrolase	  (UCH)	  
	  
	   The	  UCH	   is	   a	   small	   family	   of	  DUBs,	   comprising	   of	   4	  members	   only,	   namely	  
UCHL1,	  UCHL3,	  UCHL5	  and	  BAP1.	  The	  UCH	  domain	  has	  a	  size	  of	  about	  210	  aa.	  For	  
UCHL1	   and	   UCHL3,	   the	   catalytic	   domain	   spans	   almost	   the	   entire	   length	   of	   the	  
protein	   (Komander	   et	   al.,	   2009).	   UCHL5	   has	   the	   UCH	   domain	   on	   the	   N-­‐terminus,	  
followed	  by	  an	  extension	  of	  about	  100aa,	  which	  is	  important	  for	  its	  incorporation	  to	  
the	  proteasome	  subunit	  Rpn13	   (Hamazaki	  et	  al.,	  2006;	  Qiu	  et	  al.,	  2006;	  Yao	  et	  al.,	  
2006).	  BAP1	  is	  the	  largest	  member	  among	  the	  UCHs	  with	  a	  size	  of	  730	  aa.	  It	  has	  its	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UCH	  domain	  on	  the	  N-­‐terminus,	  and	  two	  predicted	  nuclear	  localisation	  signals	  (NLS)	  
at	  the	  N-­‐terminus.	  	  
	  
	   In	  vitro	  studies	  to	  assess	  the	  DUB	  activity	  of	  UCHL1	  and	  UCHL3	  show	  that	  the	  
two	  proteins	  are	  unable	  to	  process	  linear,	  Lys48	  or	  Lys63-­‐linked	  tetraubiquitin	  chain	  
(Komander	  et	  al.,	  2009).	  An	  explanation	  was	  offered	  when	   the	  structure	  of	  UCHL3	  
was	   revealed	   that	   there	   is	   a	   prominent	   loop	   covering	   its	   active	   site,	   hindering	  
substrate	   accessibility	   (Johnston	   et	   al.,	   1997).	   Upon	   ubiquitin	   binding,	   this	   loop	  
straddles	   the	  C-­‐terminal	   residues	  of	  ubiquitin	   that	   resides	   in	   the	  UCHL3	  active	   site	  
(Johnston	  et	  al.,	  1999).	  Due	  to	  the	  presence	  of	  this	  loop,	  it	  is	  unlikely	  for	  the	  UCHs	  to	  
accommodate	  ubiquitin	  chains	  or	  ubiquitylated	  proteins	  that	  are	  too	  large	  to	  fit	  into	  
the	  space	  allowed	  by	  the	  loop.	  It	  is	  therefore	  proposed	  that	  UCHs	  can	  only	  remove	  
ubiquitin	  from	  small	  peptide	  conjugates,	  such	  as	  the	  degradative	  fragments	  resulting	  
from	  proteasomal	  or	  lysosomal	  degradation	  (Komander	  et	  al.,	  2009).	  However,	  there	  
is	   evidence	   showing	   activity	   of	   UCH	   enzymes	   on	   unfolded	   large	   substrates	   and,	  
accordingly,	  can	  potentially	  deubiquitylate	  termini	  of	  proteins,	  which	  can	  fit	  into	  the	  
covered-­‐active	  site	  (Johnston	  et	  al.,	  1999).	  	  	  	  	  
	  
	  
1.2.3.4.5	   Machado-­‐Joseph	  disease	  proteins	  (MJD)	  	  
	  
	   The	  MJD	  family	  also	  has	  four	  members,	  namely	  ATXN3,	  ATXN3L,	  JOSD1	  and	  
JOSD2,	  characterised	  by	  the	  presence	  of	  catalytic	   Josephin	  domain,	  which	  was	  first	  
identified	   by	   bioinformatics	   (Scheel	   et	   al.,	   2003).	   ATXN3	   is	   the	   most	   well-­‐known	  
member	  of	  the	  family	  and	   is	   found	  mutated	   in	  Machado-­‐Joseph	  disease,	  a	   form	  of	  
neurodegenerative	   disorder	   termed	   spinocerebellar	   ataxia	   (Riess	   et	   al.,	   2008).	   All	  
four	   members	   of	   the	   MJD	   family	   are	   able	   to	   hydrolyse	   Lys48-­‐	   and	   Lys63-­‐linked	  
polyubiquitin	  chains	  in	  vitro	  (Weeks	  et	  al.,	  2011).	  The	  Josephin	  domain	  of	  ATXN3	  was	  
shown	  to	  exhibit	  deneddylase	  activity	  against	  substrate	  modified	  by	  NEDD8,	  which	  is	  
a	  ubiquitin	   like	  molecule	   (Ferro	  et	  al.,	  2007).	  Together,	   these	  observations	   indicate	  
that	   Josephins	   may	   be	   promiscuous	   DUBs	   exhibiting	   low	   level	   of	   substrate	  
specificity.	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   Nuclear	  magnetic	  resonance	  (NMR)	  studies	  of	  the	  Josephin	  domain	  of	  ATXN3	  
reveal	  the	  presence	  of	  a	  large	  helical	   lever	  that	  limits	  accessibility	  to	  the	  active	  site	  
(Mao	  et	  al.,	  2005;	  Nicastro	  et	  al.,	  2005).	  Nicastro	  and	  colleagues	  showed	  that	  ATXN3	  
has	   two	   distinct,	   contiguous	   ubiquitin	   binding	   sites	   (Nicastro	   et	   al.,	   2009).	   By	  
performing	   a	   NMR-­‐based	   docking	   analysis,	   it	   was	   shown	   that	   this	   helical	   arm	   is	  
displaced	   upon	   docking	   of	   a	   diubiquitin	   onto	   ATXN3,	   suggesting	   that	   ubiquitin	  
binding	  favours	  an	  active	  conformation	  of	  ATXN3.	  Interestingly,	  ubiquitylation	  of	  the	  
Josephin	  domain	   itself	  activates	  an	  active	  conformation	  of	   the	  enzyme	  (Todi	  et	  al.,	  
2009).	  This	  leads	  to	  the	  speculation	  that	  ubiquitylation	  renders	  the	  helical	  lever	  in	  an	  
open	  conformation	  (Komander,	  2010).	  	  	  
	  
	  
1.2.3.4.6	   Ovarian	  tumour	  proteases	  (OTU)	  
	  
	   There	  are	  16	  OTU	  family	  DUBs	   in	  human	  that	  have	  been	  described	  to	  date,	  
and	   they	   are	   cysteine	   proteases	   with	   an	   incomplete	   catalytic	   triad	   that	   lacks	   the	  
aspartate	  or	  asparagine	  residues	  (Balakirev	  et	  al.,	  2003).	  The	  OTU	  catalytic	  core	  has	  a	  
size	   between	   150	   and	   200	   aa.	   Although	   the	   OTU	   domain	   adopts	   a	   very	   different	  
structure	   from	   the	  USP	   domain,	   the	   catalytic	   residues	   of	   the	   two	   classes	   of	   DUBs	  
superpose	  well	   (Komander	  and	  Barford,	  2008).	  However,	  unlike	  the	  USPs,	   the	  OTU	  
DUBs	  are	  more	  divergent	  at	  both	  sequence	  and	  structural	  levels,	  and	  can	  be	  further	  
divided	   into	   three	  subfamilies,	  namely	  Otubains,	  OTU-­‐domain	   (OTUD)	  and	  A20-­‐like	  
OTUs	   (Komander	   et	   al.,	   2009).	   The	   Otubains	   comprise	   of	   only	   two	   DUBs,	   namely	  
OTUB1	  and	  OTUB2,	  and	   they	  are	   the	  smallest	  among	   the	  OTUs,	  with	  a	   size	  of	   less	  
than	  280	  aa,	  whereas	  the	  OTUDs	  represent	  the	  largest	  OTU	  subfamily.	  	  The	  A20-­‐like	  
OTUs	  are	  the	  largest	  OTUs	  and	  have	  an	  extended	  catalytic	  core	  of	  ~360	  aa.	  
	  
Similar	   to	  some	  USP	  domains,	  ubiquitin	  binding	   to	   the	  distal	  binding	  site	  of	  
the	  OTU	  domain	  of	  yeast	  OTU1	  induces	  a	  disorder-­‐to-­‐order	  transition	  (Messick	  et	  al.,	  
2008).	   An	   unproductive	   configuration	   of	   active	   site	   has	   also	   been	   reported	   for	  
OTUB1	   and	   that	   conformational	   change	   is	   required	   for	   activation	   of	   the	   enzyme	  
(Edelmann	  et	  al.,	  2009).	  Such	  an	  inactive	  conformation	  of	  enzyme	  at	  resting	  state	  is	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not	   unique	   to	   OTUs	   but	   have	   also	   been	   described	   in	   other	   DUB	   families	   and	   it	   is	  
proposed	   to	  minimise	  oxidative	  stress	   to	   the	  catalytic	   cysteine	   residue	   (Komander,	  
2010).	  	  
	  
Multiple	   members	   of	   the	   OTU	   DUBs	   exhibit	   high	   chain	   linkage	   specificity.	  
TRABID	  and	  DUBA	  preferentially	  acts	  on	  Lys63-­‐linked	  chains	   (Kayagaki	  et	  al.,	  2007;	  
Komander	  et	  al	  2009b)	  while	  OTUB1	  is	  Lys48-­‐specific	  (Edelmann	  et	  al.,2009).	  	  
	  
	  
1.2.3.4.7	   JAB1/MPN/Mov4	  metalloenzymes	  (JAMM)	  	  
	  
	   There	  are	  8	  members	  of	  the	  JAMM	  family	  DUBs	  and	  their	  size	  varies	  from	  300	  
to	   over	   2000	   aa,	   but	   the	   conserved	   JAMM	  domain	   is	   only	   about	   100	   aa.	  Multiple	  
members	   of	   the	   JAMM	  DUBs	   are	   found	   operating	   as	   part	   of	   a	  multimeric	   protein	  
complex	   (Komander,	   2010).	   POH1	   (also	   known	   as	   PSMD14)	   is	   associated	   to	   the	  
proteasome	  and	  plays	  a	  role	  in	  recycling	  of	  ubiquitin	  chains,	  thereby	  contributing	  to	  
ubiquitin	   homeostasis	   (Finley,	   2009).	   AMSH	   (associated	   molecule	   with	   the	   SH3	  
domain	  of	  STAM)	  and	  AMSH-­‐LP	  (AMSH-­‐like	  protein)	  are	  associated	  to	  the	  endosomal	  
sorting	   complex	   required	   for	   transport	   (ESCRT)	   and	   are	   involved	   in	   trafficking	   of	  
membrane	   protein	   (Williams	   and	   Urbé,	   2007).	   CSN5	   forms	   part	   of	   the	   COP9	  
signalosome	  and	  deneddylates	   the	  Cullin	  E3	   ligase	   (Cope	  et	  al.,	  2002).	  MYSM1	   is	  a	  
component	   of	   the	   histone	   deubiquitinase	   complex	   (Zhu	   et	   al.,	   2007).	   BRCC36	   has	  
been	  found	  in	  the	  BRCA1	  A	  complex	  involved	  in	  DNA	  repair	  processes	  (Dong	  et	  al.,	  
2003)	   and	   in	   the	   BRCC36	   isopeptidase	   complex	   for	   which	   the	   cellular	   function	   is	  
unknown	  (Cooper	  et	  al.,	  2009).	  
	  
	   Interestingly,	   six	   of	   the	   eight	   human	   JAMMs,	   (CSN5,	   AMSH	   (McCullough	  et	  
al.,	   2004),	  AMSH-­‐LP,	  BRCC36	   (Cooper	  et	  al.,	   2009),	  POH1	  and	  MYSM1)	  are	  able	   to	  
process	   Lys63-­‐linked	   ubiquitin	   chains	   (Komander	   et	   al.,	   2009).	   Given	   the	   diverse	  
roles	  of	  Lys63	  ubiquitin	  linkages,	  the	  linkage	  specificity	  of	  the	  JAMMs	  suggests	  their	  
important	  regulatory	  roles.	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1.2.3.5	  	   Cellular	  roles	  of	  ubiquitylation	  	  
	   	  
Ubiquitylation	  is	  involved	  in	  the	  regulation	  of	  diverse	  cellular	  processes,	  such	  
as	  proteasomal-­‐mediated	  protein	  degradation,	  endocytic	   trafficking,	   transcriptional	  
regulation	  and	  cell	  signalling.	  	  	  
	  
	  
1.2.3.5.1	   Proteasomal-­‐mediated	  protein	  degradation	  
	   	  
	   Ubiquitylation	   was	   first	   identified	   as	   a	   post-­‐translational	   modification	   that	  
targets	   protein	   for	   degradation	   by	   the	   proteasome	   (Ciechanover,	   2005).	   The	  
proteasomal-­‐mediated	  protein	  degradation	   is	   important	   for	  cellular	  processes	  such	  
as	  protein	  quality	  control,	  antigen	  processing,	  signal	  transduction,	  cell	  cycle	  control,	  
cell	  differentiation	  and	  apoptosis	  (Voges	  et	  al.,	  1999).	  Besides,	  the	  proteasome	  also	  
serves	   an	   important	   function	   of	   retrieving	   ubiquitin	   prior	   to	   degradation	   of	   the	  
polyubiquitylated	   substrates,	   thereby	   contributing	   to	   ubiquitin	   homeostasis	  
(Komander	  et	  al.,	  2009).	  This	  is	  achieved	  by	  the	  activities	  of	  the	  three	  proteasomal-­‐
associated	   DUBs,	   namely	   POH1,	   USP14	   and	   UCHL5,	   which	   can	   remove	   ubiquitin	  
chains	   from	   the	   substrates.	   Besides,	   there	   is	   also	   a	   growing	   notion	   that	   the	  DUBs	  
provide	  a	  proof-­‐reading	  mechanism	  by	  facilitating	  release	  of	  substrate	  proteins	  from	  
the	  proteasome	  if	  they	  are	  not	  commited	  to	  degradation	  within	  a	  given	  time	  window	  
(Clague	  and	  Urbé,	  2010).	   Jacobson	  and	  colleagues	  demonstrated	   that	   the	   levels	  of	  
Lys63-­‐linked	   ubiquitin	   chains	   are	   unaffected	   by	   short-­‐time	   inhibition	   of	  
proteasomes.	   While	   both	   Lys48-­‐	   and	   Lys63-­‐linked	   ubiquitin	   chains	   bind	   to	  
proteasome	   with	   comparable	   affinities	   in	   vitro,	   Lys63-­‐linked	   ubiquitin	   chains	   are	  
deubiquitylated	  six-­‐fold	  more	  rapidly	  than	  Lys48-­‐linked	  ubiquitin	  chains.	  Moreover,	  
UbcH10	  conjugated	  to	  Lys48-­‐linked	  tetraubiquitin	  chain	  is	  targeted	  for	  proteasomal	  
degradation	   whereas	   Lys63-­‐linked	   tetraubiquitin	   chain	   conjugated	   to	   UbcH10	   is	  
rapidly	  	  deubiquitylated	  but	  UbcH10	  is	  not	  efficiently	  degraded.	  Together,	  these	  data	  
suggest	   that	   the	   preferential	   proteasomal	   DUB	   activity	   towards	   Lys63-­‐linked	  
ubiquitin	  chains	  is	  selecting	  against	  Lys63-­‐chain	  modified	  substrates	  for	  proteasomal	  
degradation	  (Jacobson	  et	  al.,	  2009).	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1.2.3.5.2	   Endocytic	  trafficking	  	  	  
	  
	   The	  first	  evidence	  for	  the	  role	  of	  ubiquitylation	  in	  membrane	  trafficking	  came	  
from	  the	  work	  of	  Hicke	  and	  Riezman,	  which	  demonstrated	  that	  efficient	  endocytosis	  
of	  Ste2p,	  a	  G-­‐protein	  coupled	  membrane	  receptor	  in	  yeast,	  requires	  ubiquitylation	  of	  
the	   protein	   (Hicke	   and	   Riezman,	   1996).	   This	   was	   later	   shown	   to	   be	   a	   signal	   for	  
endocytosis	   of	   other	  membrane	   proteins,	   such	   as	   the	   yeast	   uracil	   permease	   Fur4	  
(Galan	   et	   al.,	   1996),	   growth	   hormone	   receptor	   in	   Chinese	   hamster	   (Strous	   et	   al.,	  
1996)	   and	   epidermal	   growth	   factor	   receptor	   in	   human	   (Stang	  et	   al.,	   2004).	  Unlike	  
proteasomal	   degradation	   of	   protein,	   which	   requires	   polyubiquitylation	   of	   the	  
substrate,	   monoubiquitylation	   suffices	   as	   a	   signal	   for	   endocytosis	   (Terrell	   et	   al.,	  
1998;	  Haglund	  et	  al.,	  2003).	  	  
	  
While	  ubiquitylation	  was	  first	  discovered	  to	  be	  a	  signal	  for	  endocytosis,	  it	  was	  
later	   revealed	   that	   it	   plays	   a	   more	   prominent	   role	   as	   a	   signal	   for	   sorting	   of	  
membrane	   proteins	   into	   the	   intraluminal	   vesicles	   (ILVs)	   during	   formation	   of	  
multivesicular	   bodies	   (Hurley	   and	   Stenmark,	   2011).	   Following	   endocytosis,	   the	  
ubiquitylated	  membrane	  protein	  trafficks	  to	  the	  early	  endosome	  and	  is	  captured	  by	  
the	   endosomal	   sorting	   complex	   for	   transport	   (ESCRT)	   machineries.	   The	   ESCRT	  
machineries	   then	  mediate	   the	   sorting	  of	   the	  ubiquitylated	   cargo	  protein	   into	   ILVs.	  
Multiple	   components	   of	   the	   ESCRT	   complexes	   contain	   ubiquitin-­‐binding	   domains,	  
which	   allow	   them	   to	   interact	   with	   the	   ubiquitylated	   cargo	   and	   therefore	   ensures	  
efficient	  concentration	  of	  the	  cargo	  into	  a	  MVB	  (Railborg	  and	  Stenmark,	  2009).	  Both	  
hepatocyte	  growth	   factor	   regulated	   substrate	   (Hrs)	   and	   signal	   transducing	  adaptor	  
molecule	  (Swanson	  et	  al.,2003)	  of	  ESCRT-­‐0	  bind	  ubiquitylated	  cargo	  via	  their	  UIMs.	  
Tsg101	  (tumour	  suppressor	  gene	  101)	  of	  ESCRT-­‐I	  binds	  ubiquitin	  via	  its	  ubiquitin	  E2	  
variant	  	  (UEV)	  domain	  whereas	  ubiquitin	  binding	  of	  Vps36	  of	  ESCRT-­‐II	  is	  conferred	  by	  
its	  GLUE	  (GRAM-­‐like	  ubiquitin-­‐binding	  in	  Eap45)	  domain.	  	  
	  
Although	   ubiquitylation	   signals	   sorting	   of	   proteins	   into	   the	   MVBs,	   the	  
deubiquitylation	  of	  the	  cargo	  by	  a	  DUB	  is	  also	  essential	  for	  efficient	  sorting	  (Raiborg	  
and	  Stenmark,	  2009).	  In	  mammalian	  cells,	  two	  DUBs	  of	  different	  families,	  AMSH	  and	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USP8	   (also	   known	   as	   UBPY),	   are	   found	   recruited	   to	   ESCRT-­‐0	   (through	   interaction	  
with	  STAM)	  (McCullough	  et	  al.,	  2006;	  (Mizuno	  et	  al.,	  2006;	  Row	  et	  al.,	  2006),	  ESCRT-­‐
II	   (through	   interaction	   with	   Alix)	   (Luhtala	   and	   Odorizzi,	   2004)	   and	   ESCRT-­‐III	  
complexes	   (through	   interaction	   with	   CHMP3)	   (Agromayor	   and	   Martin-­‐Serrano,	  
2006).	  The	  DUBs	  may	  play	  a	  role	  in	  promoting	  disengagement	  of	  the	  cargo	  from	  the	  
ESCRT	  machineries	   or	   to	   deubiquitylate	   cargo	   that	   is	   not	   destined	   for	   sorting	   into	  
MVB	   (Williams	   and	   Urbé,	   2007;	   Raiborg	   and	   Stenmark,	   2009).	   Proteins	   which	   are	  
sorted	  into	  the	  MVB	  are	  eventually	  degraded	  via	  the	  lysosomal	  pathway.	  	  
	  
Several	  receptor	  tyrosine	  kinases	  (RTKs),	  such	  as	  EGFR,	  Met	  receptor	  for	  HGF	  
and	   platelet-­‐derived	   growth	   factor	   receptor	   (PDGFR),	   upon	   stimulation	   by	   their	  
cognate	   ligands,	   become	   ubiquitylated	   by	   the	   RING	   E3	   ligase	   Cbl	   (Marmor	   and	  
Yarden	   2004).	   The	   polyubiquitylation	   results	   in	   their	   endocytosis	   and	   subsequent	  
sorting	   into	   the	  MVB	  before	   fusion	  with	   lysosome	   for	   degradation.	   Therefore,	   the	  
ubiquitin-­‐mediated	   endocytosis	   and	   sorting,	   serve	   as	   an	   important	   mechanism	   to	  
prevent	  persistent	  activation	  of	  the	  signalling	  pathways.	  	  
	  
	  
1.2.3.5.3	   Ubiquitin	  and	  transcriptional	  regulation	  
	  
	   Both	  the	  proteolytic	  and	  non-­‐proteolytic	  function	  encoded	  by	  ubiquitylation	  
are	  implicated	  in	  the	  process	  of	  transcriptional	  regulation	  (Geng	  et	  al.	  2012).	  	  
	   	  
The	  level	  of	  transcriptional	  activators,	  repressors	  and	  their	  coactivators	  need	  
to	  be	  tightly	  regulated	  in	  order	  to	  fine-­‐tune	  the	  transcriptional	  programme	  that	  they	  
regulate	   (Muratani	   and	   Tansey,	   2003;	   Geng	   et	   al.,	   2012).	   This	   is	   achieved	   by	   the	  
activity	  of	  the	  UPS	  to	  degrade	  these	  proteins	  when	  their	  functions	  are	  not	  required.	  
One	   of	   the	   best-­‐studied	   examples	   of	   this	   is	   the	   regulation	   of	  β-­‐catenin	   level	   (see	  
section	   1.1.2.2.2	   for	   detailed	   description).	   There	   are	   also	   specific	   examples	  where	  
the	   transcriptional	   activators	   are	   subjected	   to	   limited	   proteolysis	   by	   the	   UPS	   to	  
become	   functional.	   For	   example,	   the	   C-­‐terminus	   of	   the	   p105	   precursor	   protein	   is	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degraded	  by	  the	  UPS,	  leaving	  the	  N-­‐terminal	  p50,	  which	  becomes	  part	  of	  the	  NFκB	  
transcription	  complex	  (Palombella	  et	  al.,	  1994).	  	  	  
	  
	   Non-­‐proteolytic	   ubiquitylations	   are	   also	   implicated	   in	   regulation	   of	  
transcription	   (Geng	   et	   al.,	   2012).	   There	   are	   multiple	   mechanisms	   by	   which	  
ubiquitylation	   can	   influence	   activities	   of	   transcriptional	   proteins.	   Firstly,	  
ubiquitylation	  can	  affect	   localisation	  of	  the	  transcription	  proteins.	  For	  example,	  the	  
monoubiquitylation	   of	   FOXO4,	   a	   transcription	   factor	   induced	   upon	   cellular	   stress,	  
results	   in	   its	   translocation	   to	   the	   nucleus	   for	   transcriptional	   activation	   while	   its	  
deubiquitylation	  by	  USP7	  results	  in	  its	  nuclear	  exclusion	  (van	  der	  Horst	  et	  al.,	  2006).	  
Ubiquitylation	  has	  also	  been	  proposed	   to	  allow	   temporal	   control	  of	   transcriptional	  
activity.	   SRC-­‐3	   (steroid	   receptor	   coactivator-­‐3),	   a	   coactivator	   for	  hormone-­‐liganded	  
transcription	  factor,	  becomes	  activated	  upon	  monoubiquitylation	  (Wu	  et	  al.,	  2007).	  
The	  extension	  of	   the	  ubiquitin	  chain	  on	  SCR-­‐3	  beyond	  a	  certain	   limit	   renders	   it	   for	  
proteasome	   mediated	   degradation.	   The	   time	   taken	   for	   extension	   of	   the	  
polyubiquitin	   chain	   prior	   to	   degradation	   therefore	   acts	   as	   a	   “molecular	   clock”	   to	  
define	   a	   time	   window	   for	   which	   SRC-­‐3	   can	   activates	   transcription.	   There	   is	   also	  
evidence	   to	   indicate	  ubiquitylation	  affects	  binding	  affinity	  of	   transcription	  proteins	  
to	   their	   target	   sites,	   both	   positively	   and	   negatively	   (Geng	   et	   al.,	   2012).	  
Monoubiquitylation	  of	  the	  yeast	  activator	  Gal4	  enables	  it	  to	  bind	  firmly	  to	  chromatin	  
without	   being	   stripped	   off	   by	   the	   ATPases	   resident	   in	   the	   19S	   base	   complex	   of	  
proteasome	  (Archer	  et	  al.,	  2008).	  	  
	  
	   Besides,	  ubiquitylation	  also	  affects	  chromatin	  structure	  and	  function	  through	  
its	   regulatory	   role	   on	   histones.	   It	   is	   evident	   now	   that	   histone	   ubiquitylation	   is	  
abundant	   within	   cell	   and	   is	   important	   for	   control	   of	   gene	   activity	   (Weake	   and	  
Workman	  2008).	  Ubiquitylation	  of	  histone	  H2A	  is	  typically	  implicated	  in	  compaction	  
of	   chromatin,	   thereby	   repressing	   transcription	   whereas	   H2B	   ubiquitylation	   is	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1.2.3.5.4	   Ubiquitin-­‐dependent	   regulation	   of	   the	   canonical	   Wnt	   signalling	  
pathway	  	  
	  
	   Ubiquitylation	   is	   also	   implicated	   in	   regulation	   of	   different	   aspects	   of	   cell	  
signalling	   pathways,	   by	   regulating	   its	   stability	   of	   signalling	   components,	   activating	  
downstream	   signalling	   through	   proteolytic	   processing	   and	   providing	   a	   surface	   of	  
interaction	   through	   ubiquitin	   chains	   (Haglund	   and	   Dikic,	   2005).	   While	   the	   role	   of	  
ubiquitylation	   in	   cell	   signalling	   is	   best	   exemplified	   by	   its	   implication	   in	   the	   NFκB	  
signalling	   pathway	   (Skaug	   et	   al.,	   2009),	   there	   is	   also	   an	   expanding	   repertoire	   of	  
literature	   reporting	   the	   ubiquitin-­‐dependent	   regulation	   of	   the	   Wnt	   signalling	  
pathway.	  	  
	  
	   Multiple	  components	  of	  the	  canonical	  Wnt	  signalling	  pathway	  are	  subjected	  
to	   modification	   by	   ubiquitylation,	   which	   alters	   their	   stability,	   binding	   affinity,	  
localisation	   and	   activity	   (Tauriello	   and	   Maurice,	   2010).	   As	   mentioned	   before	   (see	  
section	   1.1.2.2.2),	   the	   level	   of	   β-­‐catenin,	   the	   key	   signal	   transducing	   molecule	   of	  
canonical	   Wnt	   signalling	   pathway,	   is	   tightly	   regulated	   by	   the	   UPS	   and	   its	  
ubiquitylation	  is	  mediated	  by	  βTrCP	  (Aberle	  et	  al.,	  1997).	  In	  fact,	  there	  are	  also	  other	  
E3	   ligases	   capable	   of	   ubiquitylating	   β-­‐catenin.	   Siah-­‐1,	   a	   RING	   E3	   ligase,	   which	   is	  
upregulated	  upon	  genotoxic	  stress-­‐mediated	  p53	  activation,	  ubiquitylates	  β-­‐catenin	  
in	   a	   phosphorylation	   independent	   manner	   and	   targets	   it	   for	   proteasomal	  
degradation	   (Liu	   et	   al.,	   2001;	   Matsuzawa	   and	   Reed,	   2001).	   Jade-­‐1,	   is	   another	   E3	  
ligase	   that	   ubiquitylates	   β-­‐catenin	   in	   a	   phosphorylation-­‐dependent	   manner,	   such	  
that	  GSK3β	   activity	   is	   a	   prerequisite	   for	   its	   action	   (Chitalia	  et	   al.,	   2008).	   However,	  
unlike	   βTrCP-­‐mediated	   regulation	   of	   β-­‐catenin,	   Jade-­‐1-­‐mediated	   regulation	   of	   β-­‐
catenin	  is	  involved	  both	  in	  the	  absence	  and	  presence	  of	  a	  Wnt	  ligand	  (Tauriello	  and	  
Maurice,	  2010).	  However,	  it	  was	  recently	  revealed	  that,	  ubiquitylation	  on	  β-­‐catenin	  
does	   not	   always	   entail	   proteolysis.	   The	   EDD	   (E3	   ligase	   identified	   by	   differential	  
display),	   a	   HECT	   E3	   ligase,	   ubiquitylates	   β-­‐catenin,	   which	   leads	   to	   its	   enhanced	  
stability	   and	   activity,	   thereby	  upregulating	  Wnt	   signalling	   (Hay-­‐Koren	  et	   al.,	   2011).	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Importantly,	   the	   EDD	   catalyses	   formation	   of	   Lys11-­‐	   or	   Lys29-­‐linked	   polyubiquitin	  
chain,	  instead	  of	  the	  proteolytic-­‐encoding	  Lys48-­‐linked	  chain.	  	  	  	  
	  
	   Besides,	  both	  APC	  and	  Axin,	  the	  components	  of	  the	  destruction	  complex	  of	  β-­‐
catenin,	   are	   regulated	  by	   ubiquitylation.	   Similar	   to	  β-­‐catenin,	   the	   ubiquitylation	  of	  
APC	  by	   EDD	   (discovered	  4	   years	   before	   role	   of	   EDD	  on	  β-­‐catenin	   stabilisation	  was	  
known),	  results	  in	  its	  enhanced	  stabilisation	  and	  facilitates	  β-­‐catenin	  downregulation	  
when	  Wnt	   ligand	   is	   absent	   (Ohshima	  et	   al.,	   2007).	   Conversely,	   upon	   activation	   by	  
Wnt	   ligand,	   APC	   is	   ubiquitylated	   by	   a	   yet-­‐to-­‐be	   identified	   E3	   ligase	   and	   is	  
subsequently	  degraded	  by	   the	  proteasome	   (Choi	  et	  al.,	   2004).	  On	   the	  other	  hand,	  
the	  COP9	  signalosome	  associated	  DUB,	  USP15	  has	  been	  shown	  to	  be	  the	  DUB	  that	  
deubiquitylates	  APC	  and	  leads	  to	  its	  stabilisation	  (Huang	  et	  al.,	  2009).	  	  Recently,	  Tran	  
and	  colleagues	  identified	  TRABID,	  an	  OTU	  DUB,	  regulates	  the	  Wnt	  signalling	  pathway	  
through	   its	   activity	  on	  APC	   (Tran	  et	  al.,	   2008).	   siRNA	  depletion	  of	   TRABID	   leads	   to	  
hyperubiquitylation	   of	   APC	   (possibly	   by	   Lys63-­‐linked	   ubiquitin	   chains	   given	   the	  
strong	  preference	  of	  TRABID	  for	  this	   linkage	  type)	  but	  does	  not	  affect	  APC	  stability	  
(nor	  that	  of	  β-­‐catenin).	  Of	  note,	  APC	  has	  been	  shown	  to	  also	  act	  downstream	  of	  β-­‐
catenin	   stabilisation	   and	   repress	   β-­‐catenin	   mediated	  Wnt	   signalling	   (Sierra	   et	   al.,	  
2006).	  Therefore,	  it	  is	  suggested	  that	  ubiquitylation	  of	  APC	  by	  Lys63-­‐linked	  ubiquitin	  
chain	   leads	   to	   enhanced	   repressive	   activity	  mediated	   by	   APC.	   On	   the	   other	   hand,	  
Stability	  of	  Axin	  is	  regulated	  by	  USP34,	  such	  that	  siRNA	  depletion	  of	  USP34	  results	  in	  
downregulation	   of	   Axin	   (Lui	   et	   al.,	   2011).	   The	   stabilisation	   of	   Axin,	   in	   this	   case,	   is	  
however	   required	   for	   β-­‐catenin-­‐mediated	   transcription	   activation	   but	   the	  
mechanism	  of	  this	  warrants	  further	  research	  efforts.	  	  
	  
	   Dishevelled	   (Dvl),	   which	   is	   important	   for	   both	   canonical	   and	   non-­‐canonical	  
Wnt	  signalling,	  also	  undergoes	  ubiquitin-­‐dependent	  regulation.	  The	  ubiquitylation	  of	  
Dvl	   by	   Kelch-­‐like	   12	   (KLHL12)-­‐Cullin3	   E3	   ligase	   complex	   following	  Wnt	   stimulation	  
results	  in	  its	  proteasomal	  degradation	  (Angers	  et	  al.,	  2006).	  Recently,	  ITCH,	  a	  HECT-­‐
containing	  Nedd4-­‐like	  ubiquitin	  ligase,	  has	  also	  been	  shown	  to	  ubiquitylate	  Dvl	   in	  a	  
phosphorylation	   dependent	   manner	   and	   renders	   it	   for	   proteasomal	   degradation	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(Wei	  et	  al.,	  2012).	  In	  both	  cases,	  the	  ubiquitylation	  and	  degradation	  of	  Dvl	  represent	  
a	  negative	  feedback	  mechanism	  to	  downregulate	  Wnt	  signalling	  following	  activation	  
of	   the	   pathway.	   In	   addition	   to	   regulating	   its	   stability,	   the	   ubiquitylation	   of	   Dvl	   by	  
Lys63-­‐linked	  chain,	  has	  been	  associated	  with	  Dvl	  polymerisation	  and	  stabilisation	  of	  
the	  complex,	  and	  is	  important	  for	  activation	  of	  Wnt	  signalling	  pathway	  (Tauriello	  et	  
al.,	   2010).	   The	   Lys63-­‐linked	   chain	   appended	   to	   Dvl	   can	   be	   removed	   by	   a	   tumour	  
suppressor	   DUB,	   CYLD,	   which	   is	   mutated	   in	   cylindroma	   tumor,	   thereby	   activating	  
Wnt	  signalling.	  	  
	  
	   Recently,	   two	   independent	  groups	  published	   in	  Nature,	  the	   identification	  of	  
two	  homologous	  transmembrane	  RING	  E3	  ligases,	  namely	  RNF43	  (ring	  finger	  43)	  and	  
ZNRF3	  (zinc	  and	  ring	  finger	  3)	  for	  their	  roles	  in	  regulating	  the	  Wnt	  receptor	  complex	  
(Hao	   et	   al.,	   2012;	   Koo	   et	   al.,	   2012).	   Both	   of	   the	   E3	   ligases	   are	   acting	   as	   negative	  
regulators	   of	   the	   Wnt	   signaling	   pathway,	   by	   promoting	   ubiquitylation	   and	  
subsequent	  degradation	  of	  the	  Frizzled	  receptor	  and	  LRP6	  co-­‐receptor.	  	  	  
	  
	  
1.2.3.6	  	   Deubiquitylases	  and	  cancer	  	  
	  
	   Many	   proteins	   regulated	   by	   the	   UPS	   are	   involved	   in	   cellular	   processes	  
germane	  to	  tumourigenesis	  and	  tumour	  progression,	  such	  as	  cell-­‐cycle	  progression,	  
cell	   adhesion,	   apoptosis,	   endocytic	   trafficking	   of	   receptors	   and	   gene	   transcription	  
(Hoeller	   and	  Dikic,	   2009).	  Among	   the	  multiple	   components	  of	   the	  UPS,	   the	   role	  of	  
DUBs	   in	  cancer	   is	  of	  particular	   interest	   to	  our	   lab.	  Since	  ubiquitylation	  of	  a	  protein	  
can	  affect	  its	  stability	  or	  signalling	  function,	  the	  removal	  of	  the	  appended	  ubiquitin(s)	  
therefore	   also	   affects	   either	   of	   these	   two	   aspects,	   but	   in	   the	   opposite	   direction	  
(Sacco	  et	  al.,	  2010).	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Figure	   1.17.	   Deubiquitylases	   are	   important	   regulators	   of	   oncogenes	   and	   tumour	  
suppressor	  proteins.	  The	  loss	  of	  function	  of	  DUBs	  and	  their	  overexpression	  can	  both	  
lead	   to	  development	  of	   cancer.	  DUBs	   regulate	   the	   stability	  of	  an	  oncoprotein	   (e.g.	  
Mdm2)	   or	   a	   tumour	   suppressor	   by	   rescuing	   it	   from	  proteasomal	   degradation	   (e.g.	  
p53).	  	  	  Also,	  DUBs	  can	  regulate	  their	  activity	  (activation	  or	  inactivation)	  by	  editing	  the	  
chains	  appended	  to	  the	  substrates.	  Activation	  may	  refer	  to	  engagement	  in	  signalling	  
protein	  network	   (e.g.	  Dvl)	  or	   translocation	  to	   the	  nucleus	   (e.g.	  FOXO).	  Examples	  of	  
DUBs	  implicated	  in	  cancer	  development	  are	  shown	  with	  their	  cognate	  targets.	  	  
	  
Considering	   the	   stabilising	   effect	   of	   DUBs	   by	   rescuing	   proteins	   from	  
degradation,	   in	   the	   context	   of	   cancer,	   the	   overexpression	   of	   a	   DUB	   regulating	   an	  
oncogenic	   protein	   therefore	   favours	   tumour	   progression	   and	   vice	   versa,	  while	   the	  
opposite	  is	  true	  for	  a	  tumour	  suppressor	  protein	  (Figure	  1.17).	  The	  regulation	  of	  the	  
tumour	  suppressor	  p53	  and	  its	  E3	  ligase,	  MDM2,	  by	  USP7	  is	  a	  good	  embodiment	  of	  
this	   mode	   of	   regulatory	   mechanism.	   Ubiquitylation	   of	   p53	   by	   MDM2	   and	  
autoubiquitylation	   of	   MDM2	   result	   in	   their	   proteasomal	   degradation.	   Therefore,	  
USP7	   has	   a	   dual	   effect	   on	   p53	   stability,	   depending	   on	   whether	   it	   predominantly	  
deubiquitylates	   p53	   or	   MDM2.	   Volgelstein’s	   group	   demonstrated	   that	   under	  
physiological	  condition,	  MDM2	   is	   the	  preferred	  substrate	  of	  USP7	  since	   the	   loss	  of	  
the	  DUB	   leads	   to	   a	   stabilisation	   of	   p53	  while	  MDM2	   is	   degraded	   (Cummins	  et	   al.,	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required	  for	  the	  activation	  of	  a	  signalling	  pathway,	  such	  as	  the	  case	  of	  Lys63-­‐linked	  
modification	   of	   Dvl	   which	   promotes	   Wnt	   signalling	   upstream	   of	   β-­‐catenin,	   the	  
removal	   of	   the	   ubiquitin	   chain	   by	   CYLD	   leads	   to	   suppression	   of	   the	   pathway	  
(Tauriello	   et	   al.,	   2010).	   On	   the	   other	   hand,	   downstream	   of	   β-­‐catenin	   in	   the	  Wnt	  
signalling	  pathway,	  the	  ubiquitylation	  of	  APC	  by	  Lys63-­‐linked	  chain	  actually	  leads	  to	  
attenuation	   of	   Wnt	   signalling	   and	   deubiquitylation	   of	   APC	   by	   TRABID	   leads	   to	  
activation	  of	  the	  pathway	  (Sierra	  et	  al.,	  2006).	  	  
	  	  
	  
1.2.3.6.1	   Emerging	  roles	  of	  BAP1	  in	  cancer	  	  
	  
	   BAP1	   is	   a	   DUB,	   the	   mutations	   of	   which,	   has	   been	   associated	   with	   a	   wide	  
range	  of	  cancers,	   revealing	   its	   tumor	  suppressive	   role	   (White	  and	  Harper,	  2012).	   It	  
also	  turns	  out	  to	  play	  a	  regulatory	  role	  on	  β-­‐catenin,	  a	  proto-­‐oncogene	  based	  on	  my	  
work	  discussed	  in	  chapter	  4.	  	  
	  
	   BAP1	  (BRCA1-­‐associated	  protein	  1)	   is	  the	  largest	  member	  of	  the	  UCH	  family	  
of	  DUB	  comprising	  of	  729	  amino	  acids.	  It	  was	  first	  identified	  as	  an	  interacting	  partner	  
of	  the	  tumour	  suppressor	  BRCA1	  (breast	  and	  ovarian	  cancer	  susceptibility	  protein	  1)	  
(Jensen	  et	  al.,	  1998;	  Jensen	  and	  Rauscher,	  1999).	  	  The	  first	  240	  aa	  of	  BAP1	  comprises	  
its	  UCH	  domain	  and	  there	  are	  two	  putative	  nuclear	  localisation	  signals	  (NLS)	  close	  to	  
its	  C-­‐terminus.	   It	   also	  has	  a	  predicted	   coiled	   coil	   domain	  at	   the	  C-­‐terminus	   (Figure	  
1.18).	  	  
	  
The	  role	  of	  BAP1	  as	  a	  tumour	  suppressor	  was	  already	  recognised	  at	  the	  time	  
when	   it	   was	   discovered	   (Jensen	   et	   al.,	   1998).	   Its	   activity	  was	   required	   for	   BRCA1-­‐
mediated	   inhibition	   of	   breast	   cancer	   cell	   growth	   and	   intragenic	   homozygous	  
rearrangement	   and	   deletions	   of	   BAP1	   was	   detected	   in	   lung	   carcinoma	   cell	   lines.	  
However,	  BAP1	  was	  only	  confirmed	  as	  a	  bona	  fide	  tumor	  suppressor	  two	  years	  ago	  
following	   exome	   sequencing	   of	   metastatic	   uveal	   melanoma	   (UM)	   (Harbour	   et	   al.,	  
2010).	   BAP1	  was	   found	  mutated	   in	   only	   one	   of	   twenty-­‐six	   samples	   of	   class	   I	   (low	  
metastatic	   risk)	  UM	  but	  was	   found	  mutated	   in	   twenty-­‐six	  out	  of	   thirty-­‐one	   class	  2	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UM	  (high	  metastatic	   risk)	   samples	   that	  were	  analysed.	   siRNA	  depletion	  of	  BAP1	   in	  
92.1	  UM.1	  cells,	  which	  did	  not	  harbour	  detectable	  BAP1	  mutation,	   led	   the	  cells	   to	  
acquire	   features	   reminiscent	   of	   class	   2	   clinical	   biopsy	   samples.	   Together,	   these	  
suggest	  that	   loss	  of	  BAP1	  is	  a	  prerequisite	  for	  acquisition	  of	  metastatic	  state	  of	  the	  
cancer.	   Importantly,	   in	   this	   study,	   it	   was	   revealed	   that	   BAP1	   mutations	   are	  
heterogenous	  and	  can	  be	  detected	  along	  the	  gene	  (Figure	  1.19).	  It	  is	  intriguing	  how	  
these	   heterogenous	   mutations	   can	   all	   lead	   to	   the	   same	   biological	   outcome.	   The	  
study	   by	   Harbour	   and	   colleagues	   was	   followed	   by	   detection	   of	   BAP1	   somatic	  
mutations	   in	   malignant	   pleural	   mesothelioma	   (Bott	   et	   al.,	   2011)	   and	   renal	   cell	  
carcinoma	   (Pena-­‐Llopis	   et	   al.,	   2012),	   and	   germline	   mutations	   in	   familial	   cancer	  
predisposition	  syndromes	  such	  as	  malignant	  mesothelioma	  (Testa	  et	  al.,	  2011)	  and	  
melanocytic	   tumours	   (Wiesner	  et	  al.,	   2011).	  More	   recently,	   using	  a	  BAP1-­‐deficient	  
mouse	   model,	   Dey	   and	   colleagues	   demonstrated	   that	   the	   loss	   of	   BAP1	   led	   to	  
development	  of	  myeloproliferative	  disorder,	  which	  is	  reminiscent	  of	  human	  chronic	  
myelomonocytic	  leukaemia	  (CMML)	  (Dey	  et	  al.,	  2012).	  	  
	  
	  
Figure	  1.18.	  Domain	  structure	  of	  BAP1.	  BAP1	  has	  a	  conserved	  UCH	  domain	  on	  its	  N-­‐
terminus	  and	  two	  nuclear	  localisation	  signals	  (NLS)	  are	  found	  at	  its	  C-­‐terminus.	  The	  
C-­‐terminus	   also	   has	   a	   predicted	   coiled	   coil	   domain.	   Binding	   sites	   for	   known	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homozygously	   deleted,	   Ventii	   and	   colleagues	   showed	   that	   BAP1	   exerts	   growth	  
suppressive	  effect	  on	   the	  cell	   line	  by	  affecting	   the	  cell	   cycle,	   such	   that	  progression	  
through	  the	  G1-­‐S	  checkpoint	  is	  sped	  up,	  and	  subsequently	  results	  in	  induction	  of	  cell	  
death	  (Ventii	  et	  al.,	  2008).	  Importantly,	  the	  growth	  suppression	  mediated	  by	  BAP1	  is	  
dependent	  on	  its	  enzymatic	  activity	  and	  nuclear	  localisation.	  The	  promotion	  of	  G1/S	  
transition	  during	  cell	  cycle	  by	  BAP1	  has	  also	  been	  demonstrated	  in	  HeLa	  (Nishikawa	  
et	  al.,	  2009)	  and	  MCF10A	  cells	  (Machida	  et	  al.,	  2009).	  The	  role	  of	  BAP1	  on	  cell	  cycle	  
progression	  is	   likely	  mediated	  through	  its	  regulatory	  role	  on	  HCF-­‐1	  (Host	  cell	  factor	  
1),	  which	   is	   known	   to	   play	   a	   role	   in	   transcriptional	   control	   of	   cell	   cycle	   regulation	  
(Tyagi	   et	   al.,	   2007;	   Eletr	   and	  Wilkinson,	   2011).	   Three	   independent	   in	   vitro	   studies	  
(Machida	  et	  al.,	  2009;	  Sowa	  et	  al.,	  2009;	  Yu	  et	  al.,	  2010)	  and	  an	  in	  vivo	  study	  (Dey	  et	  
al.,	  2012)	  have	  all	  identified	  HCF-­‐1	  as	  the	  key	  interacting	  partner	  of	  BAP1,	  and	  other	  
proteins	   also	   found	   in	   the	   complex	   include	   ASXL1	   (additional	   sex	   combs	   like	   1),	  
ASXL2,	   OGT	   (O	   linked-­‐N-­‐acetylglucosamine	   transferase),	   FOXK1	   (forkhead	   box	   K1)	  
and	  FOXK2.	  BAP1	   is	  acting	  as	  part	  of	  a	   transcriptional	  complex	  that	   regulates	  gene	  
transcription	   (Yu	   et	   al.,	   2010).	   Yu	   and	   colleagues	   showed	   that	   siRNA	   depletion	   of	  
BAP1	  leads	  to	  deregulation	  of	  expression	  of	  1244	  genes,	  which	  are	  involved	  in	  wide	  
range	  of	  cellular	  processes	  including	  cell	  cycle,	  DNA	  replication	  and	  repair,	  cell	  death,	  
cellular	  growth	  and	  proliferation	  and	  cellular	  assembly.	  They	   further	  demonstrated	  
that	   BAP1	   associates	   with	   transcriptionally	   active	   chromatin	   and	   forms	   a	   ternary	  
complex	   together	   with	   HCF-­‐1	   and	   YY1	   (Yin	   Yang	   1)	   to	   regulate	   gene	   expression	  
relevant	  to	  cell	  cycle	  progression.	  	  	  
	  
These	  studies	  provide	  a	  foundation,	  which	  further	  understanding	  on	  the	  role	  
of	  BAP1	  in	  tumour	  suppression	  can	  be	  built	  upon.	  It	  is	  intriguing	  how	  the	  wide	  range	  
of	   genes	   affected	   by	   BAP1	   coordinate	   and	   culminate	   in	   consistent	   tumour	  
suppression	  effect	  in	  different	  cancer	  types.	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Figure	  1.19.	  Map	  of	  BAP1	  gene	  and	  positions	  of	  BAP1	  mutations	  detected	  in	  uveal	  
melanoma.	  BAP1	  contains	  17	  exons	  (light	  blue	  boxes)	  that	  encode	  a	  729	  aa	  protein	  
and	   the	   mutations	   detected	   are	   shown	   below	   the	   figure	   as	   indicated.	   Region	  
corresponding	  to	  UCH	  domain	  of	  BAP1	  (pink	  box)	  and	  regions	  involved	  in	  binding	  to	  
HCF1	  and	  BRCA1	  (orange	  boxes)	  are	  shown	  above	  the	  figure	  as	  indicated.	  The	  critical	  
Cys91	   (C),	   His169	   (H)	   and	   Asp184	   (D)	   residues	   in	   the	   catalytic	   sites	   and	   nuclear	  
localisation	  signals	  (NLS1	  and	  2)	  are	  indicated	  (Harbour	  et	  al.,	  2010).	  	  	  
	   	  	  
	  
	  
1.3	   RNA	  interference	  	  
	  
In	   1984,	   Mizuno	   et	   al.	   provided	   the	   first	   evidence	   in	   Escherichia	   coli	   that	  
ribonucleic	   acid	   (RNA)	   can	   regulate	   gene	   expression	   post-­‐transcriptionally	   via	  
complementary	   binding	   of	   a	   RNA	   transcript	   to	   the	   corresponding	  messenger	   RNA,	  
thereby	   inhibiting	   protein	   translation.	   About	   a	   decade	   later,	   two	   groups	  
independently	   identified	   the	   gene	   lin-­‐4,	   which	   encodes	   small	   RNA	   (later	   termed	  
microRNA	   by	   Victor	   Ambros)	   that	   hybridises	   to	   3’	   UTR	   of	   lin-­‐14	   gene	   owing	   to	   its	  
sequence	  complementarity	  and	  regulates	  lin-­‐14	  expression	  via	  a	  post-­‐transcriptional	  
mechanism	   during	   the	   development	   of	   Caenorhabditis	   elegans	   (Lee	   et	   al.,	   1993;	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Wightman	   et	   al.,	   1993).	   	   The	   significance	   of	   this	   finding	   is	   however	   not	   well	  
appreciated	  until	  a	  second	  member	  of	  such	  small	  RNA,	  let-­‐7	  was	  identified	  again	  in	  
C.	   elegans	   and	   more	   importantly,	   similar	   sequences	   were	   found	   in	   other	   species	  
(Reinhart	  et	  al.,	  2000).	  	  
	  
In	   parallel	   to	   this,	   a	   phenomenon	   called	   post-­‐transcriptional	   gene	   silencing	  
(PTGS)	  was	   first	   described	   in	  1990,	  where	   an	  exogenously	   introduced	   cloned	  gene	  
into	   the	   plant	   genome	   was	   found	   to	   inhibit	   expression	   of	   homologous	   gene	  
sequences	  and	  considerable	  amount	  of	  evidence	  were	  demonstrated	  by	  subsequent	  
investigations	  of	  viral	  infection	  in	  plants,	  providing	  clues	  to	  the	  mechanisms	  of	  PTGS.	  
This	   was	   followed	   by	   verification	   of	   similar	   process	   called	   quelling	   in	   the	   fungus	  
Neurospora	  crassa.	  	  
	  
These	   independent	   findings	   provided	   clear	   evidence	   indicating	   the	   roles	   of	  
RNA	  in	  gene	  regulation	  but	  the	  haze	  of	  these	  gene	  silencing	  events	  were	  not	  cleared	  
until	  the	  ground	  breaking	  discovery	  of	  RNA	  interference	  (RNAi)	  by	  Andrew	  Fire	  and	  
Craig	  Mello	  in	  1998	  (Fire	  et	  al.,	  1998).	  In	  essence,	  in	  their	  seminal	  paper	  published	  in	  
Nature,	   Fire	   and	   colleagues	   demonstrated	   that	   double	   stranded	  RNA	   (dsRNA),	   but	  
not	   single	   stranded	   RNA,	   which	   correspond	   to	   a	   mature	  mRNA	   sequence,	   is	   very	  
potent	  to	  cause	  gene	  silencing	  by	  inducing	  degradation	  of	  the	  endogenous	  mRNA,	  in	  
a	   non-­‐stoichiometric	   fashion	   and	   such	   effect	   is	   transmissible	   between	   tissues	   and	  
progenies.	  	  
	  
Ever	  since	  then,	  there	  was	  an	  explosion	  of	  information	  for	  the	  mechanisms	  of	  
RNAi.	   A	   hallmark	   of	   RNAi	   is	   the	   generation	   of	   short	   (20-­‐30	   nucleotides)	   dsRNA	  by	  
RNAseIII	  enzymes	  (Siomi	  and	  Siomi,	  2009).	  In	  general,	  small	  RNAs	  can	  be	  categorized	  
into	  two	  classes	  based	  on	  their	  origin,	  namely	  siRNAs	  generated	  by	  cleavage	  of	  long	  
exogenous	  long	  dsRNA	  precursors	  and	  microRNAs	  generated	  following	  processing	  of	  
genome-­‐encoded	   stem-­‐loop	   structures.	   The	   siRNAs	   generated	  by	  Dicer	   are	  ~21-­‐25	  
nucleotide	  duplexes	  flanked	  by	  a	  phosphate	  group	  on	  both	  of	  its	  5’	  ends,	  and	  the	  3’	  
ends	  are	  flanked	  by	  nucleotide.	  The	  binding	  of	  Dicer	  to	  dsRNA	  is	  mediated	  by	  its	  PAZ	  
(Piwi	   Argonaut	   and	   Zwille)	   domain	   and	   the	   processing	   of	   dsRNAs	   into	   siRNAs	   is	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catalysed	   by	   its	   two	   RNAseIII	   domains	   (Zhang	   et	   al.,	   2004).	   	   The	   siRNA	   duplex	   is	  
subsequently	  loaded	  onto	  Argonaut	  protein	  and	  is	  incorporated	  into	  the	  RISC	  (RNA-­‐
induced	  silencing	  complex)	  complex,	  where	  the	  duplex	  is	  unwound,	  leaving	  a	  single	  
stranded	  guiding	  siRNA	  which	  guides	  the	  complex	  by	  sequence	  complementarity	  to	  
target	   mRNA	   and	   the	   RISC	   complex	   then	   cleaves	   the	   target	   mRNA,	   thereby	  
preventing	  protein	  expression	  of	  the	  target	  gene	  (Figure	  1.20).	  
	  
	  
Figure	   1.20.	   Mechanisms	   of	   generation	   of	   short	   RNAs.	   Long	   double-­‐stranded	  
exogenous	   RNA	   is	   processed	   into	   21-­‐23	   nucleotides	   siRNA.	   The	   double-­‐stranded	  
siRNA	  is	   loaded	  onto	  the	  RISC	  (RNA-­‐induced	  silencing	  complex)	  complex	  where	  the	  
siRNA	  is	  unwind,	   leaving	  a	  single	  stranded	  guiding	  siRNA	  which	  guides	  the	  complex	  
by	   sequence	   complementarity	   to	   target	  mRNA	  and	   the	  RISC	   complex	   then	   cleaves	  
the	  target	  mRNA.	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1.3.1	  	   Application	  of	  siRNA	  technology	  in	  mammalian	  cells	  
	   	  
Initial	  efforts	  to	  apply	  the	  siRNA	  technology	  in	  mammalian	  cell	  lines	  in	  culture	  
were	  precluded	  by	  non-­‐specific	  activation	  of	  antiviral	  responses	  triggered	  by	  dsRNA	  
longer	   than	   30	   nucleotides	   (Yang	   et	   al.,	   2001;	   Elbashir	   et	   al.,	   2001;	   Caplen	   et	   al.,	  
2001).	  However,	  the	  Tuschl	  group	  has	  managed	  to	  circumvent	  this	   issue	  by	  using	  a	  
chemically	   synthesised	  21-­‐nucleotide	   long	   siRNA	  duplex	   (instead	  of	   a	   long	  dsRNA),	  
which	   is	   able	   to	   induce	   gene	   silencing	  upon	   introduction	  of	   the	   siRNA	  duplex	   into	  
mammalian	   cells	   (Elbashir	  et	   al.,	   2001).	   This	   represents	   an	   important	  milestone	   in	  
functional	   annotation	   of	   genes	   in	   the	   mammalian	   systems,	   in	   which	   functions	   of	  
many	  genes	  remain	  to	  be	  elucidated	  and	  has	  initiated	  efforts	  to	  perform	  large-­‐scale	  
screening	   experiments	   to	   reverse	   genetic	   analysis	   (Ito	   et	   al.,	   2005).	   The	   Bernards	  
group	   and	   Elledge	   group	  were	   among	   the	   first	   to	   perform	   large-­‐scale	  mammalian	  
siRNA	  screening	  experiments	  (Paddison	  et	  al.,	  2004;	  Berns	  et	  al.	  2004).	  The	  Bernards	  
group	  developed	  a	  short-­‐hairpin	  RNA	  (shRNA)	  library	  against	  7914	  human	  genes	  and	  
subsequently	  performed	  a	   screen	   to	   identify	   genes	   involved	   in	   the	  p53-­‐dependent	  
proliferation	  arrest	  (Berns	  et	  al.,	  2004).	  	  They	  created	  a	  primary	  human	  fibroblast	  cell	  
line	   expressing	   murine	   telomerase	   catalytic	   subunit	   (TERT)	   and	   temperature	  
sensitive	   allele	  of	   SV40	   large	  T	   antigen,	   and	  a	   temperature	   shift	   to	  39˚C	   is	   able	   to	  
induce	  proliferation	  arrest	  in	  a	  p53-­‐dependent	  manner.	  Using	  this	  cell	  system,	  they	  
performed	   a	   RNAi	   screen	   and	   identified	   six	   genes,	   which	   when	   silenced,	   could	  
suppress	  the	  proliferation	  arrest	  induced	  by	  temperature	  shift.	  One	  of	  those	  genes	  is	  
p53	  itself,	  underscoring	  the	  quality	  of	  the	  shRNA	  library	  generated.	  	  
	  
As	   opposed	   to	   genome	  wide	   siRNA	   libraries	   which	   are	   laborious	   and	   cost-­‐
intensive	  to	  generate,	  there	  are	  also	  rationally	  designed	  siRNA	  libraries	  comprising	  of	  
siRNAs	   targeting	  a	  particular	  protein	   family	   (Cullen	  and	  Arndt,	  2005).	  For	  example,	  
Aza-­‐Blanc	   and	   colleagues	   generated	   a	   synthetic	   siRNA	   library	   against	   510	   kinases	  
(Aza-­‐Blanc	  et	  al.,	  2003).	  	  Using	  the	  library,	  they	  have	  identified	  several	  genes	  which	  
are	  involved	  in	  TNF-­‐related	  apoptosis	  inducing	  ligand	  (TRAIL)-­‐induced	  apoptosis.	  Our	  
laboratory	   also	   adopts	   the	   similar	   strategy.	  We	   utilise	   a	   siRNA	   library	   against	   the	  
human	  DUBs	  to	  reveal	  functional	  roles	  of	  this	  class	  of	  enzymes.	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1.3.2	   Off-­‐target	  effects	  of	  siRNAs	  
	  
	   During	  its	  early	  applications,	  siRNAs	  were	  thought	  to	  be	  highly	  specific,	  that	  
target	  genes,	  were	  shown	  to	  be	  specifically	  silenced	  by	  complementary	  siRNAs	  only	  
(Caplen	  et	  al,	  2001;	  Tuschl	  et	  al.,	  1999).	  Moreover,	  a	  single	  mismatch	  at	  the	  cleavage	  
site	  of	  the	  siRNA	  is	  sufficient	  to	  abolish	  silencing	  effect	  (Elbashir,	  2001;	  Amarzguioui	  
et	  al.,	  2003;	  Holen	  et	  al,	  2002).	  However,	  with	  burgeoning	  experimental	  data,	  there	  
was	   a	   growing	   notion	   of	   alternative	  mechanisms	   of	   transcript	   targeting	   by	   siRNAs	  
(Jackson	   and	   Linsley,	   2010).	   Several	   genome-­‐scale	   expression	   profiling	   studies	  
following	  siRNA	  depletion	  of	  specific	  target	  genes	  revealed	  the	  off-­‐target	  activity	  of	  
siRNAs	   (Chi	   et	   al.,	   2003;	   Jackson	   et	   al.,	   2003;	   Semizarov	   et	   al.,	   2003).	   Following	  
silencing	   the	   same	   gene	   using	   different	   siRNAs,	   it	   was	   revealed	   by	   microarray	  
profiling	   that	   each	   siRNA	   exhibited	   a	   unique,	   sequence-­‐dependent	   signature	  
(Jackson	   et	   al.,	   2003).	   Sequence	   analysis	   of	   the	   transcripts,	   which	   were	   non-­‐
specifically	  silenced	  revealed	  that	  their	  3’	  UTRs	  were	  complementary	  to	  the	  5’	  end	  of	  
the	   siRNA	   guide	   strand.	   Notably,	   8	   complementary	   nucleotides	   to	   the	   siRNA	   are	  
sufficient	   to	   cause	   an	   off-­‐target	   effect.	   Subsequent	   works	   then	   established	   that	  
sequence	  complementarity	  to	  the	  5’	  end	  of	  the	  siRNA	  guide	  strand	  is	  responsible	  for	  
off-­‐target	   gene	   silencing	   events	   (Jackson	   et	   al.,	   2006;	   Birmingham	   et	   al.,	   2006).	   It	  
was	   later	   revealed	   that	   the	   phenomenon	   of	   off-­‐target	   silencing	   shares	   the	   same	  
regulatory	  mechanism	  with	  microRNA-­‐mediated	  gene	  silencing	  (Jackson	  and	  Linsley,	  
2010).	   As	   is	   the	   case	   for	   siRNA,	   the	   hundreds	   of	   mRNA	   targets	   regulated	   by	   a	  
microRNA	  has,	  in	  their	  3’	  UTR,	  a	  sequence,	  which	  is	  complementary	  to	  the	  5’	  end	  of	  
the	  microRNA	  guide	  strand,	  known	  as	  the	  “seed	  region”	  (Wightman	  et	  al.,	  1999;	  Lai,	  
2002).	  The	  seed	  region	  plays	  pivotal	  role	  in	  target	  recognition	  by	  the	  microRNAs	  and	  
is	  highly	  conserved	  among	  the	  metazoan	  microRNAs	   (Lewis	  et	  al.,	  2003;	  Lim	  et	  al.,	  
2003).	   In	  other	  words,	   the	  5’	  end	  of	   the	  guide	  strand	  of	  siRNAs	   is	  acting	  as	  a	  seed	  
region	  motif	  to	  target	  and	  inhibit	  a	  wide	  array	  of	  genes.	  	  	  	  
	  
	   To	  distinguish	  between	  on-­‐	  and	  off-­‐	  targets,	  a	  common	  approach	  is	  to	  silence	  
the	   same	   gene	   with	   multiple	   siRNAs	   (Jackson	   and	   Linsley,	   2010).	   Several	   siRNAs	  
yielding	   the	   same	   phenotypic	   output	   is	   a	   strong	   indication	   of	   an	   on-­‐target	   effect.	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Another	  approach	   to	  confirm	  a	  phenotype	   resulting	   from	  the	  siRNA	  depletion	  of	  a	  
gene	   is	   to	   rescue	   the	   phenotype	   by	   reintroducing	   into	   the	   cell	   a	   siRNA-­‐resistant	  
version	   of	   the	   same	   target	   gene	   (Cullen,	   2006;	   Echeverri	   et	   al.,	   2006).	   However,	  
these	  experiments	  are	  technically	  challenging	  and	  interpretation	  of	  the	  experimental	  
results	  can	  be	  difficult	  due	  to	  issues	  of	  transfection	  efficiency	  and	  expression	  levels	  
(Jackson	   and	   Linsley,	   2010).	   Endonuclease-­‐prepared	   esiRNA	   (esiRNA)	   represents	  
another	   solution	   to	   the	   problem	   of	   off-­‐target	   effects	   (Kittler	   and	   Buccholz,	   2005)	  
(discussed	  in	  more	  detailed	  in	  Chapter	  5).	  Essentially,	  esiRNA	  comprises	  of	  a	  complex	  
mixture	   of	   siRNA	   generated	   by	   random	   cleavage	   of	   a	   long	   dsRNA	   and	   it	   has	   been	  
demonstrated	  that	  an	   increasing	  complexity	  of	  pool	  of	   siRNAs	  minimises	  off-­‐target	  
effects	  (Kittler	  et	  al.,	  2004).	  	  	  
	  
	  
1.4	   Aims	  of	  this	  study	  	  
	   	  
As	   discussed	   in	   the	   previous	   two	   sections	   of	   this	   chapter,	   both	   the	   core	  
components	  of	  AJ,	  E-­‐cadherin	  and	  β-­‐catenin,	  are	  implicated	  in	  cancer	  development,	  
where	   E-­‐cadherin	   is	   acting	   as	   a	   tumour	   suppressor	   and	  dysregulation	  of	  β-­‐catenin	  
stability	   is	   oncogenic.	   Along	   with	   this	   notion,	   there	   is	   emerging	   evidence	  
demonstrating	   ubiquitylation	   as	   one	   of	   the	   key	   post-­‐translational	   modifications	  
involved	  in	  regulation	  of	  these	  two	  proteins,	  and	  that	  the	  aberration	  in	  the	  ubiquitin-­‐
related	  machineries	  can	  also	  culminate	  in	  cancer	  development.	  Among	  the	  multiple	  
aspects	  of	  ubiquitin-­‐mediated	  cellular	  processes,	  our	  laboratory	  has	  a	  major	  interest	  
in	  understanding	   the	   roles	  of	   the	  human	  deubiquitylases,	   the	   functions	  of	  most	  of	  
which	  are	  yet	   to	  be	  annotated.	  One	  common	  approach	  we	  undertake	   to	  annotate	  
function	  of	  the	  deubiquitylases	  is	  siRNA	  DUB	  library	  screen.	  	  
	  
	   The	  aims	  of	  my	  research	  project	  are:	  	  
• to	  develop	  an	  assay	  to	  robustly	  assess	  E-­‐cadherin	  status	  in	  a	  human	  cancer	  cell	  line.	  	  
• to	   utilise	   this	   assay	   as	   a	   readout	   for	   a	   siRNA	   DUB	   library	   screen	   to	   identify	   DUBs	  
involved	  in	  E-­‐cadherin	  regulation.	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• to	   identify	   DUBs	   involved	   in	   regulation	   of	   E-­‐cadherin	   at	   steady	   state	   conditions	  
following	  siRNA	  DUB	  library	  screen.	  
• to	   identify	   DUBs	   involved	   in	   regulation	   of	   β-­‐catenin	   at	   steady	   state	   conditions	  
following	  siRNA	  DUB	  library	  screen.	  	  
• to	   decipher	   the	  mechanisms	   by	  which	   E-­‐cadherin	   or	  β-­‐catenin	   is	   regulated	   by	   the	  
DUBs	  identified.	  	  
• to	  characterise	  the	  DUBs	  involved	  in	  E-­‐cadherin	  or	  β-­‐catenin	  regulation.	  	  
• to	  develop	  an	  endonuclease-­‐prepared	  siRNA	  (esiRNA)	  DUB	  library	  as	  an	  alternative	  
tool	  to	  siRNA.	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Chapter	  2	  




2.1	   	   Molecular	  Biology	  
	  
2.1.1	  	   	   Materials	  	  
	  
Deoxynucleotide	   mix	   (100mM,	   ♯200415)	   and	   PfuUltra	   Hotstart	   DNA	  
Polymerase	  (♯600390)	  were	  obtained	  from	  Stratagene	  (La	  Jolla,	  CA,	  USA).	  Taq	  DNA	  
Polymerase	   (BIO-­‐21040)	  was	  obtained	   from	  Bioline	   (London,	  UK).	  Gateway	  BP	  and	  
LR	   clonase®	   II	   enzyme	   mix	   (♯11789-­‐020	   and	   ♯11791-­‐100	   respectively),	   DH5α	  
subcloning	   efficiency	   cells	   (♯18265-­‐017),	   S.O.C.	   medium	   (♯15544-­‐034)	   and	  
electrophoresis	   grade	   agarose	   were	   from	   Invitrogen	   (Paisley,	   UK).	   XL1-­‐Blue	  
supercompetent	   cells	   (♯200236)	   were	   obtained	   from	   Agilent	   Technologies	   (Santa	  
Clara,	  CA,	  USA).	  TAE	  buffer	  was	  obtained	  from	  National	  Diagnostics	  (Hull,	  UK).	  Luria-­‐
Bertani	   broth	   (♯LAB191)	  was	   obtained	   from	   Lab	  M	   (Bury,	  UK).	  Miniprep	   (♯27106),	  
HiSpeed	  Maxiprep	  (♯12633),	  RNeasy	  Mini	  (♯74106),	  gel	  extraction	  (♯28604)	  and	  PCR	  
purification	   (♯28704)	   kits	   were	   all	   obtained	   from	   QIAGEN	   (Crawley,	   UK).	   Quick	  
Ligation	  Kit	  (♯M2200S),	  1kDA	  (♯N3232),	  	  100bp	  (♯N3231),	  and	  Low	  Molecular	  Weight	  
DNA	   ladder	   (♯N3233)	   were	   obtained	   from	   New	   England	   Biolab	   (Herts,	   UK).	   PCR	  
Nucleotide	  Mix	  (♯C1441),	  RNasin®	  plus	  RNAse	  inhibitor	  (♯N2611)	  and	  nuclease	  free	  
water	  (♯P1193)	  were	  obtained	  from	  Promega	  (Madison,	  WI,	  USA).	  M-­‐MulV	  Reverse	  
transcriptase	   (♯EP0352)	   was	   obtained	   from	   Thermo	   Scientific	   Inc	   (Waltham,	   MA,	  
USA).	  All	  primers	  were	  ordered	  from	  Eurofins	  MWG	  Operon	  (Ebersberg,	  Germany).	  
All	  other	  chemicals	  were	  obtained	  from	  Sigma	  Aldrich	  (Poole,	  UK)	  unless	  otherwise	  
stated.	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2.1.2	   	   Polymerase	  Chain	  Reaction	  (PCR)	  
	  
PCR	   (Mullis	   et	   al.,	   1986)	   were	   performed	   to	   amplify	   DNA	   sequences	   for	  
subsequent	   cloning,	   to	   detect	   presence	   of	   plasmid	   containing	   genes	   of	   interest	  
transformed	  into	  bacteria,	  and	  to	  prepare	  template	  for	   in	  vitro	  transcription	  during	  
esiRNA	  production.	  In	  this	  study,	  two	  DNA	  polymerases	  were	  used,	  namely	  Taq	  DNA	  
Polymerase	   (Bioline)	  and	  PfuUltra	  Hotstart	  DNA	  Polymerase	   (Stratagene).	  Taq	  DNA	  
polymerase	  was	  used	  for	  bacteria	  colony	  PCR	  (B-­‐PCR)	  to	  identify	  colonies	  positive	  for	  
desired	  plasmids.	   PfuUltra	  Hotstart	  DNA	  polymerase	  was	   used	   in	   PCR	   reactions	   to	  
amplify	   full	   length	   or	   fragments	   of	   desired	   genes.	   In	   the	   latter	   PCR	   reactions,	  
plasmids	  were	  used	  as	  templates	  unless	  otherwise	  specified.	  PCR	  reaction	  mixtures	  
were	  set	  up	  as	  summarised	  in	  Table	  2.1	  and	  Table	  2.2,	  in	  0.5ml	  ThermowellTM	  tubes	  
(Corning)	  at	  room	  temperature.	  PCR	  reactions	  were	  then	  allowed	  to	  run	  according	  to	  





Table	  2.1.	  PCR	  reaction	  mixtures	  for	  Taq	  DNA	  Polymerase.	  	  	  	  
Reagents	   B-­‐PCR	  
NH4	  Buffer	  (10X)	   2µl	  
MgCl2	  (50mM)	   0.8µl	  
dNTPs	  	  (100mM)	   0.4µl	  
Fwd	  Primer	  	  (10µM)	   0.5µl	  
Rev	  Primer	  (10µM)	   0.5µl	  
Taq	  Polymerase	  (5U/µl)	   0.1µl	  
NaOH	  (20mM)	   -­‐	  
Water	   15.7µl	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Table	  2.2.	  PCR	  reaction	  mixtures	  for	  PfuUltra	  Hotstart	  DNA	  Polymerase.	  
Reagents	   	  
PfuUltra	  HF	  Reaction	  Buffer	  (10X)	   5µl	  
Template	  (25ng/µl)	   1µl	  
dNTPs	  	  (100mM)	   0.5µl	  
Fwd	  Primer	  	  (10µM)	   1.25µl	  
Rev	  Primer	  (10µM)	   1.25µl	  
PfuUltra	  HS	  DNA	  Polymerase	  (2.5U/µl)	   1µl	  
Water	   40µl	  





Table	  2.3.	  Thermal	  cycler	  programme	  for	  Taq	  DNA	  polymerase.	  	  
Segment	   Step	   No.	   of	  
cycles	  	  
Temperature	  	   Duration	  
1	   Initial	  
Denaturation	  
1	   95˚C	   5	  min	  
Denaturation	   95˚C	   1	  min	  




72˚C	   1	  min	  /kb	  
3	   Final	  
Extension	  





Table	  2.4.	  Thermal	  cycler	  programme	  for	  PfuUltra	  Hotstart	  DNA	  polymerase.	  	  
Segment	   Step	   No.	   of	  
cycles	  	  
Temperature	  	   Duration	  
1	   Initial	  
Denaturation	  
1	   95˚C	   5	  min	  
Denaturation	   95˚C	   1	  min	  




68˚C	   1	  min	  /kb	  
3	   Final	  
Extension	  
1	   68˚C	   5	  min	  
	  
	  
The	   B-­‐PCR	   reactions	   were	   performed	   using	   primers	   specific	   to	   the	   vector	  
pCR4TOPO	  or	  pDONR223.	  The	  primer	  sequences	  are	  shown	  in	  Table	  2.5.	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Table	   2.5.	   Primers	   used	   for	   bacterial	   colony	   PCR.	   Sequences	   are	   in	   5’	   to	   3’	  
direction.	  
Target	   Primer	  Name	   Primer	  Sequence	  
pCR4TOPO	   M13F	   CTGGCCGTCTTTTAC	  
pCR4TOPO	   M13R	   CAGGAAACAGCTATGAC	  
pDONR223	   GateF2	   TCGCGTTAACGCTAGCATGGAT	  





The	  primers	  used	  to	  amplify	  full	   length	  or	  fragments	  of	  USP38	  were	  flanked	  
by	  GATEWAYTM	  recombination	  sequence	  on	  their	  5’	  ends.	  This	  allows	  shuttling	  of	  the	  
amplified	   regions	   into	   a	  GatewayTM	  entry	   vector	   and	   subsequently	   into	   any	  of	   the	  
GatewayTM	   expression	   vectors.	   An	   additional	   restriction	   site	   for	   specific	  
endonuclease	   is	   also	   incorporated	   at	   the	   3’	   end	   of	   the	   GatewayTM	   recombination	  
sequence.	   This	   enables	   transfer	   of	   the	   amplified	   regions	   into	   expression	   vectors,	  
which	  are	  not	  GatewayTM	  compatible,	  by	  simple	  DNA	  ligation	  reaction.	  At	  the	  3’	  end	  
of	   the	   restriction	   site	   is	   the	   Kozak	   sequence,	   ACC,	   which	   favours	   initiation	   of	  
translation	  at	  the	  ATG	  start	  codon	  in	  higher	  eukaryotes	  (Kozak,	  1987;	  Kozak,	  1990).	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Table	   2.6.	   List	   of	   “Gateway”	   primers	   used	   to	   amplify	   full	   length	   or	   regions	   of	  
USP38.	  GATEWAYTM	  compatible	  attB	  flanking	  sequences	  are	  highlighted	  in	  bold	  and	  
added	  endonuclease	  restriction	  sites	  are	  highlighted	  in	  red.	  Kozak	  sequence	  inserted	  
into	  the	  forward	  primers	  is	  shown	  underlined	  and	  stop	  codon	  in	  reverse	  primers	  are	  
highlighted	  in	  blue.	  
Primer	  Name	   Primer	  Sequence	  
JLW_USP38_F_GW_EcoRI	   GAATTCACAAGTTTGTACAAAAAAGCAGGCTGGGAATTCACCATGGACAAGATCCTGGAGGGC	  C	  
JLW_USP38_F_GW_HindIII	   GAATTCACAAGTTTGTACAAAAAAGCAGGCTGGAAGCTTACCATGGACAAGATCCTGGAGGGCC	  
JLW_USP38_R_GW_SalI	   GGGGACCACTTTGTACAAGAAAGCTGGGTGGTCGACTTAAAATACGAGTCTGCCAACTGTAT	  
JLW_USP38_F_1321_GW_BamHI	   GAATTCACAAGTTTGTACAAAAAAGCAGGCTGGGGATCCACCGAAACTGGGAAAACTGGTC	  
JLW_USP38_R_2838_GW_SalI	   GGGGACCACTTTGTACAAGAAAGCTGGGTGGTCGACTTATACAAAAGCACATAAGCTGTG	  
JLW_USP38_R_1323_GW_SalI	   GGGGACCACTTTGTACAAGAAAGCTGGGTGGTCGACTTATTCAGATTTTCCAGAAAGTCTAG	  
JLW_USP38_F_1321_GW_EcoRI	   GAATTCACAAGTTTGTACAAAAAAGCAGGCTGGGAATTCACCGAAACTGGGAAAACTGGTC	  
JLW_USP38_R_1314_GW_SalI	   GGGGACCACTTTGTACAAGAAAGCTGGGTGGTCGACTTATCCAGAAAGTCTAGACAAGCAAG	  
	  
	  
2.1.3	  	   	   DNA	  agarose	  gel	  electrophoresis	  	  
	  
	  
	   Agarose	   gels	   (between	   0.8	   –	   2%)	  were	   prepared	   by	   adding	   electrophoresis	  
grade	   agarose	   powder	   to	   1X	   TAE	  buffer	   (40mM	  Tris	   Acetate,	   1mM	  Na2EDTA).	   The	  
mixture	   was	   then	   heated	   using	   a	   microwave	   to	   fully	   dissolve	   the	   agarose.	   The	  
agarose	   solution	   was	   allowed	   to	   cool	   down	   at	   room	   temperature	   for	   about	   15	  
minutes,	   after	   which	   ethidium	   bromide	   was	   added	   to	   a	   final	   concentration	   of	  
0.5µg/ml.	   The	   gel	  was	   then	   poured	   and	   allowed	   to	   set	   at	   room	   temperature.	   10X	  
DNA	  Sample	  buffer	   (5%	  w/v	  glycerol,	  0.1mM	  EDTA,	  0.04%	  bromophenol	  blue)	  was	  
added	  to	  DNA	  sample	  at	  a	  ratio	  of	  1:10	  (i.e.	  1µl	  10X	  DNA	  sample	  buffer	  to	  10µl	  DNA	  
sample)	  and	  mixed	  well	  by	  gentle	  vortexing.	  The	  samples	  were	  then	  loaded	  onto	  the	  
gel,	  along	  with	  10-­‐15µl	  per	  lane	  of	  DNA	  ladder	  standard,	  and	  resolved	  in	  TAE	  buffer,	  
in	   a	   Fisherbrand	   horizontal	   midi	   electrophoresis	   tank	   (Fisher	   Scientific,	  
Loughborough,	  UK),	  at	  110V	  to	  120V	  for	  an	  hour.	  DNA	  bands	  were	  visualized	  using	  
an	  ultraviolet	  light	  source.	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2.1.4	  	   	   Bacterial	  transformation	  	  
	  
	   For	  each	  transformation	  reaction,	  50µl	  of	  competent	  cells	  was	  thawed	  on	  ice	  
and	  transferred	  to	  a	  polypropylene	  tube.	  Less	  than	  100ng	  of	  DNA	  was	  added	  to	  the	  
cell	  suspension	  and	  incubated	  on	  ice	  for	  20	  minutes.	   	  The	  cell	  suspension	  was	  then	  
heat-­‐shocked	  at	  42˚C	  in	  a	  water	  bath	  for	  45	  seconds	  and	  placed	  immediately	  on	  ice	  
after	   that	   for	   2	   minutes.	   200µl	   of	   S.O.C.	   (super	   optimal	   broth	   with	   catabolite	  
repression)	  medium	  was	   then	  added	   to	   the	   cell	   suspension	   and	   the	  bacteria	  were	  
shaken	  at	  250rpm	  for	  1	  hour.	  Bacterial	  cells	  were	  then	  spread	  on	  selective	  LB	  agar	  
plates	  and	  incubated	  at	  37˚C	  overnight.	  	  	  
	  
2.1.5	   	   Site-­‐directed	  mutagenesis	  
	  
Site-­‐directed	   mutagenesis	   was	   performed	   to	   generate	   the	   catalytically	  
inactive	   mutant	   of	   USP38	   and	   BAP1,	   and	   siRNA	   resistant	   plasmid	   of	   BAP1.	   	   The	  
reaction	   was	   carried	   out	   using	   the	   QuickChange	   site-­‐directed	   mutagenesis	   kit	  
(Agilent	   Technologies)	   and	   PfuUltra	   Hotstart	   DNA	   Polymerase.	   The	   mutagenesis	  
reaction	  was	  performed	  using	  pairs	  of	  complementary	  primers	  covering	   the	   region	  
to	   be	  mutagenised	   (single	   or	  multiple	   base(s)	   change)	   as	   shown	   in	   Table	   2.7.	   The	  
template	  used	  was	  either	  pDONR223-­‐USP38	  or	  pDONR223-­‐BAP1.	  Reaction	  mixtures	  
were	  set	  up	  in	  0.65ml	  ThermowellTM	  at	  room	  temperature	  as	  shown	  in	  Table	  2.8	  and	  
reactions	  were	  allowed	  to	  run	  according	  to	  the	  thermal	  cycle	  programmes	  as	  shown	  
in	  Table	  2.9.	   	  At	   the	  end	  of	   the	  PCR	   reactions,	  1µl	  of	  DpnI	   restriction	  enzyme	  was	  
added	   and	   the	   mixture	   incubated	   at	   37˚C	   for	   1	   hour.	   DpnI	   restriction	   enzyme	  
recognises	  the	  DNA	  sequence	  GATC	  with	  methylation	  of	  the	  Adenine	  nucleotide.	  The	  
purpose	  of	  this	  step	  is	  to	  remove	  the	  wildtype	  plasmids	  purified	  from	  bacteria,	  which	  
were	   modified	   by	   	   methylation.	   The	   newly	   generated	   plasmids	   by	   PCR	   reactions	  
were	  not	  methylated	  and	  therefore	  were	  not	  recognised	  by	  the	  DpnI	  enzyme.	  	  After	  
that,	   2-­‐5µl	   of	   the	   final	   reacted	   mixtures	   were	   used	   to	   transform	   XL1Blue	   cells.	  
Plasmids	  were	  then	  purified	  from	  positive	  transformants	  using	  MiniPrep	  Kit	  (Qiagen)	  
and	   tested	   by	   restriction	   digest.	   Candidate	   mutated	   plasmids	   were	   then	   sent	   for	  
sequencing	  and	  glycerol	  stock	  was	  made.	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Table	   2.7.	   Site-­‐directed	   mutagenesis	   primers.	   Mutated	   nucleotide	   residues	   are	  
shown	  in	  upper	  case	  letters.	  	  	  











TGt	   à	  







tGt	   à	  







gCc	   à	  














Table	  2.8.	  Reaction	  mixtures	  for	  site-­‐directed	  mutagenesis.	  	  
Reagents	   	  
PfuUltra	  HF	  Reaction	  Buffer	  (10X)	   5µl	  
Template	  (25ng/µl)	   1µl	  
dNTPs	  	  (100mM)	   0.5µl	  
Fwd	  Primer	  	  (10µM)	   1.25µl	  
Rev	  Primer	  (10µM)	   1.25µl	  
PfuUltra	  HS	  DNA	  Polymerase	  (2.5U/µl)	   1µl	  
Water	   40µl	  




Table	  2.9.	  Thermal	  cycler	  programme	  for	  site-­‐directed	  mutagenesis.	  	  
Segment	   No.	  of	  cycles	  	   Temperature	  	   Duration	  
1	   1	   95˚C	   30	  sec	  
95˚C	   30	  sec	  
55˚C	   1	  min	  
2	   15	  
68˚C	   2	  min	  /kb	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2.1.6	   	   TOPO	  cloning	  	  
	  
	   TOPO	   cloning	   reaction	   allows	   direct	   insertion	   of	   PCR	   products	   into	   the	  
pCR4®Blunt-­‐TOPO	   vector,	   catalysed	   by	   blunt	   end	   topoisomerase.	   ORFs	   of	   interest	  
were	  first	  amplified	  by	  PCR	  and	  resolved	  on	  a	  DNA	  agarose	  gel.	  The	  PCR	  product	  was	  
then	  extracted	  from	  the	  gel	  using	  the	  gel	  extraction	  kit	   from	  QIAGEN	  and	  used	  for	  
TOPO	  cloning	  reaction.	  TOPO	  cloning	  reactions	  were	  set	  up	  on	  ice	  as	  shown	  in	  Table	  
2.10	  and	  were	  then	  incubated	  at	  room	  temperature	  for	  15	  minutes.	  After	  that,	  6µl	  of	  
reaction	  mixture	  was	  used	  to	  transform	  MACH1	  competent	  cells.	  Cells	  were	  spread	  
on	   LB	   agar	   plates	   containing	   Ampicillin	   (100mg/ml)	   or	   Kanamycin	   (10mg/ml)	   and	  
were	   incubated	   overnight	   at	   37˚C.	   	   On	   the	   next	   day,	   bacterial	   colony	   PCR	   (see	  
section	  2.1.2)	  was	  performed,	  using	  M13F	  and	  M13R	  primers,	   for	  a	  minimum	  of	  4	  
bacterial	  colonies	  to	  screen	  for	  positive	  transformants.	  Mini-­‐prep	  cultures	  were	  then	  
set	   up	   for	   positive	   transformants	   and	   DNA	  was	   purified	   from	   bacterial	   culture	   by	  
QIAGEN	  MiniPrep	   Kit.	   The	   purified	   DNA	  was	   subsequently	   subjected	   to	   diagnostic	  
test	   digest	   and	   DNA,	   which	   was	   tested	   positive	   was	   then	   sent	   for	   sequencing.	  
Glycerol	   stocks	   of	   bacterial	   colonies	   transformed	   with	   sequence-­‐verified	  
pCR4®Blunt-­‐TOPO	  constructs	  were	  made	  as	  described	  in	  section	  2.1.9.	  	  
	  
	  
Table	  2.10.	  Reaction	  mixture	  for	  TOPO	  cloning	  reaction.	  	  
Reagent	   Volume	  
pCR4®Blunt-­‐TOPO	  vector	   1	  µl	  
Salt	  solution	   1	  µl	  
PCR	  product	   4	  µl	  




2.1.7	  	   	   Gateway	  cloning	  	  
	  
	   Gateway	   cloning	   (Hartley	   et	   al.,	   2000)	  was	   performed	   to	   allow	   shuffling	   of	  
open	  reading	  frames	  into	  plasmids	  of	  interest.	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2.1.7.1	  	   Gateway	  BP	  cloning	  reaction	  
	  
	   PCR	  products	  of	  ORFs	  flanked	  by	  attB	  recombination	  sites	  were	  inserted	  into	  
the	  pDONR223	  entry	  vector	  by	  BP	  recombination	  reaction.	  BP	  reactions	  were	  carried	  
out	   using	   a	   specific	   insert	   to	   entry	   vector	   ratio,	   which	   was	   calculated	   using	   the	  
following	  formula:	  	  
	  
Amount	  of	  insert	  (ng)	  =	  125	  x	  size	  of	  ORF	  x	  660	  	  
	   	   	   	   	   	   	  	  	  	  	  	  	  106	  	  
	  
	   BP	  reaction	  tubes	  were	  set	  up	  on	  ice	  as	  shown	  in	  Table	  2.11,	  and	  incubated	  
at	  25˚C	  for	  1.5	  hour.	  After	  this,	  1µl	  of	  Proteinase	  K	  (from	  BP	  reaction	  kit,	  Invitrogen)	  
was	  added	  to	   the	  reaction	  mixture	  and	   incubated	   for	  10	  minutes	  at	  37˚C	   to	  digest	  
the	  BP	  clonase	  enzyme.	  6µl	  of	  reaction	  mixture	  was	  then	  used	  to	  transform	  50µl	  of	  
XL1-­‐Blue	   competent	   cells.	   These	   cells	   were	   spread	   on	   LB	   agar	   plates	   containing	  
Spectinomycin	  (100µg/ml)	  and	  the	  plates	  were	  incubated	  overnight	  at	  37˚C.	  On	  the	  
next	  day,	  bacterial	  colony	  PCR	  (see	  section	  2.1.2)	  was	  performed,	  using	  GateF2	  and	  
GateR1	   primers,	   for	   a	   minimum	   of	   5	   bacterial	   colonies	   to	   screen	   for	   positive	  
transformants.	  Miniprep	  cultures	  were	   then	  set	  up	   for	  positive	   transformants	   	  and	  
DNA	  was	  purified	  from	  bacterial	  culture	  by	  QIAGEN	  MiniPrep	  Kit.	  The	  purified	  DNA	  
was	   subsequently	   subjected	   to	   diagnostic	   test	   digest	   and	   DNA,	   which	   was	   tested	  
positive	  was	  then	  sent	  for	  sequencing.	  	  
	  
	  
Table	  2.11.	  Reaction	  mixture	  for	  BP	  cloning	  reaction.	  	  
Reagent	   Volume	  
BP	  clonase	  II	  enzyme	  mix	  	   2	  µl	  
pDONR223	  vector	  (300ng/µl)	   1	  µl	  
PCR	  product	  or	  linearized	  pCR4Blunt-­‐TOPO	  construct	   x	  µl	  
Sterile	  water	   y	  µl	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2.1.7.2	  	   Gateway	  LR	  Cloning	  Reaction	  	  
	  
	   Gateway	   LR	   reaction	   allows	   the	   shuttling	   of	   DNA	   insert	   from	   entry	   vector	  
(pDONR223)	   to	   destination	   vectors	   by	   recombination	   reaction,	   catalysed	   by	   LR	  
clonase	  enzyme.	  LR	  cloning	  reactions	  were	  set	  up	  on	  ice	  as	  shown	  in	  Table	  2.12	  and	  
the	   reaction	   tubes	  were	   incubated	   at	   25˚C	   for	   1.5	   hour.	   Following	   the	   incubation	  
period,	   1µl	   of	   Proteinase	   K	   (Invitrogen)	   was	   added	   to	   the	   reaction	   mixture	   and	  
incubated	  at	  37˚C	  for	  10	  minutes.	  	  
	  
	  
Table	  2.12.	  Reaction	  mixture	  for	  LR	  cloning	  reaction.	  	  
Reagent	   Volume	  
BP	  clonase	  II	  enzyme	  mix	  	   2	  µl	  
pDONR223	  vector	  (300ng/µl)	   1	  µl	  
PCR	  product	  or	  linearized	  pCR4Blunt-­‐TOPO	  construct	   x	  µl	  
Sterile	  water	   y	  µl	  




	   6µl	  of	  reaction	  mixture	  was	  then	  used	  to	  transform	  50µl	  of	  DH5α	  competent	  
cells.	  These	  cells	  were	  spread	  on	  LB	  agar	  plates	  containing	  Kanamycin	  (10mg/ml)	  and	  
the	   plates	  were	   incubated	   overnight	   at	   37˚C.	  On	   the	   next	   day,	   at	   least	   3	   colonies	  
were	   picked	   to	   set	   up	  miniprep	   cultures	   and	  DNA	  was	   purified	   from	   the	   bacterial	  
culture	   on	   the	   following	   day	   by	   QIAGEN	   MiniPrep	   Kit.	   The	   purified	   DNA	   was	  
subsequently	   subjected	   to	   diagnostic	   test	   digest	   and	   colonies	   carrying	   plasmids	  
positive	  for	  test	  digest	  were	  used	  to	  make	  glycerol	  stocks.	  	  
	  
	  
2.1.8	   	   Restriction	  Digest	  	  
	  
	   Restriction	  digest	  reactions	  were	  set	  up	  as	  shown	  in	  Table	  2.13	  and	  incubated	  
at	  the	  optimal	  temperature	  (mostly	  37˚C)	  for	  the	  restriction	  endonucleases	  used	  and	  
for	  1	  hour.	  Typically,	  800ng	  of	  DNA	  sample	  was	  used	  for	  diagnostic	  test	  digest	  and	  
5µg	  of	  DNA	  sample	  was	  used	  for	  restriction	  cloning.	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Table	  2.13.	  Reaction	  mixture	  for	  restriction	  digest.	  	  
DNA	  sample	   x	  µl	  
Restriction	  endonuclease	   1.0	  µl	  
Reaction	  buffer	   1.5	  µl	  
BSA	   1.5	  µl	  
Sterile	  water	   y	  µl	  




2.1.9	   	   Restriction	  Cloning	  
	  
	   Restriction	   cloning	   was	   performed,	   using	   the	   Quick	   Ligation	   kit	   from	   NEB.	  
Insert	  was	  excised	  from	  an	  original	  vector	  using	  a	  pair	  of	  restriction	  endonucleases	  
(see	   section	   2.1.7),	   and	   the	   destination	   vector	   to	   which	   the	   insert	   is	   going	   to	   be	  
ligated	  was	  also	  digested	  with	  a	  compatible	  pair	  of	  restriction	  endonucleases	  (i.e.	  the	  
sticky	  ends	  generated	  following	  restriction	  digest	  are	  complementary	  to	  each	  other).	  
Typically,	  100ng	  of	  restriction-­‐digested	   insert	  was	   incubated	  with	  vector	  at	  a	  molar	  
ratio	  of	  1:3.	  Ligation	  reactions	  were	  set	  up	  as	  shown	  in	  Table	  2.14	  on	  ice,	  and	  were	  
incubated	   at	   room	   temperature	   for	   10	  minutes.	   6µl	   of	   reaction	  mixture	  was	   then	  
used	  to	  transform	  50µl	  of	  DH5α	  competent	  cells.	  These	  cells	  were	  spread	  on	  LB	  agar	  
plates	   containing	   Kanamycin	   and	   the	  plates	  were	   incubated	  overnight	   at	   37˚C.	  On	  
the	  next	  day,	  at	   least	  4	  colonies	  were	  picked	  to	  set	  up	  miniprep	  cultures	  and	  DNA	  
was	  purified	  from	  the	  bacterial	  culture	  on	  the	  following	  day	  by	  QIAGEN	  MiniPrep	  Kit.	  
The	  purified	  DNA	  was	  subsequently	  subjected	  to	  diagnostic	  test	  digest	  and	  colonies	  
carrying	  plasmids	  positive	  for	  test	  digest	  were	  used	  to	  make	  glycerol	  stocks.	  	  
	  
Table	  2.14.	  Reaction	  mixture	  for	  ligation	  reaction.	  	  
Restriction	  digested	  insert	  (100ng)	   x	  µl	  
Restriction	  digested	  vector	  	   y	  µl	  
2X	  Quick	  Ligase	  Buffer	   5	  µl	  
Quick	  Ligase	   0.5	  µl	  
Sterile	  water	   z	  µl	  
Total	  volume	   10	  µl	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2.1.10	  	  	   Glycerol	  Stock	  	  
	  
	   To	  make	  glycerol	   stocks	  of	   transformed	  bacteria,	  5ml	  of	  overnight	  bacterial	  
culture	  in	  LB	  medium	  (inoculated	  from	  a	  single	  bacterial	  colony)	  was	  spun	  down	  at	  
4000rpm	   in	   a	   centrifuge.	   Supernatant	  was	   then	   discarded	   and	   the	   bacterial	   pellet	  




2.1.11	  	  	   Reverse	  Transcription	  
	  
	   mRNA	   was	   harvested	   from	   a	   monolayer	   of	   adherent	   cells	   using	   QIAGEN	  
RNeasy	   Kit	   as	   per	  manufacturer	   guidelines.	   The	   concentration	   of	   the	   RNA	   extract	  
was	  measured	   using	   a	   NanoDrop	   Spectrophotometer	   ND1000	   at	   a	   wavelength	   of	  
260nm.	   1µg	   of	   mRNA	   was	   then	   diluted	   with	   sterile	   water	   to	   a	   volume	   of	   10µl,	  
followed	  by	  addition	  of	  1µl	  of	  oligo	  DT	  primers.	  The	  mixture	  was	  then	  incubated	  at	  
70˚C	  for	  5	  minutes	  to	  allow	  priming	  of	  the	  oligo	  DT	  primers	  to	  poly-­‐A	  tails	  of	  mRNA.	  
In	   the	  mean	  time,	  a	   reaction	  buffer	  mixture	  was	  prepared	  as	  shown	   in	  Table	  2.15.	  
8µl	  of	  this	  reaction	  buffer	  was	  then	  added	  to	  the	  tube	  with	  diluted	  mRNA	  and	  oligo	  
DT	  primers,	  and	  the	  tube	  was	  incubated	  at	  37˚C	  for	  5	  minutes.	  After	  that,	  1µl	  of	  M-­‐
MuLV	   reverse	   transcriptase	   was	   added	   to	   the	   tube	   and	   the	   reaction	  mixture	   was	  
incubated	   at	   42˚C	   for	   1	   hour,	   followed	   by	   a	   10-­‐minute	   incubation	   at	   70˚C.	   The	  
resulting	  cDNA	  was	  diluted	  to	  100µl	  with	  sterile	  water.	  	  
	  
	  
Table	  2.15.	  Reaction	  buffer	  mixture	  for	  reverse	  transcription.	  	  
5X	  reverse	  transcription	  buffer	  	   4	  µl	  
PCR	  nucleotide	  mix	  	   2	  µl	  
RNasin	   0.5	  µl	  
Nuclease	  free	  deionised	  water	   1.5	  µl	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2.1.12	  	  	   Quantitative	  Real-­‐Time	  PCR	  (QPCR)	  
	  
QPCR	  (Higuchi	  et	  al.,	  1992)	  were	  performed	  to	  determine	  the	  level	  of	  CDH1	  
mRNA	   and	   CTNNB1	  mRNA	   following	   knockdown	   of	   USP38	   and	   BAP1	   respectively.	  
QPCR	  reaction	  mixture	  was	  set	  up	  using	  DyNAmoTM	  HS	  SYBR®	  Green	  qPCR	  kit	  as	  per	  
manufacturer’s	   instruction.	   QPCR	   reactions	   were	   allowed	   to	   run	   on	   iQ5	   real-­‐time	  




Table	  2.16.	  QPCR	  setting.	  
Segment	   Step	   No.	  of	  
cycles	  
Temperature	  	   Duration	  
1	   Initial	  
Denaturation	  
1	   95˚C	   15	  min	  
Denaturation	   95˚C	   10	  sec	  




72˚C	   30	  sec	  
3	   Melting	   curve	  
analysis	  




Fluorescence	  measurement	  of	   each	   reaction	  well	  was	   taken	  at	   real	   time	  at	  
the	   end	   of	   each	   cycle	   of	   the	   second	   segment.	   The	   quantity	   of	   the	   target	   gene	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2.2	  	   	   Cell	  Biology	  	  
	  
2.2.1	   	   	  Materials	  	  
	  
OligofectamineTM	   transfection	   reagent	   (♯12252-­‐011),	   LipofectamineTM	   LTX	  
reagent	   (♯15338-­‐100)	   and	   all	   cell	   culture	   reagents	   were	   obtained	   from	   Invitrogen	  
unless	  otherwise	  stated	  (Paisley,	  UK).	  HiperFect	  transfection	  reagent	  (♯301705)	  was	  
obtained	   from	  QIAGEN	   (Crawley,	  UK).	  GeneJuice®	   transfection	   reagent	   (♯70967-­‐3),	  
Folimycin	   (♯344085)	  and	  Lactacystin	   (♯426100)	  were	  obtained	   from	  EMD	  Millipore	  
(Darmstadt,	  Germany).	  All	  other	  chemicals	  were	  obtained	  from	  Sigma	  Aldrich	  (Poole,	  
UK)	   unless	   otherwise	   stated.	   All	   plasticware	   was	   obtained	   from	   Corning	   Inc	   (NY,	  
USA).	   	   HGF	   was	   received	   as	   a	   kind	   gift	   from	   George	   Vande	   Woude	   (Van	   Andel	  
Research	  Institute,	  Grand	  Rapids,	  MI).	  	  
	  
2.2.2	   	   Cell	  Culture	  
	  
Unless	  otherwise	  stated,	  all	  human	  cell	  lines	  (MCF7,	  SW480,	  HEK293T,	  A549	  
and	  DU145)	  were	  maintained	  in	  Dulbecco’s	  Modified	  Eagle	  Medium	  (DMEM)	  (Gibco,	  
Paisley,	   UK),	   supplemented	   with	   10%	   heat-­‐inactivated	   foetal	   bovine	   serum	   (FBS),	  
0.1mM	  MEM	  non-­‐essential	  amino	  acids	  (Gibco),	  100	  units	  ml-­‐1	  Penicillin	  (Gibco)	  and	  
100	  units	  ml-­‐1	   Streptomycin	   (Gibco).	   All	   cells	  were	   incubated	   at	   37˚C,	   5%	  CO2.	   For	  
maintenance,	  confluent	  layer	  of	  cells	  (90-­‐95%)	  were	  detached	  from	  dish	  using	  0.05%	  
Trypsin	  with	   EDTA	   (Gibco)	   and	  were	   split	   at	   the	   following	   densities	   for	   every	   two	  
days:	  
	  
Table	  2.17.	  Splitting	  density	  of	  different	  cell	  lines.	  
Cell	  Line	   Split	  Density	  
MCF7	   1	  in	  3	  
A549	   1	  in	  5	  
SW480	   1	  in	  3	  
HEK293T	   1	  in	  8	  
HeLa	   1	  in	  5	  
DU145	   1	  in	  5	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siRNA	   transfection	  of	  A549,	  MCF7,	  HeLa	   and	  HEK293T	   cells	  was	   performed	  
using	   oligofectamine.	   Typically,	   cells	   were	   seeded	   into	   wells	   of	   6-­‐well	   plate	   and	  
incubated	  overnight	  at	  37˚C.	  On	  the	  next	  day,	  the	  cells	  were	  washed	  with	  PBS	  and	  
800µl	   of	   no	   addition	   DMEM	   (DMEM	  without	   FBS)	  was	   added.	   2µl	   of	   20µM	   siRNA	  
oligos	  was	  first	  added	  to	  180µl	  of	  OptiMEM	  (Invitrogen).	   In	  a	  separate	  tube,	  3µl	  of	  
oligofectamine	  transfection	  reagent	  was	  added	  to	  13µl	  of	  OptiMEM,	  and	  mixed	  by	  
vortexing.	   	   Both	   solutions	  were	   left	   to	   stand	   at	   room	   temperature	   for	   5	  minutes.	  
After	   that,	   the	   solutions	   were	   mixed	   together,	   vortexed	   and	   left	   stand	   at	   room	  
temperature	   for	   20	   minutes.	   The	   200µl	   of	   transfection	   mixture	   was	   then	   added	  
dropwise	  to	  each	  well	  and	  the	  resulting	  concentration	  of	  siRNA	  oligos	  is	  40nM.	  The	  
cells	   were	   then	   incubated	   at	   37˚C	   for	   4-­‐6	   hours,	   after	   which	   the	   medium	   was	  
replaced	  with	  full	  DMEM	  (DMEM	  containing	  10%	  FBS).	  Cells	  were	  normally	  lysed	  or	  
fixed	  72	  hours	  post-­‐transfection.	  	  
	  
siRNA	   transfection	   of	   SW480	   cells	   was	   performed	   using	   HiperFect	  
transfection	  reagent	  (QIAGEN).	  Typically,	  cells	  were	  seeded	  into	  wells	  of	  6-­‐well	  plate	  
and	   incubated	  overnight	  at	  37˚C.	  On	  the	  next	  day,	  the	  cells	  were	  washed	  with	  PBS	  
and	   800µl	   of	   no	   addition	   DMEM	   was	   added.	   2µl	   of	   20µM	   siRNA	   oligos	   was	   first	  
added	  to	  183µl	  of	  OptiMEM	  (Invitrogen),	  mixed	  well	  by	  vortexting	  and	  left	  stand	  at	  
room	  temperature	  for	  5	  minutes.	  After	  that,	  15µl	  of	  HiperFect	  transfection	  reagent	  
was	   added	   and	   the	   transfection	  mixture	  was	  mixed	  by	   vortexing	   and	   left	   stand	   at	  
room	   temperature	   for	   20	   minutes.	   	   The	   200µl	   of	   transfection	   mixture	   was	   then	  
added	   dropwise	   to	   each	   well	   and	   the	   resulting	   concentration	   of	   siRNA	   oligos	   is	  
40nM.	  The	  cells	  were	  then	  incubated	  at	  37˚C	  for	  4-­‐6	  hours,	  after	  which	  the	  medium	  
was	  replaced	  with	  full	  fresh	  DMEM.	  Cells	  were	  normally	  lysed	  or	  fixed	  72	  hours	  post-­‐
transfection.	  	  
	  
2.2.4	   	   DNA	  Transfection	  	  
	  
GeneJuice	  was	  used	  for	  transient	  DNA	  transfection	  of	  HeLa	  and	  HEK293T	  and	  
LipoFectamine	  LTX	  was	  used	  for	  transient	  DNA	  transfection	  of	  MCF7.	  Typically,	  cells	  
were	   seeded	   into	   wells	   of	   6-­‐well	   plate	   and	   incubated	   overnight	   at	   37˚C.	   On	   the	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following	   day,	   the	  medium	   in	   the	   well	   was	   replaced	   by	   1ml	   fresh	   full	   DMEM.	   To	  
prepare	   the	   transfection	  mixture,	   typically	  1µg	  of	  plasmid	  was	  added	   to	  150µl	   (for	  
GeneJuice	   transfection)	   or	   500µl	   (for	   Lipofectamine	   LTX	   transfection)	   of	   OptiMEM	  
and	  mixed	  well	  by	  gentle	  vortexing.	  Then,	  3µl	  of	  GeneJuice	  or	  6µl	  of	  Lipofectamine	  
LTX	   transfection	   reagent	  was	   added,	   followed	   by	   vortexing,	   and	   standing	   at	   room	  
temperature	   for	   20	   minutes.	   The	   transfection	   mixture	   was	   subsequently	   added	  
dropwise	  into	  the	  corresponding	  well.	  Cells	  were	  then	  incubated	  at	  37˚C	  and	  lysed	  or	  
fixed	  24	  hours	  post-­‐transfection.	  	  
	  
2.2.5	   	   Cell	  Aggregation	  Assay	  	  
	  
	   A	  cell	  aggregation	  assay	  (Nola	  et	  al.,	  2012)	  was	  performed	  to	  assess	  ability	  of	  
MCF7	   cells	   to	   aggregate	   following	   knockdown	   of	   USP38	   (see	   chapter	   3,	   section	  
3.2.5).	   Typically,	  monolayer	   of	   adherent	   cells	   were	  washed	   twice	  with	  warm	   PBS,	  
followed	  by	  addition	  of	  2ml	  (for	  a	  well	  of	  a	  6-­‐well	  plate)	  of	  2mM	  EDTA	  in	  PBS.	  Cells	  
were	   then	   incubated	   at	   37˚C	   for	   about	   15	   minutes	   until	   they	   detached	   from	   the	  
plate.	  4	  ml	  of	  full	  DMEM	  was	  added	  and	  cells	  were	  pipetted	  up	  and	  down	  10	  times	  
to	   separate	   cells	   from	   each	   other.	   Then,	   cell	   number	   was	   counted	   using	   a	  
haematocytometer	  and	  cells	  were	  resuspended	  to	  a	  density	  of	  5	  x	  105	  cells	  per	  ml.	  
The	  lid	  of	  a	  6cm	  dish	  was	   inverted	  and	  several	  20µl	  droplets	  of	  the	  cell	  suspension	  
were	  then	  pipetted	  onto	  the	  inner	  side	  of	  the	  lid,	  and	  the	  dish	  was	  filled	  with	  3ml	  of	  
sterile	  water.	  The	  lid	  was	  quickly	  put	  on	  top	  of	  the	  dish,	  so	  that	  the	  cells	  would	  fall	  to	  
the	  tip	  of	  the	  droplet	  by	  gravity,	  and	  incubated	  at	  37˚C	  for	  2	  hours.	  A	  phase	  contrast	  
image	  of	  each	  droplet	  was	  taken	  at	  1	  hour	  intervals.	  	  
	  
2.3	  	   	   Protein	  Biochemistry	  
	  
2.3.1	   	   Materials	  	  
	  
BL21	   expression	   competent	   cells	   (♯200131)	   were	   obtained	   from	   Agilent	  
Technologies	   (Santa	   Clara,	   CA,	   USA).	   Protein	   G	   Sepharose	   (♯P3296)	   and	   Protein	   A	  
Sepharose	   (♯P9424)	   were	   obtained	   from	   Sigma	   Aldrich.	   BCA	   protein	   assay	   kit	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(♯23225)	   and	   Glutathione-­‐agarose	   beads	   (♯15160)	   were	   obtained	   from	   Pierce	  
Biotechnology	   (Rockford,	   IL,	   USA).	   Bio-­‐Rad	   Protein	   Assay	   Kit	   (♯500-­‐0002)	   was	  
obtained	   from	   Bio-­‐Rad	   (Hemel	   Hempstead,	   UK).	   Protran	  Nitrocellulose	  Membrane	  
(♯B3-­‐0042),	   ProtoGel	   Resolving	   Buffer	   (♯B9-­‐0010),	   ProtoGel	   Stacking	   Buffer	   (♯B9-­‐
0014),	   SDS	  PAGE	  Tank	  Buffer,	  10X	   (♯B9-­‐0032),	  ProtoGel	   (♯A2-­‐0072)	  were	  obtained	  
from	   GeneFlow	   (Elmhurst,	   UK).	   NuPAGE®	   4-­‐12%	   Bis-­‐Tris	   gels	   (♯NP0321BOX,	  
♯NP0323BOX,	  ♯NP0326BOX,	  ♯WG1402BOX)	   and	  NuPAGE®	  MOPS	  20X	   SDS	  Running	  
Buffer	   (♯NP-­‐0001-­‐02)	   were	   obtained	   from	   Invitrogen	   (Paisley,	   UK).	   All	   other	  
chemicals	  were	  obtained	  from	  Sigma-­‐Aldrich	  (Poole,	  UK)	  unless	  otherwise	  stated.	  	  
	  
	  
2.3.2	   	   Bacterial	  Protein	  Purification	  
	  
GST-­‐tagged	  RNAse	   III	  protein	  was	  purified	   from	  BL21	  expression	  competent	  
cells.	  BL21	  cells	  were	  first	  transformed	  with	  pGEX2T-­‐RNAse	  III	   (Section	  2.1.4)	  and	  a	  
colony	  tested	  positive	  for	  the	  plasmid	  was	  picked	  and	  grown	  overnight	  in	  50ml	  of	  LB	  
medium	   (+	   Ampicillin)	   at	   37˚C	   and	  with	   shaking	   at	   250rpm.	   The	   overnight	   culture	  
was	  used	  to	  set	  up	  a	  2	  x	  500ml	  LB	  (+	  Ampicillin)	  at	  a	  1	  in	  20	  dilution,	  and	  was	  allowed	  
to	   grow	   until	   the	   optical	   density	   (600nm)	   reached	   0.8.	   Protein	   expression	   of	   GST-­‐
RNAse	   III	   was	   then	   induced	   with	   the	   addition	   of	   IPTG	   at	   a	   final	   concentration	   of	  
0.4mM	  for	  4	  hours	  at	  37˚C.	  
	  
	  Following	   protein	   expression	   induction,	   bacteria	   was	   pelleted	   at	   4000rpm	  
and	  4˚C	  for	  15	  minutes.	  The	  bacterial	  pellet	  was	  resuspended	  in	  50ml	  of	  lysis	  buffer	  
(150mM	  NaCl	  in	  PBS	  plus	  bacterial	  protease	  inhibitor	  cocktail),	  transferred	  to	  a	  50ml	  
Falcon	   tube	   and	   centrifuged	   at	   4000rpm.	   The	   supernatant	  was	   discarded	   and	   the	  
pellet	   resuspended	   in	   25ml	   of	   lysis	   buffer.	   Lysozyme	   was	   then	   added	   to	   the	   cell	  
suspension,	  at	  a	  concentration	  of	  1mg/ml,	  and	  the	  cell	  suspension	  was	  incubated	  on	  
ice	  for	  15	  minutes.	  	  
	  
Bacterial	  cells	  were	  then	  lysed	  using	  a	  sonicator	  probe,	  4	  times	  30	  seconds	  at	  
a	   power	   of	   10	   and	   on	   ice.	   The	   resulting	   crude	   lysate	   was	   spun,	   in	   Optima	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ultracentrifuge,	   at	  55,000g	   for	  30	  minutes.	   The	   supernatant	  was	   collected	  and	   the	  
pellet	  was	  resuspended	  to	  the	  original	  volume.	  The	  supernatant	  was	  then	  combined	  
with	   1.3ml	   of	   75%	   (v/v)	   slurry	   glutathione-­‐agarose	   beads	   (prewashed	   three	   times	  
using	  PBS)	  in	  a	  50ml	  Falcon	  tube,	  and	  was	  incubated	  at	  4˚C	  on	  a	  rotating	  wheel	  for	  2	  
hours.	  The	  agarose	  beads	  were	  then	  spun	  down	  at	  4000rpm	  for	  5	  minutes	  at	  4˚C	  and	  
the	  supernatant	  was	  retained.	  To	  wash	  the	  beads,	   they	  were	  resuspended	   in	  20ml	  
PBS	  (plus	  dithiothreitol)	  and	  spun	  down	  at	  1000rpm,	  4˚c	  for	  1	  minute.	  This	  step	  was	  
repeated	  3	   times.	  Then,	   the	  protein	  was	  eluated	  4	   times	  using	  1ml	  50mM	  Tris-­‐HCl	  
(pH	   8.0)	   plus	   10mM	   reduced	   glutathione	   at	   room	   temperature	   for	   10	   minutes.	  
Eluates	   were	   collected,	   combined	   to	   a	   final	   volume	   of	   about	   4ml	   and	   dialysed	  
against	   2	   x	   1000ml	   of	   dialysis	   buffer	   (20mM	  HEPES-­‐KOH,	   100mM	   KCl	   and	   0.2mM	  
DTT;	  pH	  7.6).	  	  
	  
	  
2.3.3	   	   Cell	  Lysis	  for	  Protein	  Harvest	  
	  
Monolayer	  of	  adherent	  cells	  were	  washed	  twice	  with	  ice-­‐cold	  PBS	  on	  ice	  and	  
lysed	   with	   NP40	   lysis	   buffer	   (0.5%	   (w/v)	   NP40,	   25mM	   Tris	   pH	   7.5,	   100mM	   NaCl,	  
50mM	  NaF)	   plus	   phosphatase	   inhibitor	   cocktail	   II	   (Sigma	   Aldrich)	   and	  mammalian	  
protease	  inhibitor	  (Sigma	  Aldrich).	  	  
	  
	  
2.3.4	   	   Protein	  Assay	  
	  
The	  protein	  concentration	  of	  cell	  lysates	  was	  quantified	  using	  the	  BCA	  protein	  
assay	  kit	  (♯23225,	  Pierce,	  UK)	  or	  the	  Bio-­‐Rad	  Protein	  Assay	  Kit	  (♯500-­‐0002)	  according	  
to	  the	  manufacturer’s	  instructions.	  	  
	  
2.3.5	   	   Co-­‐immunoprecipitation	  	  
	  
Cells	  were	  lysed	  as	  described	  in	  section	  2.3.2.	  Protein	  concentration	  of	  lysate	  
was	   determined	   (see	   section	   2.3.4)	   and	   the	   lysates	   were	   adjusted	   to	   equal	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concentration	  using	   lysis	  buffer	   in	  a	   fresh	   tube	   (typically,	  500-­‐800µg	  of	  protein	   for	  
each	   co-­‐immunoprecipitation).	   Antibody	   against	   protein	   of	   interest	   (1µg	   per	   µg	   of	  
lysate)	  and	  30µl	  of	  50%	  (v/v)	  slurry	  protein-­‐G	  (for	  primary	  antibodies	  raised	  in	  mice	  
or	   sheeps)	   or	   protein-­‐A	   (for	   primary	   antibodies	   raised	   in	   rabbits)	   Sepharose	  were	  
added	  and	  incubated	  on	  a	  rotating	  wheel	  at	  4˚C	  for	  1-­‐2	  hour.	  Beads	  were	  pelleted	  at	  
top	   speed	   in	   a	   bench	   top	   centrifuge	   and	  washed	   3	   times	   with	   YP-­‐IP	   buffer	   (0.1%	  
(w/v)	  NP40,	  25mM	  Tris	  pH	  7.5,	  150mM	  NaCl),	  followed	  by	  a	  final	  wash	  in	  10mM	  Tris	  
pH	  8.0.	  Proteins	  bound	  to	  beads	  were	  then	  retrieved	  by	  boiling	  the	  beads	  in	  30µl	  3X	  
sample	  buffer	  for	  5	  minutes.	  	  	  
	  
2.3.6	   	   SDS	  polyacrylamide	  gel	  electrophoresis	  (SDS-­‐PAGE)	  	  
	  
Sodium	   dodecyl	   sulfate	   (SDS)	   Polyacrylamide	   gel	   electrophoresis	   was	  
performed	   using	   the	   BioRad	   system	   or	   precast	   NuPAGE®	   4-­‐12%	   Bis-­‐Tris	   gels	  
(Invitrogen,	  Paisley,	  UK).	  	  
	  
For	  the	  BioRad	  system,	  gels	  were	  poured	  at	  the	  following	  concentrations:	  
	  
Table	  2.18.	  Recipe	  for	  pouring	  two	  resolving	  gels.	  	  
Percentage	  Gel	   8%	  (v/v)	   10%	  (v/v)	   12%	  (v/v)	  
Protogel	  (ml)	   5.3	   6.7	   8	  
Protogel	  Resolving	  (ml)	   5.2	   5.2	   5.2	  
Water	  (ml)	   9.2	   7.9	   6.6	  
Temed	  (µl)	   15	   15	   15	  
10%	  (w/v)	  APS	  (µl)	   150	   150	   150	  
Total	  Volume	  (ml)	   ~20ml	   ~20ml	   ~20ml	  
	  
	  
Table	  2.19.	  Recipe	  for	  pouring	  two	  4%	  (v/v)	  stacking	  gel.	  	  
Protogel	  (ml)	   1.3	  
Protogel	  Stacking	  (ml)	   2.5	  
Water	  (ml)	   6.1	  
Temed	  (µl)	   50	  
10%	  (w/v)	  APS	  (µl)	   10	  
Total	  Volume	  (ml)	   ~10ml	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SDS-­‐PAGE	   using	   precast	   NuPAGE®	   4-­‐12%	   Bis-­‐Tris	   gel	   was	   performed	   at	   a	  
constant	  voltage	  of	  200V	  for	  55	  minutes	  (mini	  gel)	  or	  65	  minutes	  (midi	  gel).	  BioRad	  
gels	  were	  typically	  run	  at	  90V	  for	  15	  minutes	  followed	  by	  135V	  for	  70	  minutes.	  	  
	  
	  
2.3.7	  	   	   Western	  Blotting	  	  
	  
Western	   blotting	   (Burnette,	   1981)	   was	   performed	   to	   transfer	   proteins	  
resolved	   on	   polyacrylamide	   gel	   to	   nitrocellulose	   membrane.	   Proteins	   were	  
transferred	   from	   polyacrylamide	   gels	   onto	   0.45µm	   Protran®	   nitrocellulose	  
membrane	   (Geneflow)	   at	   a	   constant	   current	   of	   0.8	   –	   0.9A	   for	   an	   hour.	   Following	  
transfer,	   Ponceau-­‐S	   stain	   (Sigma	   Aldrich)	   was	   used	   to	   stain	   the	   blot	   to	   visualise	  
successful	   transfer	   of	   protein.	   The	   Ponceau-­‐S	   stain	  was	   removed	   by	  washing	  with	  
PBS.	  The	  blot	  was	   then	  blocked	   for	  a	  minimum	  of	  1	  hour	  using	  a	  suitable	  blocking	  
buffer,	  which	   is	  compatible	  with	  the	  primary	  antibodies	  to	  be	  used.	  Typically,	  blots	  
were	  blocked	  with	  5%	  Marvel	  milk	  powder	  in	  TBS	  (20mM	  Tris,	  137mM	  NaCl,	  pH	  7.6)	  
containing	   0.1%	   Tween20	   (hence	   TBS-­‐T).	   Blots	   were	   then	   incubated	   with	   primary	  
antibody	   for	  an	   indicated	   length	  of	   time	   (see	  Table	  2.20).	  Blots	  were	  washed	   for	  3	  
times	   4	  minutes	   using	   TBS-­‐T,	   followed	   by	   incubation	  with	   fluorophore	   conjugated	  
secondary	   antibody	   (see	   Table	   2.21)	   at	   room	   temperature	   for	   an	   hour.	   Before	  
acquisition	  of	  a	  blot	  image,	  the	  blot	  was	  washed	  for	  3	  times	  4	  minutes	  using	  TBS-­‐T,	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Immunogen	   Manufacturer	   Blocking	  
buffer	  
Dilution	  
HECD1	   E-­‐cadherin	   N-­‐term	  
CRUK	  /Abcam	  
(♯ab1416)	   Milk	  
1:1000	  
EP700Y	   E-­‐cadherin	   N-­‐term	  
Abcam	  
(♯ab40772)	   Milk	  
1:2000	  
M168	   E-­‐cadherin	   C-­‐term	  
Abcam	  
(♯ab76055)	   Milk	  
1:1000	  








E247	   β-­‐catenin	   Near	  N-­‐term	   Abcam	  (♯ab32572)	   Milk	  
1:1000	  








α-­‐tubulin	   C-­‐term	   Sigma	  (♯T6074)	   Milk/BSA	   1:10000	  
Anti-­‐
actin	  
Actin	   SGPSIVHRKCF	   Sigma	  (♯A2066)	   Milk/BSA	   1:2000	  
Anti-­‐GFP	   GFP	   N/A	   Ian	  Prior	   Milk	   1:1000	  
FK2	   Ubiquitin	  	   N/A	   Millipore	  ((♯04263)	  
BSA	   1:1000	  
USP8	   USP8	   aa	  239	  -­‐	  377	   Sigma	  (♯HPA004869)	  
Milk	   1:1000	  
USP9X	   USP9X	   N/A	   Bethyl	  (♯A301-­‐350)	  
Milk	   1:1000	  
USP15	   USP15	   N/A	   Bethyl	  (♯A300-­‐923A)	  
Milk	   1:1000	  
USP20	   USP20	   N/A	   Bethyl	  (♯A301-­‐189A)	  
Milk	   1:1000	  
USP38	   USP38	   aa	  700	  -­‐	  750	   Abcam	  
(ab72244)	  
Milk	   1:2000	  
BAP1	   BAP1	   aa	  430	  -­‐	  729	   Santa	  Cruz	  (♯sc28383)	  
Milk	   1:1000	  
A20	   A20/TNFAIP3	   Full	  length	   Santa	  Cruz	  (♯sc52910)	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Table	  2.21.	  Secondary	  antibodies	  for	  Western	  blotting.	  All	  antibodies	  were	  used	  in	  
the	  same	  blocking	  buffer	  as	  primary	  antibodies.	  	  	  
Secondary	  Antibody	  	   Manufacturer	   Catalogue	  No.	  	   Dilution	  
Donkey	  anti-­‐mouse	  IRDye	  800CW	   LICOR	  Biosciences	   926-­‐32212	   1:15000	  
Donkey	  anti-­‐mouse	  IRDye	  680CW	   LICOR	  Biosciences	   926-­‐32222	   1:15000	  
Donkey	  anti-­‐rabbit	  IRDye	  800CW	   LICOR	  Biosciences	   926-­‐32213	   1:15000	  
Donkey	  anti-­‐rabbit	  IRDye	  680CW	   LICOR	  Biosciences	   926-­‐32223	   1:15000	  
Donkey	  anti-­‐sheep	  IRDye	  800CW	   LICOR	  Biosciences	   926-­‐32214	   1:15000	  




2.3.8	   Immunofluorescence	  staining	  	  
	  
Cells	   grown	   on	   coverslips	   were	   washed	   twice	   with	   room	   temperature	   PBS	  
before	  incubation	  with	  4%	  paraformaldehyde	  in	  PBS	  for	  15	  minutes.	  Cells	  were	  then	  
washed	  twice	  using	  PBS	  and	  incubated	  with	  50mM	  ammonium	  chloride	  in	  PBS	  for	  15	  
minutes,	  followed	  by	  a	  further	  two	  rinses	  with	  PBS.	  Then,	  cells	  were	  permeabilised	  
using	  0.2%	  Triton	   (w/v)/PBS	   for	  4	  minutes	  and	   then	  blocked	  with	  10%	  goat	   serum	  
/PBS	   for	   30	  minutes.	   Cells	  were	   then	   incubated	  with	   primary	   antibody	   in	   5%	   goat	  
serum/PBS	   (see	   Table	   2.22	   for	   list	   of	   primary	   antibodies	   used)	   for	   20	   minutes,	  
followed	  by	   3	  washes	   in	   PBS	   and	   incubation	  with	   secondary	   antibodies	   (see	   Table	  
2.23	   for	   list	   of	   secondary	   antibodies	   used)	   in	   5%	   goat	   serum/PBS	   for	   20	  minutes.	  
Cells	  were	  then	  washed	  another	  3	  times	  in	  PBS,	  dipped	  into	  sterile	  deionised	  water	  
and	   mounted	   onto	   slides	   with	   Mowiol	   plus	   4’,6-­‐diamidino-­‐2-­‐phenylindole	   (DAPI)	  
stain.	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Table	  2.22.	  Primary	  antibodies	  used	  for	  immunofluorescence	  staining.	  Blocking	  





	  Immunogen	   Manufacturer	   Dilution	  




EP700Y	   E-­‐cadherin	   N-­‐term	   Abcam	  (♯ab40772)	   1:2000	  
M168	   E-­‐cadherin	   C-­‐term	   Abcam	  (♯ab76055)	   1:1000	  




Cell	  Signaling	  (♯3195)	   1:1000	  
E247	   β-­‐catenin	   Near	  N-­‐term	   Abcam	  (♯ab32572)	   1:1000	  
8E7	   β-­‐catenin	   HSGATTTAP	   Millipore	  (♯05-­‐665)	   1:1000	  
BAP1	   BAP1 aa	  430	  -­‐	  729	   Santa	  Cruz	  (♯sc28383)	   1:1000	  
H4A3	   LAMP-­‐1 N/A	   DSHB	  	   1:50	  
CD63	   CD63 N/A	   Biodesign	  (♯N42768M)	   1:100	  	  
EEA1	  243/3	   EEA1 N/A	   Ian	  Mills	   1:500	  
	  
	  
Table	  2.23.	  Secondary	  antibodies	  used	  for	  immunofluorescence	  staining.	  	  
Secondary	  Antibody	  	   Manufacturer	   Catalogue	  No.	  	   Dilution	  	  
Donkey	  anti-­‐sheep	  AF488	   Invitrogen	   A11015	   1:500	  
Donkey	  anti-­‐sheep	  AF594	   Invitrogen	   A11016	   1:500	  
Donkey	  anti-­‐rabbit	  AF488	   Invitrogen	   A21206	   1:500	  
Donkey	  anti-­‐rabbit	  AF594	   Invitrogen	   A21207	   1:500	  
Donkey	  anti-­‐mouse	  AF488	   Invitrogen	   A21202	   1:500	  
Donkey	  anti-­‐mouse	  AF594	   Invitrogen	   A21203	   1:500	  
	  
	  
2.4	   esiRNA	  Production	  
	  
	   An	  esiRNA	  DUB	  library	  was	  generated	  to	  facilitate	  further	  screening	  efforts	  in	  
the	  laboratory.	  	  
	  
2.4.1	  	   Materials	  
	  
HotStarTaq	   Master	   Mix	   Kit	   (♯203446)	   and	   QIAquick	   Gel	   Extraction	   Kit	  
(♯28704)	   were	   obtained	   from	   Qiagen	   (Crawley,	   UK).	   MEGAscript	   T7	   in	   vitro	  
Transcription	   Kit	  was	   obtained	   from	  Ambion,	   Life	   Technologies	   (Paisley,	   UK).	   GST-­‐
RNASeIII	   was	   prepared	   by	   myself.	   Q-­‐Sepharose	   Fast	   Flow	   (♯17-­‐0510-­‐01)	   was	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obtained	   from	   GE	   Healthcare	   (UK).	   1kDA	   (♯N3232),	   	   100bp	   (♯N3231),	   and	   Low	  
Molecular	  Weight	   DNA	   ladder	   (♯N3233)	   were	   obtained	   from	   New	   England	   Biolab	  
(Herts,	   UK).	   Empty	   Bio-­‐Spin	   Chromatography	   Column	   was	   obtained	   from	   Bio-­‐Rad	  
(Hemel	   Hempstead,	   UK).	   All	   other	   chemicals	   were	   obtained	   from	   Sigma	   Aldrich	  
(Poole,	  UK)	  unless	  otherwise	  stated.	  	  
	  
2.4.2	   Polymerase	  Chain	  Reaction	  	  
	  
PCR	  were	  performed	  to	  obtain	  PCR	  products	  as	  templates	  for	  the	  subsequent	  
stage	   of	   in	   vitro	   transcription	   (IVT)	   reaction	   to	   produce	   double-­‐stranded	   RNA	  
(dsRNA).	  PCR	  products	  of	  esiRNA	  regions	  of	  the	  following	  DUBs	  were	  amplified	  from	  
ORFs	  which	  were	  already	  cloned	  in	  the	  lab:	  CYLD,	  USP1,	  USP2A,	  USP3,	  USP4,	  USP5,	  
USP6,	   USP7,	   USP8,	   USP9X,	   USP10,	   USP11,	   USP12,	   USP13,	   USP14,	   USP15,	   USP16,	  
USP18,	  USP19,	  USP20,	  USP21,	  USP25,	  USP26,	  USP28,	  USP29,	  USP30,	  USP32,	  USP33,	  
USP36,	  USP38,	  USP39,	  USP42,	  USP44,	  USP45,	  USP46,	  USP47,	  USP48,	  USP49,	  USP50,	  
USP52,	  USP53,	  USP54,	  USPL1,	  BAP1,	  UCHL1,	  UCHL3,	  UCHL5,	   JOSD1,	   JOSD2,	  BRCC3,	  
CSN5,	  CSN6,	  EIF3H,	  EIF3S5,	  MPND,	  MYSM1,	  PSMD14,	  PSMD7,	  STAMBP,	  STAMBPL1,	  
OTUB1,	   OTUB2,	   OTUD3,	   OTUD4,	   OTUD5,	   OTUD6A,	   OTUD6B,	   OTUD7B,	   TNFAIP3,	  
VCPIP1,	   YOD1,	   ZRANB1,	   GFP.	   The	   primer	   pairs	   used	   are	   flanked	   by	   T7	   promoter	  
sequence	  (for	   IVT)	  and	  are	  summarised	   in	  Appendix	  2.1.	  These	  PCR	  reactions	  were	  
set	   up	   using	   HotStarTaq	   Master	   Mix	   Kit	   (Qiagen)	   according	   to	   manufacturer’s	  
instruction	  and	  the	  reaction	  setting	  was	  as	  follows:	  
	  
Table	  2.24.	  Thermal	  cycler	  programme	  for	  PCR	  reactions	  to	  amplify	  esiRNA	  region.	  	  
Segment	   Step	   No.	   of	  
cycles	  	  
Temperature	  	   Duration	  
1	   Initial	  
Denaturation	  
1	   95˚C	   5	  min	  
Denaturation	   95˚C	   1	  min	  




72˚C	   1	  min	  /kb	  
3	   Final	  
Extension	  
1	   72˚C	   5	  min	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PCR	  products	  of	  esiRNA	  regions	  of	   the	   following	  DUBs	  were	  amplified	   from	  
cDNA	   of	  MCF7	   cells:	   DUB3,	   DUB4,	   USP17,	   USP22,	   USP24,	   USP27X,	   USP31,	   USP34,	  
USP35,	  USP37,	  USP40,	  USP43,	  ATXN3,	  ATXN3L,	  PARP22,	  PRPF8,	  OTUD7A.	  cDNA	  was	  
prepared	   from	  MCF7	  RNA	   extract	   as	   described	   in	   section	   2.1.11.	   The	   primer	   pairs	  
used	  are	  flanked	  by	  T7	  promoter	  sequence	  (for	  IVT)	  and	  are	  summarised	  in	  Appendix	  
2.1.	  The	  PCR	  reactions	  were	  set	  up	  using	  Pfu	  Ultra	  DNA	  polymerase	  as	  described	  in	  
section	   2.1.2	   (Table	   2.2).	   These	   PCR	   products	   were	   then	   cloned	   into	   pCR4®Blunt-­‐
TOPO	  vectors	  as	  described	  in	  section	  2.1.6.	  The	  resulting	  plasmids	  were	  sequenced	  
verified	   and	   a	   glycerol	   stock	   of	   each	   plasmid	  was	  made.	   The	   list	   of	   plasmids	   that	  
were	  generated	  were	  summarised	  in	  Appendix	  2.2.	  	  
	  
2.4.3	   In	  vitro	  transcription	  
	  
PCR	  products	  that	  were	  obtained	  from	  ORFs	  of	  DUBs	  were	  analysed	  by	  DNA	  
agarose	   gel	   electrophoresis	   and	   were	   purified	   using	   QIAquick	   gel	   extraction	   kit	  
(Qiagen)	   according	   to	   manufacturer’s	   instructions.	   DUBs	   for	   which	   their	   esiRNA	  
region	   were	   inserted	   into	   pCR4®Blunt-­‐TOPO	   vectors,	   the	   esiRNA	   region	   were	  
released	   from	   10µg	   of	   the	   plasmid	   by	   restriction	   digest	   using	   EcoRI.	   The	   esiRNA	  
regions	   and	   vector	   backbones	   resulting	   from	   the	   digest	   were	   resolved	   by	   DNA	  
agarose	   gel	   electrophoresis	   and	   were	   purified	   using	   QIAquick	   gel	   extraction	   kit	  
(Qiagen)	  according	  to	  manufacturer’s	  instructions.	  	  
	  
The	   in	  vitro	  transcription	  (IVT)	  reactions	  were	  set	  up	  using	  MEGAscript	  T7	  in	  
vitro	  Transcription	  Kit	  (Ambion,	  Life	  Technologies)	  as	  follow:	  
	  
Table	  2.25.	  Reaction	  mixtures	  for	  IVT	  reactions.	  	  
10x	  T7	  reaction	  buffer	   1	  µl	  
UTP	  (75mM)	   1	  µl	  
GTP	  (75mM)	   1	  µl	  
ATP	  (75mM)	   1	  µl	  
CTP	  (75mM)	   1	  µl	  
T7	  enzyme	  mix	  	   1	  µl	  
PCR	  product	  /	  EcoRI-­‐digested	  insert	   4	  µl	  
Total	  volume	  	   10	  µl	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The	  IVT	  reaction	  was	  performed	  according	  to	  the	  following	  setting:	  
	  
	  
Table	  2.26.	  Thermal	  cycler	  programme	  for	  IVT	  reactions.	  	  
Stages	   Setting	  
In	  vitro	  transcription	   • 12	  hr	  at	  37°C*	  (i.e.	  o/n)	  
Denaturation	   • 3	  min	  at	  90°C	  
• Ramp	  to	  70°C	  with	  0.1°C/s	  	  
• 3	  min	  at	  70°C	  
• Ramp	  to	  50°C	  with	  0.1°C/s	  
• 3	  min	  at	  50°C	  
Annealing	   • Ramp	  to	  25°C	  with	  0.1°C/s	  	  
	  	  	  
	   0.4µl	  of	  the	  IVT	  product	  was	  mixed	  with	  9.6µl	  of	  2X	  DNA	  sample	  buffer	  and	  
was	   run	  on	  a	  1.5%	  DNA	  agarose	  gel,	   at	  120V	   for	  50	  minutes.	  A	   thick	  band	  of	  RNA	  
should	  be	  seen	  for	  successful	  IVT	  reactions.	  The	  rest	  of	  the	  IVT	  product	  was	  used	  for	  
the	  subsequent	  digestion	  step.	  	  
	  
	  
2.4.4	   Double-­‐stranded	  RNA	  digestion	  	  
	  
	   Prior	  to	  dsRNA	  digestion	  using	  purified	  recombinant	  GST-­‐RNAseIII,	  a	  digestion	  
buffer	  was	  prepared	  according	  to	  the	  recipe	  shown	  in	  Table	  2.33.	  pH	  of	  the	  solution	  
was	  adjusted	  to	  7.9.	  	  
	  
	  
Table	  2.27.	  Recipe	  of	  dsRNA	  digestion	  buffer.	  	  
Stock	  Solutions	   Volume	   [Final]	  
1M	  Tris-­‐HCl	   2	  ml	   20mM	  
5M	  NaCl	   2.8	  ml	   140mM	  
0.1M	  EDTA	   0.5	  ml	   0.5mM	  
1M	  MgCl2	   0.5	  ml	   5mM	  
2.5M	  KCl	   108	  µl	   2.7mM	  
1M	  DTT	   0.1	  ml	   1mM	  
Glycerol	   5	  ml	   5%	  (v/v)	  
Water	   89	  ml	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   For	   the	   digestion	   reaction,	   9.6µl	   of	   IVT	   product	   was	   mixed	   with	   86.4µl	   of	  
dsRNA	  digestion	  buffer	  and	  4µl	  of	  1.5µg/µl	  GST-­‐RNAse	  III.	  The	  reaction	  mixture	  was	  
incubated	  on	  a	   thermomixer	  at	  23˚C,	  with	  agitation	  at	  1000rpm	  for	  4	  hours.	  Then,	  
the	  temperature	  was	  increased	  to	  37˚C	  and	  the	  reaction	  mixture	  was	  incubated	  with	  
agitation	  at	  1000rpm	  for	  another	  2-­‐3	  hours.	  3µl	  of	  the	  digestion	  product	  was	  mixed	  
with	   3µl	   5X	  DNA	   sample	   buffer	   and	  was	   run	   alongside	   low	  molecular	  weight	  DNA	  
ladder	   (NEB)	   on	   2.5%	  DNA	  Agarose	   gel	   at	   120V	   for	   50	  minutes.	  Digestion	   product	  
was	  expected	  to	  be	  a	  smear	  between	  18-­‐25bp.	  	  
	  
2.4.5	   	   esiRNA	  purification	  	  
	  
	   Several	  buffers,	  namely	  wash	  buffer,	  equilibration	  buffer	  and	  elution	  buffer,	  
were	  prepared	  according	  to	  the	  recipes	  as	  summarised	  in	  Table	  2.34,	  2.35	  and	  2.36	  
respectively.	  All	  buffers	  were	  adjusted	  to	  pH	  8.0	  and	  kept	  on	  ice	  prior	  to	  use.	  	  
	  
	  
Table	  2.28.	  Recipe	  of	  wash	  buffer.	  	  
Stock	  	   Amount	  to	  be	  used	   [Final]	  
1M	  Tris-­‐HCl	   2ml	   20mM	  
5M	  NaCl	   8ml	   400mM	  
0.1M	  EDTA	   1ml	   1mM	  




Table	  2.29.	  Recipe	  of	  equilibration	  buffer.	  	  
Stock	  	   Amount	  to	  be	  used	   [Final]	  
1M	  Tris-­‐HCl	   2ml	   20mM	  
5M	  NaCl	   6ml	   300mM	  
0.1M	  EDTA	   1ml	   1mM	  
Water	   91ml	   	  
	  
	  
Table	  2.30.	  Recipe	  of	  elution	  buffer.	  	  
Stock	  	   Amount	  to	  be	  used	   [Final]	  
1M	  Tris-­‐HCl	   2ml	   20mM	  
5M	  NaCl	   10.4ml	   520mM	  
0.1M	  EDTA	   1ml	   1mM	  
Water	   86.6ml	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200µl	   of	   Q-­‐Sepharose	   was	   added	   to	   an	   empty	   spin	   column	   and	   the	   spin	  
column	   was	   transferred	   onto	   a	   2	   ml	   microcentrifuge	   tube.	   500µl	   of	   equilibration	  
buffer	  was	  added	  to	  the	  spin	  column	  and	  the	  column	  was	  centrifuged	  at	  1000g	  for	  1	  
minute,	   and	   the	   flowthrough	  was	   discarded.	   This	   step	  was	   repeated	   once.	   All	   the	  
dsRNA	  digestion	  product	  was	  then	  load	  into	  the	  column	  and	  was	  allowed	  to	  incubate	  
at	   room	   temperature	   for	   5	   minutes.	   The	   spin	   columns	   were	   then	   centrifuged	   at	  
1000g	  for	  1	  minutes	  and	  the	  flowthrough	  was	  discarded.	  500µl	  of	  wash	  buffer	  was	  
then	  added,	  the	  spin	  columns	  were	  then	  centrifuged	  at	  1000g	  for	  1	  minute	  and	  the	  
flowthrough	  was	   discarded.	   The	   spin	   columns	  were	   then	   transferred	   to	   clean	   2ml	  
Eppendorf	   tubes	   and	  300µl	   of	   elution	  buffer	  was	   added	   to	   each	   column.	   The	   spin	  
columns	  together	  with	  the	  Eppendorf	  tubes	  were	  centrifuged	  at	  1000g	  for	  1	  minute.	  
This	   step	  was	   repeated	  once	  and	  the	  spin	  columns	  were	  discarded.	  Then,	  300µl	  of	  
isopropanol	  was	  added	  to	  the	  600µl	  of	  eluate	  and	  mixed	  by	  vortexing.	  The	  mixture	  
was	  then	  stored	  at	   -­‐20˚C	   for	  at	   least	  3	  hours	  or	  overnight	   to	  allow	  precipitation	  of	  
esiRNA.	   Following	   this	   incubation,	   the	   solution	   was	   centrifuged	   at	   15000g	   for	   25	  
minutes	  at	  4˚C	  and	  the	  supernatant	  was	  discarded.	  The	  pelleted	  esiRNA	  was	  washed	  
with	  500µl	  ice-­‐cold	  70%	  (V/V)	  ethanol,	  centrifuged	  at	  15000g	  for	  15	  minutes	  and	  the	  
supernatant	  was	  discarded.	  This	  step	  was	  repeated	  once.	  The	  esiRNA	  pellet	  was	  then	  
allowed	   to	   dry	   in	   a	   Speed	  Vac	  machine	   at	   45˚C.	   The	  pellet	  was	   dissolved	   in	   100µl	  
RNAse-­‐free	   water	   and	   concentration	   of	   esiRNA	   was	   measured	   using	   a	   NanoDrop	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Chapter	  3	  :	  
Identification	  of	  
Deubiquitylases	  Involved	  in	  
Regulation	  of	  E-­‐cadherin	  
	  
	  
3.1	  	   	   Introduction	  	  
	  
It	   has	   been	   demonstrated	   that	   the	   ubiquitylation	   of	   E-­‐cadherin	   by	   the	   E3	  
ligase,	   Hakai	   can	   lead	   to	   its	   internalisation	   via	   the	   endocytic	   pathway	   and	  
subsequent	   trafficking	   to	   the	   lysosome	   for	   degradation	   (Fujita	   et	   al.,	   2002).	  
However,	   the	   identity	   of	   deubiquitylases,	   which	   can	   reverse	   or	   regulate	   these	  
processes,	  remains	  elusive.	  The	  work	  presented	  in	  this	  chapter	  aims	  to	  identify	  the	  
deubiquitylases,	  which	   regulate	   E-­‐cadherin	   expression	   level	   or	   trafficking,	  with	   the	  
following	  aims:	  (i)	  to	  develop	  a	  robust	  assay	  to	  assess	  E-­‐cadherin	  status	  in	  a	  human	  
cancer	   cell	   line,	   (ii)	   to	   perform	   a	   siRNA	   DUB	   library	   screen	   to	   identify	   potential	  
regulators	   of	   E-­‐cadherin	  within	   the	  deubiquitylase	   family,	   (iii)	   to	   validate	   potential	  
targets	   identified	   from	  this	  siRNA	  screen	  and	   (iv)	   to	  understand	  the	  mechanism	  by	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3.2	  	   	   Developing	  an	  assay	  to	  assess	  E-­‐cadherin	  status	  	  
	  
3.2.1	   	   Hepatocyte	  Growth	  Factor	   induces	   scattering	  of	  epithelial	   cells	  but	  
does	  not	  affect	  E-­‐cadherin	  protein	  level	  	  
	  
	   As	   mentioned	   above,	   ubiquitylation	   of	   E-­‐cadherin	   commits	   it	   to	   lysosomal	  
degradation	  (Fujita	  et	  al.,	  2002;	  Bonazzi	  et	  al.,	  2008	  )	  and	  there	  are	  multiple	  points	  
during	   the	   process	   at	   which	   deubiquitylases	   can	   execute	   their	   regulatory	   roles.	  
Hepatocyte	   growth	   factor	   (HGF),	   also	   known	   as	   scatter	   factor,	   is	   known	   to	   induce	  
dissociation	   of	   the	  AJ	   complex	   (Hiscox	   and	   Jiang,	   1999)	   and	   in	   some	   instance,	   the	  
degradation	  of	  E-­‐cadherin	   (Miura	  et	  al.,	   2001).	   Stimulation	  of	  Madin-­‐Darby	  Canine	  
Kidney	   (MDCK)	   epithelial	   cells	   by	   HGF	   for	   example	   results	   in	   ubiquitylation	   and	  
subsequent	  degradation	  of	  E-­‐cadherin	  (Fujita	  et	  al.,	  2002).	   In	  order	  to	  follow	  up	  on	  
these	  observations,	  a	  panel	  of	  human	  cancer	  cell	  lines	  were	  stimulated	  with	  HGF	  and	  
the	   effect	   on	   E-­‐cadherin	   status	   was	   assessed.	   Among	   the	   tested	   cell	   lines,	   HGF	  
stimulation	   did	   not	   affect	   E-­‐cadherin	   in	   HT29	   (colon	   cancer)	   and	   MCF7	   (breast	  
cancer)	   cells,	   whereas	   a	   slight	   decrease	   in	   E-­‐cadherin	   was	   observed	   with	   DU145	  




Figure	   3.1.	   HGF	   stimulation	   did	   not	   result	   in	   a	   significant	   change	   in	   E-­‐cadherin	  
level.	   4	   different	   human	   cancer	   cell	   lines,	   HT29,	  MCF7,	   DU145	   and	   HCT116	   were	  
stimulated	  with	  HGF	  at	  50ng/ml	  in	  full	  serum	  medium	  for	  different	  lengths	  of	  time.	  
Cells	  were	   lysed	  using	  NP40	   lysis	  buffer	  after	  each	  time	  point	  and	  20µg	   lysate	  was	  
analysed	   by	   10%	   SDS-­‐PAGE	   followed	   by	   immunoblotting	   using	   HECD1	   antibody	  
against	  E-­‐cadherin.	  Actin	  was	  used	  as	  a	  loading	  control.	  	  Experiments	  were	  repeated	  
twice	  and	  representative	  blot	  image	  is	  presented.	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   In	  parallel	   to	   the	  biochemical	  detection	  of	  E-­‐cadherin,	   the	   localisation	  of	  E-­‐
cadherin	   was	   examined,	   following	   HGF	   stimulation	   of	   the	   different	   cell	   lines	   by	  
immunofluorescence	   (Figure	   3.2).	   Unstimulated	   cells	   were	   tightly	   bound	   to	   each	  
other,	  as	  evident	  by	  strong	  E-­‐cadherin	  staining.	  The	  HGF	  stimulation	  resulted	  in	  the	  
detachment	   of	   the	   cells,	   with	   a	   decrease	   in	   E-­‐cadherin	   staining	   on	   the	   plasma	  
membrane	   and	   a	   progressive	   change	   in	   phenotype,	   over	   the	   24-­‐hour	   period:	  
Unstimulated	  HT29	  cells	  were	  cobblestone-­‐shaped	  and	  tightly	  packed	  with	  strong	  E-­‐
cadherin	  staining	  at	  cell-­‐to-­‐cell	  contacts.	  Following	  HGF	  stimulation,	  the	  cells	  slowly	  
detached	  from	  each	  other	  and	  were	  more	  flattened	  out,	  and	  dispersing	  staining	  of	  E-­‐
cadherin	  can	  be	  seen	  at	  24	  hour	  time	  point,	  while	  membrane	  staining	  of	  E-­‐cadherin	  
was	   still	   detectable	   in	   some	   cells;	   MCF7	   cells	   started	   to	   detach	   from	   each	   other	  
following	  HGF	  stimulation,	  and	  became	  more	  flattened	  in	  shape,	  but	  still	  maintained	  
partial	  contact	  at	  the	  end	  of	  the	  24-­‐hour	  period.	  The	  detached	  cells	  also	  started	  to	  
form	  lamellipodia,	  which	  became	  more	  prominent	  after	  9	  hours;	  DU145	  exhibited	  a	  
relatively	   drastic	   change	   in	   phenotype	   following	   HGF	   stimulation.	   Unstimulated	  
DU145	  cells	  were	  rounder	  in	  shape	  and	  were	  attached	  to	  each	  other	  as	  evident	  by	  E-­‐
cadherin	   staining	   at	   cellular	   junction.	   Upon	   HGF	   stimulation,	   the	   cells	   started	   to	  
come	   apart	   and	   at	   the	   end	   of	   24	   hours,	   they	   exhibited	   fibroblastic	   features	   with	  
elongated	   cell	   shape	   and	   almost	   complete	   detachment	   from	   each	   other.	   HCT116	  
cells,	  before	  stimulation,	  were	  tightly	  packed	  with	  each	  other	  and	  strong	  E-­‐cadherin	  
staining	  was	  observed	  at	  cellular	  junctions.	  HGF	  stimulation	  of	  these	  cells	  resulted	  in	  
partial	  detachment	  of	  cells	  from	  each	  other,	  where	  island	  of	  cells	  hollowed	  out	  and	  
formed	  circles	  of	  cells,	  with	  neighbouring	  cells	  still	  bound	  to	  each	  other.	  In	  all	  cases,	  
no	  obvious	  redistribution	  of	  E-­‐cadherin	  into	  specific	  sub-­‐cellular	  compartments	  was	  
observed.	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Figure	   3.2.	   HGF	   stimulation	   resulted	   in	   dissolution	   of	   adherens	   junction	   and	  
scattering	  of	  cancer	  cells.	  Cells	  were	  stimulated	  with	  50ng/ml	  of	  HGF	  stimulation	  in	  
full	   serum	  medium	   and	   were	   subjected	   to	   paraformaldehyde	   fixation	   at	   different	  
time	   points.	   Cells	   were	   then	   immunostained	   with	   HECD1	   antibody	   against	   E-­‐
cadherin,	  followed	  by	  secondary	  antibody.	  (Scale	  bar	  =	  10µm).	  
	  
	  
3.2.2	   	   E-­‐cadherin	   is	   constitutively	  degraded	  via	   the	   lysosomal	  pathway	   in	  
MCF7	  cells	  	  
	  
	   MDCK	  cells	  stimulated	  with	  HGF	  lose	  their	  E-­‐cadherin	  as	  soon	  as	  3	  hours	  after	  
stimulation	   (Fujita	   et	   al.,	   2002).	   However,	   in	   the	   tested	   human	   cancer	   cell	   lines,	  
despite	   the	   dissolution	   of	   adherens	   junction	   observed	   following	   HGF	   stimulation,	  
loss	   of	   E-­‐cadherin	   was	   only	   apparent	   in	   DU145	   and	   HCT116	   after	   24	   hours	   of	  
stimulation.	   One	   possible	   explanation	   is	   that	   the	   transcriptional	   inactivation	   of	   E-­‐
cadherin	  gene	  expression	  required	  more	   than	  24	  hours,	  and	  the	   loss	  of	  E-­‐cadherin	  
through	  degradation	  was	  masked	  by	  its	  continual	  synthesis.	  Therefore,	  to	  check	  if	  E-­‐
cadherin	  was	  degraded	  following	  HGF	  stimulation,	  I	  repeated	  the	  experiments	  in	  the	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presence	  of	  a	  proteasomal	   inhibitor,	  Lactacystin	  or	   lysosomal	  ATPase	  proton	  pump	  
inhibitor,	   Folimycin	   (Figure	  3.3).	   The	  use	  of	   the	   inhibitors	  was	   expected	   to	   lead	   to	  
accumulation	   of	   full	   length	   or	   degradative	   intermediate	   products	   of	   E-­‐cadherin.	  
Interestingly,	  in	  MCF7	  cells,	  Folimycin	  but	  not	  Lactacystin	  treatment	  revealed	  a	  lower	  
molecular	   weight	   band	   of	   E-­‐cadherin,	   which	   accumulated	   in	   a	   time-­‐dependent	  
manner	  (Figure	  3.3A).	  The	  E-­‐cadherin	  fragment	  ran	  at	  around	  80kDa,	  corresponding	  
to	   the	   extracellular	   domain	   of	   E-­‐cadherin.	   Notably,	   the	   accumulation	   of	   this	   E-­‐
cadherin	   fragment	   was	   independent	   of	   HGF	   stimulation,	   suggesting	   constitutive	  
turnover	  of	  E-­‐cadherin	  via	   the	   lysosomal	  pathway.	  When	  cells	  were	   treated	  with	  a	  
combination	   of	   Lactacystin	   and	   Folimycin,	   the	   accumulation	   of	   this	   E-­‐cadherin	  
fragment	  was	   less	   pronounced	   as	   compared	   to	   cells	   treated	  with	   Folimycin	   alone.	  
This	  could	  be	  explained	  by	  the	  fact	  that	  the	  turnover	  of	  membrane	  protein	  requires	  
the	   cooperation	   of	   proteasomal	   and	   lysosomal	   degradation	   pathway,	   as	   was	  
previously	  shown	  for	  Met	  receptor	  (Hammond	  et	  al.,	  2001).	  No	  obvious	  changes	  in	  
E-­‐cadherin	   level	  were	  observed	  with	  different	  combinations	  of	  treatment	  in	  DU145	  
cells	  (Figure	  3B).	  	  
	  
	  
Figure	  3.3.	  E-­‐cadherin	  is	  constitutively	  degraded	  in	  MCF7,	  but	  not	  DU145,	  cells	  via	  
the	  lysosomal	  pathway.	  (A)	  MCF7	  and	  (B)	  DU145	  cells	  were	  incubated	  ±	  50ng/ml	  of	  
HGF	  in	  the	  presence	  or	  absence	  of	  10µM	  Lactacystin	  and/or	  100nM	  of	  Folimycin,	  for	  
indicated	   lengths	  of	   time.	  Cells	  were	   lysed	  and	  analysed	  by	  SDS-­‐PAGE,	   followed	  by	  
immunoblotting	   for	  E-­‐cadherin.	  Western	  Blot	   images	  were	  acquired	  using	  an	   infra-­‐
red	  scanner	  (Odyssey,	  LICOR).	  	  
A	  
B	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Figure	   3.4.	   The	   80kDa	   E-­‐cadherin	   fragment	   corresponds	   to	   the	   extracellular	  
domain.	  (A)	  MCF7	  cells	  were	  treated	  with	  10µM	  MG132	  or	  100nM	  Folimycin	  for	  9	  
hours	  before	   lysis.	  Cell	   lysates	  were	  analysed	  by	  SDS-­‐PAGE	   followed	  by	   transfer	   to	  
nitrocellulose	   membrane.	   The	   blot	   was	   probed	   with	   M168	   or	   HECD1	   primary	  
antibodies,	  and	   images	  were	  acquired	  using	  an	   infra-­‐red	  scanner	   (Odyssey,	  LICOR).	  
(B)	   Topology	   of	   E-­‐cadherin	   antibody	   binding	   sites.	   	   The	   HECD1	   antibody	   binds	   to	  
extracellular	   domain	   of	   E-­‐cadherin	   whereas	   the	   M168	   antibody	   binds	   to	   the	  
cytoplasmic	  domain	  of	  E-­‐cadherin.	  	  
	  
	  
To	   characterise	   the	   80kDa	   E-­‐cadherin	   fragment,	   two	   different	   E-­‐cadherin	  
antibodies	  were	  used,	  namely	  M168,	  which	   recognises	   the	   cytoplasmic	  C-­‐terminus	  
and	  HECD1,	  which	  recognises	  the	  extracellular	  N-­‐terminus.	  As	  seen	  in	  Figure	  3.4,	  the	  
80kDa	   E-­‐cadherin	   fragment	   was	   only	   recognised	   by	   the	   HECD1	   antibody	   but	   not	  
M168,	  indicating	  it	  was	  the	  extracellular	  domain	  of	  E-­‐cadherin.	  	  
	  
Observation	  by	  immunofluorescence	  miscroscopy	  of	  MCF7	  cells	  treated	  with	  
Folimycin	   showed	   focal	  accumulation	  of	   the	  E-­‐cadherin	   staining,	   in	   the	  perinuclear	  
area	   and	   inhibited	   full	   scattering	   of	   MCF7	   cells	   following	   HGF	   stimulation	   (Figure	  
3.5).	   To	   determine	   the	   subcellular	   compartment	   which	   the	   E-­‐cadherin	   fragment	  
occupies,	   MCF7	   cells	   were	   labelled	   with	   several	   cellular	   compartment	   markers,	  
namely	  EEA1	  for	  the	  early	  endosomes	  (Mu	  et	  al.,	  1995)	  (Figure	  3.6),	  CD63	  (Metzelaar	  
et	  al.,	  1991)	  (Figure	  3.7)	  and	  LAMP1	  (Carlsson	  et	  al.,	  1988)	  (Figure	  3.8)	  for	  lysosomes,	  
and	  colocalisation	  of	  E-­‐cadherin	  with	  these	  markers	  were	  determined	  using	  confocal	  
microscopy.	   The	   E-­‐cadherin	   fragment	   accumulated	   following	   Folimycin	   treatment	  
was	  mostly	  excluded	  from	  the	  early	  endosomes,	  as	  no	  colocalisation	  was	  observed	  
between	   E-­‐cadherin	   and	   EEA1.	   Noticeably,	   the	   Folimycin	   treatment	   resulted	   in	  
B	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change	  in	  distribution	  of	  the	  EEA1	  markers:	  punctae	  of	  EEA1	  positive	  compartments	  
were	  observed	   throughout	   the	   cytoplasm	   in	  non-­‐treated	   cells,	   and	  at	   least	   after	  6	  
hours	   of	   Folimycin	   treatment,	   the	   number	   of	   EEA1	   positive	   compartments	   was	  




Figure	   3.5.	   E-­‐cadherin	   accumulated	   in	   the	   perinuclear	   region	   after	   Folimycin	  
treatment.	  MCF7	  cells	  were	  treated	  with	  50ng/ml	  HGF	  and/or	  100nM	  Folimycin	  for	  
indicated	   lengths	   of	   time.	   Cells	   were	   then	   fixed	   with	   4%	   paraformaldehyde	   and	  
immunostained	  with	  HECD1	  antibody.	  Scale	  bar	  =	  10µm.	  
	  
	  
E-­‐cadherin	  showed	  colocalisation	  with	  both	  the	  lysosomal	  markers,	  CD63	  and	  
LAMP1,	   although	   not	   all	   E-­‐cadherin	   positive	   compartments	   were	   co-­‐labelled	   with	  
either	  of	  the	  markers.	  It	   is	  also	  worth	  noting	  that	  Folimycin	  treatment	  resulted	  in	  a	  
change	   in	   distribution	   of	   the	   lysosomal	   marker	   positive	   compartment:	   whereas	  
untreated	  cells	  showed	  diffuse	  cytoplasmic	  staining	  of	  CD63	  and	  LAMP1,	   lysosomal	  
marker	   positive	   compartments	   exhibited	   peri-­‐nuclear	   accumulation	   in	   Folimycin	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treated	   cells.	   Together,	   the	   results	   in	   this	   section	   suggest	   that	   in	   MCF7	   cells,	   E-­‐
cadherin	  is	  constitutively	  internalised	  and	  is	  degraded	  via	  the	  lysosomal	  pathway.	  	  
	  
	  
Figure	   3.6	   E-­‐cadherin	   fragment	   accumulated	   following	   Folimycin	   treatment	   does	  
not	   colocalise	   with	   an	   early	   endosomal	   marker.	   MCF7	   cells	   were	   treated	   with	  
100nM	   Folimycin	   for	   indicated	   lengths	   of	   time.	   Cells	   were	   then	   fixed	   with	   4%	  
paraformaldehyde	   and	   immunostained	   with	   HECD1	   and	   EEA1	   antibodies.	   Images	  
were	  acquired	  using	  a	  confocal	  microscope	  and	  laser	  intensity	  was	  adjusted	  for	  each	  
image	  to	  avoid	  oversaturation	  of	  signal.	  	  
	   105	  
	  
Figure	   3.7	   E-­‐cadherin	   fragment	   accumulated	   following	   Folimycin	   treatment	  
colocalises	  with	  CD63.	  MCF7	  cells	  were	  treated	  with	  100nM	  Folimycin	  for	  indicated	  
lengths	   of	   time.	   Cells	   were	   then	   fixed	   with	   4%	   paraformaldehyde	   and	  
immunostained	   with	   EP700Y	   antibody	   against	   E-­‐cadherin	   and	   anti-­‐CD63	   antibody.	  
Images	  were	  acquired	  using	  a	  confocal	  microscope	  and	  laser	  intensity	  was	  adjusted	  
for	  each	  image	  to	  avoid	  oversaturation	  of	  signal.	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Figure	   3.8	   E-­‐cadherin	   fragment	   accumulated	   following	   Folimycin	   treatment	  
colocalises	   with	   LAMP1.	   MCF7	   cells	   were	   treated	   with	   100nM	   Folimycin	   for	  
indicated	   lengths	   of	   time.	   Cells	   were	   then	   fixed	   with	   4%	   paraformaldehyde	   and	  
immunostained	  with	  EP700Y	  antibody	  against	  E-­‐cadherin	  and	  anti-­‐LAMP1	  antibody.	  
Images	  were	  acquired	  using	  a	  confocal	  microscope	  and	  laser	  intensity	  was	  adjusted	  
for	  each	  image	  to	  avoid	  oversaturation	  of	  signal.	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3.2.3	  	   	   Identification	  of	  DUBs	  regulating	  E-­‐cadherin	  in	  MCF7	  
	  
As	  the	  accumulation	  of	  80kDa	  E-­‐cadherin	  following	  Folimycin	  treatment	  was	  
a	  very	   robust	  effect	  and	  could	  possibly	   reflect	  a	  ubiquitin	  dependent	  sorting	  event	  
(Raiborg	  and	  Stenmark,	  2009),	  it	  was	  used	  as	  a	  biochemical	  read	  out	  for	  a	  siRNA	  DUB	  
library	  screen.	  The	  ratio	  of	  the	  full	  length	  E-­‐cadherin	  to	  80kDa	  fragment	  should	  serve	  
as	   an	   indicator	  of	   the	   trafficking	   status	  of	   E-­‐cadherin,	  where	  a	  high	   ratio	   indicates	  
stabilisation	   of	   E-­‐cadherin	   and/or	   less	   degradation,	   while	   a	   low	   ratio	   indicates	  
degradation	   of	   the	   molecule	   is	   favored.	   Another	   parameter	   I	   monitored	   was	   the	  
total	  E-­‐cadherin	   level,	  which	  was	   represented	  by	   the	   sum	  of	   full	   length	  E-­‐cadherin	  
and	   the	   80kDa	   fragment.	   This	   could	   identify	   DUBs	   involved	   in	   transcription	   or	  
translation	  as	  well	  as	  protein	  turnover.	  To	  carry	  out	  the	  screen,	  siRNA	  knockdown	  of	  
a	  panel	  of	  92	  human	  DUBs	  was	  performed	  in	  MCF7	  cells,	  using	  a	  DUB	  siRNA	  library	  
purchased	  from	  QIAGEN	  (See	  section	  2.2.3	  for	  experimental	  procedures).	  Cells	  were	  
allowed	  to	  grow	  for	  72	  hours	  following	  which	  they	  were	  treated	  with	  Folimycin	  for	  6	  
hours	  at	  100nM.	  After	  that,	  cells	  were	  lysed	  and	  the	  lysates	  were	  analysed	  by	  SDS-­‐
PAGE	  in	  combination	  with	  immunoblotting.	  The	  experimental	  workflow	  is	  shown	  in	  
Figure	  3.9.	  
	  
	   I	  have	  run	  3	  sets	  of	  gels,	   i.e.	  3	  technical	  repeats	  of	  the	  screen	  samples.	  The	  
technical	  repeats	  were	  essential	  as	  western	  blotting	  is	  quite	  a	  variable	  technique,	  in	  
that	  the	  transfer	  of	  proteins	  from	  polyacrylamide	  gel	  to	  nitrocellulose	  membrane	  is	  
not	   always	   consistent	   and	   hence	   results	   based	   on	   one	   gel	   only	   may	   be	   biased	  
(Aksamitiene	  et	  al.,	  2007).	  Figure	  3.10	  shows	  a	  representative	  blot	   image	  from	  the	  
screen.	  At	  first	  glance,	  as	  compared	  to	  siControl	  sample,	  knockdown	  of	  DUBs	  such	  as	  
USP14,	   USP19	   and	   USP41	   resulted	   in	   a	   stronger	   accumulation	   of	   the	   80kDa	   E-­‐
cadherin	   fragment,	   whereas	   the	   silencing	   of	   USP44	   and	   OTUB2	   resulted	   in	   less	  
accumulation	  of	  the	  80kDa	  fragment	  (highlighted	  in	  bold	  in	  Figure	  3.10).	  Besides,	  a	  
total	  decrease	   in	  E-­‐cadherin	   level	  was	  observed	  with	  the	  knockdown	  of	  USP32	  and	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Figure	  3.9.	  Experimental	  workflow	  of	  siRNA	  DUB	  library	  screen.	  	  
	  
	  
	   Densitometric	   analysis	   was	   performed	   to	   determine	   relative	   amounts	   of	  
proteins	   that	   were	   present	   and	   statistical	   analysis	   was	   done	   in	   several	   ways.	   To	  
identify	   DUBs	  whose	   knockdown	   affect	   E-­‐cadherin	   trafficking,	   the	   ratio	   of	   the	   full	  
length	   E-­‐cadherin	   to	   the	   80kDa	   E-­‐cadherin	   fragment	   was	   first	   derived.	   Then,	   all	  
samples	  were	  ranked	  according	  to	  the	  deviation	  of	  their	  ratios	  from	  that	  of	  the	  non-­‐
targeting	  control	  on	  corresponding	  gels	  (Figure	  3.11A).	  	  As	  an	  alternative	  approach,	  
the	  samples	  were	  ranked	  based	  on	  the	  deviation	  of	  their	  ratios	  from	  the	  median	  of	  
the	   combined	   (4	   gels)	   data	   set	   (Figure	  3.11B)	   and	   the	  median	   sample	  on	  each	   gel	  
(Figure	   3.11C).	   The	   different	   statistical	   approaches	   provided	   similar	   top	   hits,	  
although	   in	   slightly	   different	  order.	  USP40,	  USP38,	  OTUB2	  and	  USP8	  were	   the	   top	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fragment	  ratio,	  as	  determined	  by	  all	  3	  statistical	  approaches.	  This	  observed	  increase	  




Figure	   3.10.	   siRNA	   DUB	   library	   screen	   to	   identify	   DUBs	   regulating	   E-­‐cadherin	   in	  
MCF7.	  MCF7	  cells	  were	  transfected	  with	  pools	  of	  4	  single	  oligos,	  each	  pool	  targeting	  
1	   of	   92	   DUBs,	   at	   a	   final	   concentration	   of	   40nM.	   Cells	   were	   treated	   with	   100nM	  
Folimycin	   for	  6	  hours	  72	  hours	  post-­‐transfection.	  Cells	  were	   lysed	  using	  NP40	   lysis	  
buffer.	   Lysates	   were	   run	   on	   0.8%	   SDS-­‐PAGE	   gels	   and	   transferred	   to	   nitrocellulose	  
membrane	  before	  immunoblotting	  with	  HECD1	  antibody	  for	  E-­‐cadherin.	  Tubulin	  and	  
actin	  were	  used	  as	  loading	  control.	  Gel	  images	  were	  acquired	  by	  an	  infra-­‐red	  scanner	  
(Odyssey,	  LICOR).	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   USP41,	  USP4,	  USP14,	  USP6,	  USP17	  and	  OTUD6A,	  on	  the	  other	  hand,	  were	  the	  
top	  hits,	  which	  when	  depleted,	  resulted	   in	  a	  decrease	   in	  the	  ratio.	  Among	  these,	   it	  
was	  quite	  apparent,	  judging	  from	  the	  gel	  image,	  that	  the	  decrease	  in	  ratio	  observed	  
with	  knockdown	  of	  USP41	  and	  USP14,	  was	  due	  to	  a	  more	  pronounced	  accumulation	  
of	  the	  80kDa	  E-­‐cadherin	  fragment.	  
	  
	   Candidate	  DUBs,	  which	  appeared	  in	  the	  top	  3	  as	  identified	  by	  at	  least	  2	  out	  of	  
the	   3	   different	   quantitation	   methods,	   were	   then	   selected	   for	   subsequent	  
deconvolution	   experiments	   to	   evaluate	   the	   possibility	   of	   off-­‐target	   effects	   (Figure	  
3.12).	   STAMBP	   and	   STAMBPL1	   (McCullough	   et	   al.,	   2004;	   Nakamura	   et	   al.,	   2006),	  
although	   was	   only	   identified	   by	   1	   statistical	   approaches	   as	   top	   hit,	   were	   also	  
included	   as	   they	   are	   endosomal-­‐associated	   DUBs	   and	   may	   therefore	   affect	   E-­‐
cadherin	   trafficking.	   	   The	   observed	   increase	   in	   full	   length	   E-­‐cadherin	   to	   80kDa	   E-­‐
cadherin	  fragment	  ratio	  following	  knockdown	  of	  USP12	  and	  USP40	  was	  likely	  due	  to	  
an	  off-­‐target	  effect	  as	  only	  1	  out	  of	  the	  4	  oligos	  recapitulated	  the	  pool	  knockdown	  
effect,	   where	   the	   ratio	  was	   increased.	   For	   all	   the	   other	   DUBs,	   at	   least	   3	   out	   of	   4	  
oligos	   reproduced	   the	   pool	   knockdown	   effect,	   indicating	   a	   genuine	   effect	   on	   the	  
profile	  of	  E-­‐cadherin	  as	  a	  result	  of	  the	  loss	  of	  the	  corresponding	  DUBs.	  Among	  these,	  
the	  change	  in	  ratio	  due	  to	  knockdown	  of	  USP38	  was	  the	  most	  dramatic,	  and	  3	  out	  of	  
4	  single	  oligos	  had	  the	  same	  effect	  as	  the	  pool	  oligos.	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Figure	   3.11.	  Change	  of	   full	   length	   E-­‐cadherin	   to	   80kDa	  E-­‐cadherin	   fragment	   ratio	  
following	  DUBs	  knockdown.	  Densitometric	  analysis	  was	  performed	  using	  ImageJ	  to	  
determine	  relative	  amount	  of	  full	  length	  E-­‐cadherin	  and	  80kDa	  E-­‐cadherin	  fragment	  
for	  each	  knockdown	  sample,	  and	  ratios	  between	  the	  two	  were	  derived.	  The	  ratio	  of	  
each	  sample	  was	  then	  normalised	  and	  expressed	  as	  a	  percentage	  change	  relative	  to	  
the	  (A)	  siControl	  sample	  on	  corresponding	  gel	  and	  (B)	  median	  of	  the	  whole	  data	  set,	  
i.e.	  ratios	  of	  samples	  from	  all	  gels	  and	  	  (C)	  median	  sample	  on	  corresponding	  gel.	  Data	  
shown	  represents	  average	  of	  3	   technical	   repeats	  and	  only	   the	  top	  6	  candidates	  on	  
both	  positive	  and	  negative	  ends	  were	  shown.	  Error	  bars	  indicate	  standard	  deviation	  
of	  data.	  	  





Figure	  3.12.	  Deconvolution	  of	  targets	  which	  altered	  full	  length	  E-­‐cadherin	  to	  80kDa	  
E-­‐cadherin	  fragment	  ratio.	  (A)	  and	  (B)	  MCF7	  cells	  were	  transfected	  with	  single	  oligos	  
against	  candidate	  DUBs	  at	  40nM	  for	  72	  hours.	  Cells	  were	  then	  treated	  with	  100nM	  
Folimycin	  for	  6	  hours.	  Cell	  were	  lysed	  using	  NP40	  lysis	  buffer.	  Lysates	  were	  resolved	  
by	   SDS-­‐PAGE	   and	   immunoblotted	   for	   E-­‐cadherin,	   USP4	   and	   STAMBP.	   Tubulin	   was	  
used	  as	  loading	  control.	  Gel	  images	  were	  acquired	  by	  an	  infra-­‐red	  scanner	  (Odyssey,	  
LICOR).	  Arrows	  indicate	  direction	  of	  change	  of	  E-­‐cadherin	  level	  following	  knockdown	  
of	  the	  chosen	  DUBs	  in	  screen.	  (C)	  Densitometric	  analysis	  was	  performed	  using	  Image	  
J	  to	  determine	  band	  intensity	  and	  change	  in	  full	  length	  E-­‐cadherin	  to	  80kDa	  fragment	  
ratio	   with	   respect	   to	   siControl	   sample	   was	   determined.	   Data	   shown	   represents	  
average	  of	  3	  technical	  repeats,	  and	  the	  5	  columns	  for	  each	  DUB	  represents	  oligos	  1,	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   I	  have	  also	  determined	  the	  change	  in	  total	  E-­‐cadherin	  level,	  i.e.	  the	  summed	  
intensity	  of	  both	  full	   length	  E-­‐cadherin	  and	  80kDa	  E-­‐cadherin	  fragment,	  normalised	  
to	   tubulin	   or	   actin,	   following	   knockdown	  of	   individual	  DUBs	   (Figure	   3.13).	   The	   top	  
candidate	  DUBs,	  which	  when	  depleted	  resulted	  in	  significant	  reduction	  in	  E-­‐cadherin	  
level,	  were	  USP38,	  USP32,	  MYSM1,	  BAP1	  and	  USP16,	  whereas	   the	  DUBs	   for	  which	  
depletion	  resulted	  in	  an	  increase	  in	  total	  E-­‐cadherin	  level	  were	  USP19,	  USP22,	  USP6,	  
OTUD1,	  USP20,	  and	  USP31.	  Out	  of	  the	  12	  top	  candidates	  shown	  for	  data	  normalised	  
to	  tubulin	  or	  actin,	  only	  6	  (USP19,	  USP31,	  OTUD1	  on	  positive	  end	  and	  USP38,	  USP32	  
and	  USP16	  on	  negative	  end)	  were	  identified	  with	  both	  methods	  of	  normalisation	  but	  
in	  different	  orders.	  Among	  the	  listed	  candidates,	  the	  identification	  of	  USP19,	  USP32	  
and	  USP38	  was	   anticipated	   based	   on	   visual	   judgment	   of	   the	   immunoblots,	   where	  
more	  intense	  bands	  of	  both	  full	  length	  and	  truncated	  E-­‐cadherin	  were	  observed	  for	  
USP19,	  and	  the	  bands	  for	  USP32	  and	  USP38	  were	  relatively	  faint.	  While	  a	  significant	  
increase	   in	   total	   E-­‐cadherin	   level	  was	   visible	   for	  USP41	   knockdown	   sample	   (Figure	  
3.10),	   the	   DUB	   was	   however	   not	   listed	   as	   1	   of	   the	   top	   hits.	   This	   highlights	   the	  
reliability	   issue	  of	   the	  quantitation	  results	  due	  to	  normalisation	  to	  tubulin	  or	  actin,	  
since	  the	  bands	  for	  these	  two	  loading	  controls	  were	  not	  sharp.	  	  	  
	  
	   Based	   on	   the	   quantitation	   of	   the	   change	   in	   full	   length	   E-­‐cadherin	   level,	  
USP19,	   USP32,	   USP38	   and	   USP41	   were	   chosen	   for	   deconvolution	   (Figure	   3.13),	  
where	   the	   latter	   two	   DUBs	   were	   already	   chosen	   based	   on	   the	   effect	   of	   their	  
depletion	   on	   E-­‐cadherin	   ratio	   (Figure	   3.12).	   For	  USP32,	   although	   3	   out	   of	   4	   oligos	  
resulted	  in	  depletion	  of	  E-­‐cadherin	  level,	  the	  effect	  was	  less	  marked	  compared	  with	  
the	  original	  screen	  (<20%	  v.s.	  ~40%).	  For	  USP38,	  oligos	  1,	  2	  and	  4	  resulted	  in	  >40%	  
depletion	   of	   E-­‐cadherin,	   reproducing	   the	   pool	   knockdown	   effect	   observed	   in	   the	  
screen.	  	  For	  both	  USP19	  and	  USP41,	  3	  out	  of	  4	  oligos	  resulted	  in	  a	  minimum	  increase	  
of	  40%	  in	  total	  E-­‐cadherin	  level.	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Figure	   3.13.	   Change	   in	   total	   E-­‐cadherin	   level	   following	   knockdown	   of	   individual	  
DUBs.	   Densitometric	   analysis	   was	   performed	   using	   ImageJ	   to	   determine	   relative	  
amount	   of	   full	   length	   E-­‐cadherin	   and	   80kDa	   E-­‐cadherin	   fragment	   for	   each	  
knockdown	  sample,	  and	  the	  sum	  of	  the	  two	  was	  calculated	  and	  was	  normalised	  to	  
(A)	  actin	  and	  (B)	  tubulin.	  The	  normalised	  E-­‐cadherin	  levels	  were	  then	  expressed	  as	  a	  
percentage	   deviation	   from	   the	   siControl	   samples.	   Samples	   were	   then	   ranked	   in	  
ascending	  order.	  Data	  shown	  represents	  average	  of	  3	  technical	  repeats	  and	  only	  the	  
top	  6	  candidates	  on	  both	  positive	  and	  negative	  ends	  were	  shown.	  Error	  bars	  indicate	  
standard	  deviation	  of	  each	  sample.	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Figure	   3.14.	   Deconvolution	   of	   targets	   which	   altered	   total	   E-­‐cadherin	   level.	   (A)	  
MCF7	   cells	   were	   transfected	   with	   single	   oligos	   against	   candidate	   DUBs	   at	   a	   final	  
concentration	   of	   40nM.	   Cells	   were	   treated	  with	   100nM	   Folimycin	   for	   6	   hours,	   72	  
hours	   post-­‐transfection.	   Cells	   were	   lysed	   using	   NP40	   lysis	   buffer.	   Lysates	   were	  
resolved	   by	   SDS-­‐PAGE	   and	   immunoblotted	   for	   E-­‐cadherin	   and	   tubulin.	   Gel	   images	  
were	  acquired	  by	  infra-­‐red	  scanner	  (Odyssey,	  LICOR).	  (B)	  Densitometric	  analysis	  was	  
performed	  using	  Image	  J	  software	  to	  determine	  band	  intensity	  and	  sum	  of	  full	  length	  
E-­‐cadherin	   and	   80kDa	   E-­‐cadherin	   fragment	   was	   calculated,	   and	   normalised	   to	  
tubulin	   level.	   Change	   in	   total	   E-­‐cadherin	   level	   from	   that	   of	   siControl	   was	   then	  
determined	  and	  represented	  in	  graph.	  Data	  shown	  represents	  average	  of	  2	  technical	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3.2.4	  	   	   Identification	  of	  DUBs	  regulating	  E-­‐cadherin	  in	  A549	  
	  
	   Two	   colleagues	   in	   our	   laboratory,	   Joseph	   Sacco	   and	   Han	   Liu,	   performed	   a	  
large	  scale	  DUB	  library	  screen	  in	  A549	  cells	  and	  the	  NP40	  cell	  lysates	  were	  processed	  
for	   SDS-­‐PAGE	   and	   aliquoted	   into	   96-­‐well	   plates,	   serving	   as	   a	   resource	   for	   the	  
identification	  of	  DUBs	  playing	   roles	   in	   regulating	  a	   cellular	  process	  or	   stability	  of	   a	  
protein	   in	   steady	   state	   conditions	   (Figure	   3.15).	   	   I	   have	   utilised	   this	   resource	   as	   a	  




Figure	  3.15.	  Large	  scale	  DUB	  siRNA	  library	  screen.	  A549	  cells	  were	  seeded	  in	  15cm	  
dish	   and	   cells	   were	   either	   mock-­‐transfected	   or	   transfected	   with	   non-­‐targeting	  
siRNAs	   or	   pool	   of	   4	   single	   oligos	   against	   1	   of	   92	  DUBs,	   at	   a	   final	   concentration	   of	  
40nM.	   Cells	   were	   lysed	   using	   NP40	   lysis	   buffer	   72	   hours	   post-­‐transfection	   and	  
following	   protein	   assay,	   lysates	  were	   boiled	  with	   sample	   buffer	   and	   adjusted	   to	   a	  
concentration	  0.8µg/µl.	  Finally,	  25µl	  of	  each	  knockdown	  samples	  was	  arrayed	  on	  96-­‐
well	  plates.	  (experiment	  was	  performed	  by	  Liu	  and	  Sacco)	  	  
Knockdown of 96 DUBs using a 
DUB siRNA library from Qiagen 
72hrs KD Protein 
Harvest 
Short spin 
Sample buffer added to 
give samples of 1mg/ml  
Boil 98oC for 
10 min 
Pipette each sample  
into appropriate well 
Transfer 25ul of each sample and control into 
a 96 well plate using multichannel pipette 
1.2 ml 96-well plate 
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Figure	   3.16.	   siRNA	   DUB	   library	   screen	   to	   identify	   DUBs	   regulating	   E-­‐cadherin	   in	  
A549.	  NP40	   lysates	   from	   large	  scale	  DUB	  screen	  performed	  by	  Sacco	  and	  Liu	  were	  
resolved	  on	   10%	   SDS-­‐PAGE	   gels,	   followed	  by	  Western	  Blotting.	   Blots	  were	   probed	  
with	  antibodies	  against	  E-­‐cadherin,	   tubulin	  and	  actin.	  Gel	   images	  were	  acquired	  by	  
an	   infra-­‐red	  scanner	   (Odyssey,	   LICOR).	  Notes	   :	  Control	  =	  mock	  knockdown	  without	  
oligo;	  siControl1	  =	  knockdown	  with	  non-­‐targeting	  oligos.	  	  
	  
	  
	   Figure	   3.16	   shows	   the	   representative	   blot	   image	   acquired	   for	   this	   set	   of	  
experiments.	   At	   first	   glance,	   depletion	   of	   a	   number	   of	   DUBs	   on	   Gel1	   resulted	   in	  
visible	   increase	   in	  E-­‐cadherin	   level	  as	  compared	  to	  the	  controls.	  Across	  all	  the	  gels,	  
TNFAIP3,	  USP27X	   and	  USP49	   resulted	   in	   the	  most	   dramatic	   increase	   in	   E-­‐cadherin	  
level.	  	  
	  
	  	   Densitometric	   analysis	   of	   the	   blot	   images	   was	   performed	   to	   give	   a	  
quantitative	   measurement	   of	   the	   E-­‐cadherin	   level	   (Figure	   3.17).	   The	   top	   DUB	  
candidates,	  which	  when	  silenced	  resulted	  in	  significant	  increase	  in	  E-­‐cadherin	  level,	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as	  determined	  by	  both	  quantitation	  approaches,	  were	  TNFAIP3,	  USP27X,	  USP49	  and	  
USP42,	   in	   agreement	   with	   the	   visual	   observation.	   On	   the	   other	   end	   of	   the	   graph	  
were	  ZRANB1,	  OTUB2,	  USP38	  and	  PAN2,	  which	  when	  silenced	  resulted	  in	  depletion	  
of	  E-­‐cadherin.	  OTUD6A	  did	  not	  appear	  in	  the	  top	  hit	  lists,	  although	  it	  was	  quite	  close	  
to	  the	  negative	  end.	  
	  
	   	  
Figure	   3.17.	   Change	   in	   E-­‐cadherin	   level	   following	   knockdown	  of	   individual	  DUBs.	  
Densitometric	  analysis	  was	  performed	  using	  ImageJ	  to	  determine	  relative	  amount	  of	  
E-­‐cadherin	  for	  each	  knockdown	  sample	  and	  E-­‐cadherin	   level	  was	  normalised	  to	   (A)	  
tubulin	  or	  (B)	  actin.	  	  The	  percentage	  change	  in	  E-­‐cadherin	  level	  relative	  to	  that	  of	  the	  
median	  sample	  was	  calculated	  and	  log-­‐transformed.	  Data	  shown	  represents	  average	  
of	  3	  technical	  repeats	  and	  error	  bars	  represent	  standard	  deviation.	  	  
A	  
B	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Figure	   3.18.	   Summary	   of	   DUBs	  whose	   knockdown	   result	   in	   change	   in	   E-­‐cadherin	  
level.	   Summary	   was	   based	   on	   results	   of	   siRNA	   DUB	   library	   screen	   performed	   in	  
MCF7	  and	  A549	  (presented	  in	  Figure	  3.13	  and	  Figure	  3.17	  respectively).	  Only	  DUBs,	  
which	  are	  identified	  as	  top	  hits	  by	  both	  quantification	  results	  are	  listed.	  DUBs	  whose	  
knockdown	  resulted	  in	  increase	  in	  E-­‐cadherin	  level	  are	  highlighted	  in	  red	  while	  those	  
resulted	  in	  decrease	  in	  E-­‐cadherin	  level	  are	  highlighted	  in	  black.	  	  
	  
	  
	   Figure	  3.18	  summarises	   the	   top	  hits,	  based	  on	   their	  effect	  on	  E-­‐cadherin	  
stability,	   from	   the	   two	   separate	   siRNA	   DUB	   library	   screens	   in	   MCF7	   and	   A549	  
respectively.	  USP38	  is	  the	  only	  DUB	  which	  when	  siRNA	  depleted	  results	  in	  decrease	  
E-­‐cadherin	   level,	  while	   there	  was	  no	  overlapping	   candidates	   for	  DUBs	  which	  when	  





















	   	  	  
Figure	  3.19.	  Deconvolution	  of	  targets	  which	  resulted	  in	  change	  in	  E-­‐cadherin	  level	  
in	   A549.	   (A)	   A549	   cells	   were	   transfected	   with	   single	   oligos	   or	   pool	   oligos	   against	  
candidate	  DUBs	  at	  a	  final	  concentration	  of	  40nM.	  Cells	  were	   lysed	  using	  NP40	  lysis	  
buffer,	  and	   lysates	  were	  resolved	  by	  SDS-­‐PAGE	  and	   immunoblotted	   for	  E-­‐cadherin.	  
Gel	  images	  were	  acquired	  by	  an	  infra-­‐red	  scanner	  (Odyssey,	  LICOR).	  Arrows	  indicate	  
direction	  of	  change	  of	  E-­‐cadherin	  following	  knockdown	  of	  corresponding	  DUBs	  in	  the	  
screen.	   (B)	   Densitometric	   analysis	   was	   performed	   using	   Image	   J	   software	   to	  
determine	  E-­‐cadherin	  band	  intensity	  and	  normalised	  to	  actin	  level.	  Change	  in	  total	  E-­‐
cadherin	   level	   from	   that	   of	   non-­‐targeting	   controls	   was	   then	   determined	   and	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Among	   the	   targets	   identified	   in	   this	   screen,	   TNFAIP3,	   USP27X,	   USP49,	  
USP38	   and	   OTUD6A	   were	   chosen	   for	   deconvolution	   (Figure	   3.19).	   While	   the	   first	  
three	  candidates	  were	  chosen	  for	  the	  dramatic	  increase	  in	  E-­‐cadherin	  following	  their	  
depletion,	   the	   latter	   two	   were	   chosen	   because	   USP38	   depletion	   resulted	   in	   the	  
decrease	  in	  total	  E-­‐cadherin	  level	  while	  OTUD6A	  depletion	  decreased	  the	  full	  length	  
E-­‐cadherin	  to	  80kDa	  fragment	  ratio	  in	  MCF7	  cells.	  For	  both	  USP27X	  and	  USP49,	  the	  
repeat	  knockdown	  using	  pool	  oligos	  did	  not	   reproduce	   the	  dramatic	   increase	   in	  E-­‐
cadherin	  level	  that	  was	  observed	  during	  the	  screen.	  All	  the	  individual	  oligos	  against	  
USP27X	   and	   3	   out	   of	   4	   oligos	   against	   USP49	   did	   not	   result	   in	   any	   increase,	   but	  
decrease,	   in	   E-­‐cadherin	   level	   either.	   For	   TNFAIP3,	   oligo	   2	   and	   4	   recapitulated	   the	  
pool	   knockdown	   effect,	   resulting	   in	   increase	   in	   E-­‐cadherin	   level,	   but	   not	   to	   the	  
extent	  that	  was	  observed	  with	  the	  screen.	  While	  2	  oligos	  giving	  the	  same	  effect	  as	  
the	   pool	   oligos	   is	   sufficient	   to	   eliminate	   the	   possibility	   of	   off-­‐target	   effects,	   the	  
immunoblot	  to	  assess	  knockdown	  efficiency	  of	  TNFAIP3	  suggested	  otherwise.	  Firstly,	  
oligo	  4	  did	  not	  effectively	  silence	  TNFAIP3	  and	  interestingly,	  the	  other	  2	  oligos,	  which	  
had	   higher	   silencing	   potency,	   in	   fact	   resulted	   in	   decrease	   in	   E-­‐cadherin	   level.	   For	  
USP38,	  the	  decrease	  in	  E-­‐cadherin	  level	  following	  transfection	  of	  the	  pool	  oligos	  was	  
quite	  mild,	  and	  only	  oligo	  3	  resulted	  in	  a	  more	  dramatic	  loss	  of	  E-­‐cadherin.	  2	  out	  of	  
the	   4	   oligos	   against	   OTUD6A	   resulted	   in	   a	   slight	   decrease	   in	   E-­‐cadherin	   level.	  
Therefore,	   the	   deconvolution	   results	   for	   USP38	   and	   OTUD6A	   in	   USP38	   were	   not	  
convincing	  enough	  to	  indicate	  a	  functional	  role	  between	  the	  DUBs	  and	  E-­‐cadherin	  in	  
A549	  cells.	  	  
	  
	  
3.2.5	  	  	  	  	  	  Understanding	  the	  Functional	  Relationship	  between	  USP38	  and	  E-­‐cadherin	  
	  
Among	  the	  DUBs	  that	  were	  chosen	  for	  deconvolution,	  USP38	  was	  followed	  
up	   as	   its	   depletion	   resulted	   in	   a	   dramatic	   change	   in	   the	   E-­‐cadherin	   ratio	   and	   a	  
significant	  reduction	  in	  the	  total	  E-­‐cadherin	  level	  in	  MCF7	  cells.	  	  
	  
	   A	   QPCR	   experiment	   was	   performed	   to	   measure	   the	   level	   of	   E-­‐cadherin	  
mRNA.	  The	  loss	  of	  E-­‐cadherin	  at	  the	  protein	  level	  was	  accompanied	  by	  an	  increase	  in	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E-­‐cadherin	  mRNA	  level	  (Figure	  3.20),	  indicating	  USP38	  does	  not	  regulate	  E-­‐cadherin	  
at	  transcriptional	  level.	  	  In	  fact,	  an	  inverse	  correlation	  was	  observed	  between	  the	  E-­‐
cadherin	  protein	  and	  mRNA	  level:	  in	  the	  cases	  where	  amount	  of	  E-­‐cadherin	  protein	  
was	  reduced	  (induced	  by	  oligo	  1,	  2	  and	  4),	  an	  increase	  of	  >30%	  in	  E-­‐cadherin	  mRNA	  
level	  was	   detected;	  while	  when	   the	   E-­‐cadherin	   protein	   level	   increased,	   E-­‐cadherin	  
mRNA	  level	  was	  reduced.	  	  
	  
	  
Figure	  3.20.	  USP38	  does	  not	  regulate	  E-­‐cadherin	  at	  transcriptional	  level.	  MCF7	  cells	  
were	  transfected	  with	  single	  oligos	  against	  USP38	  at	  a	  final	  concentration	  of	  40nM.	  
RNA	  was	  extracted	  72	  hours	  post	   transfection	  and	   cDNA	  was	  prepared	  by	   reverse	  
transcription.	  QPCR	  was	  performed	  using	  an	  iQ5	  Real-­‐Time	  PCR	  system	  (Biorad),	  and	  
intron	  spanning	  primer	  pairs	  were	  used	   to	  measure	   the	  mRNA	   level	  of	  E-­‐cadherin,	  
USP38	  and	  actin.	  All	  data	  were	  normalised	  to	  actin	  level	  and	  data	  shown	  represents	  
results	  of	  2	  biological	  repeats.	  Error	  bars	  represent	  standard	  deviation	  of	  data.	  	  
	  
	   The	  stability	  of	  E-­‐cadherin	  was	  then	  checked	  following	  siRNA	  depletion	  of	  
USP38	   by	   treating	  MCF7	   cells	  with	   cycloheximide,	  which	   inhibits	   protein	   synthesis	  
(Ennis	   and	   Lubin,	   1964),	   for	   different	   lengths	   of	   time.	   Cycloheximide	   treatment	  
resulted	   in	   decrease	   in	   E-­‐cadherin	   level	   over	   time,	   whether	   or	   not	   USP38	   was	  
depleted	  (Figure	  3.21A	  and	  B).	   	  siRNA	  depletion	  of	  USP38	  in	  MCF7	  cells	  resulted	   in	  
decrease	  in	  E-­‐cadherin	  level	  compared	  to	  cells	  transfected	  with	  non-­‐targeting	  siRNA	  
oligo.	  However,	   the	   rates	   of	   reduction	   of	   E-­‐cadherin	   level	   following	   cycloheximide	  
treatment	  were	  the	  same	  for	  both	  control	  and	  USP38-­‐depleted	  cells	  (Figure	  3.21C).	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Figure	  3.21.	  Loss	  of	  USP38	  did	  not	  alter	  rate	  of	  E-­‐cadherin	  degradation.	  MCF7	  cells	  
were	   transfected	   with	   non-­‐targeting	   siRNA	   (siControl)	   or	   pool	   of	   oligos	   against	  
USP38	  at	  a	   final	  concentration	  of	  40nM	  for	  72	  hours.	  Cells	  were	  then	  treated	  with	  
cycloheximide	  (CHX)	  for	   indicated	  lengths	  of	  time,	  after	  when	  cells	  were	  lysed	  with	  
NP40	   lysis	   buffer.	   (A)	   Cell	   lysate	   was	   then	   resolved	   on	   4-­‐12%	   SDS-­‐PAGE	   and	  
transferred	   to	   nitrocellulose	  membrane.	   The	  membrane	  was	   then	   immunoblotted	  
with	  antibodies	   for	  E-­‐cadherin,	  USP38,	   tubulin	  and	  actin.	   (B)	  and	   (C)	  Densitometric	  
analysis	  of	  blot	   image	   in	   (A)	  was	  performed	  to	  determine	  relative	  E-­‐cadherin	   level,	  
normalised	  to	  tubulin,	  at	  different	  time	  points.	  Data	  presented	  represent	  average	  of	  
2	  biological	  repeats.	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   As	  an	  alternative	  approach	  to	  siRNA	  knockdown,	  I	  transfected	  MCF7	  cells	  
with	   GFP-­‐tagged	  USP38	   plasmid,	   to	   check	   if	   E-­‐cadherin	   level	  would	   change	   in	   the	  
opposite	  direction	   in	  comparison	  to	  USP38	  depletion.	  Overexpression	  of	  USP38	  did	  
not	  seem	  to	  alter	  the	   level	  of	  E-­‐cadherin,	  nor	  did	   it	  cause	  any	  significant	  change	   in	  




Figure	  3.22.	  Overexpression	  of	  USP38	  does	  not	  affect	  E-­‐cadherin	  status.	  (A)	  MCF7	  
cells	   were	   transfected	   with	   0.5µg	   GFP	   or	   1µg	   GFP-­‐USP38	   plasmid,	   and	   cells	   were	  
treated	  with	  10µl	  DMSO	  or	  100nM	  Folimycin	  for	  6	  hours	  24	  hours	  post-­‐transfection.	  
Cells	   were	   lysed	   using	   NP40	   buffer	   and	   resolved	   by	   SDS-­‐PAGE,	   followed	   by	  
immunoblotting.	   Gel	   images	  were	   acquired	   by	   infra-­‐red	   scanner	   (Odyssey,	   LICOR).	  
(B)	   Densitrometric	   analysis	   was	   performed	   using	   ImageJ	   to	   determine	   total	   E-­‐
cadherin	   level	   and	   ratio	   between	   full	   length	   and	   80kDa	   E-­‐cadherin.	   Transfection	  
efficiency	  was	  between	  30-­‐35%.	  	  
	  
	  
	   Since	  E-­‐cadherin	  is	  down-­‐regulated	  following	  siRNA	  depletion	  of	  USP38,	  it	  
was	  expected	   that	   the	  cell-­‐cell	   adhesion	  would	  be	  affected.	   I	   therefore	  decided	   to	  
perform	   a	   “hanging	   drop	   cell	   aggregation”	   assay	   (Figure	   3.23)	   to	  measure	   cell-­‐cell	  
contact	  assembly	  (Nola	  et	  al.,	  2012).	  Prior	  to	  assessing	  the	  effect	  of	  USP38	  depletion	  
on	   formation	   of	   cell-­‐cell	   contact,	   I	   conducted	   an	   experiment	   to	   determine	   the	  
optimal	  cell	  number	  for	  this	  assay.	  At	  the	  starting	  of	  the	  experiment,	  the	  cells	  were	  
more	   dispersed	   and	   segregated	   from	   each	   other	   in	   small	   groups.	   For	   droplets	   of	  
higher	   cell	   densities,	   7.5	   x	   104	   cells/ml	   and	   10	   x	   104	   cells/ml,	   the	   cells	   were	   very	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densities,	   the	  cells	  were	  moving	   towards	   the	  centre	  of	   the	  droplet	  and	  aggregated	  




Figure	   3.23.	   Schematic	   diagram	   of	   “hanging	   drop	   cell	   aggregation”	   assay.	  
Monolayer	   of	   adherent	   cells	   were	   disaggregated	   with	   2mM	   EDTA/PBS	   and	  
resuspended	  in	  full	  DMEM.	  20µl	  of	  cell	  suspension	  was	  pipetted	  onto	  the	  inner	  side	  
of	   lid	   of	   a	   petri	   dish	   and	   the	   lid	   was	   inverted	   onto	   a	   petri	   dish	   containing	   sterile	  
water	  (“Before”).	  The	  whole	  set	  up	  was	  incubated	  at	  37˚C	  for	  specific	  length	  of	  time	  
so	  that	  cells	  were	  allowed	  to	  fall	   to	  the	  tip	  of	  the	  droplet	  by	  gravity	  and	  aggregate	  
(“After”).	  Note:	  Image	  was	  not	  drawn	  to	  scale.	  	  
	  
	   	  
	   I	  then	  decided	  to	  seed	  cells	  at	  density	  of	  5	  x	  104	  cells/ml	  since	  at	  this	  cell	  
density,	   cells	  were	  not	   clumped	  altogether	  at	   the	   initial	   time	  point	  and	   the	   size	  of	  
cell	   aggregate	   at	   the	   end	   of	   the	   experiment	   was	   of	   medium	   size	   relative	   to	   cell	  
aggregates	   formed	  with	  other	  cell	  densities.	  The	  depletion	  of	  E-­‐cadherin	  abolished	  
drastically	  the	  ability	  of	  cells	  to	  aggregate,	  as	  at	  the	  end	  of	  the	  2-­‐hour	  incubation,	  the	  
cells	  were	  mostly	   segregated	   from	  each	  other	   (Figure	   3.25A;	   see	  Appendix	   3.1	   for	  
magnified	   images	   at	   2	   hour	   time	   point).	   The	   siRNA	   depletion	   of	   E-­‐cadherin	   was	  
accompanied	  by	  a	  dramatic	  loss	  of	  β-­‐catenin	  (Figure	  3.25B).	  The	  siRNA	  depletion	  of	  
USP38	   resulted	   in	   a	   slight	   decrease	   of	   E-­‐cadherin	   and	   more	   than	   50%	   loss	   of	   β-­‐
catenin,	  but	  the	  cells	  were	  still	  able	  to	  aggregate.	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Figure	  3.24.	  Optimisation	  of	  cell	  number	  for	  “hanging	  drop	  cell	  aggregation”	  assay.	  
Monolayer	  of	  MCF7	  cells	  grown	  in	  10cm	  dish	  were	  detached	  by	  incubating	  the	  cells	  
with	   5ml	   of	   2mM	   EDTA/PBS	   at	   37˚C,	   for	   20	   minutes.	   The	   cells	   were	   further	  
disaggregated	  by	  pipetting	  up	  and	  down,	  and	  cell	  number	  was	  determined	  using	  a	  
haematocytometer.	  After	  that,	  cells	  were	  resuspended	  in	  full	  DMEM	  at	  the	  following	  
densities:	  1	  x	  104	  cells/ml,	  2.5	  x	  104	  cells/ml,	  5	  x	  104	  cells/ml,	  7.5	  x	  104	  cells/ml,	  10	  x	  
104	  cells/ml.	  20µl	  of	  each	  of	  the	  cell	  suspension	  was	  pipetted	  onto	  the	  inner	  side	  of	  
lid	  of	  a	  petri	  dish	  and	  the	  lid	  was	  inverted	  onto	  a	  petri	  dish	  containing	  sterile	  water	  
(“Before”).	  The	  whole	  set	  up	  was	  incubated	  at	  37˚C.	  Images	  of	  cells	  were	  acquired	  at	  












Figure	   3.25.	   USP38	   depletion	   did	   not	   abolish	   ability	   of	   cells	   to	   aggregate.	  MCF7	  
cells	   were	   transfected	   with	   non-­‐targeting	   siRNA	   oligo	   or	   siRNA	   oligo	   against	   E-­‐
cadherin	   or	   USP38,	  with	   a	   final	   concentration	   of	   40nM	   for	   72	   hours.	   (A)	   After	   72	  
hours,	  cells	  were	  detached	  from	  wells	  by	  incubation	  with	  2ml	  of	  2mM	  EDTA/PBS	  for	  
20	  minutes	  at	  37˚C.	  The	  cells	  were	  further	  disaggregated	  by	  pipetting	  up	  and	  down,	  
and	  cell	  number	  was	  determined	  using	  a	  haematocytometer.	  After	  that,	  cells	  were	  
resuspended	   in	   full	   DMEM	   at	   5	   x	   104	   cells/ml.	   20µl	   of	   the	   cell	   suspension	   was	  
pipetted	  onto	  the	  inner	  side	  of	  lid	  of	  a	  petri	  dish	  and	  the	  lid	  was	  inverted	  onto	  a	  petri	  
dish	   containing	   sterile	  water	   (“Before”).	   The	  whole	   set	   up	  was	   incubated	   at	   37˚C.	  
Images	  of	  cells	  were	  acquired	  at	  0	  hr,	  1	  hr	  and	  2	  hr.	  	  (see	  Appendix	  3.1	  for	  magnified	  
images	  at	  2	  hour	  time	  point)	  (B)	  Cells	  were	  lysed	  using	  NP40	  lysis	  buffer.	  Lysate	  was	  
resolved	   by	   SDS-­‐PAGE	   and	   transferred	   to	   nitrocellulose	   membrane,	   followed	   by	  
immunoblotting	  for	  E-­‐cadherin,	  β-­‐catenin,	  USP38	  and	  tubulin.	  	  
A	  
B	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3.3	   Discussion	  
	  
	   It	   has	   been	   demonstrated	   in	   MDCK	   (Fujita	   et	   al.,	   2002)	   and	   HT29	  
(Swaminathan	   and	   Cartwright	   2012)	   cell	   lines	   that	   HGF	   stimulation	   leads	   to	   the	  
ubiquitylation	  of	  E-­‐cadherin	  by	  Hakai,	  and	  its	  subsequent	  endocytosis.	  Therefore,	  at	  
the	  initial	  stage	  of	  my	  project,	  I	  intended	  to	  identify	  DUB(s),	  which	  is/are	  involved	  in	  
HGF-­‐dependent	   regulation	   of	   E-­‐cadherin	   in	   human	   cancer	   cells	   and	   began	   by	  
stimulating	  a	  panel	  of	  human	  cancer	  cell	  lines	  with	  HGF.	  HGF	  is	  known	  to	  be	  able	  to	  
induce	  dissociation	  of	  epithelial	  cells	  (Stella	  and	  Comoglio,	  1999).	  Indeed,	  for	  all	  the	  
cancer	   cell	   lines	   (HT29,	   MCF7,	   DU145,	   HCT116)	   stimulated,	   the	   cells	   were	   more	  
detached	  from	  each	  other	  (Figure	  3.2).	  MCF7	  and	  HT29	  became	  more	  flattened	  out	  
with	   relatively	   round	   cell	   shape,	   and	   their	   E-­‐cadherin	   level	   remained	   unchanged	  
after	  HGF	  stimulation	  (Figure	  3.1).	  It	  was	  previously	  reported	  that	  HGF	  stimulation	  of	  
HT29	   and	   MCF7	   led	   to	   dissolution	   of	   AJ	   and	   internalisation	   of	   E-­‐cadherin	  
(Reshetnikova	   et	   al.,	   2007;	   Matteucci	   et	   al.,	   2006).	   Based	   on	   observation	   of	   my	  
experiments,	  although	  dissolution	  of	  AJ	  was	  observable	  following	  HGF	  stimulation	  of	  
these	  cells,	  the	  cytoplasmic	  distribution	  of	  E-­‐cadherin	  was	  less	  distinct.	  	  For	  the	  case	  
of	  MCF7,	  the	  different	  observations	  could	  be	  due	  to	  the	  difference	  in	  length	  of	  time	  
when	  cells	  were	   fixed	  after	  HGF	  stimulation.	  Matteucci	  and	  colleagues	   fixed	  MCF7	  
cells	   following	  1	   and	  2	  hours	  of	  HGF	   stimulation,	   and	   they	  observed	  prominent	   E-­‐
cadherin	   staining	   in	   cytoplasm	   at	   1	   hour,	   and	   at	   the	   second	   hour,	   E-­‐cadherin	  was	  
observed	  around	  the	  nucleus	  but	  not	  in	  the	  cytoplasm	  (Matteucci	  et	  al.,	  2006).	  As	  for	  
my	  experiment,	  the	  MCF7	  cells	  were	  fixed	  at	  3,	  6	  and	  9	  hours	  after	  HGF	  stimulation.	  
Moreover,	  in	  this	  study,	  they	  used	  an	  antibody	  against	  the	  C-­‐terminus	  of	  E-­‐cadherin,	  
while	  I	  used	  an	  antibody	  against	  the	  N-­‐terminal	  extracellular	  domain	  of	  E-­‐cadherin.	  
Given	   the	   loss	   of	   E-­‐cadherin	   staining	   from	   the	   plasma	   membrane,	   the	   lack	   of	  
detection	  of	  E-­‐cadherin	  in	  cytoplasm	  and/or	  nucleus	  	  was	  probably	  due	  to	  limitation	  
of	   the	   antibody	   used	   to	   detect	   internalised	   E-­‐cadherin	   or	   varying	   experimental	  
conditions.	  Despite	  E-­‐cadherin	  internalisation,	  HGF	  stimulation	  did	  not	  result	  in	  loss	  
of	   E-­‐cadherin.	   This	   has	   been	   previously	   reported	   in	  MCF7	   cells,	   but	   in	   this	   study,	  
MCF7	   was	   stimulated	   with	   HGF	   for	   an	   hour	   only	   (Matteucci	   et	   al.,	   2006)	   while	   I	  
stimulated	  the	  cells	  for	  up	  to	  24	  hours.	  On	  the	  other	  hand,	  DU145	  and	  HCT116	  cells	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experienced	  a	  drastic	  change	   in	  cell	  shape	  to	  become	  more	  elongated	  (Figure	  3.2),	  
reminiscent	   of	   cells	   undergoing	   epithelial-­‐to-­‐mesenchymal	   transition	   (EMT),	   a	  
cellular	  process	  which	  can	  be	  triggered	  by	  HGF	  stimulation	  (Thiery,	  2003;	  Hube	  et	  al.,	  
2005).	  The	  E-­‐cadherin	  level	  of	  both	  of	  these	  cell	  lines	  were	  reduced	  after	  24	  hours	  of	  
HGF	  stimulation	  (Figure	  3.1),	  in	  agreement	  with	  previous	  reports	  (Miura	  et	  al.,	  2001;	  
Saitoh	  et	  al.,	  2009).	  At	  least	  based	  on	  the	  observations	  of	  the	  response	  of	  these	  cell	  
lines	   to	   HGF,	   there	   was	   a	   correlation	   between	   E-­‐cadherin	   level	   and	   change	   in	  
morphology	  of	  cells	  following	  HGF	  stimulation:	  in	  cells	  where	  E-­‐cadherin	  protein	  was	  
reduced,	  the	  cells	  underwent	  more	  drastic	  change	  in	  cell	  morphology.	  Indeed,	  loss	  of	  
E-­‐cadherin	  is	  considered	  one	  of	  the	  hallmarks	  of	  cells	  having	  undergone	  EMT	  (Cano	  
et	  al.,	  2000).	  
	  
	   By	  treating	  cells	  with	  Folimycin,	  a	  lysosomal	  vacuolar	  ATPase	  inhibitor	  (Muroi	  
et	   al.,	   1993),	   it	   was	   revealed	   that	   E-­‐cadherin	   is	   constitutively	   degraded	   via	   the	  
lysosomal	  pathway	  in	  MCF7,	  as	  suggested	  by	  the	  stabilisation	  of	  an	  80kDa	  E-­‐cadherin	  
fragment	  (Figure	  3.3).	  This	  is	  also	  supported	  by	  the	  colocalisation	  of	  E-­‐cadherin	  with	  
two	   lysosomal	   markers,	   namely	   LAMP1	   and	   CD63,	   following	   Folimycin	   treatment,	  
indicating	   accumulation	   of	   E-­‐cadherin	   in	   these	   compartments	   due	   to	   blockage	   of	  
degradation.	  	  It	  has	  been	  previously	  reported	  that	  in	  a	  confluent	  layer	  of	  MDCK	  cells,	  
E-­‐cadherin	   is	   endocytosed	   and	   recycled	   back	   to	   the	   plasma	   membrane	   under	  
physiological	   conditions	   (Le	  et	   al.,	   1999)	   and	   it	  was	   also	   demonstrated	   in	   isolated	  
MCF7	   cells	   that	   unbound	   E-­‐cadherin	   on	   cell	   surface	   undergoes	   constitutive	  
internalisation	  mainly	  via	  a	  clathrin-­‐independent	  pathway	  (Paterson	  et	  al.,	  2003),	  but	  
constitutive	  degradation	  of	  E-­‐cadherin	  under	  steady-­‐state	  condition	  has	  never	  been	  
reported.	  Since	  E-­‐cadherin	  staining	  was	  still	  retained	  on	  plasma	  membrane	  following	  
Folimycin	   treatment	   (Figure	   3.5),	   this	   suggests	   that	   the	   recycling	   of	   E-­‐cadherin	   to	  
plasma	  membrane	  was	  not	  impaired.	  Moreover,	  the	  unchanged	  level	  of	  full	  length	  E-­‐
cadherin	   (Figure	   3.3)	   suggests	   that	   the	   continual	   loss	   of	   E-­‐cadherin	   by	   lysosomal	  
degradation	  was	   replenished	  by	  continual	   synthesis	  of	  E-­‐cadherin.	   It	   is	  known	  that	  
the	  trafficking	  of	  membrane	  associated	  protein	  via	  the	  endo-­‐lysosomal	  pathway	  is	  a	  
ubiquitin-­‐dependent	  process	  (Clague	  et	  al.,	  2012)	  and	  this	  is	  also	  likely	  the	  case	  for	  E-­‐
cadherin,	   which	   has	   also	   been	   shown	   to	   undergo	   ubiquitin-­‐dependent	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internalisation.	  However,	   I	  did	  not	  assess	  ubiquitylation	   status	  of	  E-­‐cadherin	   in	  my	  
study.	  	  	  
	  
I	   then	   decided	   to	   use	   the	   relative	   level	   of	   the	   full	   length	   E-­‐cadherin	   and	  
80kDa	  E-­‐cadherin	  fragment	  as	  biochemical	  readout	  for	  a	  siRNA	  DUB	   library	  screen.	  
One	  added	  benefit	  of	  measuring	  the	  ratio	  of	  full	   length	  E-­‐cadherin	  to	  the	  80kDa	  E-­‐
cadherin	  fragment	  is	  that	  both	  of	  the	  bands	  are	  recognised	  by	  the	  same	  antibody	  at	  
the	   same	  affinity,	   and	   it	   does	  not	   require	  normalisation	   to	   tubulin	  or	   actin.	   I	   have	  
done	   3	   technical	   replicates	   of	   the	   Western	   blot	   analysis,	   which	   is	   necessary.	  
Although	  Western	  Blotting	  is	  useful	  in	  detecting	  changes	  in	  protein	  levels,	  there	  are	  
several	  major	  sources	  of	  errors	  to	  this	  technique,	  including	  quality	  of	  polyacrylamide	  
gels	   used	   (for	   instance,	   gel	   heterogeneity	   can	   lead	   to	   unequal	   protein	  
electrophoresis	  and	  protein	  transfer),	  efficacy	  and	  consistency	  of	  protein	  transfer	  to	  
nitrocellulose	   membrane,	   composition	   of	   buffers	   used,	   procedures	   of	   setting	   up	  
transfer	   and	  quality	  of	   antibodies	  used	   (Aksamitiene	  et	  al.,	   2007).	   These	  problems	  
can	  be	  augmented	  by	  use	  of	   large	  gels	  for	  high-­‐throughput	  studies,	  which	  was	  also	  
the	  case	  for	  my	  experiments.	   	  Therefore,	  more	  technical	  replicates	  of	  Western	  blot	  
analysis	   are	  essential	   to	  allow	   statistically	   significant	  quantitation	  and	   therefore	   to	  
increase	   confidence	   of	   an	   observed	   change.	   However,	   a	   more	   drastic	   change	   in	  
protein	  level	  is	  less	  sensitive	  to	  these	  technical	  issues.	  For	  example,	  in	  the	  siRNA	  DUB	  
screen	  performed	   in	  A549,	  knockdown	  of	  USP27X,	  USP49	  and	  TNFAIP3	   led	   to	  very	  
significant	   change	   in	   E-­‐cadherin	   level,	   which	   was	   highly	   reproducible	   between	  
technical	  replicates	  (Figure	  3.16).	  In	  order	  to	  confidently	  choose	  potential	  targets	  for	  
deconvolution,	  I	  have	  also	  used	  3	  different	  statistical	  approaches	  to	  analyse	  the	  data	  
and	  selected	  some	  candidates	  for	  deconvolution.	  	  
	  
USP4,	   USP14,	   USP41,	   OTUD6A,	   STAMBP	   and	   STAMBPL1	   were	   the	   DUBs,	  
which	   when	   depleted,	   resulted	   in	   decrease	   in	   full	   length	   E-­‐cadherin	   to	   80kDa	  
fragment	  ratio.	  None	  of	  these	  DUBs	  has	  a	  clear	  role	  in	  regulation	  of	  AJ	  components.	  
USP4	   has	   been	   implicated	   in	   regulation	   of	   diverse	   cellular	   processes,	   including	  
splicing	  of	  mRNA	  (Song	  et	  al.,	  2010)	  and	  regulation	  of	  signaling	  pathways	   including	  
NF-­‐κB	   signaling	   (Fan	   et	   al.,	   2011;	   Xiao	   et	   al.,	   2012),	   TGF-­‐β	   signaling	   (Zhang	   et	   al.,	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2012)	   and	  Wnt	   signaling	   (Zhao	  et	  al.,	   209).	  USP41	  has	  been	   reported	   to	  be	  a	  pro-­‐
apoptotic	   DUB	   as	   its	   overexpression	   	   leads	   to	   activation	   of	   caspase-­‐3	   and	  
downregulation	   of	   p21,	   p27	   and	   cyclin	   B,	  which	   are	   positive	   regulators	   of	   the	   cell	  
cycle	  (Gewies	  and	  Grimm,	  2003).	  The	  biological	  function	  of	  OTUD6A	  is	  unknown.	  	  
	  
USP14	  is	  a	  proteasome-­‐associated	  DUB	  and	  is	  important	  for	  the	  disassembly	  
of	   polyubiquitin	   chain	   (Borodovsky	  et	   al.,	   2001).	  Using	   an	   in	   vitro	  deubiquitylation	  
assay,	  Hu	  et	  al.	  demonstrated	  that	  USP14	  removes	  ubiquitin	  from	  the	  distal	  end	  of	  a	  
K48-­‐linked	   polyubiquitin	   chain	   (Hu	   et	   al.,	   2005).	   There	   is	   growing	   evidence	  
suggesting	   that	   K63-­‐linked	   ubiquitin	   chain	   is	   the	   main	   chain	   type	   for	   sorting	   into	  
multivescular	  body	  and	  lysosome	  (Duncan	  et	  al.,	  2006;	  Lauwers	  et	  al.,	  2009).	  If	  that	  
is	  also	  true	  for	  the	  case	  of	  E-­‐cadherin	  lysosomal	  degradation,	  the	  change	  in	  the	  full	  
length	   to	   80kDa	   E-­‐cadherin	   fragment	   ratio	   may	   not	   be	   a	   direct	   effect	   of	   loss	   of	  
USP14.	  	  
	  
STAMBP,	  signal	  transducing	  adaptor	  molecule	  (Swanson,	  Kang	  et	  al.)	  binding	  
protein,	   also	   known	   as	   AMSH,	   is	   a	  DUB	   localises	   to	   the	   endosomal	   compartments	  
(McCullough	  et	  al.,	  2004)	  and	  shows	   linkage	  specificity	  for	  K63-­‐linked	  polyubiquitin	  
chains	   (McCullough	   et	   al.,	   2006).	   siRNA	   depletion	   of	   STAMBP	   accelerates	  
degradation	   of	   epidermal	   growth	   factor	   receptor	   (Siegfried,	   Chou	   et	   al.)	   following	  
EGF	   stimulation,	   suggesting	   its	   negative	   regulatory	   role	   in	   ubiquitin-­‐dependent	  
sorting	   of	   EGFR	   to	   lysosomes	   (McCullough	   et	   al.,	   2004).	   The	   overexpression	   of	  
catalytically	   inactive	   mutant	   of	   STAMBP	   results	   in	   accumulation	   of	   ubiquitylated	  
proteins	   on	   endosomes,	   suggesting	   a	   more	   general	   role	   of	   STAMBP	   in	   regulating	  
sorting	   of	   ubiquitylated	   cargo.	   	   If	   this	   regulatory	   role	   of	   STAMBP	   on	   EGFR	   is	  
extendable	  to	  other	  ubiquitylated	  cargo,	  such	  as	  E-­‐cadherin,	  it	  explains	  the	  observed	  
decrease	   in	   full	   length	   E-­‐cadherin	   to	   80kDa	   E-­‐cadherin	   fragment	   ratio,	   as	   an	  
increased	   ratio	   indicates	   that	   E-­‐cadherin	   degradation	   is	   favoured.	   STAMBPL1,	   also	  
known	   as	   AMSH-­‐LP,	   is	   a	   close	   homolog	   of	   STAMBP.	   Similar	   to	   STAMBP,	   it	   also	  
localises	  to	  the	  endosomal	  compartment,	  owing	  to	  a	  clathrin-­‐binding	  sites	  conserved	  
between	   the	   two	   proteins,	   and	   overexpression	   of	   catalytically	   inactive	   mutant	   of	  
STAMBPL1	   resulted	   in	   accumulation	   of	   ubiquitylated	   proteins	   on	   endosomes	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(Nakamura	  et	  al.,	   2006).	   This	   evidence	   suggests	   functional	   redundancy	  of	   STAMBP	  
and	   STAMBPL1	   in	   regulation	   of	   ubiquitylated	   cargos	   on	   the	   endosome.	   (However,	  
STAMBP	   and	   STAMBPL1	   are	   not	   functionally	   redundant	   in	   regulation	   of	   TGFβ	  
signaling	   based	   on	   unpublished	   research	   data	   by	   Monika	   Chojnowska,	   an	   ex-­‐
colleague	   in	   our	   laboratory).	   	   Therefore,	   it	   is	   not	   unexpected	   that	   their	   siRNA	  
depletion	   resulted	   in	   similar	   change,	   i.e.	   decrease,	   in	   the	   full	   length	   E-­‐cadherin	   to	  
80kDa	  E-­‐cadherin	  fragment	  ratio.	  ?
	  
USP8,	  USP12,	  USP38	  and	  USP40	  were	  the	  DUBs,	  which	  when	  siRNA	  depleted,	  
resulted	   in	   increase	   in	   full	   length	   E-­‐cadherin	   to	   80kDa	   E-­‐cadherin	   fragment	   ratio	  
(Figure	   3.12).	   Among	   these,	   effect	   of	  USP12	   and	  USP40	   knockdown	  on	   E-­‐cadherin	  
ratio	  was	   confirmed	   to	   be	   off-­‐target	   effect.	  USP8	   is	   also	   an	   endosomal	   associated	  
DUB	  and	  it	  has	  been	  demonstrated	  in	  our	  lab	  that	  siRNA	  depletion	  of	  USP8	  resulted	  
in	  delayed	  degradation	  of	  EGFR	  upon	  EGF	  stimulation	   (Row	  et	  al.,	  2006).	  This	  may	  
happen	   as	   a	   result	   of	   a	   sorting	   defect	   due	   to	   loss	   of	   STAM,	  which	   is	   stabilised	   by	  
USP8.	   	  Such	  a	   regulatory	  mechanism	  may	  account	   for	   the	   increase	   in	   full	   length	  E-­‐
cadherin	  to	  80kDa	  E-­‐cadherin	  fragment	  ratio.	  	  
	  
Among	  the	  targets	  that	  were	  deconvoluted,	  I	  decided	  to	  focus	  on	  USP38.	  This	  
was	  because	  the	  siRNA	  depletion	  of	  USP38	  resulted	  in	  the	  most	  dramatic	  increase	  in	  
the	   full	   length	   E-­‐cadherin	   to	   80kDa	   E-­‐cadherin	   fragment	   ratio,	   accompanied	   by	   a	  
significant	  loss	  of	  E-­‐cadherin.	  	  Moreover,	  USP38	  was	  an	  unstudied	  DUB	  that	  I	  wanted	  
to	  characterise	  (See	  Chapter	  6).	  	  The	  loss	  of	  E-­‐cadherin	  protein	  following	  knockdown	  
of	  USP38	  was	  not	  accompanied	  by	  a	  decrease	  in	  E-­‐cadherin	  mRNA	  (Figure	  3.20).	   In	  
fact,	  the	  E-­‐cadherin	  mRNA	  level	  increased	  following	  USP38	  knockdown.	  This	  suggests	  
USP38	  does	  not	  exert	   its	   regulatory	   role	  on	  E-­‐cadherin	  at	   the	   transcriptional	   level.	  
The	   loss	   of	   E-­‐cadherin	   protein	   possibly	   activates	   a	   feedback	   mechanism,	   which	  
attempts	   to	   counteract	   the	   loss	   by	   promoting	   the	   gene	   expression	   of	   E-­‐cadherin.	  
While	   DUBs	   can	   enhance	   stability	   of	   its	   substrate	   by	   rescuing	   the	   protein	   from	  
proteasomal	  or	   lysosomal	  degradation,	  this	  was	  also	  not	  the	  case	  for	  USP38	  and	  E-­‐
cadherin,	   since	   siRNA	   depletion	   of	   USP38	   did	   not	   lead	   to	   enhanced	   E-­‐cadherin	  
turnover	  (Figure	  3.21).	  In	  other	  words,	  USP38	  does	  not	  regulate	  E-­‐cadherin	  at	  post-­‐
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translational	   level.	   However,	   it	   is	   worth	   noting	   that	   this	   experiment	   used	  
Cycloheximide	   to	   inhibit	   protein	   translation	   and	   the	   inhibitor	   may	   lead	   to	  
undesirable	   effects	   to	   other	   processes	   within	   cells,	   such	   as	   protein	   degradation.	  
Nevertheless,	  putting	  the	  results	  of	  the	  two	  experiments	  together	  (Figure	  3.20	  and	  
Figure	  3.21),	  there	  is	  only	  one	  possibility	  left	  for	  the	  effect	  of	  USP38	  knockdown	  on	  
E-­‐cadherin,	  which	  is	  the	  loss	  of	  USP38	  negatively	  impacts	  on	  E-­‐cadherin	  translation.	  
This	   is	   a	   likely	   explanation	   since	  USP38	  was	   found	   interacting	  with	   two	   ribosomal	  
proteins,	  namely	  ribosomal	  protein	  L7	  (RPL7)	  and	  40S	  ribosomal	  protein	  S12	  (RPS12)	  
(Sowa	   et	   al.,	   2009),	   implicating	   a	   role	   of	   USP38	   in	   regulation	   of	   the	   translational	  
machinery.	   In	   that	   case,	   the	  effect	  of	  USP38	  knockdown	  may	  not	  be	   specific	   to	   E-­‐
cadherin,	  but	  represents	  a	  general	  defect	  in	  protein	  translation.	  I	  have	  however	  not	  
tested	  this	  hypothesis	  during	  the	  course	  of	  my	  research	  project.	  	  	  
	  
I	   was	   not	   able	   to	   verify	   further	   the	   functional	   relationship	   between	   E-­‐
cadherin	   and	  USP38.	   If	   USP38	   is	   acting	   directly	   on	   E-­‐cadherin	   and	   rescues	   it	   from	  
lysosomal	  degradation,	  it	  would	  be	  expected	  that	  following	  its	  overexpression,	  both	  
E-­‐cadherin	  level	  and	  the	  ratio	  of	  the	  full	  length	  to	  80kDa	  E-­‐cadherin	  fragment	  to	  be	  
increased.	  The	  fact	  that	  both	  of	  these	  measurements	  were	  not	  altered	  (Figure	  3.22)	  
therefore	  suggests	  that	  the	  concentration	  of	  USP38	  is	  not	  limiting	  in	  regulation	  of	  E-­‐
cadherin.	  Another	  possible	  explanation	   is	   that	  USP38	  does	  not	  exert	   its	   regulatory	  
role	  directly	  on	  E-­‐cadherin	  This	  may	  be	  supported	  by	  the	  observation	  that	  β-­‐catenin	  
was	  more	  significantly	  reduced	  than	  E-­‐cadherin	  following	  USP38	  knockdown	  (Figure	  
3.25B).	   Since	   both	   E-­‐cadherin	   and	   β-­‐catenin	   are	   co-­‐regulated	   in	   the	   AJ	   complex	  
formation	  (Chen	  et	  al.,	  1999),	  it	  is	  possible	  that	  the	  reduction	  in	  E-­‐cadherin	  level	  was	  
secondary	  to	  the	  loss	  of	  β-­‐catenin.	  	  	  
	  
While	   loss	   of	   E-­‐cadherin	   following	   USP38	   knockdown	   was	   apparent,	   such	  
extent	  of	   loss	  was	  not	   sufficient	   to	  abolish	  AJ	   formation	  and	   cell	   aggregation.	   This	  
suggests	   expression	   level	   of	   E-­‐cadherin	   on	   the	   plasma	  membrane	  was	  maintained	  
despite	   the	   loss	   of	   E-­‐cadherin,	   probably	   by	   enhancing	   E-­‐cadherin	   recycling	   as	  
indicated	   by	   the	   increased	   full	   length	   to	   80kDa	   E-­‐cadherin	   ratio.	   Only	   when	   E-­‐
cadherin	  was	  significantly	  depleted,	  the	  ability	  of	  cells	  to	  aggregate	  was	  abrogated.	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3.4	  	   Conclusion	  
	  
	   In	   conclusion,	   through	   the	  works	  presented	   in	   this	   chapter,	   I	  demonstrated	  
that	  E-­‐cadherin	  undergoes	  constitutive	  turnover	  via	  the	  lysosomal	  pathway	  in	  MCF7	  
cells.	  Such	  mode	  of	  E-­‐cadherin	  regulation	  was	  however	  not	  seen	   in	  other	  cell	   lines	  
tested.	   In	   the	   effort	   to	   identify	   DUBs	   regulating	   E-­‐cadherin,	   I	   found	  USP38,	  which	  
affects	   indirectly	  turnover	  of	  E-­‐cadherin	  protein.	  The	  mechanism	  of	  how	  these	  two	  
proteins	   are	   functionally	   related	  was	   however	   not	   uncovered.	   To	   understand	   this,	  
one	   possible	   direction	   of	   future	   work	   is	   to	   assess	   effect	   of	   USP38	   knockdown	   on	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Chapter	  4	  
Identification	  of	  
Deubiquitylases	  Involved	  in	  
Regulation	  of	  β–catenin	  
	  
	  
4.1	  	   Introduction	  	  
	  
	   β-­‐catenin,	  together	  with	  α-­‐	  and	  γ-­‐catenin,	  was	  first	   identified	  by	  Ozawa	  and	  
colleagues	   in	   1989	   as	   a	   cytoplasmic	   binding	   partner	   of	   E-­‐cadherin,	   providing	   a	  
physical	   anchorage	   of	   the	   E-­‐cadherin	   molecules	   on	   the	   plasma	  membrane	   to	   the	  
actin	  cytoskeleton	   (Ozawa	  et	  al.,	  1989;	  Ozawa	  et	  al.,	  1990).	  A	   few	  years	   later,	   two	  
independent	   groups	   discovered	   the	   interaction	   of	   β-­‐catenin	   with	   the	   tumor	  
suppressor	   gene,	   adenomatous	   polyposis	   coli	   (APC)	   (Rubinfeld	   et	   al.,	   1993;	   Su	   et	  
al.,1993)	   and	   Nusse’s	   group	   demonstrated	   its	   role	   in	   mediating	   Wnt	   signaling	  
(Noordermeer	   et	   al.,	   1994).	   This	   dual	   role	   of	   β-­‐catenin	   in	   two	   different	   cellular	  
processes,	   cell-­‐cell	   adhesion	   and	   development,	   which	   are	   both	   related	   to	   cancer	  
development,	  has	  drawn	  immense	  research	  interest	  to	  understand	  its	  regulation.	  	  
	  
	   It	   is	   now	   know	   that	   the	   tight	   regulation	   of	   cytoplasmic	   level	   of	   β-­‐catenin	  
protein	  is	  under	  the	  control	  of	  the	  ubiquitin-­‐proteasome	  system	  (UPS)	  (Aberle	  et	  al.,	  
1997;	   reviewed	   in	   Logan	   and	   Nusse,	   2004).	   In	   fact,	   there	   is	   burgeoning	   evidence	  
showing	   the	   role	   of	  UPS	   as	   a	  master	   regulator	   of	  Wnt	   signaling	   at	  multiple	   levels,	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through	  its	  regulation	  of	  different	  protein	  components	  of	  the	  pathway.	  For	  example,	  
K48-­‐linked	  ubiquitylation	  of	  APC	  (Choi	  et	  al.,	  2004),	  Dishevelled	  (Angers	  et	  al.,	  2006)	  
and	  Axin	  (Lui	  et	  al.,	  2011)	  targets	  them	  for	  proteasomal	  degradation	  whereas	  K63-­‐
linked	  ubiquitylation	  of	  APC	  (Tran	  et	  al.,	  2008)	  and	  Dishevelled	  (Tauriello	  et	  al.,	  2010)	  
affects	   their	   activity	   in	   transducing	  Wnt	   signaling	   cascades.	   The	   DUBs,	   which	   can	  
deubiquitylate	  these	  proteins	  have	  also	  been	  identified,	  namely	  Trabid	  for	  APC	  (Tran	  
et	  al.,	  2008),	  CYLD	  for	  Dishevelled	  (Tauriello	  et	  al.,	  2010)	  and	  USP34	  for	  Axin	  (Lui	  et	  
al.,	  2011).	  While	  the	  regulation	  of	  these	  Wnt	  signaling	  components	  by	  the	  UPS	  can	  
affect	  β-­‐catenin	  regulation	   indirectly,	   the	  DUB	  which	  directly	   regulates	  β-­‐catenin	   is	  
yet	  to	  be	  identified.	  	  
	  
	   The	  work	  presented	  in	  this	  chapter	  aims	  (i)	  to	  identify	  DUB(s)	   involved	  in	  β-­‐
catenin	   regulation	   and	   (ii)	   to	   characterise	   the	   functional	   relationship	   between	   the	  
DUB(s)	  and	  β-­‐catenin.	  	  
	  
	  
4.2	  	   Results	  	  
	  
4.2.1	   Identification	  of	  BAP1	  as	  a	  potential	  DUB	  regulating	  β-­‐catenin	  
	  
To	   identify	   DUBs	   involved	   in	   the	   regulation	   of	   β-­‐catenin	   at	   steady	   state,	   I	  
have	  used	  the	  large-­‐scale	  DUB	  library	  screen	  A549	  lysate	  (described	  in	  section	  3.2.4)	  
for	   SDS-­‐PAGE	   and	  Western	   Blot	   analysis.	   2	   96-­‐well	   plates	   of	   lysates	  were	   run	   and	  
Figure	  4.1	   shows	  a	   representative	  blot	   image	  acquired	   for	   this	   set	  of	  experiments.	  
Across	  the	  gels,	  there	  were	  multiple	  samples	  with	  higher	  levels	  of	  β-­‐catenin	  relative	  
to	   control,	   such	   as	   the	   knockdown	   samples	   of	   UCHL3,	   USP6,	   USP27X,	   USP54	   and	  
TNFAIP3.	  On	  the	  other	  hand,	  significant	  loss	  of	  β-­‐catenin	  following	  DUBs	  knockdown	  
was	  less	  obvious	  as	  judged	  by	  eye.	  	  
	  
Densitometric	   analysis	   of	   the	   blot	   images	   was	   performed	   to	   give	   a	  
quantitative	   measurement	   of	   the	   β-­‐catenin	   level	   (Figure	   4.2).	   The	   DUBs,	   whose	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knockdown	   resulted	   in	   at	   least	   a	   2-­‐fold	   increase	   in	   β-­‐catenin	   level	   were	   USP27X,	  
TNFAIP3,	   USP54	   and	   USP32.	   Among	   these,	   the	   effect	   of	   USP27X	   and	   TNFAIP3	  
depletion	  was	   the	  most	   dramatic,	   resulting	   in	   about	   a	   4-­‐fold	   increase	   in	  β-­‐catenin	  
level.	  On	  the	  other	  hand,	  siRNA	  depletion	  of	  BAP1,	  USP9Y,	  DUB4,	  PSMD7,	  STAMBPL1	  




Figure	  4.1.	  siRNA	  DUB	  library	  screen	  to	  identify	  DUBs	  regulating	  β–catenin	  in	  A549	  
cells.	  NP40	  samples	  from	  a	  large	  scale	  A549	  DUB	  screen	  (Figure	  3.15)	  were	  resolved	  
on	   10%	   SDS-­‐PAGE	   gels	   and	   transferred	   to	   nitrocellulose	   membrane	   before	  
immunoblotting	   with	   antibody	   against	   β-­‐catenin	   and	   tubulin.	   Blot	   images	   were	  






	   138	  
	  	  
Figure	  4.2.	  Change	  in	  β–catenin	  level	  following	  knockdown	  of	  DUBs.	  Densitometric	  
analysis	   of	   blot	   images	   (Figure	   4.1)	   was	   performed	   using	   ImageJ	   to	   determine	  
relative	  amount	  of	  β–catenin	   level,	  normalised	   to	   the	   level	  of	   tubulin	  and	  median.	  
The	  normalised	  β–catenin	   level	  was	  then	   log-­‐transformed	  and	  ranked	   in	  ascending	  
order.	   Columns	  exceeding	   the	  dotted	   line	   represent	   samples	  with	  more	   than	   two-­‐




















Figure	  4.3.	  Deconvolution	  of	   targets	  which	  altered	  β–catenin	   level.	   (A)	  A549	  cells	  
were	  transfected	  with	  single	  oligos	  against	  candidate	  DUBs	  at	  a	  final	  concentration	  
of	   40nM.	   Cell	   were	   lysed	   using	   NP40	   lysis	   buffer	   72	   hours	   later.	   Lysates	   were	  
resolved	   by	   SDS-­‐PAGE	   and	   immunoblotted	   for β–catenin	   and	   tubulin.	   Gel	   images	  
were	   acquired	   by	   infra-­‐red	   scanner	   (Odyssey,	   LICOR).	   Note:	   The	   siControl	   and	  
knockdown	  samples	  of	  USP27X	  were	  run	  on	  the	  same	  gel,	  and	  part	  of	   the	  gel	  was	  
cropped	  as	  indicated	  by	  the	  dotted	  lines.	  (B)	  Densitometric	  analysis	  was	  performed	  
using	  Image	  J	  to	  determine	  the	  level	  of	  β–catenin	  following	  normalisation	  to	  tubulin	  
level.	  The	  normalised	  β–catenin	  of	  each	  sample	  was	  then	  again	  normalised	  to	  that	  of	  
the	  siControl	  sample	  and	  was	  log	  transformed.	  	  Data	  shown	  represents	  average	  of	  3	  
technical	   repeats,	   and	   the	   5	   columns	   each	   represents	   oligo	   1,	   2,	   3,	   4	   and	   pool	  
respectively	  (See	  Figure	  3.18	  for	  knockdown	  efficiency	  of	  TNFAIP3).	  
A	  
B	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From	   both	   ends,	   only	   the	   top	   3	   candidates	   were	   chosen	   for	   subsequent	  
deconvolution	  experiments	  (Figure	  4.3).	  For	  BAP1,	  the	  knockdown	  using	  pool	  oligos	  
reproduced	  the	  decrease	  in	  β-­‐catenin	  level	  as	  was	  observed	  in	  the	  screen,	  and	  oligos	  
3	   and	   4	   recapitulated	   the	   pool	   knockdown	   effect.	   Immunoblotting	   with	   BAP1	  
antibody	  confirmed	  that	  BAP1	  was	  significantly	  depleted	  in	  all	  knockdown	  samples.	  
Among	  the	  knockdown	  performed	  using	  single	  oligos,	  oligo	  3	  gave	  the	  most	  dramatic	  
depletion	  in	  β-­‐catenin	  level.	  Both	  the	  USP9Y	  and	  DUB4	  knockdown	  using	  pool	  oligos	  
did	  not	  reproduce	  the	  decreased	  β-­‐catenin	   level	  observed	  in	  the	  screen	  and	  the	  β-­‐
catenin	   level	  was	  similar	  to	  that	  of	  the	  non-­‐targeting	  siRNA	  (siControl)	  sample.	  The	  
knockdown	  performed	  using	  single	  oligos	  against	  these	  2	  DUBs	  also	  did	  not	  result	  in	  
significant	  change	  in	  β-­‐catenin	  level	  compared	  to	  the	  siControl	  sample.	  	  	  
	  
The	   knockdown	   of	   USP54	   using	   pool	   oligos	   reproduced	   the	   increased	   β-­‐
catenin	   level	   that	   was	   observed	   in	   the	   screen.	   However,	   this	   effect	   of	   USP54	  
depletion	  on	  β-­‐catenin	   level	  was	  only	  recapitulated	  by	  oligo	  4,	  but	  not	  the	  other	  3	  
oligos,	   suggesting	   the	   increase	   in	   β-­‐catenin	   level	   was	   an	   off-­‐target	   effect.	   The	  
knockdown	   using	   pool	   oligos	   against	   TNFAIP3	   did	   not	   reproduce	   the	   increased	  β-­‐
catenin	  level	  observed	  in	  the	  screen.	  Among	  the	  single	  oligos	  against	  TNFAIP3,	  only	  
oligo	  1	  resulted	  in	  a	  slight	  increase	  in	  β-­‐catenin	  level	  relative	  to	  the	  siControl	  (Figure	  
4.3A)	  while	  knockdown	  using	  oligos	  3	  and	  4	  resulted	  in	  depletion	  of	  β-­‐catenin.	  Since	  
all	  4	  oligos	   resulted	   in	  depletion	  of	  TNFAIP3	   (Figure	  3.18)	  and	   that	   the	  knockdown	  
effect	  of	  TNFAIP3	  on	  β-­‐catenin	  level	  was	  not	  consistent,	  the	  observed	  increase	  in	  β-­‐
catenin	   level	   following	   TNFAIP3	   knockdown	   in	   the	   screen	   was	   very	   likely	   an	   off-­‐
target	  effect.	  The	  knockdown	  of	  USP27X	  using	  pool	  oligos	  again	  resulted	  in	  about	  a	  
4-­‐fold	  increase	  in	  β-­‐catenin	  level.	  However,	  none	  of	  the	  4	  single	  oligos	  recapitulated	  
such	  an	  extent	  of	  increase:	  where	  oligos	  1	  and	  2	  resulted	  in	  a	  marginal	  increase	  in	  β-­‐
catenin	   level	  while	  oligo	  3	  and	  4	  resulted	  in	  a	  marginal	  decrease	  in	  β-­‐catenin	   level.	  
Knockdown	   efficiency	   of	   USP27X	   was	   not	   checked	   since	   the	   antibody	   for	   USP27X	  
was	   not	   available	   in	   our	   laboratory.	   Hence,	   among	   the	   targets	   that	   were	  
deconvoluted,	  only	  BAP1	  emerged	  as	  a	  potential	  regulator	  of	  β-­‐catenin.	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To	  check	  if	  the	  regulatory	  role	  of	  BAP1	  on	  β-­‐catenin	  is	  unique	  to	  A549	  cells	  or	  
not,	  I	  then	  explored	  the	  consequence	  of	  BAP1	  depletion	  in	  two	  other	  human	  cancer	  
cell	   lines,	   namely	   MCF7	   and	   SW480	   cells.	   MCF7	   cell	   was	   chosen	   because	   I	   have	  
performed	  E-­‐cadherin	  related	  experiments	  in	  this	  cell	  line	  (see	  Chapter	  3)	  and	  given	  
the	  known	  function	  of	  E-­‐cadherin	  and	  β-­‐catenin	  as	  core	  components	  of	  the	  AJ,	  using	  
the	  same	  cell	   line	  would	  allow	  me	  to	  determine	   the	   interrelationship	  between	   the	  
DUBs	   idenfied	   and	   the	   two	  proteins.	   SW480	   cell	  was	   chosen	  because	   this	   cell	   line	  
harbours	  a	  truncation	  mutation	  in	  APC,	  so	  β-­‐catenin	  is	  not	  efficiently	  degraded	  and	  
aberrantly	  stabilised	   in	   this	  cell	   line.	   It	  would	  be	  of	   therapeutic	   interest	   to	  check	   if	  
loss	   of	   BAP1	   function	   can	   affect	  β-­‐catenin	   in	   this	   cell	   line.	   The	   siRNA	  depletion	   of	  
BAP1	  by	  all	  4	  oligos	  also	  resulted	  in	  decrease	  in	  β-­‐catenin	  level	  in	  MCF7	  cells	  (Figure	  
4.4A),	  indicating	  that	  the	  regulatory	  role	  of	  BAP1	  on	  β-­‐catenin	  was	  not	  restricted	  to	  
A549	   cells	   only.	   However,	   for	   the	   case	   of	   BAP1	   depletion	   in	   SW480	   cells	   (Figure	  
4.4B),	   only	   oligo	   1	   resulted	   in	   a	   significant	   depletion	  of	  β-­‐catenin,	  while	   the	  other	  
oligos	   did	   not	   result	   in	   change	   in	  β-­‐catenin	   level.	   Therefore,	   I	   did	   not	   pursue	   any	  
further	  with	  SW480	  cells.	  	  
	  
When	   observed	   under	   microscope,	   for	   A549,	   the	   control	   cells	   (mock	  
transfected	  or	   transfected	  with	  non-­‐targeting	   siRNA),	   showed	  prominent	  β-­‐catenin	  
staining	   on	   the	   plasma	   membrane	   at	   cell-­‐to-­‐cell	   junction	   and	   a	   strong	   nuclear	  
staining	   for	  BAP1	   (Figure	  4.5A).	   For	   cells	   transfected	  with	   the	   siRNA	  oligos	   against	  
BAP1,	   the	   nuclear	   staining	   of	   BAP1	  was	  much	  weaker,	   indicating	   the	   depletion	   of	  
BAP1.	   In	   these	   cells,	   the	   β-­‐catenin	   staining	   on	   the	   plasma	   membrane	   was	   much	  
weaker,	  which	  is	  in	  agreement	  with	  the	  biochemical	  data	  (Figure	  4.3A).	  	  
	  
MCF7	  cells,	  which	  were	  mock	  transfected	  or	   transfected	  with	  non-­‐targeting	  
siRNA,	   were	   tightly	   bound	   to	   each	   other	   with	   prominent	   β-­‐catenin	   at	   cell-­‐to-­‐cell	  
junction	  and	  strong	  nuclear	  staining	  for	  BAP1.	  Similar	  to	  A549	  cells,	  the	  MCF7	  cells	  
transfected	   with	   siRNA	   oligos	   against	   BAP1	   showed	   less	   β-­‐catenin	   on	   the	   plasma	  
	   142	  
membrane	   and	   weaker	   nuclear	   staining	   of	   BAP1,	   indicating	   BAP1	   depletion.	  
Moreover,	  as	  seen	  in	  Figure	  4.5B,	  cells	  transfected	  with	  oligos	  2,	  3	  and	  4	  were	  clearly	  








Figure	  4.4.	  BAP1	  depletion	  in	  MCF7	  and	  SW480	  cells.	  (A)	  MCF7	  and	  (B)	  SW480	  cells	  
were	   transfected	   using	   transfection	   reagent	   alone	   (mock)	   or	   non-­‐targeting	   siRNA	  
oligo	  (siControl)	  or	  siRNA	  single	  oligos	  against	  BAP1	  (40nM)	  for	  72	  hours.	  Cell	  were	  
lysed	  using	  NP40	  lysis	  buffer	  72	  hours	  later.	  Lysates	  were	  resolved	  on	  4-­‐12%	  NuPAGE	  
gel	  and	   immunoblotted	   for β–catenin,	   BAP1	   and	   actin.	  Gel	   images	  were	  acquired	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Figure	  4.5.	  BAP1	  depletion	  decreases	  β–catenin	  level	  on	  plasma	  membrane	  in	  (A)	  
A549	   and	   (B)	  MCF7	   cells.	   Cells	  were	   transfected	   using	   siRNA	   single	   oligos	   against	  
BAP1	   at	   40nM	   for	   72	   hours.	   After	   that,	   cells	   were	   fixed	   in	   0.4%	   PFA/PBS,	  
permeabilised	   and	   immunostained	   with	   antibody	   against	   b–catenin	   and	   BAP1.	  
Images	  were	  acquired	  using	  Nikon	  microscope	  and	  the	  image	  setting	  was	  the	  same	  
for	  all	  images	  (Scale	  bar	  =	  10µm).	  	  
A	  
B	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Figure	  4.6.	  siRNA	  depletion	  of	  BAP1	  resulted	  in	  decrease	  in	  β–catenin	  mRNA	  level.	  Cells	  were	  transfected	  using	  siRNA	  single	  oligos	  (40nM)	  for	  72	  hours	  and	  mRNA	  was	   purified	   using	   RNeasy	   Kit.	   1µg	   of	   mRNA	   was	   reverse-­‐transcribed	   and	  subjected	   to	  QPCR	  analysis.	  Two	  biological	   replicates	  were	  analysed	  and	  QPCR	  reactions	  were	  set	  up	  in	  triplicate	  for	  each	  biological	  replicate.	  	  
	  
I	  have	  also	  measured	  the	  mRNA	  level	  of	  β-­‐catenin	  following	  BAP1	  knockdown	  
in	  MCF7	  and	  the	  experiment	  was	  done	  twice.	  siRNA	  depletion	  of	  BAP1	  using	  oligos	  2,	  
3	  and	  4	  resulted	  in	  a	  decrease	  of	  	  β-­‐catenin	  mRNA	  by	  20-­‐40%,	  which	  was	  consistent	  
for	  both	  biological	  repeats	  (Figure	  4.6).	  For	  knockdown	  using	  siRNA	  oligo	  1,	  at	  least	  
in	  one	  experiment,	  there	  was	  a	  decrease	  of	  β-­‐catenin	  mRNA	  by	  about	  50%.	  	  
	  
When	   BAP1	   was	   transiently	   overexpressed	   in	   MCF7	   cells,	   there	   was	   a	  
reproducible	   (the	   experiment	  was	   repeated	   three	   times),	   higher	   level	   of	  β-­‐catenin	  
compared	   to	   cells	   transiently	   overexpressing	   GFP	   (Figure	   4.7A).	   This	   suggested	   a	  
positive	  regulatory	  role	  of	  BAP1	  on	  β-­‐catenin	  in	  MCF7.	  To	  assess	  if	  this	  is	  dependent	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of	   BAP1,	   namely	   BAP1-­‐C91S	   and	   BAP1-­‐A95D.	   Both	   of	   these	   mutants	   lack	  
deubiquitylating	   activity	   based	   on	   in	   vitro	   studies	   (Ventii	   et	   al.,	   2008).	   The	  
overexpression	  of	  these	  two	  mutants	  did	  not	  lead	  to	  change	  in	  β-­‐catenin	  level,	  while	  
the	  overexpression	  of	  wildtype	  BAP1	  resulted	   in	  a	  higher	   level	  of	  β-­‐catenin	   (Figure	  
4.7B).	  At	  face	  value,	  it	  seemed	  regulatory	  of	  BAP1	  on	  β-­‐catenin	  is	  dependent	  on	  its	  
catalytic	  activity.	  However,	  the	  expression	  level	  of	  the	  mutant	  BAP1	  was	  not	  as	  high	  
as	  that	  of	  the	  wildtype	  BAP1	  and	  this	  difference	  in	  expression	  level	  may	  account	  for	  
the	   lack	   of	   effect.	   	   In	   this	   experiment,	   I	   also	   observed	   an	   extra	   lower	   molecular	  
weight	  band	  below	  the	  β-­‐catenin	  band,	  which	  was	  likely	  a	  non-­‐specific	  band.	  This	  is	  
because	   in	   the	   two	  experiments	   shown	   in	  Figure	  4.7,	   the	  same	  antibody	  was	  used	  
and	  β-­‐catenin	   always	   runs	   slightly	   below	   the	  97.2kDa	  marker.	  Moreover,	   that	  was	  
the	  band	  which	  showed	  an	  increase	  when	  wildtype	  BAP1	  was	  overexpressed,	  which	  
is	  a	  very	  reproducible	  effect	  of	  BAP1	  overexpression.	  	  
	  
	   	  	  	  
Figure	   4.7.	   Upregulaton	   of	   β–catenin	   following	   BAP1	   overexpression.	  MCF7	  cells	  
were	  transfected	  with	  0.5µg	  of	  GFP	  empty	  vector	  or	  1µg	  of	  GFP-­‐tagged	  BAP1,	  BAP1-­‐
C91S	   and	   BAP1-­‐A95D	   fusion	   plasmids.	   Cell	   were	   lysed	   using	   NP40	   lysis	   buffer	   24	  
hours	   later	  and	   lysates	  were	  resolved	  on	  4-­‐12%	  NuPAGE	  gels	  and	   immunoblottded	  
for β–catenin,	   GFP	   and	   actin.	   Blot	   images	   were	   acquired	   by	   infra-­‐red	   scanner	  
(Odyssey,	  LICOR).	  Transfection	  efficiency	  was	  not	  determined	  in	  this	  experiment.	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To	  further	  investigate	  the	  role	  of	  BAP1	  on	  β-­‐catenin	  regulation,	  I	  decided	  to	  
do	  a	  rescue	  experiment.	  Before	  carrying	  out	  that	  experiments,	  I	  had	  to	  optimise	  the	  
cell	  number	  to	  be	  seeded.	  This	  is	  because	  depletion	  of	  BAP1	  led	  to	  lower	  number	  of	  
cells	   at	   the	   end	   of	   72	   hours	   of	   transfection	   as	   evident	   by	   the	   lower	   protein	  
concentration	  of	  lysates	  obtained	  (Figure	  4.8).	  The	  depletion	  of	  BAP1	  using	  oligos	  1,	  
2	   and	  3	   led	   to	   at	   least	   40%	   less	   cells	   compared	   to	   control	   samples	   after	   72	  hours	  
incubation	  post-­‐transfection,	  whereas	   the	   reduction	   in	  cell	  number	   for	  oligo	  4	  was	  
less	   dramatic.	   A	   rescue	   experiment	   involves	   siRNA	   transfection	   and	   DNA	  
transfection,	   which	   cause	   stress	   to	   the	   cells	   and	   can	   lead	   to	   extensive	   cell	   death.	  
Therefore,	  more	  cells	  should	  be	  seeded	  at	  the	  beginning	  of	  a	  rescue	  experiment	  to	  





Figure	   4.8.	   Relative	   protein	   concentration	   of	   MCF7	   cell	   lysates	   following	   BAP1	  
knockdown.	  MCF7	  cells	  were	  transfected	  using	  non-­‐targeting	  siRNA	  oligos	  or	  siRNA	  
oligos	  against	  BAP1	  at	  40nM	  for	  72	  hours.	  Cell	  were	  lysed	  using	  NP40	  lysis	  buffer	  72	  
hours	   later.	   Bradford	   protein	   assay	   was	   performed	   to	   determine	   protein	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Figure	  4.9.	   The	   loss	  of	  β–catenin	   and	  E-­‐cadherin	   following	  BAP1	  depletion	   is	   not	  
dependent	   on	   cell	   density.	  MCF7	   cells	  were	   transfected	   using	   siRNA	   single	   oligos	  
against	  BAP1	  at	  40nM	  for	  72	  hours.	  Cell	  were	  lysed	  using	  NP40	  lysis	  buffer	  72	  hours	  
later.	   Lysates	   were	   resolved	   on	   4-­‐12%	   NuPAGE	   gel	   and	   immunoblotted	   for	  β–
catenin,	  E-­‐cadherin,	  BAP1,	  tubulin	  and	  actin.	  Gel	  images	  were	  acquired	  by	  infra-­‐red	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For	  this	  purpose,	  I	  have	  seeded	  30%	  (6.56	  x	  104	  cells/well)	  or	  40%	  (7.28	  x	  104	  
cells/well)	  more	   cells	   in	  wells	   of	   12-­‐well	   plates	   for	   transfection	   using	   siRNA	   oligos	  
against	   BAP1,	   compared	   to	   transfection	   using	   non-­‐targeting	   siRNA	   (5.2	   x	   104	  
cells/well).	  For	  both	  cell	  densities,	  BAP1	  was	  significantly	  depleted	  by	  all	   the	  siRNA	  
oligos	  (Figure	  4.9),	  and	  this	  was	  accompanied	  by	  a	  reduced	  level	  of	  β-­‐catenin	  protein	  
in	   all	   cases	   as	   compared	   to	   the	   control	   samples	   (mock	   and	   siControl).	   In	   this	  
experiment,	   the	   level	   of	   E-­‐cadherin	   protein	   was	   also	   quantified.	   For	   both	   cell	  
densities,	  BAP1	  depletion	  using	  oligos	  1	  resulted	  in	  a	  marginal	  decrease	  in	  E-­‐cadherin	  
protein,	  whereas	  knockdown	  using	  oligos	  2	  and	  3	  resulted	  in	  reduction	  of	  E-­‐cadherin	  
protein	  level	  by	  about	  20-­‐30%.	  For	  oligo	  4,	  the	  E-­‐cadherin	  protein	  level	  was	  similar	  to	  
that	  of	  the	  control	  sample	  for	  both	  cell	  densities.	  	  
	  
I	  have	  then	  decided	  to	  seed	  40%	  more	  cells	  per	  well	  (i.e.	  1.82	  x	  105	  cells/well	  
of	   a	   6-­‐well	   plate)	   for	   the	   rescue	   experiment.	   In	   order	   to	   accumulate	   more	   cells	  
expressing	  BAP1	   (wildtype	  or	  mutants),	   I	   performed	   the	  DNA	  plasmid	   transfection	  
the	  day	  after	  siRNA	  transfection,	  so	  that	  the	  cells	  had	  48	  hours	  (instead	  of	  24	  hours)	  
to	  express	  BAP1	  prior	  to	  cell	  lysis.	  
	  
I	   have	   also	   tried	   to	   generate	   BAP1	   plasmids,	   which	   are	   resistant	   to	   siRNA	  
oligos	  by	  site	  directed	  mutagenesis,	  but	  successful	  mutation	  was	  only	  obtained	   for	  
resistance	  against	  BAP1	  siRNA	  oligo	  3.	  Therefore,	  I	  used	  BAP1	  siRNA	  oligo	  3	  for	  BAP1	  
depletion.	   The	   rescue	   experiment	   was	   performed	   twice	   and	   the	   transfection	  
efficiency	  of	  these	  experiments	  was	  between	  28-­‐33%.	  Depletion	  of	  BAP1	  resulted	  in	  
lower	  level	  of	  β-­‐catenin	  and	  E-­‐cadherin,	  compared	  to	  the	  control	  samples,	  regardless	  
of	   the	   plasmid	   that	   was	   transfected.	   Among	   the	   BAP1	   depleted	   samples,	   the	   β-­‐
catenin	   level	   of	   cells	   transfected	   with	   GFP-­‐BAP1	   and	   GFP-­‐BAP1-­‐C91S	   was	   slightly	  
higher	   than	   that	   of	   cells	   transfected	   with	   GFP,	   indicating	   rescue	   of	   β-­‐catenin	   by	  
BAP1,	   but	   ,at	   face	   value,	   the	   rescue	   is	   independent	   of	   catalytic	   activity	   of	   BAP1.	  
However,	  the	  level	  of	  β-­‐catenin	  was	  only	  partially	  recovered	  as	  it	  was	  still	  lower	  than	  
that	  of	  the	  control	  samples.	  This	  is	  not	  unexpected	  since	  only	  about	  one-­‐third	  of	  the	  
cells	  were	  transfected	  with	  the	  siRNa	  resistant	  GFP-­‐BAP1.	  Expression	  of	  GFP-­‐BAP1-­‐
A95D	  on	  the	  other	  hand	  did	  not	  increase	  the	  level	  of	  β-­‐catenin.	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The	  different	  GFP-­‐tagged	  BAP1	  proteins	  showed	  differential	  expression	  level.	  
The	  wildtype	  BAP1	  always	  had	  a	  higher	  expression	  level	  compared	  to	  the	  BAP1-­‐C91S	  
and	  BAP1-­‐A95D	  mutants,	   and	   that	   the	  expression	   level	   of	  BAP1-­‐A95D	  mutant	  was	  
the	   lowest	  among	  the	  different	  samples.	   Intriguingly,	  the	  expression	   level	  of	  BAP1-­‐
A95D	  mutant	   in	  cells	  already	  depleted	  of	  endogenous	  BAP1	  was	  significantly	  much	  
lower	   than	   cells,	   which	   were	   mock-­‐transfected	   or	   transfected	   with	   non-­‐targeting	  
siRNA	   oligo.	   When	   the	   blot	   image	   for	   immunoblotting	   using	   GFP	   antibody	   was	  
adjusted	   to	   higher	   intensity	   level,	   smear	   of	   higher	   molecular	   weight	   GFP-­‐tagged	  
wildtype	   BAP1	   and	   BAP1-­‐C91S	  mutant	   was	   observed.	  While	   the	   higher	   molecular	  
weight	   smear	  of	  BAP1-­‐C91S	  mutant	  was	  more	  prominent	   than	   the	  wildtype	  BAP1,	  
the	  higher	  molecular	  weight	  form	  of	  BAP1-­‐A95D	  mutant	  was	  hardly	  visible.	  	  
	  
Multiple	  studies	  have	  identified	  BAP1	  as	  a	  tumour	  suppressor	  gene	  (Ventii	  et	  
al.,	   2008;	   Machida	   et	   al.,	   2009),	   drawing	   immense	   interest	   to	   understand	   the	  
biological	  function	  of	  this	  protein	  and	  its	  relevance	  to	  cancer	  progression.	  From	  the	  
experimental	   results	   in	   the	   previous	   section,	   there	   was	   clearly	   a	   functional	   link	  
between	   β-­‐catenin	   and	   BAP1,	   and	   the	   different	   mutations	   in	   BAP1	   resulted	   in	  
different	  fate	  of	  the	  protein	  itself.	  
	  
	   To	   further	   characterise	   BAP1,	   I	   have	   performed	   an	   immunoprecipitation	  
experiment	  by	  pulling	  down	  the	  GFP-­‐tagged	  proteins	  and	  confirmed	  that	  the	  higher	  
molecular	   weight	   smear	   was	   polyubiquitylated	   form	   of	   GFP-­‐BAP1.	   The	   GFP-­‐BAP1-­‐
C91S	   was	   much	   more	   heavily	   ubiquitylated	   compared	   to	   the	   wildtype	   GFP-­‐BAP1,	  
whereas	  polyubiquitylation	  of	  the	  mutant	  GFP-­‐BAP1-­‐A95D	  was	  not	  detected	  (Figure	  
4.11).	   Both	   the	  BAP1	  mutants	   and	  wildtype	  BAP1	   showed	  nuclear	   localisation	   and	  
diffuse	   localisation	   in	   the	   cytoplasm	   (Figure	   4.12).	   However,	   the	   GFP-­‐BAP1-­‐A95D	  
showed	  more	  prominent	  cytoplasmic	  localisation	  than	  the	  wildtype	  BAP1	  and	  BAP1-­‐
C91S.	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Figure	   4.10.	   Transient	   expression	   of	   siRNA	   resistant	   BAP1	   rescues	   β–catenin	  
following	  loss	  of	  endogenous	  BAP1.	  (A)	  MCF7	  cells	  were	  transfected	  without	  siRNA	  
(Mock),	  or	  non-­‐targeting	  siRNA	  oligo	  or	  siRNA	  oligo	  3	  against	  BAP1	  at	  40nM	  the	  day	  
after	  seeding.	  48	  hours	  later,	  cells	  were	  transfected	  with	  the	  different	  plasmids.	  Cells	  
were	  lysed	  another	  24	  hours	  later	  using	  NP40	  lysis	  buffer.(B)	  Lysates	  were	  resolved	  
on	   4-­‐12%	   NuPAGE	   gel	   and	   immunoblotted	   for	  β–catenin,	   GFP,	   E-­‐cadherin	   and	  
tubulin.	  Blot	   images	  were	  acquired	  by	   infra-­‐red	  scanner	  (Odyssey,	  LICOR).	  Plasmids	  
marked	  with	  “*”	  are	  siRNA	  resistant	   to	  siBAP1-­‐OL3.	  Densitrometric	  analysis	  of	  blot	  
was	   performed	   to	   determine	   relative	   level	   of	   (C)	   	  β–catenin	   and	   (D)	   E-­‐cadherin	  
following	  normalisation	  to	  tubulin.	  	  
	  	  	  




Figure	  4.11.	  Wildtype	  and	  C91S	  mutant	  BAP1	  are	  polyubiquitylated	  but	  not	  BAP1-­‐
A95D	  mutant.	   	  5.8µg	  of	  each	  of	  the	   indicated	  plasmids	  was	  transfected	   into	  MCF7	  
cells	  grown	  in	  10cm	  dish	  and	  cells	  were	  lysed	  24	  hours	  later	  using	  NP40	  lysis	  buffer.	  
For	   co-­‐immunoprecipitation,	   600µg	   of	   protein	   was	   incubated	   with	   1µl	   of	   GFP	  
antibody	  and	  protein	  G	  sepharose	  beads	  in	  a	  final	  volume	  of	  480µl,	  for	  1.5	  hour	  at	  
4˚C	  on	  a	  rotating	  wheel.	  Purified	  protein	  complexes	  were	  resolved	  on	  4-­‐12%	  NuPAGE	  
gel,	   transferred	   to	   nitrocellulose	   membrane	   and	   immunoblotted	   for	   GFP	   or	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4.3	   Discussion	  	  
	  
By	  using	  A549	  cell	  lysates	  from	  a	  large	  scale	  DUB	  human	  library	  siRNA	  screen	  
for	  Western	   blotting	   analyses,	   I	   shortlisted	   6	   DUBs	   for	   subsequent	   verification	   by	  
deconvolution	   of	   the	   pool	   of	   oligos.	   In	   the	   screen,	   siRNA	   depletion	   of	   TNFAIP3,	  
USP27X	   and	   USP54	   resulted	   in	   at	   least	   a	   two-­‐fold	   increase	   in	   β-­‐catenin	   level.	  
Notably,	  the	  knockdown	  of	  USP27X	  and	  TNFAIP3	  also	  resulted	  in	  significant	  increase	  
in	   E-­‐cadherin,	   which	   together	   with	   β-­‐catenin,	   is	   the	   core	   component	   of	   the	   E-­‐
cadherin/catenin/actin	  complex	  at	  the	  AJ	  (Ozawa	  et	  al.,	  1989)	  and	  that	  the	  efficient	  
coupling	  of	  these	  two	  proteins	  is	  essential	  for	  the	  targeting	  of	  the	  complex	  to	  plasma	  
membrane	  (Chen	  et	  al.,	  1999).	  	  
	  
	   TNFAIP3,	  also	  known	  as	  A20,	  was	  first	  identified	  as	  a	  tumour	  necrosis	  factor	  
alpha	  (TNFα)-­‐inducible	  gene	  product	  (Dixit,	  Green	  et	  al.	  1990;	  Opipari,	  Boguski	  et	  al.	  
1990).	  Whilst	  significant	  work	  has	  been	  done	  to	  elucidate	  the	  mechanism	  by	  which	  
this	   protein	   down-­‐regulates	   NF-­‐κB	   signaling	   (Song	   et	   al.,	   1996;	   Lee	   et	   al.,	   2000;	  
Wertz	  et	  al.,	  2004),	  there	  is	  no	  previous	  report	  of	  a	  direct	  link	  between	  TNFAIP3	  with	  
regulation	   of	   cell	   adhesion	   or	   components	   of	   the	   AJ.	   The	   biological	   functions	   of	  
USP27X	  and	  USP54	  are	  still	  yet	  to	  be	  elucidated.	  In	  other	  words,	  there	  was	  no	  data	  
to	   support	   a	   possible	   role	   of	   these	  DUBs	   in	   regulation	   of	   AJ	   components.	   Using	   a	  
criterion	  of	  at	   least	  2	  oligos	  recapitulating	  pool	  knockdown	  effect,	   I	  concluded	  that	  
the	  observed	   increase	   in	  β-­‐catenin	   following	  siRNA	  depletion	  of	   these	  DUBs	   in	   the	  
screen	  could	  be	  due	  to	  off-­‐target	  effects	  and	  these	  targets	  were	  not	  pursued	  further.	  	  	  
	  
On	  the	  other	  hand,	  the	  siRNA	  depletion	  of	  BAP1,	  USP9Y	  and	  DUB4	  resulted	  in	  
significant	  decrease	  in	  β-­‐catenin.	  Among	  these,	  the	  decrease	  in	  β-­‐catenin	  following	  
siRNA	  depletion	  of	  USP9Y	  and	  DUB4	  was	  potentially	  a	   result	  of	  off-­‐target	  effect	  as	  
well.	  	  
	  
Among	   all	   the	   candidates	   that	   were	   deconvoluted,	   BAP1	   emerged	   as	   the	  
leading	  candidate	  DUB,	  for	  involvement	  in	  β-­‐catenin	  regulation	  and	  this	  role	  of	  BAP1	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was	  confirmed	  in	  a	  lung	  cancer	  cell	  line,	  A549	  and	  most	  strikingly	  in	  a	  breast	  cancer	  
cell	   line,	  MCF7.	  At	   least	   in	  MCF7	   cells,	   BAP1	   is	   acting	   as	   a	   positive	   regulator	   of	  β-­‐
catenin,	  as	  its	  depletion	  led	  to	  the	  decrease	  of	  β-­‐catenin	  protein	  level	  (Figure	  4.4A)	  
whereas	  its	  overexpression	  led	  to	  an	  increase	  in	  β-­‐catenin	  protein	  level	  (Figure	  4.7A).	  
However,	  the	  effect	  of	  BAP1	  on	  β-­‐catenin	  was	  not	  confirmed	  in	  SW480	  cells	  (Figure	  
4.4B).	  Although	  all	  siRNA	  oligos	  against	  BAP1	  resulted	  in	  efficient	  silencing	  of	  BAP1,	  
only	  oligo	  1	  led	  to	  a	  significant	  decrease	  in	  β-­‐catenin	  level.	  One	  potential	  explanation	  
to	  this	  is	  that	  SW480	  cell	  is	  expressing	  an	  isoform	  of	  BAP1,	  which	  is	  not	  targeted	  by	  
the	  other	  oligos.	  However,	  among	  the	  predicted	  splice	  variants	  of	  BAP1	  on	  Aceview,	  
none	   of	   them	   is	   uniquely	   targeted	   by	   oligo	   1	   only	   but	   not	   the	   other	   oligos.	   An	  
alternative	  method	  to	  confirm	  the	  role	  of	  BAP1	  in	  this	  case	  is	  to	  reintroduce	  a	  siRNA	  
resistant	  (to	  oligo	  1)	  version	  of	  BAP1	  into	  SW480.	  	  
	  
β-­‐catenin	  is	  known	  to	  bind	  to	  the	  cytoplasmic	  domain	  of	  E-­‐cadherin	  (Ozawa	  
et	  al.,	  1989)	  and	   the	  association	  of	   these	   two	  proteins	   is	   required	   for	   the	  efficient	  
targeting	  of	  the	  E-­‐cadherin/β-­‐catenin	  complex	  to	  the	  plasma	  membrane	  (Chen	  et	  al.,	  
1999).	   It	   has	   also	   been	   demonstrated	   in	   a	   human	   gastric	   cancer	   cell	   line,	   HSC-­‐39,	  
that	  cell-­‐cell	  adhesion	  was	  impaired	  due	  to	  mutation	  in	  β-­‐catenin,	  which	  prevented	  
formation	  of	  stable	  AJ,	  and	  hence	  cell	  aggregation	  and	  cell	  compaction,	  despite	  high	  
level	  of	  expression	  of	  E-­‐cadherin	  (Kawaniski	  et	  al.,	  1995).	  Therefore,	  the	  partial	  loss	  
of	  cell-­‐to-­‐cell	  contact	  and	  less	  compact	  monolayer	  of	  epithelial	  cells	  following	  siRNA	  
depletion	  of	  BAP1,	  was	   likely	  a	  secondary	  effect	  of	  the	  decrease	   in	  β-­‐catenin	   level.	  
Moreover,	   E-­‐cadherin	   level	  was	   also	   decreased	   following	  BAP1	   knockdown	   (Figure	  
4.10).	  	  
	  
I	  demonstrated	   that	   the	  knockdown	  of	  BAP1	   led	   to	  a	  decrease	   in	  β-­‐catenin	  
mRNA	  level	  in	  MCF7	  cell	  (Figure	  4.6).	  A	  similar	  observation	  was	  made	  by	  Harbour	  et	  
al.,	  where	  siRNA	  depletion	  of	  BAP1	  in	  a	  uveal	  melanoma	  cell	  line	  resulted	  in	  change	  
in	  expression	  levels	  of	  a	  panel	  of	  genes,	  among	  which	  included	  β-­‐catenin	  and	  it	  was	  
downregulated	   by	   about	   20%	   upon	   BAP1	   knockdown	   (Harbour	   et	   al.,	   2010).	  
Moreover,	   at	   least	   in	  HeLa	   cells,	   BAP1	  was	   found	   to	   be	  predominantly	   complexed	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with	  host	  cell	  factor	  1	  (HCF1),	  which	  is	  a	  chromatin-­‐associated	  protein	  and	  Yin	  Yang	  1	  
(YY1),	  a	  transcription	  factor	  (Machida	  et	  al.,	  2009).	  The	  catalytic	  activity	  of	  BAP1	  was	  
important	  to	  regulate	  the	  activity	  of	  this	  whole	  complex	  in	  controlling	  expression	  of	  
genes	   involved	   in	   regulation	   of	   cell	   growth	   and	   proliferation	   (Yu	   et	   al.,	   2010).	  
Together,	   these	   observations	   suggest	   that	   BAP1	   regulates	   β-­‐catenin	   at	   the	  
transcriptional	  level.	  	  
	  
The	  rescue	  experiment	  also	  indicated	  a	  regulatory	  role	  of	  BAP1	  on	  β-­‐catenin	  
(Figure	   4.10).	   In	   BAP1	   depleted	   cells,	   the	   overexpression	   of	   the	   siRNA	   resistant	  
wildtype	   BAP1	   resulted	   in	   about	   50%	   rescue	   of	   β-­‐catenin	   relative	   to	   the	   cells	  
overexpressing	   GFP.	   Considering	   the	   transfection	   efficiency	   of	   cells	   was	   between	  
28%	   and	   33%,	   the	   rescue	   effect	   was	   very	   prominent.	   In	   the	   series	   of	   rescue	  
experiments,	   I	   have	   also	   included	   two	   mutants	   of	   BAP1,	   namely	   BAP1-­‐C91S	   and	  
BAP1-­‐A95D.	   Cys91	  of	   BAP1	   is	   the	   conserved	   cysteine	   residue	   at	   the	   catalytic	   triad	  
responsible	  for	  cleavage	  of	  isopeptide	  bond	  and	  Ala95	  is	  a	  well	  conserved	  amino	  acid	  
residue	  within	   the	  UCH	  domain,	  close	   to	   the	  active	  site.	  Both	  of	   the	  mutants	  have	  
been	   shown	   to	   lack	   deubiquitylating	   activity	   based	   on	   an	   in	   vitro	   deubiquitylation	  
assay	   using	   ubiquitin	   COOH-­‐terminal	   7-­‐amido-­‐4-­‐methylcoumarin	   (Ub-­‐AMC)	   as	  
substrate	  (Ventii	  et	  al.,	  2008).	  However,	  the	  two	  mutants	  did	  not	   lead	  to	  the	  same	  
effect	  on	  β-­‐catenin.	  	  
	  
The	  BAP1-­‐C91S	  mutant	  when	  overexpressed	  in	  cells	  with	  endogenous	  level	  of	  
BAP1	   did	   not	   alter	   the	   level	   of	   β-­‐catenin,	   unlike	   the	   overexpression	   of	   wildtype	  
BAP1.	  This	  suggests	  that	  the	  positive	  regulatory	  role	  of	  BAP1	  on	  β-­‐catenin	  depends	  
on	  its	  catalytic	  activity	  (Figure	  4.7).	  However,	  contradictory	  to	  this	  observation,	  the	  
BAP1-­‐C91S	  mutant	  was	  able	  to	  recover	  β-­‐catenin	  in	  BAP1	  depleted	  cells,	  to	  a	  similar	  
extent	   as	   the	   wildtype	   BAP1,	   suggesting	   that	   the	   catalytic	   activity	   of	   BAP1	   is	  
dispensable	   for	   its	   regulatory	   role	   on	  β-­‐catenin	   expression.	   As	  mentioned	   before,	  
BAP1	  was	  found	  in	  complex	  with	  HCF1	  and	  YY1,	  and	  the	  multiprotein	  complex	  plays	  
a	  role	  in	  regulating	  expression	  of	  a	  wide	  array	  of	  genes.	  While	  the	  catalytic	  activity	  of	  
BAP1	   is	   dispensable	   for	   the	   assembly	   of	   the	   complex	   (Yu	   et	   al.,	   2010),	   work	   by	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Machida	  and	  colleagues	  suggests	  that	  the	  DUB	  activity	  is	  required	  to	  deubiquitylate	  
HCF1	   to	   allow	   regulation	   of	   cell	   proliferation	   (Machida	   et	   al.,	   2009).	   They	   also	  
demonstrated	  that	  most,	  if	  not	  all,	  endogenous	  BAP1	  is	  found	  in	  complex	  with	  HCF-­‐
1.	   HCF-­‐1	   was	   also	   found	   to	   be	   the	   top	   interacting	   partner	   of	   BAP1	   in	   mouse	   as	  
identified	  by	  mass	  spectrometry	  (Dey	  et	  al.,	  2012).	  	  
	  
In	  light	  of	  the	  above	  evidence,	  it	  is	  very	  likely	  that	  β-­‐catenin	  expression	  is	  also	  
regulated	  by	   the	   transcriptional	   complex	   containing	  BAP1	  and	  HCF-­‐1.	   There	   is	  one	  
possible	  explanation	  for	  the	  apparent	  rescue	  of	  β-­‐catenin	  by	  the	  catalytically	  inactive	  
BAP1-­‐C91S	   mutant:	   in	   a	   normal	   cell,	   there	   are	   multiple	   BAP1-­‐containing	  
transcription	   activating	   complexes,	   shifting	   in	   equilibrium	   between	   inactive	   (HCF1	  
ubiquitylated)	   or	   active	   (HCF1	   not	   ubiquitylated)	   state	   (Figure	   4.13A).	   Therefore,	  
when	  wildtype	  BAP1	  is	  overexpressed,	  there	  are	  more	  active	  transcription	  activating	  
complexes	  due	  to	  enhanced	  deubiquitylation	  of	  HCF1	  by	  BAP1,	  resulting	  in	  a	  higher	  
expression	   level	   of	   β-­‐catenin	   (Figure	   4.13B);	   whereas	   overexpression	   of	   the	  
catalytically	   inactive	  mutant	   C91S	   does	   not	   alter	   the	   active-­‐inactive	   equilibrium	  of	  
the	   transcription	   complexes	   (Figure	   4.13C).	   However,	   in	   cells	   where	   endogenous	  
BAP1	   is	   largely	   depleted,	   the	   exogenous	   BAP1,	   whether	   wildtype	   or	   mutant,	   is	  
incorporated	  into	  the	  transcription	  complexes.	  These	  complexes	  are	  mostly	  retained	  
in	  the	  active	  state	  (i.e.	  not	  ubiquitylated),	  due	  to	  limiting	  level	  of	  BAP1,	  to	  maintain	  
regulation	  of	  gene	  expression,	  which	  means	  the	  deubiquitylating	  activity	  of	  BAP1	  is	  
dispensable	   (Figure	   4.13D).	   Therefore,	   in	   cells	   where	   BAP1	   was	   already	   depleted,	  
both	  the	  wildtype	  and	  C91S	  mutant	  of	  BAP1	  can	  rescue	  β-­‐catenin	  (Figure	  4.13E	  &	  F).	  	  
	  
The	   overexpression	   of	   the	   BAP1-­‐A95D	   mutant,	   which	   also	   lacks	  
deubiquitylating	   activity,	   did	   not	   rescue	   β-­‐catenin	   level.	   If	   the	   above	   mentioned	  
mechanism	  is	  true,	  this	  observation	  is	  not	  surprising	  since	  the	  expression	  level	  of	  this	  
mutant	  was	  extremely	   low,	  as	   compared	   to	   the	  other	  BAP1	  proteins.	   In	   that	   case,	  
the	  formation	  of	  BAP1-­‐HCF-­‐1	  transcriptional	  activating	  complex	  was	  limited	  to	  allow	  
efficient	   rescue	  of	  β-­‐catenin.	  However,	   it	   is	  not	  known	  and	  not	  determined	  during	  
my	  research	  project	  whether	  the	  A95D	  mutant	  can	  interact	  with	  HCF1	  or	  not.	  	  
	  
	   157	  
	  
Figure	   4.13.	   Possible	   mechanism	   of	   β-­‐catenin	   transcriptional	   regulation	   by	   the	  
BAP1-­‐HCF-­‐1	   complex.	   At	   steady	   state,	   (A)	   HCF-­‐1	   constantly	   shifts	   in	   equilibrium	  
between	  an	  activated	  deubiquitylated	  state	  and	  an	  inactive	  polyubiquitylated	  state.	  
Association	  of	  HCF-­‐1	  with	  BAP1	  leads	  to	  its	  deubiquitylation	  and	  hence	  activation	  to	  
enable	  gene	  expression.	  (B)	  When	  wildtype	  BAP1	  is	  transiently	  overexpressed,	  more	  
active	   complexes	   of	   BAP1-­‐HCF-­‐1	   are	   formed,	   thereby	   increasing	   β-­‐catenin	  
expression	  level	  whereas	  (C)	  overexpression	  of	  BAP1-­‐C91S	  mutant	  does	  not	  shift	  the	  
equilibrium	  and	  hence	  β-­‐catenin	  expression	  level	  remains	  unaltered.	  (D)	  When	  BAP1	  
is	  depleted,	   the	  active-­‐inactive	  HCF-­‐1	  equilibrium	  favours	  a	  non-­‐ubiquitylated	   form	  
of	  HCF-­‐1,	  to	  maintain	  basal	  gene	  expression.	  Therefore,	  whether	  (E)	  wildtype	  or	  (F)	  
C91S	  mutant	  of	  BAP1	  is	  overexpressed,	  both	  of	  them	  are	  recruited	  to	  form	  an	  active	  




The	   rescue	   experiment	   also	   yielded	   some	   interesting	   observations,	  
highlighting	   the	   different	   biological	   outcome	   resulting	   from	   different	   amino	   acid	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compared	  to	  wildtype	  BAP1,	  which	  is	  an	  observation	  that	  has	  already	  been	  reported	  
(Yu	   et	   al.,	   2010).	   This	   is	   also	   a	   common	   observation	   among	   catalytically	   inactive	  
mutants	  of	  DUBs,	  such	  as	  USP4	  (Wada	  and	  Kamitani,	  2006)	  and	  USP8	  (Mizuno	  et	  al.,	  
2005),	  which	  are	  unable	  to	  self-­‐deubiquitylate.	  However,	  such	  polyubiquitylation	  of	  
A95D	   mutant	   was	   not	   observed.	   It	   is	   puzzling	   how	   the	   mutation	   of	   a	   non-­‐lysine	  
residue	   would	   abolish	   ubiquitylation	   of	   a	   protein.	   A	   structure	   of	   the	  mutant	  may	  
provide	  insight	  into	  the	  loss	  of	  ubiquitylation,	  as	  a	  single	  amino	  acid	  substitution	  may	  
result	   in	  dramatic	  conformational	  change.	  For	  example,	   it	  may	  abolishes	  the	  ability	  
of	   BAP1	   to	   bind	   to	   an	   E3	   ligase.	   Understanding	   the	   distinct	   biology	   of	   the	   A95D	  
mutant	  will	   certainly	  provide	   further	   insights	   into	   the	  cellular	   roles	  of	  BAP1.	   In	   the	  
same	   light	   of	   thought,	   it	   would	   be	   interesting	   to	   investigate	   the	   biological	  
consequence	  of	  other	  BAP1	  mutations,	  such	  as	  Q36X,	  G128R,	  H169Q	  and	  S172X	   in	  
the	   UCH	   domain,	   and	   other	   mutations	   which	   are	   found	   along	   the	   C-­‐terminal	  
extension	  of	  BAP1	  (Harbour	  et	  al.,	  2010).	  	  
	  
Secondly,	  the	  expression	   level	  of	  the	  A95D	  mutant	   is	  always	   lower	  than	  the	  
wildtype	  BAP1	  and	  C91S	  mutant	   in	  all	  conditions.	  More	  intriguingly,	  the	  expression	  
level	   of	   the	   C91S	   mutant	   was	   similar	   in	   cells	   whether	   or	   not	   BAP1	   is	   depleted,	  
whereas	  the	  A95D	  mutant	  was	  not	  well	  expressed	  in	  cells	  already	  depleted	  of	  BAP1.	  
This	  indicates	  that	  the	  presence	  of	  endogenous	  BAP1	  is	  required	  to	  maintain	  protein	  
stability	  of	  the	  A95D	  mutant.	  However,	  the	  former	  scenario	  is	  less	  likely,	  because	  if	  
the	   endogenous	   BAP1	   stabilises	   the	   A95D	   mutant	   by	   deubiquitylating	   it,	  
polyubiquitylation	  of	  the	  A95D	  mutant	  would	  be	  expected,	  but	  that	  was	  not	  the	  case	  
(Figure	   4.11).	   If	   the	   low	   expression	   level	   of	   the	   A95D	   mutant	   (which	   is	   not	  
polyubiquitylated	  like	  the	  wildtype	  BAP1	  and	  C91S	  mutant)	  is	  due	  to	  a	  transcriptional	  
defect,	   it	   is	   tempting	   to	   speculate	   that	  ubiquitylation	  of	  BAP1	   itself	   is	   required	   for	  
the	  positive	  modulation	  of	   its	   transcriptional	  activity	  or	   that	  BAP1	  ubiquitylation	   is	  
essential	   for	   its	   incorporation	   into	   a	   transcriptional	   complex.	   	   ATXN3	   is	   the	   first	  
reported	  DUB	  for	  which	  its	  ubiquitylation	  enhances	  its	  own	  catalytic	  activity	  (Todi	  et	  
al.,	  2009).	  In	  addition,	  the	  different	  sub-­‐cellular	  distribution	  of	  the	  A95D	  mutant	  may	  
account	  for	  its	  distinct	  biology	  as	  well.	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In	  summary,	  the	  work	  presented	   in	  this	  chapter	  has	  revealed	  the	  functional	  
relationship	   between	   two	   proteins	   which	   are	   highly	   relevant	   to	   cancer,	   namely	  
BAP1,	   a	   tumour	   suppressor	   gene	   which	   has	   been	   found	   to	   be	   somatically	   and	  
germline	  mutated	  (see	  section	  1.2.3.6.1)	  (White	  and	  Harper,	  2012)	  and	  β-­‐catenin,	  a	  
proto-­‐oncogenic	   gene	  whose	   aberrant	   stabilisation	   leads	   to	   activation	   of	   the	  Wnt	  
signaling	   pathway,	   which	   is	   associated	   with	   tumorigenic	   phenotypes	   such	   as	  
enhanced	   cell	   proliferation	   and	   acquisition	   of	   metastatic	   features	   (see	   section	  
1.1.2.2.3)	   (Reviewed	   in	   Giles	   et	   al.,	   2003;	   Clevers,	   2004;	  MacDonald	   et	   al.,	   2009).	  
However,	  the	  mechanism	  by	  which	  the	  regulatory	  role	  of	  BAP1	  on	  β-­‐catenin,	  at	  the	  
transcriptional	  level,	  is	  exerted	  is	  not	  fully	  elucidated.	  Much	  work	  has	  been	  done	  to	  
understand	  how	  β-­‐catenin	  is	  regulated	  post-­‐translationally	  but	  our	  understanding	  of	  
the	   transcriptional	   regulation	   of	   this	   protein	   is	   very	   limited.	   Therefore,	  my	   finding	  
here	  provides	  an	   important	   insight	   into	   the	   transcriptional	   regulation	  of	  β-­‐catenin,	  
through	   the	   involvement	  of	  a	  deubiquitinase,	  BAP1.	  Of	  note,	  BAP1	   is	   regulating	  β-­‐
catenin	  gene	  expression	  at	  steady	  state	  conditions,	  and	  the	  effect	  of	  BAP1	  depletion	  
or	   overexpression	  on	   transduction	  of	  Wnt	   signaling	  has	  not	  been	  assessed.	   Taking	  
the	   face	   value	   of	   the	   data	   presented	   in	   this	   chapter,	   it	  would	   be	   anticipated	   that	  
BAP1	   plays	   a	   positive	   regulatory	   role	   in	   Wnt	   signaling,	   implying	   an	   oncogenic	  
property	   of	   BAP1.	   Accordingly,	   the	   inhibition	   of	   BAP1	   in	   the	   treatment	   of	   cancers	  
arising	   from	   aberrant	   activation	   of	   Wnt	   signaling	   is	   a	   reasonable	   and	   potentially	  
promising	   therapeutic	   intervention.	   However,	   such	   strategy	   would	   be	   a	  
contradiction	   to	   the	   clinical	   and	   experimental	   data	   collated	   so	   far,	   which	  
demonstrate	   a	   tumour	   suppressive	   role	   of	   BAP1	   and	   its	   inhibition	   may	   have	  
tumorigenic	  effect.	  This	  highlights	  the	  need	  to	  understand	  the	  molecular	  events	  that	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Chapter	  5	  
Construction	  and	  






5.1	  	   	   Introduction	  
	  
	   An	   alternative	   siRNA	   screening	   strategy	   is	   to	   use	   endonuclease-­‐prepared	  
siRNA	   (esiRNA),	   which	   potentially	   offers	   solution	   to	   issues	   with	   siRNA.	   Quite	  
regularly,	   some	   of	   the	   potential	   candidates	   identified	   in	   siRNA	   screenings	   fail	   the	  
subsequent	  validation	  phase	  of	  deconvolution	  experiments	  due	  to	  off-­‐target	  effects,	  
a	  common	  feature	  of	  siRNA.	   In	  other	  words,	  there	   is	  always	  an	   inevitable	  waste	  of	  
money,	  effort	  and	  time	  associated	  with	  siRNA	  screening.	  Therefore,	  we	  decided	  to	  
generate	  a	  human	  DUB	  endonuclease-­‐prepared	  siRNA	  (esiRNA)	  library,	  to	  (i)	  reduce	  
incidents	   of	   false	   positive	   results	   due	   to	   off-­‐target	   effects,	   (ii)	   reduce	   cost,	   (iii)	  
complement	   current	   siRNA	   libraries	   as	   an	  alternative	  option	   for	   validation	  and	   (iv)	  
serve	  as	  a	  resource	  for	  the	  ubiquitin	  community.	  To	  verify	  the	  utility	  of	  this	  resource,	  
the	   DUB	   esiRNA	   library	   generated	   requires	   diligent	   characterization	   in	   term	   of	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knockdown	   efficiency	   of	   individual	   esiRNAs,	   consistency	   of	   silencing	   effects,	  
knockdown	  efficiency	  across	  a	  variety	  of	  cell	  lines	  and	  toxicity	  to	  cells.	  	  
	  
	  
5.1.1	   	   Endonuclease-­‐prepared	  siRNA	  (esiRNA)	  	  
	  
In	   2002,	   a	   different	   flavour	   of	   siRNA,	   generated	   by	   enzymatic	   digestion	   of	  
double	   stranded-­‐RNA	   (dsRNA),	   also	   known	   as	   endonuclease-­‐prepared	   siRNA	  
(esiRNA)	  was	   introduced	   by	  Michael	   Bishop’s	   group	   and	   this	   technology	  was	   later	  
pioneered	   by	   Frank	   Buccholz	   (Yang	   et	   al.,	   2002).	   Although	   considered	   a	   novel	  
technology,	  the	  concept	  of	  esiRNA	  is	  not	  new	  since	  the	  mechanism	  of	  silencing	  is	  the	  
same	  as	   siRNA.	   	  As	  Frank	  Buccholz	   said,	   “esiRNA	  technology	  was	  developed	  at	   the	  
same	   time	   RNAi	   hit	   mammalian	   cells”.	   Basically,	   generation	   of	   esiRNA	   is	   simply	  
mimicking	  the	  in	  vivo	  digestion	  of	  dsRNA	  in	  C.	  elegans	  in	  vitro	  with	  the	  help	  of	  RNAse	  
III	   enzyme	   from	   Escherichia	   coli	   instead	   of	   the	   eukaryotic	   Dicer.	   esiRNA	   is	   a	   very	  
attractive	  alternative	   to	  chemically	   synthesized	  siRNA	  as	   it	   is	  easy	   to	  generate	  and	  
available	  at	  relatively	   low	  price,	  without	  compromising	  the	  silencing	  efficiency.	   It	   is	  
also	   suggested	   that	   if	   offers	   a	   greater	   coverage	  of	   a	   larger	  portion	  of	   endogenous	  
mRNA,	  hence	  higher	  penetrance	  of	  the	  knockdown	  effect.	  More	  importantly,	  it	  can	  
potentially	  circumvent	  the	  problem	  of	  off-­‐target	  effects	  and	  variability	  of	  chemically	  
synthesized	  siRNA,	  due	   to	   the	  high	  complexity	  of	   the	  pool	  of	   siRNAs.	  Several	   large	  
scale	   RNAi	   screening	   experiments	   have	   been	   performed	   using	   esiRNA,	   yielding	  
insightful	   information	   and	   uncovering	   promising	   targets	   for	   the	   understanding	   of	  
cellular	  processes	  such	  as	  cytokinesis	  (Zhu	  and	  Jiang,	  2005;	  Zhu	  et	  al.,	  2005)	  and	  cell	  
cycle	  (Kittler	  et	  al.,	  2004;	  Kittler	  and	  Buccholz,	  2005).	  
	  
	  
5.2	   	   Generating	  a	  DUB	  esiRNA	  Library	  
	  
	   In	   brief,	   the	   production	   of	   esiRNA	   involves	   PCR	   amplification	   of	   a	   specific	  
gene	   sequence	   followed	  by	   in	   vitro	   transcription	   to	   generate	  dsRNA	  which	   is	   then	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enzymatically	   digested	   to	   produce	   a	   pool	   of	   esiRNA,	   20-­‐25	   nucleotides	   in	   length	  
(Figure	  5.1).	  
	  
5.2.1	  	  	   	   Design	  of	  esiRNA	  Primers	  	  
	  
5.2.1.1	  	  	  	  	  	  	  	  	  	  	  	   DEQOR	  	  
	  
The	  very	  first	  step	  towards	  generating	  an	  esiRNA	  library	  is	  to	  select	  the	  gene	  
sequence	   from	  which	   the	   corresponding	  esiRNA	   is	   to	  be	  generated	  and	  hence	   the	  
required	   primer	   pairs	   complementary	   to	   the	   sequence	   at	   the	   boundary	   can	   be	  
designed	  .	  For	  this	  purpose,	  a	  web-­‐based	  tool,	  named	  DEQOR,	  was	  developed	  for	  the	  
design	   and	   quality	   control	   of	   esiRNAs	   (Figure	   5.2;	   Henschel	   et	   al.,	   2004).	   The	   first	  
step	  in	  a	  DEQOR	  analysis	  is	  a	  BLASTN	  search	  for	  the	  source	  sequence,	  so	  that	  it	  will	  
be	   excluded	   from	   subsequent	   analysis	   for	   cross-­‐silencing	   activity	   of	   the	  
corresponding	  esiRNA.	  	  Subsequently,	  an	  in	  silico	  digestion	  of	  the	  input	  sequence	  is	  
performed,	   whereby	   a	   step-­‐size	   of	   1-­‐nucleotide	   is	   used	   to	   slide	   along	   the	   entire	  
length	  of	  input	  sequence	  and	  the	  user	  can	  customize	  the	  window	  size	  for	  length	  of	  
siRNA	  to	  be	  generated,	  between	  16	  to	  25	  nucleotides.	  	  
	  
In	   the	   next	   step,	   the	   in	   silico	   generated	   pools	   of	   siRNA	   are	   analysed	   for	  
quality	   control	   purposes	   according	   to	   optimal	   siRNA	   properties.	   There	   are	   three	  
main	   criteria	   a	   siRNA	   should	   meet	   for	   potent	   induction	   of	   gene	   silencing:	   (i)	  
asymmetry	  on	  the	  5’	  and	  3’	  ends,	  with	  an	  adenine	  (A)	  or	  thymine	  (T)	  at	  its	  5’	  end	  and	  
a	  guanine	  (G)	  or	  cytosine	  (C)	  at	  the	  3’	  end;	  (ii)	  no	  more	  than	  3	  tandem	  repeats	  of	  the	  
same	   nucleotide	   present	   within	   the	   primer	   sequence;	   (iii)	   the	   GC	   content	   of	   the	  
target	   sequence	   should	   be	   within	   the	   range	   of	   20-­‐50%.	   DEQOR	   utilizes	   a	   simple	  
penalty	  scheme	  according	  to	  the	  3	  criteria	  to	  assess	  the	  quality	  of	  esiRNA	  generated:	  
(i)	  if	  the	  siRNA	  has	  a	  “reverse	  symmetry”,	  i.e.	  a	  G/C	  at	  its	  5’	  end	  and	  an	  A/T	  at	  its	  3’	  
end,	  there	  is	  a	  penalty	  of	  7	  points	  and	  a	  penalty	  of	  3	  points	  is	  imposed	  if	  a	  G/C	  or	  A/T	  
is	   present	   on	   both	   ends;	   (ii)	   a	   7	   point	   penalty	   is	   imposed	   for	   the	   presence	   of	   3	  
tandem	  repeats	  of	  the	  same	  nucleotides;	  (iii)	  if	  GC	  content	  of	  the	  siRNA	  is	  out	  of	  the	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optimal	  range,	  the	  siRNA	  is	  penalized	  with	  1	  point	  for	  every	  1%	  deviation	  below	  20%	  
GC-­‐content	  or	  1	  point	  for	  every	  2%	  deviation	  above	  50%.	  
	  
	  
Figure	   5.1.	  Workflow	   of	   esiRNA	   production.	   Selected	   esiRNA	   region	   is	   amplified	  
using	   specific	   primers	   flanked	   with	   the	   T7	   promoter	   sequence,	   which	   allows	  
transcription	  initiation	  by	  T7	  RNA	  polymerase.	  Purified	  PCR	  product	  is	  then	  subjected	  
to	   in	   vitro	   transcription	   to	   generate	   double	   stranded	   RNA,	   which	   is	   subsequently	  
digested	  by	  RNAse	  III	  to	  produce	  random	  fragments	  of	  dsRNA	  of	  20-­‐25	  nucleotides	  in	  
length.	   esiRNA	   is	  purified	  by	   ion-­‐exchange	   column	  and	   resuspended	   in	  RNAse-­‐free	  
water.	  	  
	  
In	  addition	  to	  their	  inherent	  chemical	  properties,	  siRNAs	  are	  also	  assessed	  on	  
their	  cross-­‐silencing	  activity.	  A	  penalty	  of	  10	  points	  is	  imposed	  for	  perfect	  match	  with	  
a	   non-­‐target	  mRNA	   sequence,	   and	   for	   the	   case	  of	   a	   single	  mismatch,	   the	   siRNA	   is	  
penalized	  8	  points	   for	   a	  de-­‐central	  mismatch	  and	  2	  points	   for	   a	   central	  mismatch.	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The	  default	  penalty	  setting	  of	  DEQOR	  is	  summarized	  in	  Table	  1.	  The	  penalties	  of	  all	  
siRNA	  within	   the	   esiRNA	  mixture	   are	   summed	   up	   to	   give	   a	   quality	   score,	   and	   the	  
individual	  siRNAs	  are	  ranked	  according	  to	  their	  scores	  and	  siRNAs	  with	  score	  within	  
the	  range	  of	  -­‐5	  to	  0	  are	  considered	  to	  have	  optimal	  silencing	  capacity.	  	  
	  
Table	  5.1.	  	  	  
	   Penalty	  
Sequence	  quality	  
	  	  	  	  	  	  Reverse	  asymmetry	  
	  	  	  	  	  	  Symmetry	  
	  	  	  	  	  	  Polynucleotide	  stretch	  





	  	  	  	  	  	  Perfect	  match	  
	  	  	  	  	  	  One	  mismatch	  
	  	  	  	  	  	  	  	  	  	  	  	  	  Central	  







1	  per	  2%	  deviation	  



























	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Full	  length	  BLAST	  to	  identify	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  source	  sequence	   	   	   	   	   	   	   	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Fragmentation	  with	  sliding	  




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Entire	  sequence	  
	  
	  




	   	  	  	  	  	  	  	  	  	  	  	   	   	   	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5’	  G/C,	  3’	  A/T	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐	  -­‐poly-­‐bp-­‐	  -­‐	  	  	  	  	  	  	  	  
	  
	  	  	  	  	  	   	  	  	  	  	  	  	  	  	   	   	   	   	  	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  %GC	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Penalize	  sequence	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  BLAST	  search	  against	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Figure	  5.2.	  Workflow	  of	  a	  DEQOR	  analysis.	  First,	  a	  BLAST	  search	  is	  performed	  for	  the	  
input	  query	  to	  identify	  its	  origin,	  followed	  by	  in	  silico	  digestion	  of	  the	  sequence	  into	  
fragments	   of	   16	   to	   25	   nucleotides	   which	   act	   as	   siRNA.	   Each	   of	   these	   siRNAs	   is	  
assessed	  for	  its	  chemical	  properties	  according	  to	  the	  criteria	  for	  optimal	  siRNA	  and	  is	  
penalised	   for	   any	   deviation	   from	   such	   standards.	   In	   parallel,	   the	   siRNAs	   are	  
subjected	   to	   BLASTN	   search	   to	   assess	   for	   cross-­‐silencing	   activity.	   Together,	   these	  
analyses	   allow	   evaluation	   of	   the	   input	   query	   for	   esiRNA	   generation	   and	   this	   is	  
summarised	  by	  a	  graphical	  output.	  A	  HTML	  output	  is	  also	  generated	  for	  a	  list	  of	  off-­‐
targets.	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5.2.1.2	  	   RiDDLE	  
	  
Frank	   Buccholz	   and	   his	   group,	   by	   using	  DEQOR,	   have	   created	   a	  web-­‐based	  
database	   named	   RiDDLE,	   to	   encourage	   the	   use	   of	   esiRNA	   technology(Figure	   5.3;	  
Kittler	   et	   al.,	   2007).	   RiDDLE	   serves	   as	   an	   online	   database	   for	   design	   of	   esiRNA,	  
whereby	  users	  are	  allowed	  to	  search	  for	  esiRNA	  for	  their	  genes	  of	  interest	  based	  on	  
identity	  search	  or	  annotation	  based	  search.	  	  	  
	  
Figure	   5.3.	   Search	   page	   of	   RiDDLE.	   Users	   are	   allowed	   to	   search	   for	   targets	   of	   a	  
particular	  genome,	  using	  an	  ID	  based	  search	  or	  an	  annotation	  based	  search.	  	  
	  
Various	   pieces	   of	   information	   are	   provided	   by	   a	   typical	   search	   resulton	  
RiDDLE,	   including	   esiRNA	   sequence,	   primers	   that	   amplify	   that	   region,	   efficiency	   of	  
the	  predicted	  esiRNA	  and	  annotation	  based	  on	  Gene	  Ontology	  (GO).	  Besides,	  there	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are	   links,	  which	   lead	  users	   to	  a	  BLAST	  search	   (“NCBI”,	   “Ensembl”	  and	  “UCSC”)	  and	  
other	   pages	   containing	   relevant	   information	   to	   that	   particular	   gene,	   	   including	  
paralogues	   in	   other	   species,	   homologues	   within	   the	   same	   species	   and	   genes	  
containing	  the	  same	  domain	  as	  the	  gene	  of	  interest	  (Figure	  5.4).	  	  
	  
Figure	  5.4.	  Search	  result	  for	  CYLD	  on	  RiDDLE.	  	  
	  
To	  begin	  with	  primer	  design,	  I	  have	  first	  acquired	  the	  esiRNA	  sequence	  from	  
RiDDLE	  and	  the	  information	  is	  available	  for	  90	  out	  of	  the	  93	  human	  DUBs	  (ATXN3L,	  
USP27X	  and	  USP17	  are	  not	  found	  on	  RiDDLE).	  As	  seen	  in	  Figure	  5.4,	  the	  primer	  pairs	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5.2.1.3	  	   Optimisation	  of	  Primers	  
	  
Although	  esiRNA	  regions	  predicted	  on	  RiDDLE	  are	  meant	  to	  be	  optimal,	  there	  
were	   various	   considerations	   that	   I	   had	   to	   take	   into	   account	   before	   I	   decided	   the	  
primers	   to	  be	  used:	   (i)	   template	   for	  PCR	  amplification	  of	  esiRNA	  region;	   (ii)	  primer	  
properties;	  (iii)	  quality	  control.	  	  
(i) Template	  for	  PCR	  amplification	  of	  esiRNA	  region	  
Sebastian	   Hayes,	   a	   previous	   PhD	   student	   in	   the	   lab	   has	   built	   a	  
collection	  of	  plasmids	  containing	  the	  open	  reading	  frame	  (ORF)	  of	  75	  DUBs.	  It	  
was	   desirable	   to	   use	   these	   plasmids	   as	   template	   for	   PCR	   amplification	   of	  
esiRNA	  regions	  for	  three	  reasons:	  (i)	  amplification	  from	  cDNA	  can	  sometimes	  
be	  challenging	  due	  to	  the	  high	  complexity	  of	  DNA	  content	  and	   limitation	  of	  
sensitivity	   of	   primers	   to	   amplify	   the	   correct	   sequence;	   (ii)	   for	   amplification	  
from	   cDNA,	   the	   correct	   cDNA	   library	   has	   to	   be	   used	   as	   not	   all	   genes	   are	  
ubiquitously	  expressed;	  (iii)	  the	  plasmids	  have	  all	  been	  sequence-­‐verified	  and	  
that	  gives	  almost	  absolute	  confidence	  of	  the	  identity	  of	  PCR	  product	  purified.	  	  	  
Therefore,	   I	   performed	   alignment	   analysis	   for	   the	   predicted	   esiRNA	  
sequence	   extracted	   from	   RiDDLE	   and	   the	   cloned	   ORFs.	   Among	   the	   75	  
alignments	  done,	  53	  of	   them	  had	  perfect	   sequence	  match,	  10	  of	   them	  had	  
mismatch	  within	   the	  range	  of	  1	   to	  16	  base	  pairs,	  3	  of	   them	  were	  predicted	  
using	   different	   transcripts,	   5	   of	   them	   extended	   into	   either	   the	   5’	   or	   3’	  
untranslated	  region	  (UTR)	  of	  the	  mRNA,	  3	  were	  completely	  from	  the	  UTR	  and	  
1	  was	  not	  found	  on	  RiDDLE	  database.	  	  
For	   DUBs	   whichwe	   did	   not	   already	   possess	   as	   ORFs,	   the	   esiRNA	  
regions	  were	  amplified	  from	  cDNA.	  	  
(ii) Primer	  properties	  	  
To	   achieve	   optimal	   PCR	   amplification,	   the	   physical	   properties	   of	   primers	  
were	  optimized	  according	  to	  the	  following	  criteria:	  	  
(a) complementary	  sequence	  of	  at	  least	  18-­‐20	  nucleotides;	  	  
(b) GC	  content	  within	  the	  range	  of	  50%	  to	  70%;	  
(c) no	  complementary	  sequence	  within	  primers	  themselves;	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(d) no	  more	  than	  3	  tandem	  repeats	  of	  the	  same	  nucleotides.	  	  
For	  suggested	  primers	  which	  do	  not	  conform	  to	  this	  criteria,	  I	  redesigned	  the	  
primers	  based	  on	   sequence	  around	   the	  boundary	  of	   the	  predicted	  optimal	  esiRNA	  
region,	  thereby	  minimizing	  compromises	  to	  the	  esiRNA	  quality.	  	  	  
(iii) Quality	  control	  	  
(a) Cross-­‐silencing	  activity	  and	  sequence	  coverage	  	  
Although	  DEQOR	  is	  supposed	  to	  predict	  the	  esiRNA	  region	  of	  optimal	  quality,	  
I	   double-­‐checked	   the	   cross-­‐silencing	  activity	  on	  other	  DUBs,	   coverage	   for	  different	  
transcript	  variants	  of	  the	  same	  gene	  and	  efficiency	  of	  the	  predicted	  esiRNA	  region.	  I	  
performed	   a	   BLAST	   analysis	   for	   all	   the	   esiRNA	   sequence,	   and	   found	   9	   of	   them	   to	  
have	   cross-­‐silencing	   activity	   on	   other	   DUBs	   (USP6,	   USP9X,	   USP9Y,	   USP18,	   USP32,	  
USP41,	  DUB3	  and	  DUB4)	  and	  at	  least	  2	  of	  them	  (USP2A	  and	  UCHL5)	  did	  not	  target	  all	  
the	  known	  transcript	  variants.	  	  
	  
(b)	  Efficiency	  
While	  most	   esiRNAs	   have	   predicted	   efficiency	   of	   50	   –	   60%,	   I	   set	   a	   cut	   off	  
value	  of	  40%	  and	  any	  esiRNA	  with	  predicted	  efficiency	  of	  less	  than	  40%	  is	  considered	  
to	  be	  unsatisfactory.	  With	  this	  criterion,	  I	  have	  shortlisted	  7	  esiRNAs	  (USP2A,	  USP20,	  
USP49,	   JOSD2,	   UCHL1,	  MPND,	   OTUD6A)	   with	   predicted	   low	   knockdown	   efficiency	  
and	   tried	   to	   select	   for	   a	   different	   esiRNA	   region,	  which	   should	   give	   higher	   esiRNA	  
quality	  (>40%)	  and	  that	  was	  possible	  only	  for	  3	  (USP2A,	  USP49,	  UCHL1)	  of	  the	  7.	  	  	  
For	  primers	  which	  do	  not	  qualify	   for	  any	  of	   the	  above	  criteria,	   I	   redesigned	  
the	  primers	  by	  using	  DEQOR.	  Table	  5.2	  summarises	  the	  primer	  sequences	  that	  were	  




5.2.2	  	   	   Cloning	  of	  esiRNA	  Region	  	  
	  
	   For	  DUBs	  of	  which	  the	  esiRNA	  regions	  were	  to	  be	  amplified	  from	  cDNA,	  the	  
main	   concern	   was	   the	   identity	   of	   the	   amplified	   sequence,	   since	   cDNA	   is	   a	   highly	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complex	   mixture.	   The	   size	   of	   PCR	   product,	   although	   indicative,	   does	   not	   give	  
absolute	  confidence	  of	  sequence	  identity.	  
	  
	   To	  address	  this	   issue,	  we	  decided	  to	   insert	  the	  PCR-­‐amplified	  esiRNA	  region	  
into	   bacterial	   expression	   vectors	   and	   the	   plasmids	   purified	   from	   bacteria	   are	  
subjected	   to	   sequence	   verification.	  Having	   the	  esiRNA	   region	   cloned	   into	  plasmids	  
also	  obviates	  amplification	  from	  cDNA	  in	  the	  future	  and	  the	  esiRNA	  sequence	  can	  be	  
produced	  in	  bulk	  economically	  by	  bacterial	  amplification.	  	  
	  
	   We	   have	   decided	   to	   employ	   blunt-­‐end	   cloning	   strategy,	   using	   Zero	   Blunt®	  
TOPO®	   PCR	   Cloning	   Kit	   (Invitrogen),for	   the	   direct	   insertion	   of	   PCR	   products	   into	  
pCR®4Blunt-­‐TOPO®	  vector.	  In	  the	  kit,	  the	  plasmid	  vector	  is	  linearised	  and	  is	  covalently	  
linked	   to	   the	   Vaccinia	   virus	   topoisomerase	   I	   on	   its	   3’	   ends.	   This	   is	   a	   DNA-­‐enzyme	  
intermediate	  linked	  by	  a	  phospho-­‐tyrosyl	  bond	  between	  the	  3’	  phosphate	  group	  of	  
the	  vector	  and	  tyrosine	  residue	  274	  of	  the	  enzyme	  (Figure	  5.5;	  Shuman,	  1991).	  When	  
mixed	  with	  PCR	  product	  and	  the	  mixture	  allowed	  to	  stand	  at	  room	  temperature,	  this	  
phospho-­‐tyrosyl	  bond	  is	  attacked	  by	  the	  5’-­‐hydroxyl	  group	  of	  the	  PCR	  product	  with	  
the	   formation	   of	   a	   phosphodiester	   bond	   between	   the	   3’-­‐phosphate	   group	   of	   the	  
vector	  and	  5’-­‐hydroxyl	  group	  of	  the	  PCR	  product,	  while	  the	  enzyme	  topoisomerase	  I	  
is	  released.	  	  
	   There	  are	  several	  advantages	  of	  using	  this	  cloning	  strategy:	  	  
(i) it	   is	   highly	   efficient	   and	   rapid,	   involving	   only	   a	   one-­‐step	   reaction	   of	   5	  
minutes;	  	  
(ii) no	   extra	   sequence	   needs	   to	   be	   included	   in	   the	   primer	   for	   subsequent	  
cloning;	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Figure	   5.5.	  Principle	   of	   TOPO-­‐cloning	   reaction.	   The	  5’	   hydroxyl	   groups	  of	   the	  PCR	  
product	   attack	   the	   phospho-­‐tyrosyl	   bond	   between	   the	   vector	   and	   Topoisomerase,	  
with	  a	  concomitant	  formation	  of	  phosphodiester	  bond	  between	  the	  PCR	  product	  and	  
vector.	  	  
	  
(iii) the	  vectors	  are	  engineered	  for	  sequencing	  purpose,	  allowing	  sequencing	  
using	  various	  commercially	  available	  primers,	   such	  as	  M13F,	  M13R	  and	  
T7.	  	  
	   I	   have	   amplified	   the	   esiRNA	   regions	   from	   both	   A549	   and	  MCF7	   cDNA.	   The	  
PCR	  product	  purified	  after	  DNA	  agarose	  gel	  electrophoresis	  was	  then	  used	  for	  Zero	  
Blunt	  Topo	  Cloning	  reaction.	  5µl	  of	  the	  reaction	  mixture	  was	  used	  for	  transformation	  
of	  MACH1TM	  –	  T1	  Phage	  Resistant	  E.	  Coli	  competent	  cells	  and	  cells	  were	  inoculated	  
on	  Ampicillin	  agar	  plates.	  Colonies	  which	  gave	  positive	  results	  for	  colony	  PCR	  on	  the	  
next	  day	  were	  used	  to	  set	  up	  5ml	  overnight	  culture	  for	  plasmid	  extraction.	  Extracted	  
plasmids	   were	   subjected	   to	   restriction	   digest	   before	   being	   sent	   off	   for	   sequence	  
verification.	   	   A	   glycerol	   stock	   was	   kept	   for	   each	   clone	   with	   positive	   sequencing	  
results.	  Table	  5.2	  summarises	  the	  plasmids	  that	  were	  created.	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Figure	  5.6.Verification	  of	  pCR4Blunt-­‐TOPO	  plasmids	  containing	  esiRNA	  regions.	  A.	  
Colony	   PCR	   was	   performed	   to	   check	   presence	   of	   esiRNA	   region.	   4	   colonies	   were	  
checked	  for	  each	  bacterial	   transformation	  after	  TOPO	  cloning	  reaction.	  B.	  Plasmids	  
were	   purified	   from	   bacterial	   colonies	   qualified	   for	   colony	   PCR	   and	   subjected	   to	  
restriction	  digest	  for	  verification.	  Note:	  U	  –	  uncut;	  L	  –	  linearised;	  D	  –	  double	  cut.	  	  
	  
Table	  5.2.	  	  
DUB	   Plasmid	  	   Glycerol	  Stock	  No.	  	  
DUB3	   pCR4TOPO-­‐T7-­‐DUB3	   JL069	  
DUB4	   pCR4TOPO-­‐T7-­‐DUB4	   JL055	  
USP17	   pCR4TOPO-­‐T7-­‐USP17	   JL056	  
USP22	   pCR4TOPO-­‐T7-­‐USP22	   JL057	  
USP24	   pCR4TOPO-­‐T7-­‐USP24	   JL058	  
USP31	   pCR4TOPO-­‐T7-­‐USP31	   JL059	  
USP34	   pCR4TOPO-­‐T7-­‐USP34	   JL060	  
USP35	   pCR4TOPO-­‐T7-­‐USP35	   JL061	  
USP37	   pCR4TOPO-­‐T7-­‐USP37	   JL071	  
USP40	   pCR4TOPO-­‐T7-­‐USP40	   JL063	  
USP43	   pCR4TOPO-­‐T7-­‐USP43	   JL064	  
USP51	   pCR4TOPO-­‐T7-­‐USP51	   JL072	  
ATXN3	   pCR4TOPO-­‐T7-­‐ATXN3	   JL065	  
ATXN3L	   pCR4TOPO-­‐T7-­‐ATXN3L	   JL066	  
PRPF8	   pCR4TOPO-­‐T7-­‐PRPF8	   JL070	  
OTUD1	   pCR4TOPO-­‐T7-­‐OTUD1	   JL067	  
OTUD7A	   pCR4TOPO-­‐T7-­‐OTUD7A	   JL073	  
PARP11	   pCR4TOPO-­‐T7-­‐PARP11	   JL068	  
Table	  5.2	  pCR4Blunt-­‐TOPO	  plasmids	  containing	  esiRNA	  regions	  of	  DUBs.	  
A	  
B	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5.2.3	   	   esiRNA	  Generation	  	  
	  
5.2.3.1	  	   Preparation	  of	  DNA	  of	  esiRNA	  Region	  
	  
The	  pre-­‐cloned	   full-­‐length	  DUBs	  plasmids	   and	   the	  esiRNA	   region-­‐containing	  
plasmids	   essentially	   represent	   two	   different	   sources	   of	   esiRNA	   region.	   For	   the	  
former,	   esiRNA	   regions	  were	   PCR-­‐amplified	   from	   the	   plasmids	  with	   corresponding	  
primers	   (Fig	   5.6).	  Occasionally,	   troubleshooting	   needs	   to	   be	   done	   to	   optimize	   PCR	  
conditions,	   including	   annealing	   temperature,	   primer	   concentration	   and	   plasmid	  
concentration.	   PCR	   products	   were	   purified	   from	   gel	   after	   DNA	   agarose	   gel	  
electrophoresis	   using	   Gel	   Extraction	   Kit	   from	   QIAGEN	   according	   to	   the	  
manufacturer’s	  instruction.	  	  
	  
	  
Figure	   5.7.	   PCR	   amplification	   of	   esiRNA	   region	   from	   precloned	   plasmids.	   High	  
fidelity	  DNA	  polymerase,	  Pfu	  was	  used	  for	  PCR	  reaction	  and	  reactions	  were	  set	  up	  in	  
duplicates.	  Samples	  were	  analysed	  by	  DNA	  agarose	  gel	  electrophoresis.	  	  
	  
	   	  
On	  the	  other	  hand,	  the	  esiRNA-­‐region	  containing	  plasmids	  were	  multiplied	  by	  
growing	   the	   transformed	   bacteria	   in	   culture	   medium	   and	   the	   plasmids	   were	  
subsequently	   purified	   using	   the	   QIAGEN	   Plasmid	   MiniPrep	   Kit.	   These	   plasmids	  
cannot	   be	   used	   immediately	   for	   in	   vitro	   transcription	   because	   pCR4TOPO	   vectors	  
contain	   a	   T7	   promoter	   sequence	   70bp	   downstream	   of	   the	   PCR	   insert,	   which	   is	  
flanked	  by	  a	  T7	  promoter	  sequence	  on	  both	  ends.	  This	  may	  result	  in	  a	  mixture	  of	  IVT	  
product.	   Therefore,	   the	  esiRNA	   regions	  had	   to	  be	   isolated	   from	   the	  plasmids.	   This	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was	  achieved	  by	  digestion	  using	  EcoRI	  restriction	  enzyme,	  which	  cleaves	  the	  plasmid	  
backbones	  5-­‐base	  pairs	  upstream	  and	  downstream	  of	  the	  esiRNA	  regions.	  	  Following	  
restriction	   digest,	   the	   reaction	   mixtures	   were	   separated	   by	   DNA	   agarose	   gel	  
electrophoresis	  (Figure	  5.7)	  and	  the	  desired	  esiRNA	  regions	  were	  purified	  using	  the	  
Gel	  Extraction	  Kit	  from	  QIAGEN.	  	  
	  
Concentrations	   of	   the	   purified	   esiRNA	   regions	   were	   measured	   using	   a	  
wavelength	   NanoDrop	   2000.	   During	   each	   round	   of	   such	   preparation,	   the	   DNA	   of	  
esiRNA	  regions	  purified	  are	  enough	  for	  at	  least	  10	  in	  vitro	  transcription	  reactions	  and	  




Figure	   5.8.	   EcoRI	   digestion	  of	   pCR4TOPO	  plasmids	   containing	   esiRNA	   region.	  3µg	  
plasmids	  were	  incubated	  with	  EcoRI	  at	  37˚C	  for	  2	  hours	  and	  samples	  were	  resolved	  
on	  DNA	  agarose	  gel.	  Marked	  with	  asterisks	  are	  the	  esiRNA	  regions.	  	  
	   ?
	  
5.2.3.2	  	   In	  vitro	  Transcription	  	  
	  
	   To	  generate	  double	  stranded	  RNA	  (dsRNA)	  from	  the	  purified	  DNA	  of	  esiRNA	  
region	  by	  in	  vitro	  transcription	  (IVT),	  the	  T7	  MEGAScript®	  Kit	  from	  Ambion	  was	  used.	  
Reactions	  were	  set	  up	  as	  was	  described	  by	  Kittler	  et	  al.	   in	  2007	  (see	  Chapter	  2	   for	  
details).	  The	  IVT	  reaction	  involves	  binding	  of	  T7	  RNA	  polymerase	  to	  the	  T7	  promoter	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sequence	  on	  the	  5’	  end	  and	  subsequent	  transcription	  of	  the	  esiRNA	  region.	  The	  two	  
resulting	  single-­‐stranded	  RNAs,	  which	  are	  complementary	  to	  each	  other,	  are	  allowed	  
to	  anneal	  to	  each	  other	  to	  give	  dsRNA.	  Then,	  0.4µl	  of	   IVT	  product	  was	  analysed	  by	  
DNA	  Agarose	  gel	   to	  check	  efficiency	  of	   the	   transcription	   reaction	  and	   the	   rest	  was	  
used	  for	  RNAse	  III	  digestion.	  	  
	  
	  
Figure	  5.9.	  In	  vitro	  transcription	  of	  esiRNA	  region.	  IVT	  reaction	  was	  set	  up	  with	  4µl	  
of	  PCR	  product	  and	  6µl	  of	   reaction	  mixture	   from	  MEGAScript®	  T7	  Transcription	  Kit	  
(Ambion).	  0.3µl	  of	  reaction	  product	  was	  analysed	  on	  DNA	  agarose	  gel.	  	  
	  
	  
5.2.3.3	  	   RNAse	  III	  Digestion	  	  
	  
For	   enzymatic	   digestion	   of	   the	   long	   dsRNA	   resulting	   from	   IVT	   into	   short	  
fragments	  of	  esiRNAs,	  the	  enzyme	  Ribonuclease	   III	   (RNAse	  III)	   from	  Escherichia	  coli	  
was	   used.	   	   We	   have	   received	   a	   kind	   donation	   from	   Dr.	   Dun	   Yang	   (UCSF)	   for	   the	  
plasmid	   of	   RNAse	   III	   with	   a	   glutathione	   S	   transferase	   (GST)	   epitope	   tag	   (pGEX2T-­‐
RNAse	   III).	   The	   sequence	   of	   the	   plasmid	   was	   verified	   and	   the	   plasmid	   was	  
transformed	  into	  BL21	  competent	  cells	  for	  protein	  expression.	  To	  purify	  GST-­‐RNAse	  
III,	  I	  have	  set	  up	  1L	  overnight	  culture	  of	  BL21	  cells	  and	  GST-­‐RNAse	  III	  expression	  was	  
induced	   by	   isopropyl-­‐β-­‐D-­‐thio-­‐galactoside	   (IPTG;	   0,4mM)	   for	   3	   hours.	   After	   that,	  
bacteria	   cells	   were	   pelleted	   by	   centrifugation	   and	   lysed	   by	   sonification.	   The	   cell	  
lysate	  was	  then	  spun	  at	  55000	  rpm	  and	  GST-­‐RNAse	  III,	  which	  is	  a	  soluble	  protein,	  was	  
pulled	   down	   from	   the	   supernatant	   using	   glutathione-­‐agarose	   beads.	   Next,	   GST-­‐
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RNAse	  III	  was	  retrieved	  sequentially	  from	  the	  beads	  and	  the	  eluates	  were	  combined	  
and	  dialysed	   for	   further	  purification.	   Samples	  were	   taken	  at	  every	   step	  during	   this	  
process	   and	  analysed	  by	   SDS-­‐PAGE	   to	   check	  expression	  of	  GST-­‐RNAse	   III,	   purity	  of	  
the	  pulled	  down	  product	  and	   the	  extent	  of	  degradation.	  As	   shown	  on	   figure,	  GST-­‐
RNAse	  III	  was	  also	  found	  in	  the	  cells	  pellet	  while	  remaining	  largely	  soluble,	  and	  there	  
was	   no	   significant	   degradation	   of	   the	   protein	   detected.	   Finally,	   the	   protein	  
concentration	  of	  the	  purified	  GST-­‐RNAse	  III	  was	  determined,	  diluted	  to	  1.5µg/µl	  and	  




Figure	   5.10.	  Purification	   of	   GST-­‐RNAse	   III.	   (A)	   GST-­‐RNAse	   III	  was	   induced	   in	   BL21	  
cells	   and	   was	   purified	   from	   supernatant	   of	   the	   subsequent	   bacterial	   lysates,	   by	  
incubation	  with	  glutathione	  agarose	  beads	  at	  4˚C	  for	  3	  hours.	  Bound	  GST-­‐RNAse	  III	  
was	  eluded	   sequentially	  with	  1ml	   elution	  buffer.	   Samples	  were	   taken	   for	  bacterial	  
cells	   before	   and	   after	   induction,	   crude	   lysates	   after	   sonification,	   pellet	   after	  
centrifugation	   of	   lysate	   and	   the	   eluates,	   and	   were	   analysed	   by	   SDS-­‐PAGE.(Note:	  
Arrow	  =	  GST-­‐RNAse	  III).	  (B).	  Eluates	  were	  combined	  and	  dialysed	  against	  4L	  dialysis	  
buffer.	  Dialysed	  samples	  were	  analysed	  by	  SDS-­‐PAGE	  with	  different	  loading	  volume	  
alongside	  increasing	  amount	  of	  albumin	  to	  determine	  amount	  of	  GST-­‐RNAse	  III.	  
	  
	  
The	  dsRNA	  generated	  by	  IVT	  was	  incubated	  with	  purified	  GST-­‐RNAse	  III	  in	  an	  
esiRNA	   digestion	   buffer,	   with	   a	   total	   volume	   of	   100µl.	   The	   digestion	  mixture	   was	  
kept	  shaking	  at	  900	  rpm,	  and	  for	  4	  hours	  at	  25˚C	  followed	  by	  2	  hours	  at	  37˚C.	  3µl	  of	  
A	   B	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the	   digested	   samples	  was	   analysed	   by	   DNA	   agarose	   gel	   electrophoresis	   to	   ensure	  
complete	  digestion,	  with	  a	  single	  band	  running	  around	  25bp.	  	  
	  
	  
Figure	   5.11.	  RNAse	   III	   digested	   dsRNA.	   IVT	   products	   were	   incubated	  with	   6µg	   of	  
RNAse	  III	  and	  in	  esiRNA	  digestion	  buffer.	  Samples	  were	  kept	  shaking	  at	  900rpm	  for	  4	  
hours	  at	  25˚C	  followed	  by	  2	  hours	  at	  37˚C.	  3µl	  of	  digested	  samples	  were	  resolved	  on	  
2%	  DNA	  agarose	  gel	  at	  100V	  for	  1	  hour.	  	  
	  
	  
5.2.3.4	  	   esiRNA	  Purification	  	  
	  
	   The	  digested	  esiRNAs	  were	  purified	  by	  ion	  exchange	  column	  and	  precipitated	  
with	   isopropanol.	   The	   esiRNA	   was	   spun	   down	   by	   centrifugation	   and	   dried	   in	   a	  
SpeedVac.	  The	   resulting	  pellet	  was	   resuspended	   in	  100µl	  of	  RNAse-­‐free	  water	  and	  
concentration	   was	   measured	   using	   NanoDrop.	   50µl	   of	   each	   of	   the	   esiRNAs	   were	  
distributed	  on	  2	  96-­‐well	  plates	  (Table	  5.4),	  and	  these	  serve	  as	  a	  resource	  for	  future	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Table	  5.3	  
	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   11	   12	  
A	   CYLD	   DUB3	   DUB4	   USP1	   USP2A	   USP3	   USP4	   USP5	   USP6	   USP7	   USP8	   USP9X	  
B	   -­‐	   USP10	   USP11	   USP12	   USP13	   USP14	   USP15	   USP16	   USP17	   USP18	   USP19	   USP20	  
C	   USP21	   USP22	   USP24	   USP25	   USP26	   USP27X	   USP28	   USP29	   USP30	   USP31	   USP32	   USP33	  
D	   USP34	   USP35	   USP36	   USP37	   USP38	   USP39	   USP40	   -­‐	   USP42	   USP43	   USP44	   USP45	  
E	   USP46	   USP47	   USP48	   USP49	   USP50	   USP51	   USP52	   USP53	   USP54	   USPL1	   BAP1	   UCHL1	  
F	   UCHL3	   UCHL5	   ATXN3	   ATXN3L	   JOSD1	   JOSD2	   BRCC3	   CSN5	   CSN6	   EIF3H	   EIF3S5	   MPND	  




BPL1	   OTUB1	   OTUB2	   OTUD1	   OTUD3	   OTUD4	   OTUD5	  






B	   PARP11	  
TNFAIP
3	   VCPIP1	   YOD1	  
ZRANB
1	   GFP	   	   	  
Table	  5.3	  esiRNA	  plate	  map.	  	  
Note	  :	  Generation	  of	  esiRNA	  for	  USP9X	  and	  USP41	  was	  unsuccessful;	  esiRNA	  for	  GFP	  
was	  generated	  as	  a	  non-­‐targeting	  control.	  	  
	  
?
5.2.4	  	   	   Characterisation	  of	  theDUB	  esiRNA	  library	  
	   Since	   the	   DUB	   esiRNA	   library	   is	   a	   newly	   introduced	   resource	   in	   the	   lab,	  
characterisation	  works	  were	  carried	  out	   to	  determine	   the	  knockdown	  efficiency	  of	  
chosen	  esiRNAs,	  consistency	  of	  the	  esiRNAs,	  optimisation	  of	  the	  knockdown	  protocol	  
and	  to	  compare	  knockdown	  efficiency	  across	  a	  variety	  of	  cell	  lines.	  	  
	  
5.2.4.1	  	   Checking	  knockdown	  efficiency	  of	  esiRNA	  ?
	  
	   The	   first	   obvious	   issue	   to	   address	   is	   the	   knockdown	  efficiency	  of	   individual	  
esiRNA.	  With	   the	   limited	   resource	   (in	   term	   of	   antibody	   availability	   and	   cost)	   and	  
time,	  it	  was	  not	  feasible	  to	  determine	  the	  knockdown	  efficiency	  of	  esiRNA	  generated	  
for	  each	  and	  every	  DUB.	  I	  have	  therefore	  selected	  a	  panel	  of	  esiRNAs	  for	  which	  the	  
knockdown	   efficiency	  was	   to	   be	   assessed,	   either	   by	   immunoblotting	   (IB)	   to	   check	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protein	   level	   (if	   the	  corresponding	  antibodies	  are	  available	   in	  the	   lab)	  or	  RT-­‐PCR	  to	  
check	  mRNA	  level.	  	  
?
	   I	   first	   assessed	   the	   silencing	   efficiency	   of	   several	   DUBs	   in	  MCF7	   cells	   by	   IB	  
(Figure	  5.12).	  Transfection	  was	  performed	  with	  300ng	  of	  esiRNA	  per	  1ml	  of	  medium,	  
which	  is	  equivalent	  to	  40nM	  of	  total	  oligonucleotide.	  Cells	  were	  lysed	  72	  hours	  post-­‐
transfection	  and	  equal	  amount	  of	  lysates	  were	  loaded	  for	  SDS-­‐PAGE,	  followed	  by	  IB.	  
Densitometry	   analysis	   was	   then	   performed	   using	   Image	   J	   software	   to	   determine	  
relative	  amounts	  of	  DUB	  protein	  level	  between	  control	  and	  knockdown	  samples.	  All	  
measurements	  were	  normalised	  to	  tubulin	  level.	  	  	  
	  
In	  all	  cases,	  there	  was	  a	  visible	  depletion	  of	  individual	  DUBs	  following	  esiRNA	  
transfection.	   	   Quantification	   revealed	   varying	   knockdown	   efficiency:	   USP8	   –	   75%,	  
USP15	  –	  70%,	  USP20	  –	  70%,	  USP4	   -­‐	   ~65%,	  USP47	   -­‐	   ~65%,	  USP9X	   -­‐	   ~60%,	  USP38	  –	  
~50%,	  with	  more	  than	  50%	  of	  proteins	  depleted	  in	  general.	  	  
	  
	   In	   parallel	   to	   this,	   RT-­‐PCR	   experiments	   were	   carried	   out	   to	   determine	  
silencing	  efficiency	  of	  several	  other	  DUB	  esiRNAs.	  For	  this	  purpose,	  I	  have	  designed	  
specific	   primers	   for	   a	   panel	   of	   DUBs	   summarised	   in	   Table	   5.5.	   Primer	   pairs	   were	  
designed	   to	  amplify	   regions	  not	   greater	   than	  200bp	  and	   to	   span	   introns	  wherever	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Figure	   5.12.	   Silencing	   efficiency	   of	   selected	   esiRNAs	   determined	   by	   IB.	   (A)MCF7	  
cells	  seeded	  in	  6-­‐well	  plates	  were	  transfected	  with	  100ng	  (in	  1ml	  DMEM	  medium)	  of	  
esiRNA	   targeting	   individual	   DUBs	   or	   esiRNA	   against	   GFP	   as	   negative	   control.	   Cells	  
were	   lysed	  72	  hours	  post-­‐transfection,	   resolved	  by	  SDS-­‐PAGE	  and	  transferred	  onto	  
nitrocellulose	  membrane	  for	   IB	  with	   individual	  DUB	  antibodies	  and	  tubulin.	   Images	  
were	  acquired	  by	  infra-­‐red	  scanner	  (Odyssey,	  LICOR).	  (B)	  Densitometric	  analysis	  was	  
performed	   using	   Image	   J	   software	   to	   determine	   band	   intensity	   and	   quantification	  
was	  done	  by	  normalisation	  to	  tubulin	  and	  to	  negative	  control.	  	  
?
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Table	  5.4.	  
DUBs	   Primers	   Sequence	   Exon	   Amplicon	  
size	  /	  bp	  
Fwd	   ACACGTGCTTCCTGAATGCT	   -­‐	  USP21*	  
Rev	   AGGCTTCAGTGAGCTCTTGG	   -­‐	  
128	  
Fwd	   CATTTAGCAGGGTACAGGCAA	   1	  USP27X	  
Rev	   GATGCAGTTACAGTGGTTGGG	   1	  
128	  
Fwd	   GGGACAAGATGTTACATCATCAG	   4	  UCHL3	  
Rev	   GGTTGATCCAGATTCAAAGTGC	   4-­‐5	  
126	  
Fwd	   GTATGCAAGGTAGTTCCAGAAAC	   7-­‐8	  ATXN3	  
Rev	   TGTTGCTGCTTTTGCTGCTGT	   8	  
126	  
Fwd	   GAACCCTCATCGCAGCCTC	   2-­‐3	  JOSD2	  
Rev	   GATCAGCCCCAGTACCTGG	   3-­‐4	  
148	  
Fwd	   CTGGACTAAGGATCACCATTAC	   1-­‐2	  CSN5	  
Rev	   GACCCATCACTTCCAAGTTGC	   2	  
107	  
Fwd	   GTTCTGGCAGGGGTCTCAG	   3-­‐4	  MPND	  
Rev	   GAACCCGGATCTTGCTGTC	   4	  
121	  
Fwd	   TATGACCACCAGCCGTTGAG	   -­‐	  PRPF8*	  
Rev	   CCATATTGAGTGCCTTGGACG	   -­‐	  
193	  
Fwd	   GCGAATCCAGAGATGTTTCAC	   1-­‐2	  
PARP11	   Rev	   GTTGGTATCCGGCTGAAACATG	   2-­‐3	   148	  
Fwd	   AACCTTATTTGTAGAAAAGCTTCCTAA	  	  	  	  	  	   -­‐	  STAMBPL1*	  
Rev	   GGAATGCAATCTCCTTCAGTTTC	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   -­‐	  
101	  
Fwd	   CCGACCATCTCGACCACTTC	   -­‐	  OTUD1*	  
Rev	   GTGTCCGTTACTGAGCCAACTG	   -­‐	  
251	  
Fwd	   TGCCCAGGAATGCTACAGATAC	   -­‐	  TNFAIP3*	  
Rev	   TGGACGGGGATTTCTATCACC	   -­‐	  
228	  
Table	  5.4	  DUB	  RT-­‐PCR	  primers.	  	  
*Primers	  already	  available	  in	  lab.	  	  
	  
	   In	  this	  set	  of	  experiments,	  mRNA	  of	  MCF7	  cells	  was	  harvested	  72	  hours	  post-­‐
transfection	   of	   esiRNA	   and	   was	   reverse-­‐transcribed	   to	   give	   cDNA	   for	   RT-­‐PCR	  
reactions.	  Varying	  silencing	  efficiency	  was	  observed	  across	  the	  panel	  of	  DUBs:	  more	  
than	   90%	   for	   OTUD1,	   MPND	   and	   JOSD2;	   around	   80%	   for	   TNFAIP3,	   PARP11	   and	  
STAMBPL1;	  50-­‐60%	  for	  USP21,	  PRPF8	  and	  ATXN3.	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Figure	   5.13.	   Silencing	   efficiency	   of	   esiRNA	   determined	   by	   RT-­‐PCR.	   mRNA	   was	  
extracted	   from	   MCF7	   cells	   72	   hours	   post-­‐transfection	   using	   RNA	   extraction	   kit	  
(RNeasy	  Mini	  Kit,	  QIAGEN)	  and	  1µg	  of	  mRNA	  was	  reverse-­‐transcribed	  to	  give	  cDNA.	  
RT-­‐PCR	   reactions	  were	   set	   up	   in	   triplicates,	   with	  β–actin	   as	   a	   reference	   gene	   and	  
SYBR	  green	  reaction	  mixture	  (BioRad)	  was	  used.	  RT-­‐PCR	  results	  were	  acquired	  using	  
an	   iQ5	  Real-­‐Time	  PCR	   system	   (BioRad).	   	  mRNA	   levels	   of	  DUBs	  were	  normalized	   to	  
that	  of	  the	  control	  sample.	  	  
	  
	   	  
Among	   the	   esiRNAs	   for	  which	   the	   silencing	   efficiency	  was	   assessed,	   loss	   of	  
DUBs	   at	   protein	   level	   or	   mRNA	   level	   was	   observed,	   demonstrating	   the	   ability	   of	  
esiRNA	  to	  knockdown	  gene	  of	   interest.	  However,	   in	  most	  cases,	  silencing	  efficiency	  
was	   not	   reaching	   the	   desirable	   efficiency	   of	  more	   than	   80%.	   This	   can	   possibly	   be	  
explained	   by	   the	   fact	   that	   esiRNA	   comprises	   of	   a	   complex	   mixture	   of	   siRNAs	   of	  
heterogenous	  silencing	  potency	  due	  to	  varying	  sequence	  and	  lengths.	  Such	  variation	  
in	  silencing	  capacity	  is	  not	  uncommon	  among	  chemically	  synthesized	  siRNAs.	  In	  light	  
of	  that,	  higher	  amount	  of	  esiRNA	  might	  have	  to	  be	  used	  to	  achieve	  optimal	  silencing	  
efficiency.	   Besides,	   in	   cases	   where	   silencing	   efficiency	   was	   determined	   using	   IB,	  
longer	   half-­‐lives	   of	   proteins	   of	   interest	  may	  mask	   the	   effect	   of	   knockdown	   of	   the	  
corresponding	   genes.	   Therefore,	   proteins	   have	   to	   be	   harvested	   from	   cells	   after	   a	  
longer	   time	   period	   post-­‐transfection	   for	   the	   knockdown	   effect	   to	   be	   more	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5.2.4.2	  	   Titration	  of	  amount	  of	  esiRNA	  
	   	  
	   To	   optimize	   the	   amount	   of	   esiRNA	   used	   for	   knockdown,	   I	   have	   performed	  
knockdown	  of	  USP8	  and	  USP38	  in	  MCF7	  cells	  with	  varying	  amount	  of	  esiRNA,	  from	  
25ng	  to	  300ng	  per	  ml	  of	  medium	  at	  the	  scale	  of	  a	  6-­‐well	  plate	  (Figure	  5.14).For	  both	  
DUBs,	   there	  was	   a	   dose-­‐dependent	   effect	   of	   esiRNA,	  where	   increasing	   amount	   of	  
esiRNA	   resulted	   in	   better	   silencing	   effect.	   	   It	  was	   quite	   remarkable	   that	  with	   only	  
one-­‐twelth	   (25ng)	   of	   the	   recommended	   amount	   (300ng)	   of	   esiRNA,	   a	   silencing	  
efficiency	  of	  50-­‐60%	  was	  achieved	  for	  both	  DUBs.	  Knockdown	  with	  higher	  amount	  of	  
esiRNA	  (>400ng/ml)	  was	  not	  possible	  with	  MCF7	  cells	  because	  substantial	  cell	  death	  





Figure	  5.14.	  Increasing	  silencing	  efficiency	  with	  increasing	  amount	  of	  esiRNA	  used.	  
MCF7	   cells	   were	   transfected	   with	   varying	   amount	   of	   esiRNA	   targeting	   USP8	   or	  
USP38.	  Proteins	  were	  harvested	  from	  cells	  72	  hours	  post-­‐transfection	  and	  analysed	  
by	   SDS-­‐PAGE,	   followed	  by	   IB.	  Densitometric	   analysis	  was	  performed	  using	   Image	   J	  
software	  to	  determine	  relative	  amount	  of	  protein	  and	  amount	  of	  DUB	  present	  was	  
normalized	  to	  actin	  and	  to	  the	  control.	  	  
	  
I	  have	  also	   titrated	  PRPF8	  esiRNA	  required	   for	  optimal	  knockdown	   in	  MCF7	  
and	   A549	   cells,	   by	   checking	   the	   mRNA	   level	   (Figure	   5.15).	   Although	   a	   dose-­‐
dependent	  effect	  of	  PRPF8	  esiRNA	  was	  observed	   in	  both	  cell	   lines,	  PRPF8	  silencing	  
was	  more	  efficient	  in	  MCF7	  than	  in	  A549.	  Increasing	  esiRNA	  amount	  beyond	  300ng	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Figure	  5.15.	  Increasing	  silencing	  efficiency	  with	  increasing	  amount	  of	  esiRNA	  used.	  
MCF7	  cells	  were	  transfected	  with	  varying	  amount	  of	  PRPF8	  esiRNA.	  Total	  mRNA	  was	  
harvested	   from	   cells	   72	   hours	   post-­‐transfection	   and	   mRNA	   level	   of	   PRPF8	   was	  
assessed	  by	  QPCR.	  	  
	  
Once	  again,	   these	  experiments	  highlighted	   the	   varying	   silencing	   capacity	  of	  
esiRNA	   observable	   at	   different	   amount	   of	   esiRNA	   used.	   Titration	   of	   amount	   of	  
esiRNA	   for	   individual	   DUBs	   is	   therefore	   recommended	   to	   achieve	   optimal	  
knockdown.	  However,	  in	  the	  context	  of	  a	  screen,	  this	  is	  not	  feasible	  and	  the	  maximal	  
dose	   of	   esiRNA	   a	   particular	   cell	   line	   can	   tolerate	   should	   serve	   as	   a	   guideline	   for	  
amount	  of	  esiRNA	  used.	  	  
	  
5.2.4.5	  	   Comparison	  of	  esiRNA	  knockdown	  efficiency	  across	  cell	  lines	  
	  
	   As	  shown	  in	  Figure	  5.15,	  knockdown	  efficiency	  of	  esiRNA	  varies	  between	  cell	  
lines.	  To	  assess	  this	  in	  a	  more	  comprehensive	  manner,	  I	  have	  performed	  knockdown	  
of	  USP8	  using	  esiRNA	  in	  another	  3	  cancer	  cell	  lines,	  namely	  A549,	  SW480	  and	  HeLa	  
(Figure	  5.16).	  In	  all	  cases,	  a	  knockdown	  efficiency	  of	  greater	  than	  75%	  was	  achieved,	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Figure	   5.16.	  Consistent	   knockdown	   efficiency	   of	   USP8	   across	   different	   cell	   lines.	  
Cells	  were	  transfected	  with	  300ng	  USP8	  esiRNA.	  Proteins	  were	  harvested	  from	  cells	  
72	  hours	  post-­‐transfection	  and	  analysed	  by	  SDS-­‐PAGE,	  followed	  by	  IB.	  Densitometric	  
analysis	   was	   performed	   using	   Image	   J	   software	   to	   determine	   relative	   amount	   of	  
protein	  and	  amount	  of	  DUB	  present	  was	  normalized	  to	  actin	  and	  to	  the	  control.	  
	  
	  
5.2.4.6	  	   Determining	  consistency	  of	  esiRNA	  	  
	  
	   Since	   the	  digestion	  of	  dsRNA	   into	  esiRNA	  by	  RNAse	   III	   is	  a	   random	  process,	  
there	  is	  hence	  a	  concern	  of	  consistency	  of	  esiRNA	  prepared	  from	  different	  batches.	  
To	  address	  this,	  I	  prepared	  several	  batches	  of	  esiRNA	  for	  several	  DUBs	  with	  the	  help	  
of	   a	   summer	   student	   and	   assessed	   the	   knockdown	   efficiency	   in	   SW480,	   a	   colon	  
cancer	  cell	  line.	  	  No	  obvious	  difference	  in	  silencing	  efficiency	  was	  observed	  between	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the	  fact	  that	  dsRNA	  digestion	  is	  random,	  the	  consistency	  of	  the	  esiRNAs	  generated	  is	  
preserved	  across	  batches.	  	  
	  
	  
Figure	  5.17.	  Different	  batches	  of	  esiRNA	  lead	  to	  consistent	  knockdown	  efficiency.	  
SW480	   cells	   were	   transfected	  with	   3	   different	   batches	   of	   esiRNA	   at	   300ng/ml	   for	  
each	   set	   of	   knockdown	   and	   cells	   were	   lysed	   72	   hours	   post-­‐transfection.	   An	  
additional	  negative	  control	  using	  QIAGEN	  non-­‐targeting	  siRNA	  (NTC)	  was	  also	  set	  up.	  
Lysates	   were	   resolved	   by	   SDS-­‐PAGE	   and	   transferred	   to	   nitrocellulose	   membrane	  
followed	  by	  IB	  of	  DUBs.	  Tubulin	  was	  used	  as	  loading	  control.	  Images	  were	  acquired	  
by	  Infra	  red	  scanner	  (Odyssey,	  LICOR).	  
	  
	  
5.2.5	  	   Validation	  of	  known	  DUB-­‐protein	  functional	  relationship	  
	  
	   As	  mentioned	  before,	  one	  of	  the	  aims	  to	  generate	  a	  DUB	  esiRNA	  library	  is	  to	  
provide	   an	   alternative	   tool	   to	   validate	   known	   DUB-­‐protein	   functional	   relationship	  
determined	  by	  siRNA	  knockdown.	  For	   this	  purpose,	  esiRNA	  against	  BAP1	  was	  used	  
for	  knockdown	   in	  MCF7	   to	   reconfirm	   functional	   relationship	  between	  BAP1	  and	  β-­‐
catenin	   as	   was	   identified	   in	   Chapter	   4.	   Similar	   to	   knockdown	   using	   BAP1	   siRNA,	  
depletion	  of	  BAP1	  using	  esiRNA	  also	  resulted	  in	  loss	  of	  β-­‐catenin	  at	  the	  protein	  level	  
and	  the	  knockdown	  efficiency	  was	  as	  good	  as	  knockdown	  using	  BAP1	  siRNA	  (Figure	  
5.18).	  
	  
	   187	  
	  
Figure	   5.18.	   Knockdown	   of	   BAP1	   using	   esiRNA	   resulted	   in	   β-­‐catenin	   depletion.	  
MCF7	  cells	  were	  transfected	  with	  esiRNA	  against	  GFP	  or	  BAP1	  at	  300ng/ml	  and	  were	  
lysed	   72	   hours	   post-­‐transfection.	   Lysates	   were	   resolved	   by	   SDS-­‐PAGE	   and	  
transferred	  to	  nitrocellulose	  membrane	  followed	  by	  IB	  of	  DUBs.	  Tubulin	  was	  used	  as	  
loading	  control.	  Images	  were	  acquired	  by	  Infra	  red	  scanner	  (Odyssey,	  LICOR).	  
	  
	  
5.3	  	   	   Discussion	  	  
	  
	   The	  discovery	  of	  RNA	  interference	  (RNAi)	  by	  Andrew	  Fire	  and	  Craig	  Mello	  in	  
1998	  (Fire	  et	  al.,	  1998)	  has	  sparked	  immense	  interest	  and	  intensive	  investigations	  to	  
understand	   this	   well-­‐conserved	   cellular	   mechanism.	   The	   knowledge	   derived	   from	  
these	  works	  is	  exploited	  extensively	  in	  various	  technological	  platforms,	  ranging	  from	  
functional	  genomics	  to	  biotechnology	  to	  medicine.	  	  
	  
	   RNAi	   is	  now	  a	  routine	  experimental	   technique	  employed	   in	  the	  attempts	  to	  
annotate	   gene	   functions.	   siRNA	   library	   screens	   are	   regularly	   performed	   to	   identify	  
genes	  involved	  in	  particular	  cellular	  processes	  in	  an	  unbiased	  fashion.	  As	  powerful	  as	  
the	   technology	   is,	  and	  despite	   the	  state-­‐of-­‐the-­‐art	  algorithms	  developed	  to	  predict	  
specific	   siRNA,	   there	   is	   a	   persistent	   problem	   of	   off-­‐target	   effects,	   where	   a	   non-­‐
desired	   gene	   is	   silenced.	   To	   address	   this	   issue,	   pools	   of	   siRNAs	   comprising	   of	   2-­‐4	  
siRNAs	  are	  normally	  used,	  but	  off-­‐target	  effects	  due	  to	  1	  siRNA,	  which	  dominates	  in	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the	   pool,	   is	   sufficient	   to	  mask	   the	   effects	   of	   others.	   In	   the	   case	   of	   having	   a	   false	  
positive	  hit,	   deconvolution	  experiments,	  which	   involve	   knockdown	  using	   individual	  
siRNAs	  comprise	  the	  pool,	  can	  help	  reveal	  the	  off-­‐target	  effects.	  However,	  especially	  
in	  the	  context	  of	  a	  screen,	  a	  true	  target	  will	  be	  missed	  if	  the	  off-­‐target	  effects	  result	  
in	  a	  false	  negative	  output.	  Not	  to	  mention	  these	  validation	  experiments	  are	  cost-­‐	  and	  
time-­‐intensive.	  	  
	  
	   In	   an	   effort	   to	   develop	   an	   alternative	   strategy,	   which	   can	   potentially	  
circumvent	   the	   above-­‐mentioned	   problems	   and	   is	   available	   at	   relatively	   economic	  
price,	  Frank	  Buccholz	  and	  colleagues	  have	  developed	  esiRNA.	  In	  essence,	  esiRNA	  is	  a	  
very	  complex	  pool	  of	  siRNAs	  generated	  at	  random	  following	  enzymatic	  digestion	  of	  
dsRNA	  of	  a	  carefully	  selected	  region	  within	   the	  transcript	  of	  a	  particular	  gene.	   It	   is	  
the	  complexity	  of	  this	  pool	  that	  is	  claimed	  to	  minimize	  off-­‐target	  effects,	  and	  hence	  
gives	   greater	   specificity.	   To	   demonstrate	   this,	   Kittler	   et	   al.	   silenced	  MAPK14	   using	  
chemically	   synthesized	   siRNA,	   either	   individually	   or	   with	   an	   increasing	   number	   of	  
siRNAs	  within	  a	  pool	  of	  2	  to	  12,	  where	  concentration	  of	  individual	  siRNAs	  are	  diluted	  
with	   increasing	   complexity	   of	   the	   pool,and	   performed	   a	   genome-­‐wide	  microarray	  
expression	   profliling	   (Kittler	   et	   al.,	   2007).	   A	   less	   wide	   spread	   effect	   on	   gene	  
expression	   profile	   was	   observed	   with	   increasing	   complexity	   of	   pool,	   indicating	   a	  
much	   lower	   extent	   of	   off-­‐target	   effects.	   This	   is	   because	   in	   a	   very	   complex	   pool,	  
individual	   siRNA	   is	   present	   at	   such	   a	   low	   level	   that,	   if	   any,	   off	   target	   it	   causes	   is	  
trivial.	  	  
	  
	   Given	   the	   pitfalls	   of	   siRNAs	   and	   potential	   promises	   of	   esiRNAs,	   we	   have	  
decided	   to	   adopt	   this	   technology,	   as	   a	   complement	   to	   the	   siRNA	   technique	   and	  
eventually	  as	  a	  resource	  to	  the	  research	  community.	  Compared	  to	  the	  genome	  wide	  
esiRNA	   library	   generated	   (Kittler	   et	   al.,	   2007),	   the	   construction	   of	   a	   esiRNA	   DUB	  
library	  consisting	  of	  93	  esiRNAs	  represents	  a	  more	  humble	  effort.	  	  
	  
This	   chapter	   provides	   a	   detailed	   description	   of	   the	   works	   that	   have	   been	  
carried	  out	   to	  achieve	   this	  aim.	  The	  most	   important	  and	   the	  very	   first	   step	  was	   to	  
design	  specific	  primers	  against	  desired	  esiRNA	  region.	  Firstly,	  I	  extracted	  information	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of	   predicted	   optimal	   esiRNA	   region	   for	   individual	   DUBs	   from	   the	   online	   database	  
RiDDLE.	   Then,	   I	   checked	  whether	   it	   was	   possible	   to	   amplify	   these	   esiRNA	   regions	  
from	  the	  ORFs	  already	  cloned	   in	   the	   lab	  by	   sequence	  analysis.	  Next,	   I	   checked	   the	  
cross-­‐silencing	   activity	   of	   the	   esiRNA	   regions	   by	   doing	   a	   BLAST	   analysis.	   Although	  
DEQOR	  was	   designed	   to	   penalize	   esiRNA	   regions	  with	   high	   cross-­‐silencing	   activity,	  
unexpectedly,	   a	   few	  of	   these	  esiRNA	   regions	   showed	  extensive	  overlapping	   region	  
with	   the	   other	   DUBs.	   In	   the	   most	   extreme	   case,	   the	   predicted	   esiRNA	   region	   for	  
USP6	  was	  completely	   identical	   to	   the	  coding	  sequence	  of	   its	   close	   relative,	  USP32.	  
This	  highlighted	  potential	  limitations	  with	  the	  DEQOR	  software	  and/or	  the	  validity	  of	  
information	  available	  on	  RiDDLE.	  	  Therefore,	  in	  the	  construction	  of	  esiRNA	  against	  a	  
family	   of	   proteins	   such	   as	   DUBs,	   it	   is	   ideal	   to	   manually	   check	   the	   cross-­‐silencing	  
activity	   of	   individual	   esiRNA	   regions.	   Having	   mentioned	   that,	   it	   is	   however	   quite	  
challenging	  and	  sometimes	  impossible	  to	  generate	  specific	  esiRNA	  against	  proteins,	  
which	  are	  closely	  related,	  such	  is	  the	  case	  of	  USP9X	  and	  USP9Y.	  For	  esiRNA	  regions	  
predicted	  to	  have	  low	  efficiency,	  I	  tried	  to	  select	  alternative	  regions,	  which	  are	  more	  
efficient.	  Although	  it	  was	  only	  possible	  for	  some	  of	  the	  DUBs,	  this	  once	  again	  raised	  
the	  question	  of	  reliability	  of	  information	  available	  on	  the	  RiDDLE	  database.	  Finally,	  I	  
have	  optimized	  the	  primer	  sequence	  to	  ensure	  optimal	  qualities	  of	  primers	  for	  PCR	  
amplifications.	   The	   finalized	   esiRNA	   regions	   represented	   the	   best	   compromise	  
between	   esiRNA	   efficiency,	   specificity,	   primer	   qualities	   and	   coverage	   that	   was	  
possible.	  Following	   the	  designs	  of	  primers,	   the	  generation	  of	  esiRNA	  was	   relatively	  
straight	   forward,	   although	   trouble-­‐shootings	  were	   required	  occasionally,	   especially	  
at	  the	  stage	  of	  PCR	  amplifications.	  At	  the	  end	  of	  the	  process,	  I	  have	  only	  managed	  to	  
produce	  esiRNAs	  for	  91	  out	  of	  93	  DUBs.	  Generation	  of	  esiRNA	  for	  USP9Y	  and	  USP41	  
was	  challenging,	  because	  amplification	  of	  esiRNA	  region	  from	  cDNA	  was	  difficult.	   It	  
was	  also	  possible	  that	  the	  genes	  were	  not	  expressed	  in	  MCF7	  and	  A549	  cells,	  from	  
which	  the	  cDNAs	  were	  prepared.	  	  
	  
Following	  generation	  of	  the	  esiRNAs,	  I	  have	  selected	  some	  of	  them,	  based	  on	  
the	   resource	   available	   in	   the	   lab,	   and	   tested	   their	   silencing	   efficiency	   and	  
consistency.	  All	  the	  esiRNAs	  tested	  were	  able	  to	  induce	  silencing	  of	  their	  targets,	  but	  
with	   varying	   efficiency,	   from	   50	   –	   95%.	   The	   unsatisfactory	   silencing	   efficiency	   for	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some	   of	   the	   esiRNAs	   can	   be	   a	   concern	   as	   the	   effect	   of	   knockdown	  might	   not	   be	  
prominent	  with	  residual	  amount	  of	  enzymes	  left	  in	  the	  cells.	  The	  silencing	  efficiency	  
can	  possibly	  be	  optimized	  by	  increasing	  amount	  of	  esiRNA	  or	  extending	  the	  length	  of	  
experiment.	  However,	   there	   are	   potential	   issues	   associated	  with	   toxicity	   of	   higher	  
amount	  of	  esiRNA	  and	  longer	  time	  of	  transfection,	  and	  this	  is	  also	  dependent	  on	  the	  
type	  of	  cell	   lines	  used.	   	  Moreover,	  as	  mentioned	  before,	  optimization	  of	   individual	  
DUB	  esiRNAs	  is	  not	  possible	  in	  the	  context	  of	  an	  esiRNA	  screen.	  	  
	  
Following	  the	  characterization	  of	  the	  esiRNA	  DUB	  library,	  this	  resource	  can	  be	  
included	   into	  the	  pipeline	  of	  current	  research	  projects	   in	  the	   lab,	  either	  for	  esiRNA	  
library	   screen	   or	   as	   an	   additional	   alternative	   for	   validation	   of	   hits	   identified	   from	  
siRNA	  library	  screen.	  Besides,	   in	  the	  case	  of	   large-­‐scale	  studies	  such	  as	  proteomics,	  
esiRNA	   is	   a	   much	   cheaper	   alternative.	   We	   anticipate	   with	   a	   potentially	   higher	  
specificity	   conferred	   by	   esiRNA,	   the	   annotation	   of	   functions	   of	   DUBs	   will	   become	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Chapter	  6	  
	  




6.1	   Introduction	  
	  
	   USP38	  was	  identified	  as	  a	  potential	  DUB	  involved	  in	  regulation	  of	  E-­‐cadherin.	  
USP38	  is	  1	  of	  56	  members	  of	  the	  USP	  family	  and	  is	  1042	  amino	  acids	  in	  length.	  Other	  
than	   the	   catalytic	   domain,	   there	   is	   no	   other	   predicted	   domain	   (Figure	   6.1).	   The	  
biological	   function	   of	   USP38	   is	   still	   yet	   to	   be	   annotated.	   One	   way	   of	   assigning	  
biological	  function	  of	  a	  gene	  is	  to	  identify	  interacting	  partners	  of	  the	  gene	  product.	  
By	   immunoprecipitation	   of	   epitope-­‐tagged	   DUBs	   expressed	   in	   stable	   cell	   line	  
followed	  by	  mass	  spectrometry	  analysis,	  Sowa	  and	  colleagues	  attempted	  to	  identify	  
the	   interactome	   of	   75	   human	   DUBs	   (Sowa	   et	   al.,	   2009).	   This	   report	   identified	   5	  
proteins,	  which	   co-­‐immunoprecipitated	  with	  USP38,	  namely	  60S	   ribosomal	  protein	  
L7	  (RPL7),	  40S	  ribosomal	  protein	  S12	  (RPS12),	  Galectin	  7	  (LGALS7),	  heat	  shock	  27kDa	  
protein	  1	  (HSPB1)	  and	  homeo	  box	  (H6	  family)	  3	   (HMX3).	  Table	  6.1	  summarises	  the	  
known	  functions	  of	  these	  proteins.	  While	  their	  functions	  may	  be	  regulated	  by	  USP38,	  




Figure	  6.1	  Domain	  architecture	  of	  USP38.	  USP38	  is	  1042	  amino	  acid	   in	   length	  and	  
amino	  acids	  442-­‐946	  correspond	  to	  the	  catalytic	  USP	  domain	  of	  the	  protein.	  
	  
As	  discussed	   in	  Chapter	  3,	   I	  did	  not	  manage	   to	  decipher	   the	  mechanism	  by	  
which	  USP38	  can	  affect	  E-­‐cadherin	  regulation.	  Since	  the	  biological	  function	  of	  USP38	  
is	  unknown,	   I	  was	  very	   interested	   in	  making	  a	  contribution	  towards	  the	  knowledge	  
	   192	  
about	  this	  protein	  and	  I	  anticipated	  revealing	  aspects	  of	  its	  functions	  which	  may	  be	  
relevant	  to	  E-­‐cadherin	  regulation.	  	  
	  
	   The	   works	   presented	   in	   this	   chapter	   aim	   to	   characterise	   USP38	   by	   (i)	  
sequence	   analysis	   and	   (ii)	   creating	   truncation	   mutants	   to	   see	   effect	   on	   USP38	  
localisation.	  	  
	  
Table	  6.1	  	  
Gene	  name	  	   Description	  of	  Function	   Reference	  	  
RPL7	   Component	  of	  60S	  ribosome;	  involved	  in	  regulation	  
of	  translation	  machineries.	  	  
Seshadri	  et	  
al.,	  1993.	  	  
RPS12	   Component	  of	  40S	  ribosome.	  	   Herault	  et	  al.,	  
1991.	  	  
LGALS7	   Carbohydrate	  binding	  protein	  implicated	  in	  various	  
cellular	  processes	  including	  cell	  adhesion,	  cell-­‐matrix	  
interaction,	  apoptosis	  and	  differentiation.	  	  
St-­‐Pierre	  et	  
al.,	  2012.	  
HSPB1	   Molecular	  chaperones	  that	  are	  overexpressed	  in	  
stress	  conditions.	  	  
Arrigo	  et	  al.,	  
2007	  
	  
HMX3	   A	  transcription	  factor	  essential	  for	  development	  of	  
inner	  ear	  and	  successful	  pregnancy.	  	  
Wang	  et	  al.,	  
1998.	  	  
Table	   6.1	   Function	   of	   proteins	   co-­‐immunoprecipitated	   with	   USP38.	   The	   USP38	  
interacting	   partners	   were	   identified	   by	   Sowa	   and	   colleagues	   using	   mass	  
spectrometry	  following	  immunoprecipitation	  of	  HA-­‐tagged	  USP38	  in	  HEK293T	  stable	  
cell	   line	   expressing	   HA-­‐USP38	   (Sowa	   et	   al.,	   2009).	   The	   references	   listed	   represent	  
literature	  reports	  of	  the	  function	  of	  each	  protein.	  	  	  	  	  
6.2	   Results	  
	  
	  
6.2.1	   Sequence	  Analysis	  of	  USP38	  	  
	  
	  
	   USP38	  is	  found	  expressed	  in	  a	  number	  of	  higher	  eukaryotes,	  including	  human	  
(Homo	  sapiens),	  cow	  (Bos	  taurus),	  chicken	  (Gallus	  gallus),	  rat	  (Rattus	  norvegicus)	  and	  
mouse	  (Mus	  musculus).	  By	  performing	  a	  NCBI	  conserved	  domain	  search,	  an	  insertion	  
of	  46	  aa,	  corresponding	  to	  residues	  538	  –	  583	  in	  the	  catalytic	  domain,	  unique	  to	  the	  
human	  USP38	  was	  found	  (Figure	  4.2).	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446 GLINLGNTCYMNSVIQALFMATDFRRQVLSLNL---NGCNSLMKKLQHLFAFLAHTQREAYAPRI-FFEASRPPWFTPRS  
1   GLINLGNTCYMNSVLQALFMAKDFRRQVLSLNLprlGDSQSVMKKLQLLQAHLMHTQRRAEAPPDyFLEASRPPWFTPGS  
 
        90       100       110       120       130       140       150       160 
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522 QQDCSEYLRFLLDRLHeeekilkvqashkpseilecsetslqevaskaavltetprtsdgekTLIEKMFGGKLRTHIRCL  
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            170       180 
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602 NCRSTSQKVEAFTDLSLAFCPSSSLEN 628 
115 NCNSTSARTERFRDLDLSFPSVQDLLN 141 
Figure	   6.2	   USP38	   USP	   domain	   contains	   an	   insertion	   of	   46	   amino	   acids.	   A	   NCBI	  
conserved	  domain	  search	  was	  performed	  for	  the	  USP	  domain	  of	  USP38.	  Amino	  acid	  
residues	  in	  red	  belong	  to	  human	  USP38	  and	  amino	  acid	  residues	  in	  black	  are	  residues	  
conserved	   among	   the	   USPs.	   The	   46	   amino	   acid	   residues	   highlighted	   in	   yellow	  
represent	  an	  insertion	  unique	  to	  USP38.	  	  
	  
	  
By	  multiple	  sequence	  alignment	  of	  the	  catalytic	  domains	  of	  all	   the	  USPs,	  Ye	  
and	   colleagues	   identified	   6	   boxes	   of	   amino	   acids	   residues,	   which	   are	   conserved	  
across	  the	  USPs	  (Figure	  4.3)	  (Ye	  et	  al.,	  2009).	  USP38	  has	  all	  the	  core	  components	  of	  
the	  USP	  domain.	  It	  has	  a	  complete	  catalytic	  triad,	  comprising	  of	  the	  catalytic	  cysteine	  
residue	   in	   Box	   1,	   catalytic	   histidine	   residue	   in	   Box	   5	   and	   the	   catalytic	   asparagine	  
residue	  in	  Box	  6.	  Also,	  it	  has	  2	  Cys-­‐x-­‐x-­‐Cys	  motifs	  for	  Zinc	  binding,	  in	  Box	  3	  and	  Box	  4	  
respectively.	   The	   residues	   between	   the	   boxes	   of	   conserved	   amino	   acid	   residues	  
within	   the	   catalytic	   USP	   domain	   represent	   inserted	   sequences.	   There	   is	   no	   amino	  
acid	  insertion	  between	  Box	  1	  and	  Box	  2,	  and	  the	  largest	  insertion	  of	  90	  amino	  acids	  
is	  found	  between	  Box	  3	  and	  Box	  4.	  Sequence	  alignment	  of	  USP38	  of	  different	  species	  
revealed	   that	   the	   region	   outside	   of	   the	   catalytic	   domains	   are	   also	   very	   well	  
conserved	   across	   all	   the	   species	   and	   the	   insertions	   represent	   the	   only	   variable	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Figure	  6.3	  6	  conserved	  boxes	  of	  amino	  acids	  across	  all	  human	  USPs	  in	  USP38.	  The	  
numbered	  boxes	   indicate	  each	  of	   the	  6	  conserved	  boxes.	  The	  conserved	  boxes	  are	  
interspersed	  with	   insertions	   of	   different	   sizes	   and	   the	   catalytic	   triad	   (C454,	   H857,	  




6.2.2	   USP38	  localises	  to	  the	  cytoplasm	  and	  nucleus.	  	  
	  
	  
I	  have	  generated	  several	  mutants	  of	  USP38,	   including	  a	  catalytically	   inactive	  
mutant	   USP38	   (USP38-­‐C454A)	   and	   5	   truncation	   mutants,	   namely	   USP38-­‐1-­‐441,	  
USP38-­‐441-­‐946,	   USP38-­‐1-­‐946,	   USP38-­‐441-­‐1042	   and	   USP38-­‐∆538-­‐583	   (Figure	   6.4).	  	  
The	   USP38-­‐∆538-­‐583	   mutant	   has	   its	   insertion	   between	   box	   2	   and	   3	   of	   the	   USP	  
deleted.	  Mutants	  which	  harbour	  deletion	  of	  other	  insertions	  were	  not	  created.	  The	  
ORFs	   of	   these	   truncations	   were	   all	   cloned	   into	   GFP-­‐expression	   vector	   and	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Figure	  6.4	  Truncation	  mutants	  of	  USP38.	  	  	   	  
	  
	   Figure	   6.5	   shows	   the	   expression	   level	   of	   the	   different	   GFP-­‐tagged	   USP38	  
proteins	  in	  MCF7	  cells.	  The	  wildtype	  and	  catalytically	  inactive	  mutant	  of	  USP38	  were	  
expressed	   at	   similar	   level,	   with	   the	   mutant	   running	   at	   a	   slightly	   lower	   molecular	  
weight.	   The	   USP38-­‐1-­‐441	   and	   USP38-­‐441-­‐1042	  mutants	   were	   expressed	   at	   higher	  
level	   than	   the	   full-­‐length	   proteins,	   while	   the	   expression	   levels	   of	   USP38-­‐1-­‐946,	  
USP38-­‐441-­‐946	   and	   USP38-­‐∆538-­‐583	   mutants	   were	   lower	   than	   the	   full	   length	  
proteins.	   The	   difference	   in	   expression	   levels	   of	   these	   proteins	   could	   indicate	  
differential	  stability	  of	  the	  proteins.	  	  
	  
	   Since	   the	   stability	   of	   a	   protein	   can	   be	   regulated	   by	   post-­‐translational	  
modification	   such	  as	  ubiquitylation,	   I	   decided	   to	   check	   the	  ubiquitylation	   status	  of	  
the	  different	  USP38	  proteins	   (Figure	  6.6).	  The	  wildtype	  USP38	  showed	   low	   level	  of	  
polyubiquitylation,	   whereas	   the	   C454A	   mutant	   was	   highly	   polyubiquitylated	   as	  
indicated	  by	  the	  more	  intense	  higher	  molecular	  weight	  smear.	  The	  USP38-­‐1-­‐441	  also	  
showed	   high	   level	   of	   polyubiquitylation.	   Although	   its	   molecular	   weight	   is	   much	  
smaller,	   the	   observed	   polyubiquitylation	   smear	   ran	   at	   the	   similar	   range	   to	   the	  
USP38-­‐1-­‐946,	  which	  is	  about	  500	  amino	  acids	  longer,	  indicating	  that	  this	  truncation	  
mutant	  was	  more	  heavily	  polyubiquitylated.	  The	  other	  truncations	  mutants,	  namely	  
USP38-­‐1-­‐946,	   USP38-­‐441-­‐946	   and	   USP38-­‐∆538-­‐583,	   were	   also	   modified	   by	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polyubiquitylation,	  among	  which	  the	  latter	  was	  most	  heavily	  polyubiquitylated.	  The	  
truncation	  mutant	  USP38-­‐441-­‐1042	  was	  the	  only	  protein	  that	  showed	  no	  detectable	  
polyubiquitylation.	  	  
	  
I	   then	   checked	   the	   localisation	   of	   the	   different	   USP38	   proteins.	   Wildtype	  
USP38	  is	  found	  diffused	  in	  the	  cytoplasm	  and	  in	  the	  nucleus,	  but	  was	  excluded	  from	  
nucleoli	   (Figure	   6.7).	   The	   C454A	  mutant	   showed	   similar	   localisation	   in	  MCF7	   cells.	  
The	  truncation	  mutants	  USP38-­‐1-­‐441	  was	  found	  expressed	  in	  the	  cytoplasm	  and	  the	  
nucleus,	  but	  was	  not	  completely	  excluded	   from	  the	  nucleoli.	   	  The	  USP38-­‐441-­‐1042	  
mutant	   also	   showed	   similar	   localisation	   as	   the	   wildtype	   USP38.	   All	   the	   other	  
truncation	   mutants,	   namely	   USP38-­‐1-­‐946,	   USP38-­‐441-­‐946	   and	   USP38-­‐∆538-­‐583	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Figure	   6.5	   Expression	   level	   of	   full	   length	   and	   truncated	   USP38.	  MCF7	   cells	  were	  
transfected	  with	  the	   indicated	  plasmids	  and	  were	   lysed	  on	  the	  next	  day	  with	  NP40	  
lysis	   buffer.	   Lysates	   were	   resolved	   on	   4-­‐12%	   SDS-­‐PAGE	   followed	   by	   transfer	   to	   a	  
nitrocellulose	  membrane.	  The	  resulting	  blot	  was	   immunoblotted	  for	  GFP	  and	  actin.	  	  
Blot	   images	   were	   acquired	   using	   an	   Odyssey	   laser	   scanner.	   Images	   in	   (A)	   and	   (B)	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were	   from	   the	   same	   blot,	   and	   intensity	   of	   images	   in	   (B)	   was	   adjusted	   to	   allow	  
visualisation	  of	  low	  expression	  level	  protein.	  	  	  
	  
Figure	   6.6	  Ubiquitylation	   status	   of	  wildtype	   and	  mutant	  USP38.	  MCF7	  cells	  were	  
transfected	  with	  the	   indicated	  plasmids	  and	  were	   lysed	  on	  the	  next	  day	  with	  NP40	  
lysis	  buffer.	  For	  immunoprecipitation,	  600µg	  of	  lysate	  was	  incubated	  with	  1µl	  of	  GFP	  
antibody	   and	   protein	   G	   sepharose	   beads	   in	   a	   final	   volume	   of	   480µl	   in	   a	   1.5ml	  
Eppendorf	  tube,	  for	  1.5	  hours	  at	  4˚C	  on	  a	  rotating	  wheel.	  Purified	  protein	  complexes	  
were	   resolved	   by	   4-­‐12%	   SDS-­‐PAGE	   followed	   by	   transfer	   to	   a	   nitrocellulose	  
membrane.	  The	  resulting	  blot	  was	  immunoblotted	  for	  GFP	  and	  ubiquitin	  using	  P4G7	  
antibody.	  	  Blot	  images	  were	  acquired	  using	  an	  Odyssey	  laser	  scanner.	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Figure	  6.7	  Expression	  level	  of	  full	  length	  and	  truncated	  USP38.	  MCF7	  cells	  grown	  on	  
coverslips	   were	   transfected	   with	   the	   indicated	   plasmids	   and	   were	   fixed	   using	   4%	  
PFA/PBS	   on	   the	   next	   day.	   Coverslips	   were	   then	  mounted	   onto	  mowiol	   plus	   DAPI.	  
Images	  were	  acquired	  using	  a	  Nikon	  microscope.	  (Scale	  bar	  =	  10µm)	  	  
	  
	  
Notably,	   these	   nuclear-­‐excluded	   USP38	   mutants	   all	   had	   lower	   expressionk	  
levels	   relative	   to	   the	   truncation	  mutants	  USP38-­‐1-­‐441	  and	  USP38-­‐441-­‐1042,	  which	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6.3	   Discussion	  
	  
	   USP38	   has	   a	   relatively	   simple	   domain	   architecture.	   Other	   than	   the	   USP	  
domain,	   there	   is	   no	   other	   identifiable	   domain	   structure.	   Sequence	   alignment	  
analysis	   reveals	   that	   the	   regions	   outside	   the	   USP38	   catalytic	   domain	   (amino	   acid	  
residues	   1-­‐440	   and	   947-­‐1042)	   are	   highly	   conserved	   across	   the	   species,	   indicating	  
evolutionary	  and	  functional	  significance	  of	  these	  regions.	  The	  more	  variable	  regions	  
of	  USP38	  correspond	  to	  the	  insertions	  between	  the	  6	  boxes	  of	  conserved	  residues	  in	  
the	   catalytic	   USP	   domain	   as	   defined	   by	   Ye	   and	   colleagues	   (Ye	   et	   al.,	   2009).	   This	  
suggests	  that	  these	  insertions	  occured	  at	  a	  later	  stage	  of	  evolution.	  Such	  insertion	  of	  
amino	  acid	  sequences	  between	  the	  conserved	  boxes	  of	  USP	  domain	  is	  very	  common	  
among	   the	   USPs	   and	   some	   insertions	   contain	   independently	   folded	   domains	   with	  
specific	   functions	  (Ye	  et	  al.,	  2009).	  For	   instance,	  a	  crystallography	  study	  of	  the	  USP	  
domain	  of	  CYLD	  reveals	  that	  the	   insertion	  between	  Box	  4	  and	  Box	  5	  folds	   into	  a	  B-­‐
box	  domain,	  which	  coordinates	  2	  zinc	  ions	  and	  this	  insertion	  is	  important	  for	  nuclear	  
exclusion	  of	  CYLD	   (Komander	  et	  al.,	  2008).	  By	  applying	  consensus	   fold	   recognition,	  
Zhu	  reported	  a	  large	  number	  of	  ubiquitin	  like	  (Ubl)	  domains	  among	  the	  USPs,	  some	  
of	  which	  are	  found	  in	  the	  catalytic	  USP	  domain	  (Zhu	  et	  al.,	  2007).	  The	  USPs	  with	  Ubl	  
domains	   in	   their	   catalytic	   domain	   are	   USP4,	   USP6,	   USP11,	   USP15,	   USP19,	   USP31,	  
USP32	  and	  USP43.	  These	  Ubl	  domains	  comprise	  of	  87-­‐89	  amino	  acids	  and	  are	  found	  
in	  the	  insertion	  between	  Box	  3	  and	  Box	  4	  (Ye	  et	  al.,	  2009).	  This	   is	  however	  not	  the	  
case	  for	  insertion	  in	  USP38	  and	  there	  is	  no	  predicted	  structure	  for	  the	  insertions	  in	  
USP38.	  	  
	  
	   Localisation	   of	   a	   protein	   can	   sometimes	   provide	   clue	   to	   its	   function.	   For	  
example,	  localisation	  analysis	  of	  USP21	  reveals	  its	  regulatory	  role	  in	  centrosome	  and	  
microtubule-­‐related	   functions	   (Urbé	  et	  al.,	  2012).	  However,	   this	   is	  not	   the	  case	   for	  
USP38	  as	  it	  does	  not	  show	  specific	  localisation	  to	  a	  particular	  cellular	  compartment	  
or	  site,	  and	  is	  found	  localized	  to	  the	  nucleus	  and	  cytoplasm.	  By	  creating	  truncation	  
mutants	  of	  USP38,	   I	  discovered	  that	   the	   insertion	  between	  box	  2	  and	  box	  3	  of	   the	  
catalytic	  domain	  of	  USP38	  is	  required	  for	   its	  nuclear	   localisation,	  since	  the	  deletion	  
of	   this	   region	   leads	   to	   its	  nuclear	  exclusion	   (Figure	  6.6).	   Since	  a	   consensus	  nuclear	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localisation	  motif	   K-­‐K/R-­‐X/K/R	   is	   not	   found	   in	   this	   insertion,	   it	   is	   possible	   that	   this	  
region	   associates	   with	   other	   proteins,	   which	   is	   responsible	   for	   the	   nuclear	  
localisation	   of	   USP38	   or	   perhaps	   the	   region	   contains	   a	   novel	   nuclear	   localisation	  
motif.	   This	   is	   not	   the	   first	   instance	   of	   an	   insertion	   within	   the	   catalytic	   domain	  
affecting	   localisation	   of	   a	   DUB,	   a	   USP	   in	   particular.	   For	   instance,	   the	   B-­‐box	   found	  
within	  the	  USP	  domain	  of	  CYLD	  is	  important	  for	  its	  nuclear	  exclusion	  or	  cytoplasmic	  
retention,	  since	  the	  deletion	  of	  the	  B-­‐Box	  domain	  leads	  to	  nuclear	  localisation	  of	  the	  
mutant	  protein	  (Komander	  et	  al.,	  2008).	  The	  localisation	  of	  USP33	  is	  also	  influenced	  
by	  the	  insertion	  in	  its	  catalytic	  domain	  (Thorne	  et	  al.,	  2011).	  	  The	  insertion	  between	  
box	  3	  and	  box	  4	  of	  the	  catalytic	  domain	  of	  USP33	  contains	  a	  sequence	  shared	  by	  all	  
three	  USP33	  isoforms,	  which	   is	   important	  for	  ER-­‐association.	   Interestingly,	  deletion	  
of	   a	   specific	   8	   amino	   acids	   within	   this	   insertion	   in	   USP33	   isoform	   3	   leads	   to	   its	  
exclusive	  Golgi	   localisation.	   It	  will	  be	   interesting	   to	  assess	   the	  effect	  of	  deletion	  of	  
other	  insertions	  within	  the	  USP38	  catalytic	  domain	  on	  localisation	  of	  the	  protein.	  	  	  
	  
	   Another	  region	  required	  for	  nuclear	  localisation	  of	  USP38	  is	  the	  ~100	  amino	  
acids	  C-­‐terminal	  to	  the	  catalytic	  domain	  (947-­‐1042)	  since	  the	  deletion	  of	  this	  region	  
renders	  the	  protein	  nuclear	  excluded	  (Figure	  6.6).	  The	  localisation	  of	  USP38-­‐1-­‐441	  in	  
the	  nucleus	  however	  contradicts	  this	  statement.	  One	  possibility	  is	  that	  the	  USP38-­‐1-­‐
441	   protein	   is	   relatively	   small	   that	   it	   can	   shuttle	   freely	   between	   cytoplasm	   and	  
nucleus.	  Moreover,	  the	  USP38-­‐1-­‐441	  truncation	  mutant	  is	  not	  totally	  excluded	  from	  
the	   nucleoli,	   unlike	   the	   full	   length	   USP38	   and	   the	   441-­‐1042	   truncation	   mutants,	  
potentially	  indicating	  a	  non-­‐specific	  localisation	  of	  the	  mutant	  protein.	  	  
	  
	   The	  last	  100	  amino	  acids	  of	  USP38	  also	  does	  not	  contain	  a	  consensus	  nuclear	  
localisation	  motif	   and	   therefore	   possibly	  mediates	   interaction	  with	   other	   proteins,	  
which	  assist	  in	  translocation	  of	  USP38	  into	  the	  nucleus.	  The	  fact	  that	  the	  deletion	  of	  
either	   the	   insertion	   or	   the	   last	   ~100	   amino	   acids	   prevents	   nuclear	   localisation	   of	  
USP38	  suggests	  that	  these	  2	  stretches	  of	  amino	  acids	  are	  not	  functionally	  redundant	  
and	   are	   possibly	   important	   for	   regulatory	   role	   of	   USP38	   in	   different	   processes.	  
Besides,	  the	  nuclear	  localisation	  of	  USP38	  is	  perhaps	  important	  for	  the	  regulation	  of	  
the	   protein	   itself,	   since	   the	   nuclear	   localised	   truncation	  mutants	   (USP38-­‐441-­‐1042	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and	  USP38-­‐1-­‐441)	  are	  expressed	  at	  higher	  level	  and	  the	  nuclear	  excluded	  truncation	  
mutants	   (USP38-­‐1-­‐946,	   USP38-­‐441-­‐946,	   USP38-­‐∆538-­‐583)	   are	   expressed	   at	   lower	  
level	  (Figure	  6.5	  &	  6.6).	  	  
	  
	   I	   have	   also	   revealed	   differential	   poly-­‐ubiquitylation	   status	   of	   the	   different	  
USP38	  proteins.	  The	  catalytically	  inactive	  mutant	  of	  USP38	  is	  more	  polyubiquitylated	  
than	  the	  wildtype	  USP38.	  This	  is	  typical	  to	  catalytic	  mutant	  of	  DUB,	  as	  has	  also	  been	  
demonstrated	  for	  BAP1	  in	  Chapter	  4	  (Figure	  4.16).	  However,	  intriguingly,	  despite	  the	  
higher	  level	  of	  polyubiquitylation,	  the	  C454A	  mutant	  actually	  ran	  at	  lower	  molecular	  
weight	  than	  the	  wildtype	  (Figure	  6.6	  GFP	  blot).	  The	  band	  observed	  on	  the	  GFP	  blot	  
therefore	   represents	   a	   non-­‐ubiquitin	   modified	   species	   of	   USP38	   and	   the	   slight	  
difference	  in	  molecular	  weight	  could	  be	  due	  to	  difference	  in	  phosphorylation	  status	  
of	   the	   wildtype	   and	   mutant	   USP38.	   All	   the	   nuclear	   excluded	   USP38	   truncation	  
mutants	   were	   modified	   by	   polyubiquitylation,	   among	   which	   USP38-­‐∆538-­‐583	   was	  
most	  heavly	  polyubiquitylated.	  This	  is	  probably	  because	  the	  deletion	  of	  the	  insertion	  
sequence	   also	   abolished	   the	   catalytic	   activity	   of	   the	  USP	   domain.	   The	  USP38-­‐441-­‐
1042	  mutant	  showed	  no	  detectable	  polyubiquitylation,	  but	  this	  is	  most	  likely	  not	  due	  
to	  loss	  of	  ubiquitylation	  site	  since	  the	  USP38-­‐441-­‐946	  mutant	  was	  polyubiquitylated	  
as	  well.	  Rather,	  such	  difference	  in	  ubiquitylation	  status	  of	  the	  two	  mutants	   is	   likely	  
attributable	   to	   the	   regulation	   of	   the	   protein	   which	   is	   dependent	   on	   its	   nuclear	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6.4	   Conclusion	  
	  
	   By	   creating	   truncation	  mutants	   of	  USP38,	   I	   revealed	   the	   insertion	   between	  
box	  2	  and	  box	  3	  of	  USP	  domain	  of	  USP38	  and	  the	  last	  100	  amino	  acids	  on	  C-­‐terminus	  
are	  required	  for	  nuclear	   localisation	  of	  USP38.	  As	  the	  functional	  significance	  of	   the	  
different	  insertions	  is	  unknown,	  it	  will	  be	  interesting	  to	  check	  the	  effect	  of	  deletion	  
of	   these	   insertions	  on	  USP38	   localisation.	  From	  the	  data	  presented,	   it	   is	   likely	   that	  
the	   regulation	   of	   USP38	   itself	   is	   dependent	   on	   its	   nuclear	   localisation	   as	   the	  
truncation	  mutants	  exhibiting	  nuclear	   localisation	  has	  higher	  expression	   level	  while	  
those	  which	  are	  nuclear	  excluded	  has	   lower	  expression	   level.	  To	  annotate	  function	  
of	   USP38,	   one	   potential	   approach	   is	   to	   identify	   its	   interacting	   partners	   by	   mass	  
spectrometry	   or	   Y2H.	   Alternatively,	   global	   transcriptional	   analysis	   by	   RNA	  
sequencing	   or	   DNA	  microarray	   following	   USP38	   siRNA	   depletion	   can	   help	   identify	  












	   This	   chapter	   aims	   to	   summarise	   the	   findings	   reported	   in	   this	   thesis	   and	   to	  
outline	   future	   perspectives.	   	   There	   are	   two	   main	   strands	   of	   this	   PhD	   research	  
project,	   which	   are	   to	   identify	   DUBs	   involed	   in	   regulation	   of	   the	   AJ	   components,	  
namely	  E-­‐cadherin	  and	  β-­‐catenin.	  	  
	  
	   It	  was	  found	  in	  MCF7	  cells	  that	  E-­‐cadherin	  is	  constitutively	  degraded	  via	  the	  
lysosomal	   pathway.	   This	   observation	   is	   unique	   to	   MCF7	   cells,	   amongst	   cell	   lines	  
(DU145	   and	   A549	   cells)	   tested,	   suggesting	   different	   regulatory	   mechanisms	   of	   E-­‐
cadherin	   at	  work	   in	  different	   cell	   types.	  Although	   it	   is	   not	  within	   the	   scope	  of	   the	  
research	  aims	  of	   this	  project,	   it	  would	  be	   interesting	   to	  understand	   the	  underlying	  
genetic	   programme	   that	   dictates	   such	   mode	   of	   E-­‐cadherin	   regulation	   and	   the	  
biological	   significance	   of	   this	   mechanism	   to	   MCF7	   cells.	   Stemming	   from	   the	  
constitutive	   lysosomal	   turnover	   of	   E-­‐cadherin	   in	   MCF7	   cells,	   a	   siRNA	   DUB	   library	  
screen	   was	   performed	   and	   USP38	   was	   identified	   as	   a	   leading	   target	   involved	   in	  
regulation	   of	   E-­‐cadherin	   lysosomal	   turnover.	   Its	   depletion	   resulted	   in	   a	   significant	  
increase	  in	  the	  full	  length	  to	  80kDa	  E-­‐cadherin	  ratio.	  Notably,	  the	  loss	  of	  USP38	  also	  
resulted	   in	  a	  decrease	   in	   total	   E-­‐cadherin	   level	  but	   the	   cells	   still	   retained	  adhesive	  
properties.	   This	   loss	   of	   E-­‐cadherin	   at	   the	   protein	   level	  was	   not	   accompanied	   by	   a	  
decrease	  in	  E-­‐cadherin	  mRNA	  level	  and	  was	  not	  due	  to	  enhanced	  protein	  turnover,	  
indicating	   USP38	   does	   not	   regulate	   E-­‐cadherin	   at	   the	   transcriptional	   or	   the	   post-­‐
translational	   level.	   The	   observed	   loss	   of	   E-­‐cadherin	   was	   therefore	   likely	   due	   to	   a	  
defect	   in	   its	   translation.	   Otherwise,	   there	   could	   be	   a	   more	   intricate	   regulatory	  
network	   involving	   USP38	   and	   E-­‐cadherin	   that	   the	   experimental	   results	   obtained	  
herein	  cannot	  be	  interpreted	  straightforwardly.	  	  One	  indication	  of	  this	  came	  from	  an	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observation,	  obtained	  at	  late	  stage	  of	  the	  research	  project,	  that	  the	  siRNA	  depletion	  
of	  USP38	  resulted	  in	  a	  more	  dramatic	  decrease	  in	  β-­‐catenin	  level.	  	  
	  
For	   future	   work,	   a	   rescue	   experiment	   needs	   to	   be	   done	   to	   definitively	  
confirm	   the	   functional	   relationship	   between	   E-­‐cadherin	   and	   USP38.	   Since	   USP38	  
knockdown	   also	   leads	   to	   loss	   of	   β-­‐catenin,	   it	   is	   necessary	   to	   check	   if	   they	   are	  
functionally	   related	   and	   also	   to	   assess	   the	   effect	   of	   USP38	   knockdown	   and/or	  
overexpression	   on	   other	   AJ	   components	   or	   known	   regulators	   of	   the	   AJ.	   Besides,	  
experiments	  need	  to	  be	  done	  to	  determine	  the	  integrity	  and/or	  functionality	  of	  the	  
translational	  machinery	   after	   USP38	   depletion,	   since	   the	   ribosomal	   proteins,	   RPL7	  
and	  RPS12	  are	  found	  co-­‐immunoprecipitated	  with	  USP38	  (Sowa	  et	  al.	  ,	  2009).	  	  
	  	  
In	  parallel	   to	  the	  E-­‐cadherin	  related	  work,	  BAP1	  was	   identified	  as	  a	  positive	  
regulator	   of	   β-­‐catenin,	   since	   silencing	   of	   BAP1	   expression	   resulted	   in	   loss	   of	   β-­‐
catenin.	   Subsequent	   work	   demonstrated	   that	   BAP1	   regulates	   β-­‐catenin	   at	   the	  
transcriptional	   level.	   BAP1	   is	   now	   a	   well-­‐established	   tumour	   suppressor	   and	   has	  
been	   found	  mutated	   in	   a	   variety	   of	   cancers	   (see	   section	   1.2.3.6.1).	   On	   the	   other	  
hand,	  β-­‐catenin	   is	   a	   proto-­‐oncogene,	  whose	   aberrant	   stabilisation	   is	   implicated	   in	  
many	   cancers	   (see	   section	   1.1.2.2.3).	   Thus,	   this	   observed	   functional	   relationship	  
between	   a	   key	   tumour	   suppressor	   and	   a	   potent	   oncogene	   is	   of	   great	   research	  
interest	   and	  may	  hold	  potential	   therapeutic	   values.	   Future	  works	   should	  definitely	  
investigate	  the	  mechanism	  by	  which	  BAP1	  regulates	  β-­‐catenin	  expression.	  The	  first	  
step	   towards	   this	   goal	   is	   to	   assess	   the	   knockdown	   effect	   of	   HCF1	   and	   other	  
transcriptional	   proteins	   (co-­‐immunoprecipitated	   with	   BAP1)	   on	   β-­‐catenin	  
expression.	   BAP1	   is	   known	   to	   associate	   with	   transcriptionally	   active	   chromatin	  
(Machida	  et	  al.	  ,	  2009;	  Yu	  et	  al.	  ,	  2010).	  Therefore,	  a	  chromatin-­‐immunoprecipitation	  
(ChIP)	   assay	   should	   be	   performed	   to	   determine	   (by	   PCR)	   the	   presence	   of	   the	  
promoter	   or	   regulatory	   sequence	   of	   the	   CTNNB1	   gene	   encoding	   β-­‐catenin.	   BAP1	  
specific	   inhibitors	   offer	   an	   alternative	   strategy	   to	   assess	   BAP1-­‐dependence	   of	   β-­‐
catenin	  expression.	   From	  a	   therapeutic	  point	  of	   view,	   it	   is	   interesting	   to	   know	   the	  
effect	  of	  BAP1	  inhibition	  in	  cancers	  arising	  from	  aberrant	  β-­‐catenin	  stabilisation.	  It	  is	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also	  of	  equal	  importance	  to	  assess	  effect	  of	  BAP1	  inhibition	  in	  normal	  cells,	  since	  the	  
inhibition	  of	  a	  tumour	  suppressor	  may	  have	  tumorigenic	  consequences.	  	  Besides,	  the	  
regulatory	  role	  of	  BAP1	  in	  the	  context	  of	  Wnt	  signaling	  was	  not	  investigated	  and	  this	  
is	  another	  outstanding	  question	  to	  be	  addressed.	  	  
	  
	   Stemming	  from	  the	  interest	  to	   identify	  DUBs	  regulating	  the	  AJ	  components,	  
additional	   research	   effort	   was	   directed	   towards	   characterising	   two	   DUBs,	   namely	  
USP38	  and	  BAP1.	  	  
	  
USP38	   is	  a	  DUB	  with	  unknown	  function	  and	  has	  no	  other	  predicted	  domain	  
except	   for	   its	   USP	   domain.	   Preliminary	   characterisation	   work	   showed	   that	   USP38	  
localises	  to	  cytoplasm	  and	  nucleus.	  The	  nuclear	   localisation	  of	  USP38	  is	  dictated	  by	  
an	  insertion	  of	  46	  aa	  in	  its	  USP	  domain	  and	  the	  C-­‐terminal	  100	  aa.	  Of	  note,	  these	  two	  
regions	   are	   functionally	   redundant	   and	   therefore	   may	   regulate	   distinct	   nuclear	  
localisation-­‐dependent	   activities	  of	  USP38.	   The	  particular	   finding	   in	   relation	   to	   the	  
insertion	   in	   the	   USP38	   USP	   domain	   provides	   yet	   another	   instance	   of	   amino	   acid	  
insertion	   between	   the	   conserved	   boxes	   of	   the	   catalytic	   domain	   representing	   a	  
determinant	   of	   protein	   localisation.	   The	   functional	   roles	   of	   USP38	   have	   not	   been	  
thoroughly	   investigated.	   In	   this	   regard,	   for	   future	   functional	   annotation	   of	   USP38,	  
one	   approach	   is	   to	   perform	   gene	   expression	   profiling	   following	   USP38	   siRNA	  
depletion.	  Bioinformatic	  analysis	  of	  USP38,	  to	  determine	  potential	  functional	  motif,	  
such	   as	   phosphorylation	  motif,	   combined	  with	   cellular	   or	   biochemical	   studies,	  will	  
certainly	  facilitate	  elucidation	  of	  USP38	  function.	  
	  
On	   the	   other	   hand,	   the	   rescue	   expriment	   and	   preliminary	   works	   to	  
characterise	  BAP1	  have	  also	  led	  to	  some	  interesting	  observations,	  which	  are	  mainly	  
associated	   with	   the	   BAP1-­‐A95D	   mutant:	   The	   expression	   level	   of	   this	   mutant	   is	  
dependent	   on	   the	   presence	   of	   endogenous	   BAP1	   and	   it	   is	   not	   polyubiquitylated,	  
unlike	   the	   wildtype	   and	   C91S	   mutant.	   Moreover,	   this	   mutant	   exhibits	   a	   different	  
subcellular	  distribution.	  The	  study	  of	  this	  mutant	  may	  provide	  important	  insights	  into	  
the	  biology	  of	  BAP1.	  One	  of	  the	  first	  questions	  to	  be	  answered	  is	  whether	  the	  A95D	  
mutant	   is	  able	  to	  form	  complex	  with	  the	  known	  interacting	  partners,	  such	  as	  HCF1	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and	   YY1.	   It	   is	   also	   interesting	   to	   know	  whether	   the	   ubiquitylation	   status	   of	   BAP1	  
affects	  its	  activity	  and	  association	  with	  other	  proteins	  or	  not.	  	  A	  SILAC	  (stable	  isotope	  
labeling	   by	   amino	   acid	   in	   cell	   culture)	  mass	   spectrometry	   experiment	   to	   compare	  
immunocomplexes	  associated	  with	  wildtype	  BAP1	  and	  the	  A95D	  mutant	  may	  reveal	  
unique	  interacting	  partners.	  In	  addition,	  mass	  spectrometry	  experiment	  can	  be	  done	  
to	   identify	   cytoplasmic	   binding	   partners	   of	   BAP1,	   since	   the	   proteins	   found	   in	  
complex	  with	  BAP1	  so	  far	  are	  mostly	  nuclear	  transcriptional	  proteins	  (Machida	  et	  al.	  
,	  2009;	  Yu	  et	  al.	  ,	  2010).	  	  
	  
To	   complement	   the	   human	   DUB	   siRNA	   library	   that	   is	   available	   in	   our	  
laboratory,	  a	  human	  DUB	  esiRNA	  library	  was	  developed.	  Quality	  control	  experiments	  
upon	   a	   sample	   of	   selected	   DUBs	   have	   confirmed	   the	   ability	   of	   esiRNAs	   to	   induce	  
silencing	  of	   target	   genes,	   although	  with	   varying	   efficacy.	   The	  use	  of	   an	   alternative	  
region	   within	   the	   transcript	   for	   esiRNA	   production	   may	   improve	   knockdown	  
efficiency	   in	   these	   cases.	   Additionally,	   experiment	   conditions	   for	   efficient	  
knockdown	   in	   various	   cell	   lines	   were	   optimised.	   The	   generation	   of	   the	   esiRNAs	  
allows	  an	  alternative	  screening	  strategy,	  which	  arguably	   leads	   to	   less	   false	  positive	  
hits	   (i.e.	   less	   off-­‐target	   effects)	   and	   can	   therefore	   speed	   up	   the	   process	   of	   target	  
identification.	   Moreover,	   it	   offers	   an	   extra	   layer	   of	   validation	   to	   siRNA	   screen	  
experiments.	  Indeed,	  use	  of	  esiRNA	  against	  BAP1	  has	  validated	  the	  downregulatory	  
effect	  of	  siRNA	  depletion	  of	  BAP1	  on	  β-­‐catenin	  in	  MCF7	  cells.	  In	  addition,	  the	  use	  of	  
esiRNA	   is	   highly	   cost-­‐effective	   and	   this	   is	   especially	   desirable	   for	   large-­‐scale	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Appendix	  5.1.	  Primers	  to	  amplify	  esiRNA	  region	  ?
	  
	  
Table	  S5.1	  Primers	  to	  amplify	  esiRNA	  region.	  	  
DUBs	   Reference	  
sequence	  




F	   TGATGAAGATTGTGGCGTGTT	  CYLD	   NM_015247	  	   R	   TGAACCTTTGTCCCCAACACC	   55.2	   418bp	  
F	   CTGAAGACACAGACAGGCGAG	  DUB3*	   NM_201402	  	   R	   CACTGGCACACAAGCAGAGC	   45.1	   406bp	  
F	   CCATAGAGGCAAGCAGGAAG	  	  DUB4*	   NM_212553	  	   R	   CCAGCACAGCATAGAGGACA	  	   55.1	   512bp	  
F	   TTTGCTGCTAGTGGTTTGGAG	  USP1	   NM_003368.4	  	   R	   TGGCTGTGTATTTCCACCAAC	   66.2	   360bp	  
F	   CCAATGATGTGGTGAGCCCAT	  USP2A	   NM_004205.4	  	   R	   GCAGCGACAGCATGTTGGCT	   64.3	   449bp	  
F	   CAATGCGCTACCTTTTGGAC	  USP3	   NM_006537.2	  	   R	   TGTCTAGGCCTCTCAGTGGAA	   49.9	   518bp	  
F	   TCCACCTCAAACGTTTCTCC	  	  USP4	   NM_003363.3	  	   R	   CCTCCATCAGAGGAACCAGA	  	   56.5	   358bp	  
F	   ATGCCCAGGAGTTCTTCCTT	  	  USP5	   NM_003481.2	  	   R	   ACCCAGTCTAAGCCGAAGGT	  	   43.1	   445bp	  
F	   CCGTTGGAATCAACAGCAGC	  USP6	   NM_004505.1	  
	   R	   CCTCCTCAGGCAGATAAAGG	   51.1	   498bp	  
F	   TACGTGACTTGCTCCCAGTT	  	  USP7	   NM_003470.2	  
	   R	   ACCTGGGCCATCCCTATAAC	  	   58.0	   413bp	  
F	   TCTGGACCAGCTCTTACTGGA	  	  USP8	   NM_005154	  
	   R	   GTTTCTGCCAGGCATGTTCT	   62.9	   427bp	  




	   R	   CATTCTGCTGAATTGGCATT	  	   66.8	   351bp	  
F	   GGGCTCAGAGGTGAAACTGA	  	  USP9Y*	   NM_004654	  
	   R	   AAGCTCGCTAATTCCCTCCT	   56.1	   526bp	  
F	   GCTGATCAATAAAGGGAACTGG	  	  USP10	   NM_005153.2	  
	   R	   CAACATTTCCTCATGAAGTCCA	   53.3	   373bp	  
F	   AAGCTGGTTCCTTGTGGAGA	  	  USP11	   NM_004651.3	  
	   R	   TCGAGAACCGTGATGTGTGT	  	   47.3	   489bp	  
F	   GTCTCCAAATTCGCCTCCATC	  USP12	   NM_182488.2	  
	   R	   CGTTGGGTCTGGTGTGCTG	   56.1	   492bp	  
F	   AGATCGCCTGATGAACCAAT	  	  USP13	   NM_003940.2	  
	   R	   TGCATTGGCATTATTCTCCA	   51.3	   439bp	  
F	   TGGAGTTACCATGTGGATTGA	  	  USP14	   NM_005151.3	  
	   R	   TTGCTTCCAATTTCTGTTGC	  	   57.4	   351bp	  
USP15	   NM_006313.1	   F	   TCCGCTTACCAAACCTATGC	  	   59.7	   551bp	  
	   262	  
	   	   R	   CCTGGCTGGATTCATCATCT	  	   	   	  
F	   ACCTAACGGAAGGGAGCAAT	  	  USP16	   NM_006447.1	  
	   R	   TGTAAACATGCTTCCTTTCACC	  	   62.5	   351bp	  




	   R	   GGTGGTCTCTCTTGAGCTCT	   58.0	   449bp	  
F	   GTGCTTCTGTGAGAACTGTG	  USP18	   NM_017414.3	  
	   R	   GCACTCCATCTTCATGTAAACC	   59.1	   436bp	  
F	   CCCACAGTGCAAACAGCAC	  	  USP19	   NM_006677.1	  
	   R	   GGCTCTCGTCTACCGTTGTC	  	   42.0	   356bp	  
F	   CAAGCTCCATTCAGCCATCT	  	  USP20	   NM_006676.6	  
	   R	   TGGCAGTAGGCGATGTAGTG	  	   32.0	   489bp	  
F	   CGGTCCTCTGAGCCTTTCTA	  	  USP21	   NM_012475.4	  
	   R	   TTCAGGAACTCTTGGGCATC	  	   44.4	   356bp	  
F	   GCTCACTATGAAGAAACTGCC	  USP22*	   NM_015276.1	  
	   R	   CTACTCGTATTCCAGGAACTG	   52.1	   394bp	  
F	  
CACAGAATTATCTTTTTAATGCT
TG	  USP24*	   NM_015306	  
	   R	  
GGGAGCTGGTATAAATGAGTG
AA	  	   63.4	   353bp	  
F	   TTCAGGAAAATCAGGCCAAG	  	  USP25	   NM_013396.3	  
	   R	   GCAGCAACTGATGAAGGTGA	  	   60.8	   474bp	  
F	   TGAGCACAAGACTTCCGTTG	  	  USP26	   NM_031907.1	  
	   R	   CCAGCTTTGTGGAACTGACA	  	   55.2	   522bp	  
F	  
GGAAGCAGTGCCAAAATCAAAT
G	  USP27X*	   NM_01145073	  	   R	   TCAGTAGGCTTGTGTGTTCAT	   66.6	   489bp	  
F	   GCTCCACGAACAGTCACAGA	  	  USP28	   NM_020886.2	  
	   R	   AAACCGCCAGTTATCCTCCT	  	   64.4	   480bp	  
F	  
TGTAAGCAGAAGAGTTGTGTTG
C	  USP29	   NM_020903.2	  
	   R	   CTTTGTAGGTCGGCATTCTTG	  	   73.6	   350bp	  
F	   TGAAGAACAGGATGCTCACG	  	  USP30	   NM_032663.3	  
	   R	   TCCCTTGGCTTCAATCTTTG	  	   52.0	   412bp	  
F	   TCTGAAGCCACCATCAGAGA	  	  USP31*	   NM_020718.3	  
	   R	   CAAAAATGCAGTCGCTTTCA	  	   47.1	   419bp	  
F	   GAATGCTCCACGTGGTGGATG	  USP32	   NM_032582.3	  
	   R	   CCTGCAACAGGCTGATAACC	   71.0	   434bp	  




NM_201624	   R	   CAGACACCCTGTCACAAGTCA	  	   65.2	   365bp	  
F	   GGATCCCGTACCACTTAGAC	  USP34*	   NM_014709	  
	   R	   CCTCATTGCTAGATCCATCAC	   70.5	   470bp	  
F	   CGGATCTGTATGAGCCTGTCAT	  USP35*	   NM_020798.2	  
	   R	   CGAGCTGGACTGCTTGAGTTTC	   43.1	   491bp	  
	   263	  
F	   GAAGATCACCAAGGATGTAGG	  USP36	   NM_02590.3	  
	   R	   GGTGGAGCCATTCCTGGATAT	   57.1	   475bp	  
F	   GGTAATCCGGGTAGAGGATC	  USP37*	   NM_020935	  
	   R	   GAGGAACTGGCTGAGGAAG	   72.8	   442bp	  
F	   GAGGCGTTCCATTTGATTGT	  	  USP38	   NM_032557.5	  
	   R	   GCCAGAAAGGCAAAAAGATG	  	   58.1	   452bp	  
F	   CAACCTCCACACCCTCAAGT	  	  USP39	   NM_006590.2	  
	   R	   AGCATCTCATGGGGAGACAC	  	   58.8	   406bp	  
F	   TAAACCCGATGCAAAGGTTC	  	  USP40*	   NM_018218	  
	   R	   ACCAGCCTGTCACAAGTTCC	  	   60.6	   429bp	  
F	   CAGTGTCAGTACGTGCATCC	  USP41	   XM_036729	  
	   R	   GGTGAGCATGCTGCTGTTTC	   53.4	   519bp	  
F	   TTTATCGGACCACAGCTTCC	  	  USP42	   NM_032172.2	  
	   R	   ATCGTAGATGCGTTCGAGGT	  	   61.7	   365bp	  
F	   ACCTTACCGGAGTCCAGCTT	  	  USP43*	   XM_934221.1	  
	   R	   ACCAGCCTCATCTTGTTTGC	  	   50.5	   355bp	  
F	   TTCTGGGACTTGTCATTGGA	  	  USP44	   NM_032147.2	  
	   R	   GTAGTGCCCTGAGCCAAATC	   55.5	   438bp	  




	   R	   CATAGAAAAGAAGGTAGGCTTG	   68.3	   419bp	  
F	   CAGGGAACGCTTACCAATGA	  USP46	   NM_022832.3	  
	   R	   GATATATCTGACGTCAGGCC	   61.1	   536bp	  
F	   TAGGTGGCGTCAAGTCAACA	  	  USP47	   NM_017944	  
	   R	   CCGATCCAGGAGTTTCCATA	  	   63.5	   401bp	  




	   R	   GCCATTTCAATACACCACTCC	  	   62.1	   352bp	  
F	   AGCTGCTCAGTCAGGTCACAT	  USP49	   NM_018561.3	  
	   R	   ACCTCCCTCTGTGTTGTAGC	   64.0	   536bp	  
F	   TCACTGGCTTGTGGAACTTG	  USP50	   NM_203494.3	  
	   R	   CAAACAGCTGGGTGATGATG	  	   54.4	   432bp	  
F	   CTACCAGCGTTTCGTTTGGAG	  USP51*	   NM_201286	  
	   R	   GGAATATGGGTAAGTGCCTGG	   63.5	   513bp	  
F	   GATTACCTGCTGGATGAGAATG	  USP52	   NM_014871.3	  
	   R	   CCTGTGGGTTCACAGAATTGG	   55.5	   503bp	  
F	   TCTAGCAAGGATCCGAGTTTT	  	  USP53	   NM_019050.2	  
	   R	   CCACGTTCTTTATTTAGGTTGC	   56.9	   359bp	  
F	   GGTCGTGGTAGTGTACAAGG	  USP54	   NM_152586.3	  
	   R	   GATTGCAAAGGGAAGTGGTGG	   62.4	   547bp	  
F	   CACATGCTCATGCTGCTTCAG	  USPL1	   NM_005800.4	  
	   R	   GGTCCTGTCTCAGATGTGTG	   68.4	   546bp	  
F	   CTCGTGGAAGATTTCGGTGT	  	  BAP1	   NM_004656.2	  
	   R	   GTAGACCTTCAGCCCATCCA	  	   43.4	   516bp	  
UCHL1	   NM_004181.3	   F	   GCAGATTGAAGAGCTGAAGG	   62.0	   451bp	  
	   264	  
	   	   R	   AGAGAAGCGGACTTCTCCTT	   	   	  
F	   CGAGGTCACCAACCAGTTTC	  	  UCHL3	   NM_006002.3	  
	   R	   GTCTGACCTTCATGGGCACT	  	   62.1	   432bp	  
F	  
GCTAAGCAGGTAATTAATAATG
C	  UCHL5	   NM_015984.2	  
	   R	   GGCAACTTCTGACTGAATAGC	   71.4	   555bp	  
F	   GGGCATTTTTCTTGGATCTTT	  ATXN3*	   NM_004993.5	  
	   R	   CAGAGTTTAGGAACGCACCA	  	   67.7	   405bp	  




	   R	   TCTGTAGGTATGCCGGAAGATG	   65.7	   440bp	  
F	   CCATGGTGACACCTCACAAG	  	  JOSD1	   NM_014876.5	  
	   R	   ACACATCGGTCCTCCAACTC	  	   46.1	   408bp	  
F	   CTGGAGCTGTGTGCTGTCC	  JOSD2	   NM_138334.2	  
	   R	   TGTAGTAGACACCGTCCACCTG	  	   10.2	   352bp	  
F	   AGGTGGTTCATCTCGAGTCTG	  BRCC3	   NM_024332.3	  
	   R	   TCCAGAAGTCTCGTGGACCA	   63.1	   549bp	  
F	   TGCTCAATCAGCAGTTCCAG	  	  CSN5	   NM_006837.2	  
	   R	   ATTTTCGGTCATGCGTTTCT	  	   62.8	   420bp	  
F	   ACTCCTTTGAGCTGCTGTCC	  	  CSN6	   NM_006833	  
	   R	   CAGAGGCCTTGACGTACTCC	  	   47.3	   483bp	  
F	   CCGTGAAGCAAGTGCAGATA	  	  EIF3H	   NM_003756.2	  
	   R	   ATGCTTCAGGGGAAAAATCC	  	   61.0	   456bp	  
F	   CATCAAAGCCTACGTCAGCA	  	  EIF3S5	   NM_003754	  
	   R	   TTGCTGTTGAGCATGGTCTC	  	   50.0	   354bp	  
F	   CCACACCCTGGTGGAAGTAA	  	  MPND	   NM_032868.4	  
	   R	   TAGTCCATCTGTGCGTCGAT	   25.1	   351bp	  




	   R	   CCAGGCAGGTAATCTGAGAA	  	   69.7	   363bp	  
F	   AACAATGTGAACGTGGCATC	  	  PRPF8*	   NM_006445	  
	   R	   AAGCACATTCTTGGGAAGGA	  	   52.3	   351bp	  
F	   GCTTTGGTTGTTGGCTTTCTGG	  PSMD1
4	  
NM_005805.4	  
	   R	   GGTCCTGCTTGCCAACATTC	   70.2	   489bp	  
F	   GAAAGTCAATGCCAGGGAAA	  	  PSMD7	   NM_002811.3	  
	   R	   GGAGTTCAGTCCCTTCAAACC	  	   54.8	   361bp	  
F	   TACTTCCGCTCTGGAGTTG	  STAMB
P	  
NM_006463.3	  
	   R	   TAGGCCAGGGTCTACCTTC	   65.0	   471bp	  
F	   CTGCTTTTCCACACACCAGA	  	  STAMB
PL1	  
NM_020799.2	  
	   R	   GTGTGAAGATCAACGCTGGA	  	   58.0	   453bp	  
F	   ATTGCTGTGCAGAACCCTCT	  	  OTUB1	   NM_017670.2	  
	   R	   TCGATGAAGTGCTCGAAGAA	  	   39.9	   464bp	  
F	   TGACATTCTATCCATTCTTCGG	  OTUB2	   NM_023112.3	  
	   R	   CCATGGGCTCTACTTCGTG	   45.6	   476bp	  
OTUD1 XM_166659.7	   F	   GTGGAGAAGCAGGACAAGTA	   45.5	   527bp	  
	   265	  
F	   GTGGAGAAGCAGGACAAGTA	  *	  
	   R	   TTAGACAAGGATATGGCCATAG	   45.5	   527bp	  
F	   GGACGGCAATTGCTTGTTCAG	  OTUD3	   NM_015207.1	  
	   R	   CAGCTTCCAGGTTCTGGACT	   71.5	   557bp	  
F	   CAGGAATGGGTAGGACAAGTG	  OTUD4	   NM_199324.2	  
	   R	   CTATAGACTGCAGGATTGAGTG	   56.4	   479bp	  
F	   CTGTCTCTTCCGGGCTGTAG	  	  OTUD5	   NM_017602	  
	   R	   CCATGACTCCTCCGATGTTT	   55.0	   460bp	  
F	   ATGGATGATCCGAAGAGTGAAC	  OTUD6
A	  
NM_207320.1	  
	   R	   GCAGGAACTCGTCGACGTG	   28.4	   559bp	  
F	   CAGGAGCCAGACATATGGAAA	  	  OTUD6
B	  
NM_016023.3	  
	   R	   CCAACCGTGTAACCGAATTA	  	   61.0	   471bp	  
F	   GTACGAGAGCCTGGAAGAG	  OTUD7
A*	  
NM_130901.1	  
	   R	   GGATCCACGTCACGTTCATG	   41.1	   434bp	  
F	   GTATAAGCTGCTGCCCTTGC	  	  OTUD7
B	  
NM_020205.2	  
	   R	   AAGCTGCCCAGTTTGTTAGC	  	   39.9	   378bp	  
F	   GCAGTGAATTTGTGGAAGCA	  	  PARP11
*	  
NM_020367	  
	   R	   AAGAGCAAACCTTCCTGCAA	  	   59.4	   461bp	  
F	   CCCAGGAATGCTACAGATACC	  TNFAIP
3	  
NM_006290.2	  
	   R	   GGCTTGGAGTTCAGCTTTGG	   58.6	   556bp	  
F	   CATGGACAGCTGAGGACTGA	  	  VCPIP1	   NM_025054.4	  
	   R	   TCCCAAATTCACCTGGAAAG	  	   64.1	   424bp	  
F	   GGATCTCAGCAATGGGGATAC	  YOD1	   NM_018566.3	  
	   R	   GGAGGTGTATCTGGATCAGG	   66.4	   552bp	  
F	   AAAACTGGCCATCTGCAATC	  	  ZRANB
1	  
NM_017580.2	  
	   R	   GTGCAAACAGAGCAAGTCCA	  	   60.2	   430bp	  
Table	  S5.1	  Sequence	  of	  forward	  and	  reverse	  primers	  at	  the	  boundaries	  of	  esiRNA	  
region.	  
	  
*	  esiRNA	  region	  amplified	  from	  cDNA.	  
**	  All	  primers	  are	  flanked	  by	  the	  T7	  promoter	  sequence	  GCTAATACGACTCACTATAGGGAGAG	  
on	  their	  5’	  ends.	  	  
Note:	  F	  –	  Forward	  primer;	  R	  –	  Reverse	  primer	  
?
?
?
?
